Onsite Program

IASLC 19TH WORLD CONFERENCE ON LUNG CANCER
SEPTEMBER 23–26, 2018  TORONTO, CANADA

TAKE ACTION
Against Lung Cancer!

WWW.IASLC.ORG  #WCLC2018

CONQUERING
THORACIC CANCERS
WORLDWIDE

facebook.com/IASLC  @IASLC  iaslclung  IASLC  IASLC
Refining the Focus in Lung Cancer: New Data and Emerging Biomarkers

Sunday, 23 September 2018 | 14:30–16:00
105 MTCC
Metro Toronto Convention Centre, North Building
Toronto, ON, Canada

PROGRAM TOPICS

**Immunotherapy, Chemotherapy, or Both: Precision Medicine and NSCLC**
Rosalyn Juergens, MD, PhD
McMaster University
*Hamilton, ON, Canada*
Meeting Chair

**Investigating the Potential for I-O Therapies in SCLC and Mesothelioma**
Solange Peters, MD, PhD
University of Lausanne
*Lausanne, Switzerland*

**Emerging Potential Biomarkers in Lung Cancer Research**
Matthew Hellmann, MD
Memorial Sloan Kettering Cancer Center
*New York, NY, United States*

**Vera Hirsh, MD**
McGill University Health Center
*Montreal, QC, Canada*

**From Clinical Trials to Real-World Experience: Practical Management of NSCLC, SCLC, and Mesothelioma Treatment—Case Studies Presentation Full Panel**

This program was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.

This program has received an educational grant and in-kind support from Bristol-Myers Squibb Company.
# Table of Contents

## Section 1: Welcome

- Welcome Messages 4
- Conference Summary 14

## Section 2: IASLC and WCLC Committees

- International Association for the Study of Lung Cancer 20
  - IASLC Staff 20
  - IASLC Board of Directors 2017-2019 21
  - IASLC Foundation Board 2017-2019 21
- WCLC Committees 26
  - Local Organizing Committee 26
  - International Program Committee 27
  - International Abstract Review Committee 29

## Section 3: General Conference Information

- Registration 34
- Press and Media 35
- Information for Invited Faculty and Abstract Presenters 38
- CME Accreditation Information 40
- Onsite Services and General Information 42

## Section 4: IASLC and Conference Awards

- IASLC Distinguished Awards 48
- IASLC Foundation Award Winners 2018 54
- IASLC WCLC 2018 Conference Awards 55
  - IASLC International Mentorship Award Winners 55
- IASLC WCLC 2018 Young Investigator Award Winners 56
- IASLC WCLC 2018 Developing Nation Award Winners 57
- IASLC WCLC 2018 Patient Advocate Award Winners 57
- IASLC WCLC 2018 Nurse and Allied Health Professional Award Winners 57
- IASLC WCLC 2018 Lectureship Awards 58

## Section 5: Conference Program

- Program at a Glance 62
- Program by Track 64
- Session Overview
  - Sunday, Sept. 23, 2018 72
  - Monday, Sept. 24, 2018 74
  - Tuesday, Sept. 25, 2018 76
  - Wednesday, Sept. 26, 2018 78

## Section 6: Daily Scientific Program

- Saturday, Sept. 22, 2018 82
- Sunday, Sept. 23, 2018 82
- Monday, Sept. 24, 2018 88
- Tuesday, Sept. 25, 2018 105
- Wednesday, Sept. 26, 2018 123
# TABLE OF CONTENTS

## SECTION 7
**POSTER SESSIONS**

<table>
<thead>
<tr>
<th>DAY</th>
<th>SESSION</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday Sept. 24, 2018</td>
<td>Poster 1</td>
<td>136</td>
</tr>
<tr>
<td>Tuesday Sept. 25, 2018</td>
<td>Poster 2</td>
<td>156</td>
</tr>
<tr>
<td>Wednesday Sept. 26, 2018</td>
<td>Poster 3</td>
<td>176</td>
</tr>
</tbody>
</table>

### POSTERS AT A GLANCE

- **Monday Sept. 24, 2018**
  - Poster Session 1: 136
- **Tuesday Sept. 25, 2018**
  - Poster Session 2: 156
- **Wednesday Sept. 26, 2018**
  - Poster Session 3: 176

### POSTERS IN DETAIL

- **Monday Sept. 24, 2018**
  - Poster Session 1: 137
- **Tuesday Sept. 25, 2018**
  - Poster Session 2: 157
- **Wednesday Sept. 26, 2018**
  - Poster Session 3: 177

---

## SECTION 8
**SPONSOR AND EXHIBIT INFORMATION**

### INDUSTRY SUPPORTED SYMPOSIA AND WORKSHOPS 196

### EXHIBIT SHOWCASE SESSIONS 202

### EXHIBIT INFORMATION 203

#### Exhibit Floor Plan
- 204

#### Exhibitor Listing
- 205

#### Exhibitor Company Descriptions
- 206

### CONFERENCE SPONSORS 212

---

## SECTION 9
**AUTHOR INDEX**

- 220

---

## SECTION 10
**MAPS AND FLOOR PLANS**

- 256

---

**Please note:** Poster Sessions are not part of the IASLC CME accredited scientific program.

**Please note:** Industry Supported Symposia are not part of the IASLC CME accredited scientific program.

---

**CONFERENCE SECRETARIAT**

**International Conference Services Ltd. (ICS)**

Suite 300, 1201 West Pender Street
Vancouver, BC, Canada V6E 2V2

Phone: +1 604 681 2153
Fax: +1 604 681 1049
Email: wclc2018@icsevents.com

[www.icsevents.com](http://www.icsevents.com)
SECTION 1

Welcome

TAKE ACTION
Against Lung Cancer!
September 23–26, 2018

Dear Friends:

I am pleased to extend my warmest greetings to everyone attending the 19th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer (IASLC).

This event brings together more than 7,000 delegates from around the world to discuss the latest developments in thoracic malignancy research. I am certain that everyone in attendance will benefit from this opportunity to network and collaborate with medical experts, research scientists and other health professionals, and will leave inspired to put what they have learned into practice.

I would like to thank the IASLC for hosting this event, and for its commitment to promoting public health.

On behalf of the Government of Canada, I offer my best wishes for an enjoyable and productive conference in Toronto.

Sincerely,

The Rt. Hon. Justin P. J. Trudeau, P.C., M.P.
Prime Minister of Canada
September 2, 2018

A MESSAGE FROM PREMIER DOUG FORD

I’m pleased to extend warm greetings to all the delegates attending the International Association for the Study of Lung Cancer’s (IASLC) 19th World Conference On Lung Cancer. Welcome to Toronto.

It’s great to have the world’s leading experts, health professionals and advocates gathered here in Toronto to discuss the latest developments on lung cancer and related diseases. This is an ideal opportunity to network, share knowledge and collaborate on tackling this serious health issue.

I thank the IASLC for hosting this conference and for its commitment to understanding and eventually eliminating this often-fatal disease.

Best wishes for an informative and productive conference.

Doug Ford
Premier
WELCOME MESSAGE
FROM THE MAYOR OF TORONTO

Message from the Mayor

It gives me great pleasure to extend greetings and a warm welcome to everyone attending the International Association for the Study of Lung Cancer’s 19th World Conference on Lung Cancer.

Welcome to the 7,000 delegates from more than 100 countries who are gathering at this conference to discuss the latest developments in thoracic malignancy and research, in a setting designed for professional development and growth.

As Canada’s largest city and the fourth largest in North America, Toronto is a global centre for business, finance, arts and culture and is dedicated to being a model of sustainable development. I welcome everyone to our city and encourage you to enjoy Toronto and learn about our vibrant neighbourhoods.

On behalf of Toronto City Council, please accept my best wishes for an informative and enjoyable event.

Yours truly,

John Tory
Mayor of Toronto
WELCOME MESSAGE
FROM THE WCLC 2018 CONFERENCE PRESIDENTS

Dear Colleagues,

On behalf of the International Association for the Study of Lung Cancer (IASLC) and the Regional Organizing Committee, it is our great pleasure to welcome you to the IASLC 19th World Conference on Lung Cancer in Toronto. For the last two years we have been working tirelessly to ensure that you will have an inspiring and memorable experience in our beautiful city, and we cannot wait to see you all.

The IASLC World Conference on Lung Cancer has become the premier Conference to share and discuss the latest advances in lung cancer and thoracic malignancies. We are thrilled to announce that practice-changing abstracts will be presented in our Presidential Symposium on Tuesday, September 25. In addition, there will be more than 300 abstracts presented in Oral and Mini Oral Sessions along with over 300 invited presentations from world renowned experts in the field.

We encourage you to participate actively in the discussions and hope the meeting helps in the exchange of information and development of new collaborations. To facilitate discussions and networking opportunities we are introducing a new online tool that will allow you to ask questions and participate in live polls during the sessions.

Furthermore, we invite you to join our poster presenters during the Poster Viewing Receptions on Monday and Tuesday evening as well as on Wednesday during lunch. Posters will be on display for the entire day, but presenters will be standing by their poster during the Receptions. Please note a different set of posters will be displayed daily, so be sure to visit the Exhibit & Poster Hall each day.

We also would like to extend our gratitude and thanks to all sponsors and exhibitors for their continued support to WCLC and IASLC. Without them this Conference would not be possible.

Thank you for joining us in Toronto.
We can’t wait to see you!

Frances Shepherd, OC, OOnt, MD, FRCPC, FASCO
IASLC WCLC 2018 HONORARY CHAIR
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

Natasha Leighl, MD, MMSc, FRCSC
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

Andrea Bezjak, MDCM, MSc, FRCP
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

Gail Darling, MD, FRCSC, FACS
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

WCLC 2018 Program Highlights
• More than 500 world renowned experts as speakers, session chairs and abstract discussants representing over 33 countries
• More than 300 oral and mini oral abstract presentations
• Presidential Symposium featuring practice-changing abstracts
• More than 1,500 poster presentations
• NEW Poster Viewing Receptions
• NEW Interactive tool for live polls and online questions during sessions
• Hands on Workshops
WELCOME MESSAGE
FROM THE IASLC PRESIDENT

Dear IASLC Members, Dear Attendees,

As IASLC President for 2017-2019 it is my privilege and honor to welcome you in Toronto to attend the IASLC 19th World Conference on Lung Cancer.

Newer treatment options, biomarker-based patient segmentation and availability of biomarker-based treatment approaches have added to the treatment complexity over the years. Parallely innovative clinical-trial designs such as umbrella and basket studies or master protocols — today central components of drug development — are highlighting the need to better appraise tumor biology, drug efficacy and the potential benefits for patients. The era of precision medicine is progressively coming to stage engaging all of us in searching for robust predictive biomarkers.

More recently the therapeutic opportunities in thoracic malignancies have been dramatically changed, in a partially unexpected way, by the results of multiple phase III studies testing the role of immune-checkpoint inhibitors. New high-tech machines in the field of radiation therapy and less invasive surgical techniques are setting new standards of care.

Multidisciplinary is the key and the concept of the multidisciplinary approach is now expanding including new players such as molecular biologists and bio-informatics. We are approaching a time where more local treatments are incorporated in the treatment of advanced disease and more systemic therapies are incorporated in the treatment algorithm of early disease.

Exchange of ideas, thinking outside of the box, disruptive innovations are needed to set the bar for the cure of thoracic malignancies.

In the digital world it seems that a traditional annual meeting is not needed and outdated. I personally believe that the multidisciplinary forum, as our annual meeting fundamentally remains, it represents a unique opportunity to boost ideas through listening, discussing research ideas, expose younger generations to key opinion leaders in the field and fostering international collaborations fully surrounded by that magic, friendly atmosphere that you can breathe only at the IASLC annual meeting.

Welcome to Toronto and enjoy your time.

Giorgio V. Scagliotti, MD, PhD
IASLC PRESIDENT
Dear WCLC Participants,

It is a pleasure for me to welcome you all to the IASLC 19th World Conference on Lung Cancer!

The IASLC is a rapidly growing organization with about 7,000 members in more than 100 countries. During our 44-year history, the WCLC has been the cornerstone of our activities. WCLC connects us as we learn about new scientific and clinical advances in lung cancer and other thoracic malignancies. We meet to enhance professional networks and to make new friendships. For the IASLC, it is an important goal to bring investigators, clinicians, nurses and advocates together to interact with each other, as well as pursue important connections with our industry partners. IASLC is the home for the “lung cancer family”; we hope you sense the family atmosphere at WCLC!

For WCLC 2018, we have received more than 2,000 scientific abstracts to be presented in the different scientific categories. We are witnessing today very encouraging progress in lung cancer prevention, screening and treatment and we are confident that WCLC 2018 will bring further scientific progress and hope to the many lung cancer patients in desperate need of it.

The local Program Committee and the Program Chairs have assembled a very exciting scientific and educational program. We hope that you will enjoy the conference, learn about the newest progress in the science and clinical management of lung cancer and other thoracic malignancies, and bring it home to your respective environment and with it, give new hope for your current and future patients.

With best personal wishes,

Fred R. Hirsch, MD, PhD
IASLC CHIEF EXECUTIVE OFFICER
JOIN TODAY!

As an IASLC member, you will receive:

- Collaboration with a multidisciplinary global team of thoracic oncology experts and leaders
- Member access to the Journal of Thoracic Oncology, the premier journal in lung cancer, as well as the latest classification and staging publications
- Multidisciplinary education including the latest in groundbreaking research and treatment of thoracic malignancies

SPECIAL OFFER FOR NEW MEMBERS:
REGULAR, DEVELOPING COUNTRY AND ALLIED HEALTH Fellow, Survivor and Caregiver Memberships Complimentary

Don't forget to pick up your Member Appreciation Gift!

See us in the Exhibit Hall at Booth 100 or at the IASLC Membership Booth at Registration | Apply at iaslc.org
NEW WCLC 2018 Interactive Tool

Social Q&A
Submit questions during sessions
Like submitted questions to make them move to the top of the list

Live Audience Polling with Real-Time Results
Respond to polls and view results
Actively participate in sessions

Hassle-Free Session and Speaker Feedback
Help improve the scientific program and provide feedback with simple evaluations

Download the IASLC WCLC 2018 App and start participating!
Stay up to date with the WCLC 2018 Mobile App

Download the WCLC 2018 Mobile App!

Get 24-hour access to all Conference related information

Access to full scientific program information including abstracts

Available for iPhone, iPad, and Android

NEW FOR 2018! Participate in Live Polling
Ask Questions
MEMBERSHIP OFFER

We’re more than 7,000 strong! Won’t you join us? Take advantage of this great value now!

New Members Only

WCLC Special Offer – Join during the WCLC and get two years for the price of one. Your membership starts immediately and doesn’t end until December 31, 2020.

WCLC NEW Regular Member: US $250.00
WCLC NEW Developing Country Member: US $50.00
WCLC NEW Allied Professional Member: US $50.00
WCLC NEW Fellow/Resident/Trainee Member: Free
WCLC NEW Patient/Survivor/Caregiver Member: Free

Here are just some of the benefits you’ll receive when you become an IASLC member:

• Member access to the Journal of Thoracic Oncology
• Discounts to the IASLC World Conference on Lung Cancer and other scientific meetings
• Opportunity to make an impact by participating on IASLC member committees
• Access to the IASLC member directory

To learn more about the different levels of membership and the benefits, visit: www.iaslc.org/join

JOIN THE IASLC TODAY!

Stay up to date with the WCLC 2020 Mobile App

Download the WCLC 2020 Mobile App!
Get 24-hour access to all Conference related information
Access to full scientific program information including abstracts
Available for iPhone, iPad, and Android
NEW FOR 2020!
Participate in Live Polling
Ask Questions
Conference Venue

Metro Toronto Convention Centre (MTCC)

All Session Rooms, the Plenary Hall and the Exhibit Hall are located in the North Building - access via 255 Front Street.

Hospitality Suites and Committee Meeting Rooms are located in the South Building - access via the bridgewalk from the North Building or via Bremner Boulevard.

REGISTRATION

**MTCC North Building, Street Level 200**

- **Saturday, September 22**: 14:00 – 18:00
- **Sunday, September 23**: 06:30 – 20:00
- **Monday, September 24**: 06:30 – 15:30
- **Tuesday, September 25**: 06:30 – 15:30
- **Wednesday, September 26**: 06:30 – 15:30

EXHIBIT HALL

**MTCC North Building, Level 300, Exhibition Halls B+C**

- **Sunday, September 23** (Welcome Reception): 20:30 - 22:00
- **Monday, September 24**: 09:30 – 18:30
- **Tuesday, September 25**: 09:30 – 18:30
- **Wednesday, September 26**: 09:30 – 14:00

Coffee and snacks will be provided at no charge during the morning breaks and poster viewing receptions. Lunch will be available for purchase.
### Speaker Preview Centre

**MTCC North Building, Street Level 200, Room 204**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, September 22</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, September 23</td>
<td>06:30 – 20:00</td>
</tr>
<tr>
<td>Monday, September 24</td>
<td>06:30 – 16:00</td>
</tr>
<tr>
<td>Tuesday, September 25</td>
<td>06:30 – 16:00</td>
</tr>
<tr>
<td>Wednesday, September 26</td>
<td>06:30 – 15:00</td>
</tr>
</tbody>
</table>

### Coat and Baggage Check

**MTCC North Building, Street Level 200, Registration Area**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, September 26</td>
<td>06:30 – 17:00</td>
</tr>
</tbody>
</table>

### Poster Pick Up

**MTCC North Building, Level 300, Exhibit Hall**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, September 24</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Tuesday, September 25</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Wednesday, September 26</td>
<td>08:00 – 12:00</td>
</tr>
</tbody>
</table>

### Media Room

**MTCC North Building, Level 300, Back of Exhibit Hall (Behind Posters)**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, September 23</td>
<td>08:00 – 19:00</td>
</tr>
<tr>
<td>Monday, September 24</td>
<td>08:00 – 19:00</td>
</tr>
<tr>
<td>Tuesday, September 25</td>
<td>08:00 – 19:00</td>
</tr>
<tr>
<td>Wednesday, September 26</td>
<td>08:00 – 14:00</td>
</tr>
</tbody>
</table>

### IASLC Business Meeting

**MTCC North Building, Street Level 200, Room 202 BD**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, September 25</td>
<td>17:00 – 18:00</td>
</tr>
</tbody>
</table>

Light Refreshments will be provided
Journal of Thoracic Oncology

Meet the Editor-in-Chief
Alex A. Adjei, MD, PhD

Monday, September 24
12:00 – 13:30
Room 206 BD

A subscription to JTO is a benefit of membership in the IASLC. To join, visit www.IASLC.org
To subscribe visit jto.org
WCLC 2018 VIRTUAL MEETING

Access WCLC 2018 Sessions
Anytime, Anywhere

Get the WCLC 2018 Virtual Meeting via LIBRARY.IASLC.ORG

Never miss out on another presentation!

The WCLC 2018 Virtual Library is included in your Conference registration (check your name badge for your Access Code).

INCLUDES

Abstracts
Presentation slides
Audio/video recordings of presentations
Electronic version of most posters
Thank you for being a member!

As an IASLC member, you receive:

- Collaboration with a multidisciplinary global team of thoracic oncology experts and leaders
- Member access to the *Journal of Thoracic Oncology*, the premier journal in lung cancer, as well as the latest classification and staging publications
- Multidisciplinary education including the latest in ground-breaking research and treatment of thoracic malignancies

See us in the Exhibit Hall at Booth 100 or at the IASLC Membership Booth at Registration | Apply at iaslc.org
SECTION 2

IASLC and WCLC Committees

TAKE ACTION
Against Lung Cancer!
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes over 7,000 lung cancer specialists in over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

The IASLC mission is:

- To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies
- To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public
- To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world
IASLC BOARD OF DIRECTORS 2017–2019

Officers

**PRESIDENT**
Giorgio V. Scagliotti, Italy

**PRESIDENT ELECT**
Tetsuya Mitsudomi, Japan

**PAST PRESIDENT**
David P. Carbone, USA

**CHIEF EXECUTIVE OFFICER AND SECRETARY**
Fred R. Hirsch, USA

**TREASURER**
Tony Mok, Hong Kong

Board of Directors

Michael Boyer, Australia

Julie Brahmer, USA

Enriqueta Felip, Spain

Anne Fraser, New Zealand

David Harpole, USA

Norihiro Ikeda, Japan

Clarissa Mathias, Brazil

Yuko Nakayama, Japan

Masayuki Noguchi, Japan

Robert Pirker, Austria

Suresh Ramalingam, USA

Martin Reck, Germany

Miyako Satouchi, Japan

Takashi Seto, Japan

Heather Wakelee, USA

James Yang, Taiwan

Paul E. Van Schil, Belgium

IASLC FOUNDATION BOARD 2017–2019

Board Officers

**PRESIDENT**
Giorgio V. Scagliotti, Italy

**PRESIDENT ELECT**
Tetsuya Mitsudomi, Japan

**PAST PRESIDENT**
David P. Carbone, USA

**CHIEF EXECUTIVE OFFICER AND SECRETARY**
Fred R. Hirsch, USA

**TREASURER**
Tony Mok, Hong Kong

Board Members

Marc Braunstein, USA

Lauren Fisher, USA

Paolo Paoletti, Italy

Bruce Ratner, USA

Kathy Weber, USA

Concert

Toronto Symphony Chamber Players

playing Copland Appalachian Spring & Vivaldi’s Seasons: Spring and Autumn

Support the IASLC Foundation by attending the IASLC Foundation Concert

Sunday, September 23, 2018, 17:45 - 18:45 (Ticketed Event)
(See next page for details.)
The IASLC Foundation is proud to invite you to a benefit concert in support of the education of research fellows — who are the next generation of lung cancer physicians and scientists. This performance is given in honor of those who have been affected by lung cancer and those who have dedicated their lives to research, diagnosis and treatment of the disease.

About the IASLC Foundation

The International Association for the Study of Lung Cancer Foundation (IASLCF) is a global organization dedicated to lung cancer research through the study of lung cancer. Founded in 2014, the IASLC Foundation provides fellowships to researchers all over the world.

The IASLC Foundation’s objective is to advance the discovery of new ways to conquer lung cancer and other thoracic malignancies to help extend patient lifespans and give patients hope.
Join us!

Commit yourself to healthy lungs! Help kick off the IASLC 19th World Conference on Lung Cancer, the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, by participating in the IASLC Foundation Walk. The walk will raise much-needed awareness for lung cancer and inspire hope, compassion and solidarity by showcasing a community committed to easing the burden of these diseases. Whether you want to walk or stroll, participate as an individual or as a team, together we can take action against lung cancer!

Start: A 2.6 mile walk that will start at the Metro Toronto Convention Centre, North Building, Level 200, Room 201 F.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Registration Opens</td>
</tr>
<tr>
<td>08:00</td>
<td>Shotgun Start</td>
</tr>
<tr>
<td>09:00 – 09:30</td>
<td>Celebration and Snacks</td>
</tr>
</tbody>
</table>

REGISTRATION

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard Pre-Registration (by September 20)</td>
<td>USD 35</td>
</tr>
<tr>
<td>Survivor/Allied Health Professional</td>
<td>USD 20</td>
</tr>
<tr>
<td>Onsite Registration</td>
<td>USD 40</td>
</tr>
</tbody>
</table>

Fees include registration, t-shirt* and snacks.

* Only participants who register three weeks or more before the walk are guaranteed a t-shirt. T-shirts will be available for onsite registrants on a first-come, first-served basis only.

WWW.IASLC.ORG #WCLC2018
IASLC 2019
Meetings Schedule

IASLC 19th Lung Cancer Targeted Therapies Meeting
February 20-23, 2019 | Santa Monica, California
#LCTT19

IASLC Small Cell Lung Cancer Meeting 2019
April 3-5, 2019 | New York, New York
#SCLC19

2019 European Lung Cancer Congress
April 10-13, 2019 | Geneva, Switzerland | #ELCC19

IASLC Mesothelioma Meeting 2019
July 10-12, 2019 | New York, New York | #MESO19

IASLC 20th World Conference on Lung Cancer
September 7-10, 2019 | Barcelona, Spain
#WCLC2019

IASLC North America Conference on Lung Cancer 2019
October 9-12, 2019 | Chicago, Illinois | #NAACL19

IASLC Latin America Conference on Lung Cancer 2019
October 18-19, 2019 | Mexico City, Mexico
#LACLC19
Join us in Barcelona for the 20th WCLC!

SEPTEMBER 7–10, 2019
WCLC COMMITTEES

Local Organizing Committee

HONORARY CHAIR
Frances Shepherd, Canada

CO-PRESIDENT
Natasha Leighl, Canada

CO-PRESIDENT
Andrea Bezjak, Canada

CO-PRESIDENT
Gail Darling, Canada

MEMBERS
Alex Adjei, USA
Clarissa Baldotto, Brazil
Shantanu Banerji, Canada
Gwyn Bebb, Canada
Normand Blais, Canada
Penelope Bradbury, Canada
Julie Brahmer, USA
Ronald Burkes, Canada
Linda Coate, Ireland
Sinead Cuffe, Canada
Peter Ellis, Canada
John Goffin, Canada
Sarah Goldberg, USA
Roy Herbst, USA
Cheryl Ho, Canada
Leora Horn, USA
Pasi Janne, USA
Thomas John, Australia
Rosalyn Juergens, Canada
Geoffrey Liu, Canada
Zarnie Lwin, Australia
Mary MacNeil, Canada
Barbara Melosky, Canada
Don Morris, Canada
Garth Nicholas, Canada
Nathan Pennell, USA
Katherine Pisters, USA
Suresh Ramalingam, USA
Adrian Sacher, USA
Randeep Sangha, Canada
Lecia Sequist, USA
Yaron Shargall, Canada
Luis Ubillos, Uruguay
James Villeneuve, Canada
Heather Wakelee, USA

International Program Committee

ADVANCED NSCLC

CHAIR
Scott Laurie, Canada

CO-CHAIR
Leora Horn, USA

Carlos Gil Ferreira, Brazil
Glen Goss, Canada
Pasi Janne, USA
Clarissa Mathias, Brazil
Keunchil Park, Korea
Suresh Ramalingam, USA
Noemi Reguart, Spain
Christian Rolfo, Belgium
Qing Zhou, China

ADVOCACY

CHAIR
Paul Wheatley-Price, Canada

CO-CHAIR
Jesme Fox, UK

Bonnie Addario, USA
Andrea Ferris, USA
Kazu Hasegawa, Japan
Kim Norris, USA
Silvia Novello, Italy
Christina Sit, Canada
Jack (Howard) West, USA

BIOLOGY

CHAIR
Wan Lam, Canada

CO-CHAIR
Kwok-kin Wong, USA

Oscar Arrieta, Mexico
David Beer, USA
Robert Doebele, USA
Ramswamy Govindan, USA
Fred R. Hirsch, USA
Thomas John, Australia
Geoffrey Liu, Canada
William Lockwood, Canada
Phil Mack, USA
Matthew Meyerson, USA
Katerina Politi, USA
Daniel Tan, Singapore
Pan-Chyr Yang, Taiwan

EDUCATION

CHAIR
Barbara Melosky, Canada

CO-CHAIR
Alex Adjei, USA

Michael Boyer, Australia
Ron Burkes, Canada
Federico Cappuzzo, Italy
Randeep Sangha, Canada
Edgardo Santos, USA
### IMMUNOONCOLOGY
**CHAIR**
Desiree Hao, Canada  
**CO-CHAIR**
Solange Peters, Switzerland

- Myung-Ja Ahn, Korea  
- Fabrice Barlesi, France  
- Julie Brahmer, USA  
- Edward Garon, USA  
- Rina Hui, Australia  
- Rosalyn Juergens, Canada  
- Martin Reck, Germany  
- Naiyer Rizvi, USA  
- Adrian Sacher, USA  
- Ross Soo, Singapore  
- Yi-Long Wu, China

### MESOTHELIOMA
**CHAIR**
Anna Nowak, Australia  
**CO-CHAIR**
Marc DePerrot, Canada

- Paul Baas, Netherlands  
- Penelope Bradbury, Canada  
- Michele Carbone, USA  
- John Cho, Canada  
- Laura Donohoe, Canada  
- Dean Fennell, UK  
- Seiki Hasegawa, Japan  
- Christopher Lee, Canada  
- Isabelle Opitz, Switzerland  
- Nick Pavlakis, Australia  
- David Rice, USA  
- Kenneth Rosenzweig, USA

### OLIGOMETASTATIC NSCLC
**CHAIR**
David Palma, Canada  
**CO-CHAIR**
Joseph Salama, USA

- Hak Choy, USA  
- Laurie Gaspar, USA  
- Matthias Guckenberger, Switzerland  
- David Jones, USA  
- Mary Macneil, Canada  
- Boris Sepesi, USA

### INTERVENTIONAL DIAGNOSTICS/PULMONOLOGY
**CHAIR**
Kazuhiro Yasufuku, Canada  
**CO-CHAIR**
Kwun Fong, Australia

- Jason Aguilnik, Canada  
- Nicole Bouchard, Canada  
- Eric Edell, USA  
- Wael Hannah, Canada  
- Felix Herth, Germany  
- Hojoong Kim, Korea  
- Moishe Liberman, Canada  
- Septimiu Murgu, USA  
- Navneet Singh, India  
- Egbert Smit, Netherlands

### NURSING AND ALLIED HEALTH PROFESSIONALS
**CHAIR**
Massey Nematollahi, Canada  
**CO-CHAIR**
Patricia Hollen, USA

- Beth Eaby-Sandy, USA  
- Kathleen Gamblin, USA  
- Maria Guerin, UK  
- Pippa Labuc, UK  
- Naz Nouriany, Canada  
- Dianne Zawisz, Canada

### PATHOLOGY
**CHAIR**
Ming Tsao, Canada  
**CO-CHAIR**
Ignacio I. Wistuba, USA

### PREVENTION AND TOBACCO CONTROL
**CHAIR**
Matthew Steliga, USA  
**CO-CHAIR**
Michael Cummings, USA

- Eric Bedard, Canada  
- Wanda De Kanter, Netherlands  
- Carolyn Dresler, USA  
- Rayjean Hung, Canada  
- Jacek Jassem, Poland  
- Jamie Ostroff, USA  
- Emily Stone, Australia  
- Nise Yamaguchi, Brazil  
- Li Zhang, China

### SCREENING AND EARLY DETECTION
**CHAIR**
Christine Berg, USA  
**CO-CHAIR**
Stephen Lam, Canada

- Denise Aberle, USA  
- John Field, UK  
- John Goffin, Canada  
- Harry Groen, Netherlands  
- Norihiko Ikeda, Japan  
- Garth Nicholas, Canada  
- Nir Peled, Israel  
- Heidi Schmidt, Canada  
- Betty Tong, USA
WCLC COMMITTEES

International Program Committee

SMALL CELL LUNG CANCER/NET
CHAIR
Fiona Blackhall, UK

CO-CHAIR
Peter Ellis, Canada

Jeffrey Bogart, USA
Lauren Byers, USA
Quincy Chu, Canada
Eric Lim, UK
Francoise Mornex, France
Charles Rudin, USA
Ben Slotman, Netherlands
Sumitra Thongprasert, Thailand
Jie Wang, China
Mauro Zukin, Brazil

THYMOMA/OTHER THORACIC MALIGNANCIES
CHAIR
Heather Wakelee, USA

CO-CHAIR
Meinoshin Okumura, Japan

Anthony Brade, Canada
Wentao Fang, China
Pier Luigi Filosso, Italy
Nicolas Girard, Canada
Shaf Keshavjee, Canada
Robert Korst, USA
Andreas Rimner, USA
David Waller, UK

TREATMENT OF EARLY STAGE/LOCALIZED DISEASE
CHAIR
Hisao Asamura, Japan

CO-CHAIR
Patrick Cheung, Canada

Thomas D’Amico, USA
Jessica Donington, USA
Janet Edwards, Canada
Bob Li, USA
Tetsuya Mitsudomi, Japan
Luis Raez, USA
Ramon Rami-Porta, Spain
Tomohito Saito, Japan
Suresh Senan, Netherlands

TARGETED THERAPY
CHAIR
Janessa Laskin, Canada

CO-CHAIR
Tony Mok, Hong Kong

David Ross Camidge, USA
Alexander Drilon, USA
Enriqueta Felip, Spain
Pilar Garrido, Spain
Shun Lu, China
Zofia Piotrowska, USA
Karen Reckamp, USA
Lecia Sequist, USA
Ben Solomon, Australia
James Yang, Taiwan

TREATMENT IN THE REAL WORLD - SUPPORT, SURVIVORSHIP, SYSTEMS RESEARCH
CHAIR
Meredith Giuliani, Canada

CO-CHAIR
Martin Stockler, Australia

Carlos Barrios, Brazil
David Dawe, Canada
Bill Evans, Canada
David Gerber, USA
Cheryl Ho, Canada
Ronan Kelly, USA
Biniam Kidane, Canada
Gilberto Lopes, Brazil
Alex Louie, Canada
Jarushka Naidoo, USA
Taofeek Owonikoko, USA
Sadeesh Srinathan, Canada

TREATMENT OF LOCOREGIONAL DISEASE - NSCLC
CHAIR
Corinne Faivre-Finn, UK

CO-CHAIR
Paula Ugalde, Canada

Charles Butts, Canada
Hiroshi Date, Japan
Dirk de Ruysscher, Netherlands
Rui Haddad, Brazil
Feng-Ming (Spring) Kong, USA
Jocelyne Martin, Canada
Renato Martins, USA
Harvey Pass, USA
Gaetano Rocco, Italy
Eric Vallieres, USA

YOUNG INVESTIGATOR TRACK
CHAIR
Benjamin Besse, France

CO-CHAIR
Jonathon Yeung, Canada

Clarissa Baldotto, Brazil
Vladmir de Lima, Brazil
Mark Doherty, Canada
Yoshiihisa Kobayashi, Japan
Celine Mascaux, France
Tatiane Montella, Brazil
Luis Ulibios, Uruguay
Linda Coate, USA
Alex Adjei, USA
Prasad Adusumilli, USA
### International Abstract Review Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Agulnik</td>
<td>Canada</td>
</tr>
<tr>
<td>Yong Chan Ahn</td>
<td>Korea</td>
</tr>
<tr>
<td>Myung-Ju Ahn</td>
<td>Korea</td>
</tr>
<tr>
<td>Christopher Amos</td>
<td>USA</td>
</tr>
<tr>
<td>Oscar Arrieta</td>
<td>Mexico</td>
</tr>
<tr>
<td>Hisao Asamura</td>
<td>Japan</td>
</tr>
<tr>
<td>Paul Baas</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Clarissa Baldotto</td>
<td>Brazil</td>
</tr>
<tr>
<td>David Ball</td>
<td>Australia</td>
</tr>
<tr>
<td>Fabrice Barlesi</td>
<td>France</td>
</tr>
<tr>
<td>Carlos Barrios</td>
<td>Brazil</td>
</tr>
<tr>
<td>Eric Bedard</td>
<td>Canada</td>
</tr>
<tr>
<td>David Beer</td>
<td>USA</td>
</tr>
<tr>
<td>Christine Berg</td>
<td>USA</td>
</tr>
<tr>
<td>Benjamin Besse</td>
<td>France</td>
</tr>
<tr>
<td>Sarah Best</td>
<td>Australia</td>
</tr>
<tr>
<td>Levi Beverly</td>
<td>USA</td>
</tr>
<tr>
<td>Andrea Bezjak</td>
<td>Canada</td>
</tr>
<tr>
<td>Normand Blais</td>
<td>Canada</td>
</tr>
<tr>
<td>Jeffrey Bogart</td>
<td>USA</td>
</tr>
<tr>
<td>Alain Borczuk</td>
<td>USA</td>
</tr>
<tr>
<td>Nicole Bouchard</td>
<td>Canada</td>
</tr>
<tr>
<td>Michael Boyer</td>
<td>Australia</td>
</tr>
<tr>
<td>Penelope Bradbury</td>
<td>Canada</td>
</tr>
<tr>
<td>Anthony Brade</td>
<td>Canada</td>
</tr>
<tr>
<td>Jeffrey Bradley</td>
<td>USA</td>
</tr>
<tr>
<td>Julie Brahmer</td>
<td>USA</td>
</tr>
<tr>
<td>Kate Brain</td>
<td>UK</td>
</tr>
<tr>
<td>Elisabeth Brambilla</td>
<td>France</td>
</tr>
<tr>
<td>Paul Brennan</td>
<td>France</td>
</tr>
<tr>
<td>Stephanie Brule</td>
<td>Canada</td>
</tr>
<tr>
<td>Lukas Bubendorf</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Ron Burkes</td>
<td>Canada</td>
</tr>
<tr>
<td>Charles Butts</td>
<td>Canada</td>
</tr>
<tr>
<td>Lauren Byers</td>
<td>USA</td>
</tr>
<tr>
<td>Matthew Callister</td>
<td>UK</td>
</tr>
<tr>
<td>Ross Camidge</td>
<td>USA</td>
</tr>
<tr>
<td>Federico Cappuzzo</td>
<td>Italy</td>
</tr>
<tr>
<td>Michele Carbone</td>
<td>USA</td>
</tr>
<tr>
<td>K.C. Allen Chan</td>
<td>China</td>
</tr>
<tr>
<td>Patrick Cheung</td>
<td>Canada</td>
</tr>
<tr>
<td>John Cho</td>
<td>Canada</td>
</tr>
<tr>
<td>Teh-Ying Chou</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Hak Choy</td>
<td>USA</td>
</tr>
<tr>
<td>Quincy Chu</td>
<td>Canada</td>
</tr>
<tr>
<td>Jin-Haeng Chung</td>
<td>Korea</td>
</tr>
<tr>
<td>Linda Coate</td>
<td>Ireland</td>
</tr>
<tr>
<td>Vladimir Cordeiro De Lima</td>
<td>Brazil</td>
</tr>
<tr>
<td>Melissa Culligan</td>
<td>USA</td>
</tr>
<tr>
<td>K. Michael Cummings</td>
<td>USA</td>
</tr>
<tr>
<td>Walter Curran, Jr.</td>
<td>USA</td>
</tr>
<tr>
<td>Sanja Dacic</td>
<td>USA</td>
</tr>
<tr>
<td>Megan Daly</td>
<td>USA</td>
</tr>
<tr>
<td>Thomas D’Amico</td>
<td>USA</td>
</tr>
<tr>
<td>Gail Darling</td>
<td>Canada</td>
</tr>
<tr>
<td>David Dawe</td>
<td>Canada</td>
</tr>
<tr>
<td>Wanda De Kanter</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Marc De Perrot</td>
<td>Canada</td>
</tr>
<tr>
<td>Dirk De Ruysscher</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Sven Diederichs</td>
<td>Germany</td>
</tr>
<tr>
<td>Robert Doebele</td>
<td>USA</td>
</tr>
<tr>
<td>Mark Doherty</td>
<td>Canada</td>
</tr>
<tr>
<td>Laura Donahoe</td>
<td>Canada</td>
</tr>
<tr>
<td>Jessica Donington</td>
<td>USA</td>
</tr>
<tr>
<td>Carolyn Dresler</td>
<td>USA</td>
</tr>
<tr>
<td>Alexander Drilon</td>
<td>USA</td>
</tr>
<tr>
<td>Mary Duffy</td>
<td>Australia</td>
</tr>
<tr>
<td>Janet Edwards</td>
<td>Canada</td>
</tr>
<tr>
<td>Peter Ellis</td>
<td>Canada</td>
</tr>
<tr>
<td>William Evans</td>
<td>Canada</td>
</tr>
<tr>
<td>Corinne Faivre-Finn</td>
<td>UK</td>
</tr>
<tr>
<td>Vincent (Wentao) Fang</td>
<td>China</td>
</tr>
<tr>
<td>Enrique Faip</td>
<td>Spain</td>
</tr>
<tr>
<td>Dean Fennell</td>
<td>UK</td>
</tr>
<tr>
<td>Carlos Gil Ferreira</td>
<td>Brazil</td>
</tr>
<tr>
<td>Andrea Ferris</td>
<td>USA</td>
</tr>
<tr>
<td>John Field</td>
<td>UK</td>
</tr>
<tr>
<td>Pier Luigi Filosso</td>
<td>Italy</td>
</tr>
<tr>
<td>Kwun Fong</td>
<td>Australia</td>
</tr>
<tr>
<td>Jesme Fox</td>
<td>UK</td>
</tr>
<tr>
<td>Janet Freeman-Daily</td>
<td>USA</td>
</tr>
<tr>
<td>Leena Gandhi</td>
<td>USA</td>
</tr>
<tr>
<td>Edward Garon</td>
<td>USA</td>
</tr>
<tr>
<td>Pilar Garrido</td>
<td>Spain</td>
</tr>
<tr>
<td>Laurie Gaspar</td>
<td>USA</td>
</tr>
<tr>
<td>David Gerber</td>
<td>USA</td>
</tr>
<tr>
<td>Giuseppe Giaccone</td>
<td>USA</td>
</tr>
<tr>
<td>Nicolas Girard</td>
<td>France</td>
</tr>
<tr>
<td>Meredith Giuliani</td>
<td>Canada</td>
</tr>
<tr>
<td>John Goffin</td>
<td>Canada</td>
</tr>
<tr>
<td>Sarah Goldberg</td>
<td>USA</td>
</tr>
<tr>
<td>Daniel Gomez</td>
<td>USA</td>
</tr>
<tr>
<td>Ramaswamy Govindan</td>
<td>USA</td>
</tr>
<tr>
<td>Tomasz Grodzki</td>
<td>Poland</td>
</tr>
<tr>
<td>Harry Groen</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Matthias Guckenberger</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Maria Guerin</td>
<td>USA</td>
</tr>
<tr>
<td>Rui Haddad</td>
<td>Brazil</td>
</tr>
<tr>
<td>Gerard Hanna</td>
<td>UK</td>
</tr>
<tr>
<td>Waël Hanna</td>
<td>Canada</td>
</tr>
<tr>
<td>Desiree Hao</td>
<td>Canada</td>
</tr>
<tr>
<td>Kazuo Hasegawa</td>
<td>Japan</td>
</tr>
<tr>
<td>Seiki Hasegawa</td>
<td>Japan</td>
</tr>
<tr>
<td>Felix Herth</td>
<td>Germany</td>
</tr>
<tr>
<td>Cheryl Ho</td>
<td>Canada</td>
</tr>
<tr>
<td>Patricia Hollen</td>
<td>USA</td>
</tr>
<tr>
<td>Leora Horn</td>
<td>USA</td>
</tr>
<tr>
<td>Jie Hu</td>
<td>China</td>
</tr>
<tr>
<td>Rina Hui</td>
<td>Australia</td>
</tr>
<tr>
<td>Rayjean Hung</td>
<td>Canada</td>
</tr>
<tr>
<td>David Hwang</td>
<td>Canada</td>
</tr>
<tr>
<td>Norihiko Ikeda</td>
<td>Japan</td>
</tr>
<tr>
<td>Masaoki Ito</td>
<td>Japan</td>
</tr>
<tr>
<td>Pasi Jänne</td>
<td>USA</td>
</tr>
<tr>
<td>Jacek Jassem</td>
<td>Poland</td>
</tr>
<tr>
<td>Thomas John</td>
<td>Australia</td>
</tr>
<tr>
<td>David Jones</td>
<td>USA</td>
</tr>
<tr>
<td>Rosalyn Juergens</td>
<td>Canada</td>
</tr>
<tr>
<td>Ronan Kelly</td>
<td>USA</td>
</tr>
<tr>
<td>Keith Kerr</td>
<td>USA</td>
</tr>
<tr>
<td>Biniam Kidane</td>
<td>Canada</td>
</tr>
<tr>
<td>Hojoong Kim</td>
<td>Korea</td>
</tr>
<tr>
<td>Yoshihisa Kobayashi</td>
<td>Japan</td>
</tr>
<tr>
<td>Feng-Ming (Spring) Kong</td>
<td>USA</td>
</tr>
<tr>
<td>Robert Korst</td>
<td>USA</td>
</tr>
<tr>
<td>Mark Kris</td>
<td>USA</td>
</tr>
<tr>
<td>Catherine Labbe</td>
<td>Canada</td>
</tr>
<tr>
<td>Pippa Labuc</td>
<td>USA</td>
</tr>
<tr>
<td>Wan Lam</td>
<td>Canada</td>
</tr>
<tr>
<td>Stephen Lam</td>
<td>Canada</td>
</tr>
<tr>
<td>Sylvie Lantuejoul</td>
<td>France</td>
</tr>
<tr>
<td>Janessa Laskin</td>
<td>Canada</td>
</tr>
<tr>
<td>Scott Laurie</td>
<td>Canada</td>
</tr>
<tr>
<td>Christopher Lee</td>
<td>Canada</td>
</tr>
<tr>
<td>Tatiane Montella</td>
<td>Brazil</td>
</tr>
<tr>
<td>Andre Moreira</td>
<td>USA</td>
</tr>
<tr>
<td>Francoise Mornex</td>
<td>France</td>
</tr>
<tr>
<td>Septimiu Murgu</td>
<td>USA</td>
</tr>
<tr>
<td>Jarushka Naidoo</td>
<td>USA</td>
</tr>
<tr>
<td>Yuko Nakayama</td>
<td>Japan</td>
</tr>
<tr>
<td>Neal Navani</td>
<td>UK</td>
</tr>
</tbody>
</table>
# International Abstract Review Committee

Massey Nematollahi, Canada  
Garth Nicholas, Canada  
Andrew Nicholson, UK  
Kim Norris, USA  
Nazanin Nouriyan, Canada  
Silvia Novello, Italy  
Anna Nowak, Australia  
Mary O’Brien, UK  
Yuichiro Ohe, Japan  
Meinooshin Okumura, Japan  
Isabelle Opitz, Switzerland  
Raymond Osarogiagbon, USA  
Jamie Ostroff, USA  
Taofeek Owonikoko, USA  
Sukhmani Padda, USA  
David Palma, Canada  
Vali Papadimitrakopoulou, USA  
Keunchil Park, Korea  
Giulia Pasello, Italy  
Harvey Pass, USA  
Demetris Patsios, Canada  
Nick Pavlakis, Australia  
Nir Peled, Israel  
Maurice Pérol, France  
Zofia Piotrowska, USA  
Claudia Poleri, Argentina  
Katerina Politi, USA  
You-lin Qiao, China  
Elisabeth Quoix, France  
Luis Raez, USA  
Suresh Ramalingam, USA  
Ramon Rami-Porta, Spain  
Martin Reck, Germany  
Karen Reckamp, USA  
Noemi Reguart, Spain  
David Rice, USA  
Gregory Riely, USA  
Andreas Rimner, USA  
Naiyer Rizvi, USA  
Andrew Robinson, Canada  
Gaetano Rocco, Italy  
Anja Roden, USA  
Christian Rolfo, USA  
Kenneth Rosenzweig, USA  
Charles Rudin, USA  
Adrian Sacher, Canada  
Tomohito Saito, Japan  
Joseph Salama, USA  
Montse Sanchez-Cespedes, Spain  
Randeep Sangha, Canada  
Edgardo Santos, USA  
Toshiyuki Sawa, Japan  
Heidi Schmidt, Canada  
Suresh Senan, Netherlands  
Boris Sepezi, USA  
Lecia Sequist, USA  
Frances Shepherd, Canada  
Lynette Sholl, USA  
Navneet Singh, India  
Christina Sit, Canada  
Ben Slotman, Netherlands  
Egbert Smit, Netherlands  
Ben Solomon, Australia  
Ross Soo, Singapore  
David Spigel, USA  
Sadeesh Srinathan, Canada  
Matthew Steliga, USA  
Emily Stone, Australia  
Kenji Suzuki, Japan  
Martin Tammemägi, Canada  
Daniel Tan, Singapore  
Kevin ten Haaf, Netherlands  
Erik Thunnissen, Netherlands  
Betty Tong, USA  
William Travis, USA  
Ming Tsao, Canada  
Luis Uribles, Uruguay  
Paula Ugalde, Canada  
Yee Ung, Canada  
Eric Vallieres, USA  
Paul Van Schil, Belgium  
Diane Zawisza, Canada  
Li Zhang, China  
Qing Zhou, China  
Mauro Zukin, Brazil  
Johan Vansteenkiste, Belgium  
Heather Wakelee, USA  
David Waller, UK  
Jie Wang, China  
Shun-ichi Watanabe, Japan  
Maria Werner-Wasik, USA  
Howard (Jack) West, USA  
Paul Wheatley-Price, Canada  
Ignacio I. Wistuba, USA  
Yi-Long Wu, China  
Murry Wynes, USA  
Nise Yamaguchi, Brazil  
Pan-Chyr Yang, Taiwan  
Kazuhiro Yasufuku, Canada  
Yasushi Yatabe, Japan  
Jonathon Yeung, Canada  
Masaya Yotsukura, Japan  
Diane Zawisza, Canada  
Li Zhang, China  
Qing Zhou, China  
Mauro Zukin, Brazil
Thank you, IASLC members!

To our members...

Thank you for your IASLC membership and dedication to conquering lung cancer and other thoracic malignancies.

Visit the IASLC Booth (#100) in the Exhibit Hall to renew, confirm account details and pick up your member appreciation gift!

IASLC member benefits include:

• Collaboration with thoracic oncology experts and thought leaders across all disciplines
• Access to the Journal of Thoracic Oncology, the premier journal in lung cancer
• Multidisciplinary education including the latest in groundbreaking research, treatment and standard of care

Come see us at the IASLC Booth in the Exhibit Hall (Monday-Wednesday) or at the IASLC Membership Booth in the registration area (Saturday and Sunday).
Visit the IASLC’s Social Media Hub on Level 300 & JOIN THE CONVERSATION!

- **View live feeds** from Twitter and Instagram on large screens
- **Take your photo** in front of our special Niagara Falls backdrop (select country flags or signs as props)
- **Learn how to post** on social media (we’ll walk you through it!)
- Pick up our **social media tip sheet**

Remember to use the official hashtag: #WCLC2018
SECTION 3

General Conference Information

TAKE ACTION Against Lung Cancer!
REGISTRATION

HOURS OF OPERATION:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, September 22</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, September 23</td>
<td>06:30 – 20:00</td>
</tr>
<tr>
<td>Monday, September 24</td>
<td>06:30 – 15:30</td>
</tr>
<tr>
<td>Tuesday, September 25</td>
<td>06:30 – 15:30</td>
</tr>
<tr>
<td>Wednesday, September 26</td>
<td>06:30 – 15:30</td>
</tr>
</tbody>
</table>

Registration Materials

Registration Materials include:

- Name Badge including barcode for ticketed sessions
- Ribbons (if applicable)
- Abstract USB Stick
- Mini Pocket Program
- Tickets for Networking Events

Delegate Bags include:

- Printed Conference Program (only if printed version selected)
- Printed Abstract Book (only if printed version selected)
- Invitation Flyers for Industry Supported Symposia
- Additional Promotional Flyers from Sponsors and Exhibitors
- IASLC Information/Folder
- International Lung Cancer News
- Notepad
- Pen

Name Badges

Delegates and guests are requested to wear their name badge at all times in order to participate in the Scientific Sessions, Networking Events and Exhibition.
PRESS AND MEDIA

Press and Media Registration and Access
Press and Media passes are issued to journalists, including photographers and freelance journalists, after providing proof of accreditation. Pre-registered Press and Media representatives are required to check in at the regular Registration Counters. Non-registered Press and Media representatives should proceed to the New Registration counter.

Interview Policy
All interviews outside of press conferences must be arranged in advance with interviewees and must take place in IASLC approved and designated rooms. No last-minute or hallway interviews are permitted anywhere inside the conference facility. The IASLC provides designated complimentary interview rooms (Back of Exhibit Hall (Behind Posters)) for up to two hours. Sign up is required (online via http://wclc2018.iaslc.org/press-media/press-media/ or onsite in the Media Room, Back of Exhibit Hall (Behind Posters)). For questions, please see the IASLC staff in the Media Room.

Use of the IASLC WCLC Scientific Program Content
Please be aware that the information and materials displayed and/or presented at all sessions of this meeting are the property of the IASLC World Conference on Lung Cancer. Members of the media are permitted to photograph or record and transmit/share any presentation’s slides without approval from the presenter and/or the IASLC unless explicitly forbidden. All information distributed must adhere to the IASLC’s embargo policy. Commercial firms cannot copy, photocopy, transform to electronic format, reproduce or distribute information or materials displayed at this meeting without the written permission of the International Association for the Study of Lung Cancer. Use of the WCLC/IASLC name and/or logo in any fashion by any commercial entity for any purpose is expressly prohibited without the express written permission of the International Association for the Study of Lung Cancer.

Interviews conducted through photography, videotaping and audio recording are allowed for news coverage only in the following areas/events:
- Press Conferences
- Interview rooms
- Other designated locations
- Recording in common areas requires permission and/or an IASLC staff escort

Copyright
Reproduction of materials such as abstract data, posters, presentation slides, etc., requires first obtaining permission from the listed author(s) and/or presenter(s). Photography of sessions, trade show booths, event setup, etc. is prohibited by IASLC/WCLC. The WCLC has a designated staff photographer and can provide WCLC 2018 event photography for journalists who wish to run photos of the event in their given media.

Please contact Becky Bunn, IASLC Public Relations Manager at Becky.Bunn@iaslc.org for any press and media related questions.

Social Media Policy
Organizations may use social media to disseminate news and information regarding abstracts being presented at the WCLC. All information distributed through social media channels must adhere to the IASLC’s embargo policy. Organizations promoting their research through Twitter are welcome to include the IASLC’s World Conference hashtag, #WCLC2018. Members of the media are permitted to photograph or record and transmit/share on any social media platform any presentation’s slides without approval from the presenter and/or the IASLC unless explicitly forbidden. Representatives from academic institutions are permitted to share slides, but not for the media to re-transmit. Only non-flash photography is allowed of slide presentations.

For complete guidelines and media policies please refer to the Conference website at wclc2018.iaslc.org/press-media/press-media/
The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. JTO emphasizes a multidisciplinary approach, and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.

To subscribe visit jto.org

A subscription to JTO is a benefit of membership in the IASLC. To join, visit www.IASLC.org.
The IASLC Foundation awards research fellowships and young investigator grants across the globe to the next generation of lung cancer physicians, scientists and researchers.

IASLC fellowships and young investigator grants are awarded for one year. The IASLC Foundation also offers larger research grants through partnerships with like-minded organizations.

For more information visit www.iaslc.org/foundation
INFORMATION FOR INVITED FACULTY AND ABSTRACT PRESENTERS

DISCLOSURE INFORMATION
All invited speakers as well as oral and mini oral abstract presenters must include a slide with their financial disclosure information. **Without a disclosure slide you will not be allowed to present!**

PRESENTATION SLIDE TEMPLATE
All invited speakers as well as oral and mini oral abstract presenters are asked to use the IASLC/WCLC presentation slide template for their presentation.

Registration

**INVITED FACULTY** – ‘Invited Faculty’ Registration Counter (Session Chairs, Invited Speakers, Abstract Discussants)

**ABSTRACT PRESENTERS** – ‘Registered Delegate’ Counter

Speaker Preview Centre

MTCC North Building, Street Level 200, Room 204

All invited speakers as well as oral and mini oral abstract presenters are required to report to the Speaker Preview Centre at least 24 hours prior to their scheduled presentation in order to upload their presentation slides or to check their previously uploaded slides.

**NO FILE SUBMISSIONS WILL BE ACCEPTED IN THE SESSION ROOMS.**

Computers are available to preview and upload presentations. Presenters should make sure all fonts appear as expected and all sound/video clips are working properly. The final version must be submitted to the Speaker Preview Centre, no presentation submissions will be accepted in the Session Rooms.

PIN YOUR COUNTRY

Be sure to pin your country on our giant world map in the registration area on Level 200.

Check back each day to see how many countries are filled in!
SPEAKER PREVIEW CENTRE

MTCC North Building, Street Level 200, Room 204

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, September 22</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, September 23</td>
<td>06:30 – 20:00</td>
</tr>
<tr>
<td>Monday, September 24</td>
<td>06:30 – 16:00</td>
</tr>
<tr>
<td>Tuesday, September 25</td>
<td>06:30 – 16:00</td>
</tr>
<tr>
<td>Wednesday, September 26</td>
<td>06:30 – 15:00</td>
</tr>
</tbody>
</table>

Oral Abstract Presenters

- You will have a total of 10 minutes; 8 minutes of presentation, followed by 2 minutes time for questions from the audience. Time limits will be strictly enforced.
- You are asked to prepare a PPT Presentation with maximum 10 slides (not including title and disclosure slide).
- Please be in room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.
- All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.

Mini Oral Presenters

- You will have a total of 5 minutes (no Q&A). Time limits will be strictly enforced.
- Please be in room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.
- You are asked to prepare a PPT Presentation with maximum 6 slides (not including title and disclosure slide).
- All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.

Poster Presenters

All Poster Presentations/Boards are located in the Exhibit Hall on Level 300 and each Poster Board is identified with a Poster Number, which corresponds with the pre-assigned Poster Number provided in your confirmation letter and printed in the Abstract Book and this Conference Program.

P1: Poster Session 1  Sunday, September 23
P2: Poster Session 2  Monday, September 24
P3: Poster Session 3  Tuesday, September 25
Wednesday, September 26

POSTER DISPLAY TIME

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, September 24</td>
<td>09:30 – 18:30</td>
</tr>
<tr>
<td>Tuesday, September 25</td>
<td>09:30 – 18:30</td>
</tr>
<tr>
<td>Wednesday, September 26</td>
<td>09:30 – 13:30</td>
</tr>
</tbody>
</table>

PRESENTERS IN ATTENDANCE

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, September 24</td>
<td>16:45 – 18:00</td>
</tr>
<tr>
<td>Tuesday, September 25</td>
<td>16:45 – 18:00</td>
</tr>
<tr>
<td>Wednesday, September 26</td>
<td>12:00 – 13:30</td>
</tr>
</tbody>
</table>

Poster Viewing Receptions: Poster Presenters will be in attendance at their Poster

NEW Poster Viewing Receptions

A new feature introduced at WCLC2018 are the Poster Viewing Receptions. On Monday and Tuesday afternoon as well as on Wednesday during lunch you will be able to enjoy complimentary drinks and snacks while interacting with the presenters.

Poster Printing Service

If you have ordered to have your poster printed by the Conference at an additional charge, you may pick up your poster onsite.

POSTER PICK UP

MTCC North Building, Level 300, Exhibit Hall

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, September 24</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Tuesday, September 25</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Wednesday, September 26</td>
<td>08:00 – 12:00</td>
</tr>
</tbody>
</table>
section subsection text
• Evaluate the support and survivorship resources available for lung cancer patients and their families.
• Illustrate important aspects of clinical trial design and master protocols.
• Explain to more junior investigators and students on research and technology advances, and encourage them to initiate investigations in lung cancer research.

OFFICIAL LANGUAGE
The official language of the IASLC 19th World Conference on Lung Cancer is English.

DISCLAIMER
The information presented at the IASLC 19th World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

HOW TO RECEIVE YOUR CME CREDIT
A conference electronic evaluation form will be emailed to learners after the Conference and will be available on the Conference website. Participants that wish to receive CME credits will have to complete the online evaluation form in order to receive their CME certificate. CME credits will only be provided for the sessions that learners have attended. The CME certificate will be ready for you to print or save upon completion. This information is used not only to evaluate the present activity, but also to plan for future programs. Your opinion is very valuable!

No commercial support was provided to fund this live activity.

CALLING ALL ADVOCATES!
Be sure to visit the Patient Advocacy Lounge in the Exhibit Hall
• Network with other patients, survivors, caregivers and advocates
• Relax on a comfy couch and catch up on email
• Share your photos on social media using the official hashtag: #WCLC2018
• Enjoy a cup of coffee and snacks

ADVOCACY LOUNGE HOURS:
Monday
09:30-18:30
Tuesday
09:30-18:30
Wednesday
09:30-14:00
**ONSITE SERVICES AND GENERAL INFORMATION**

**IASLC WCLC 2018 OFFICIAL MOBILE APP**

Download the free IASLC WCLC 2018 mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan and exhibitor biographies, and general Conference and venue information on our easy to use app!

The app is compatible with all iOS devices (iPhone, iTouch and iPad) and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts.

**NEW INTERACTIVE AUDIENCE RESPONSE TOOL**

**TAKE ACTION** at IASLC WCLC 2018 and play an active role during the sessions by using the newly introduced interactive audience response tool. Accessible through the Conference mobile app, each session will have a link to a very simple and easy to use system that will allow you to respond to poll questions, provide valuable feedback and even ask questions, all in real time!

Be engaged and enhance your learning and experience by using this new interactive tool!

**JOIN THE CONVERSATION – IASLC WCLC 2018 OFFICIAL SOCIAL MEDIA ACCOUNTS**

The IASLC Social Media Corner is back and better! Plan to stop by the IASLC Social Media Corner on Level 300 of the MTCC North Building (at the top of the escalators) as often as you like during the Conference — there will always be something going on. Not social media savvy? No problem. We’re here to help!

**Here’s what’s happening:**
- View live feeds from Twitter, Instagram and Facebook
- Take your photo in front of our special Niagara Falls backdrop and our hashtag in 3D
- Learn how to post on social media
- Get your free gift

**IASLC WCLC 2018 VIRTUAL MEETING**

All audio and webcast recordings including presentations, abstracts and electronic versions of most posters will be available in the Virtual Meeting within 24 hours. Check your name badge for login details.

**IASLC SOCIAL MEDIA ACCOUNTS TO FOLLOW:**

- @iaslc
- iaslclung
- IASLC
- facebook.com/iaslc
- YouTube IASLC

**CONFERENCE HASHTAG: #WCLC2018**
ABSTRACTS

Abstracts selected for IASLC WCLC are presented in Oral, Mini Oral and Poster Sessions. The top five abstracts featuring practice-changing abstracts will be presented in the Presidential Symposium on Tuesday, September 25, 08:15-09:45.

All accepted and confirmed abstracts are published in a supplement of the Journal of Thoracic Oncology, which will be posted online on the JTO website in December 2018.

All accepted and confirmed abstracts except for those included in Press Releases and/or Press Conferences are also available on the Abstract USB Stick which is handed out along with your delegate bag. If you requested a printed version of the Abstract Book, please pick it up along with your delegate bag.

ABSTRACTS ONLINE

Attendees are invited to view the abstracts in the Virtual Meeting available on the Conference website. The Virtual Meeting allows searching for abstracts, topics, presenters, sessions and keywords, selecting abstracts of interest and building your own personal conference calendar. It is free for all WCLC delegates.

GET THE WCLC 2018 VIRTUAL MEETING AT library.iaslc.org

All accepted abstracts are also included in the WCLC 2018 Mobile App.

ATM

There are seven ATM machines located throughout the complex: four located on Level 200 in the North Building, one on Level 600 and two on Level 800 in the South Building.

BAGGAGE CHECK

See coat check

BREAKFAST

The Conference does NOT provide breakfast except for the Meet the Expert Sessions (Monday – Wednesday 07:00 – 08:00) or otherwise indicated in the program.

BUSINESS CENTER

MTCC North Building, Level 300

Monday – Friday 08:00 – 17:00

Services include photocopying, faxing, printing, outbound courier service, Internet access and a selection of office supplies and tools for purchase.

Phone: (416) 585-8387
Email: businesscentre@mtccc.com

CELL PHONES

As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

CERTIFICATE OF ATTENDANCE

International attendees can request a Certificate of Attendance by completing the Conference evaluation form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your Certificate of Attendance.

Exhibitors and Sponsors may scan your badge when you visit their booth or symposium. By allowing them to scan your badge you give consent to WCLC and IASLC to share your contact details with the respective sponsors and exhibitors. You may decline to have your badge scanned but will still be able to attend the Symposium.

CHARGING STATIONS

Exhibit Hall Lounges

Charging Stations are available to delegates to power up their cell phones, iPads and other electronic devices for free.

CME ACCREDITATION AND CME CERTIFICATE

This activity is planned for 25 AMA PRA Category 1 Credit(s)™. Please see page 40 in this book for further information.

International attendees can request a ‘CME Certificate’ by completing the Conference Evaluation Form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your CME Certificate.

Delegates will receive credits based on the sessions they attended. This year the badges have been encoded with RFID Technology and floor mat readers have been installed at the entrance of the official CME accredited session rooms. Attendance data will be recorded automatically as delegates enter and exit the rooms.

IMPORTANT NOTE

Exhibitors and Sponsors may scan your badge when you visit their booth or symposium. By allowing them to scan your badge you give consent to WCLC and IASLC to share your contact details with the respective sponsors and exhibitors. You may decline to have your badge scanned but will still be able to attend the symposium.

COAT AND BAGGAGE CHECK

MTCC North Building, Street Level 200, Registration Area

Wednesday, Sept. 26 06:30 – 17:00

ACCREDITATION

See CME Certificate

ATTIRE

Business casual is appropriate for all sessions and networking events. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

GET THE WCLC 2018 VIRTUAL MEETING AT library.iaslc.org

All accepted abstracts are also included in the WCLC 2018 Mobile App.

CELL PHONES

As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

CERTIFICATE OF ATTENDANCE

International attendees can request a Certificate of Attendance by completing the Conference evaluation form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your Certificate of Attendance.

Exhibitors and Sponsors may scan your badge when you visit their booth or symposium. By allowing them to scan your badge you give consent to WCLC and IASLC to share your contact details with the respective sponsors and exhibitors. You may decline to have your badge scanned but will still be able to attend the Symposium.

COAT AND BAGGAGE CHECK

MTCC North Building, Street Level 200, Registration Area

Wednesday, Sept. 26 06:30 – 17:00

ATM

There are seven ATM machines located throughout the complex: four located on Level 200 in the North Building, one on Level 600 and two on Level 800 in the South Building.

BAGGAGE CHECK

See coat check

BREAKFAST

The Conference does NOT provide breakfast except for the Meet the Expert Sessions (Monday – Wednesday 07:00 – 08:00) or otherwise indicated in the program.

BUSINESS CENTER

MTCC North Building, Level 300

Monday – Friday 08:00 – 17:00

Services include photocopying, faxing, printing, outbound courier service, Internet access and a selection of office supplies and tools for purchase.

Phone: (416) 585-8387
Email: businesscentre@mtccc.com

CELL PHONES

As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

CERTIFICATE OF ATTENDANCE

International attendees can request a Certificate of Attendance by completing the Conference evaluation form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your Certificate of Attendance.

Exhibitors and Sponsors may scan your badge when you visit their booth or symposium. By allowing them to scan your badge you give consent to WCLC and IASLC to share your contact details with the respective sponsors and exhibitors. You may decline to have your badge scanned but will still be able to attend the Symposium.

COAT AND BAGGAGE CHECK

MTCC North Building, Street Level 200, Registration Area

Wednesday, Sept. 26 06:30 – 17:00

ACCREDITATION

See CME Certificate

ATTIRE

Business casual is appropriate for all sessions and networking events. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.
ONSITE SERVICES AND
GENERAL INFORMATION

DELEGATE LOUNGES

MTCC North Building, Level 300, Exhibit Hall

Delegate Lounges are specifically designed to provide a comfortable seating area for delegates to rest, conduct brief meetings or network with colleagues.

• IASLC Membership Lounge
  Reserved for IASLC Members

• Delegate Lounge

• Patients Advocacy Lounge

EMERGENCY SERVICES AND FIRST AID

MTCC North Building, Level 200, beside Room 203 C

For fire and medical emergencies, the direct number to MTCC Security is (416) 585-8160 or 8160 from the nearest house phone. DO NOT CALL 911 as responding emergency personnel (police, ambulance, and fire department) will be unaware of the precise location required. Emergency numbers are posted at all house phones. MTCC does not have a notification system for hearing or visually impaired attendees.

IASLC Business Meeting

MTCC North Building, Street Level 200, 202 BD

Tuesday, Sept. 25 17:00 – 18:00

All IASLC Members are invited to attend the IASLC Business Meeting. Light refreshments will be provided. IASLC WCLC Travel and Advocacy Award Winners will be presented with their award.

IASLC Booth

MTCC North Building, Level 300, Exhibit Hall, Booth #100

Please visit the IASLC Booth (#100) in the Exhibit Hall for updates on membership, society-sponsored meetings and events, the IASLC Foundation, JTO and general information.

IASLC Social Media Booth

MTCC North Building, Level 300, Exhibit Hall (at top of main escalators)

Please visit the IASLC Social Media Booth and share your WCLC experience with us.

IASLC World Map

MTCC North Building, Street Level 200, Registration Area

Be sure to pin your country on our giant world map in the Registration Area, Street Level 200. Check back each day to see how many countries have filled in.

IASLC Tobacco Exhibition

MTCC North Building, Level 300, Exhibit Hall (at top of main escalators)

Don’t miss out to visit our two Tobacco Exhibits in the Exhibit Hall right at the top of the escalators.

• Evolving Cigarette
  The Evolving Cigarette explores the cigarette, its origins, variations, nicotine delivery, marketing, and inventions that support smoking.

• Flight Attendants’ Fight to End Smoking Aloft (FAMRI)
  This exhibit documents the history of smoking on commercial aircraft, highlights tobacco marketing that capitalized on the romance of flight, and the historic push by flight attendants to rid airline cabins of tobacco smoke.

INTERNET CAFÉ

MTCC North Building, Level 300, Exhibit Hall - attached to the Exhibit Showcase Theater

Keep in touch with home and office! Computers with internet and printers are available to delegates on a complimentary basis. The Internet Cafe is open during Exhibit Hall Hours. Internet sessions are limited to 15 minutes per delegate.

LOST AND FOUND

Lost and found articles are catalogued and stored for 90 days. After this period, all articles are disposed of at the sole discretion of the MTCC. Any inquiries regarding lost and found articles should be directed to the MTCC’s Security Services at (416) 585-8360.

MEDIA ROOM

MTCC North Building, Level 300, Back of Exhibit Hall (Behind Posters)

Wireless internet and a copier are available. Please see page 35 in this brochure for further information.

NEWSPAPER

A daily Conference Newspaper will be available from Sunday to Wednesday at no charge to Conference delegates. The Newspaper will be distributed at various points at the MTCC North Building. A PDF version of each edition will also be available on the Conference website.

OVERFLOW VIEWING AREAS

While the Committee has done their best to guess which sessions will be most popular, we expect some session rooms to be small with record WCLC attendance this year. Overflow Viewing Areas have been set up in the back of the Exhibit Hall. Headsets will be provided; however, a piece of ID will be required which will be given back once you return the headsets. You may use your own headsets.

PARKING

The MTCC has 1,700 indoor parking spaces between the North and South Buildings. Express-Pay (credit card) parking makes getting into and out of the parking garage a breeze! Visa, MasterCard and Amex are accepted in parking as well as cash.

Day Maximum (over 2.5 hrs): $27.00
24 hr Maximum: $32.00
**POSTERS ONLINE**

All abstracts accepted for poster presentation will be presented as traditional printed posters to be displayed on poster boards in the Exhibit Hall. In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the Virtual Meeting ([library.iaslc.org](http://library.iaslc.org)), which is free of charge to all delegates.

**PRESS**

Please see page 35 in this brochure for further information.

**PUBLIC TRANSPORTATION**

We strongly recommend that you take public transportation whenever possible. Toronto offers modern and efficient public transportation networks. For assistance, please visit the Delegate Help Desk in the MTCC North Building on Level 200.

**UP Express Airport Train**

UP Express connects Toronto Pearson International Airport to Union Station in the heart of downtown Toronto in just 25 stress-free minutes—less than half the time it often takes by car. Trains leave every 15 minutes with the first train departing Pearson Station at 05:27 and the last train departing at 00:57. There’s no easier or more convenient way to get to or from Toronto Pearson.

**RESTAURANTS**

There are plenty of restaurants choices in Toronto and within walking distance from the MTCC. The staff at the Delegate Help Desk will be happy to assist with recommendations and bookings.

**SMOKING**

The Metro Toronto Convention Centre is a smoke-free environment. All public areas, rental space, corridors, loading docks, exhibit halls and parking lots are designated non-smoking. In addition, 9 meters (30 ft) surrounding any entrance and exit, is designated as non-smoking areas. Electronic cigarettes are prohibited. The MTCC is required to enforce the no-smoking rules.

**SPEAKER PREVIEW CENTRE**

All Presenters are required to submit and/or preview their slides at least 24 hours prior to their scheduled presentation to ensure compatibility with the Conference AV Equipment.

**VIRTUAL MEETING**

All oral sessions are recorded (slides and audio) and will be made available as a Virtual Meeting through the IASLC Virtual Meeting within 24 hours.

The WCLC 2018 Virtual Meeting is included in your registration and can be accessed through [library.iaslc.org](http://library.iaslc.org).

Your personal Virtual Meeting Access Code is the same as your Delegate ID Number and can be found on your badge or through your WCLC 2018 confirmation email. After you enter your Access Code and confirm your account details, you will be able to view any presentations that have been marked as “Now Available”.

To start viewing, please visit: [library.iaslc.org](http://library.iaslc.org)

**WIRELESS INTERNET**

WCLC is providing free Premium Attendee Wireless Internet Access throughout the MTCC North Building.

Each user is allotted a download speed of 3 Mbps and an upload speed of 3 Mbps. This service is suited for attendee general usage such as checking e-mail, social media and web surfing. Users are restricted from Virtual Private Networks (VPN), Remote Desktop Protocols (RDP) and peer to peer protocols.

Wireless network is optimized to be used by devices operating in the 5GHz radio band (802.11 a/n/ac). Although the service will be offered in the 2.4GHz radio band (802.11 g/n) the service is provided best effort due to the high levels of contention and interference present on the radio band.

To connect to the Wi-Fi, connect to

Network: IASLC-WCLC 2018  
password: takeaction

**Disclaimer**

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.
Now Calling for International Participation

Contribute data to the IASLC 9th Edition Lung Cancer Staging Project

Help change the landscape of lung cancer treatment for future patients!

- New clinical and molecular elements have been added
- International participation is crucial to the project’s success
- The 9th Edition recommendations will be developed in 2022

For more information: www.iaslc.org/staging

**TIMELINE:**
The study consists of lung cancer patients diagnosed between January 1, 2011 and December 31, 2019. Cases may be submitted through 2019, with follow-up for survival through 2021.
SECTION 4

IASLC and Conference Awards

TAKE ACTION
Against Lung Cancer!
Charles Swanton, USA

Charles completed his MDPhD training in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. Charles combines his laboratory research at the Francis Crick Institute with clinical duties at UCLH as director of the CRUK UCL Lung Cancer Centre, focussed on how tumours evolve over space and time. Charles has helped to define the branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome.

Charles was made Fellow of the Royal College of Physicians in April 2011 and appointed Fellow of the Academy of Medical Sciences in 2015. Charles was awarded the Stand up to Cancer Translational Cancer Research Prize (2015), Glaxo Smithkline Biochemical Society Prize (2016), San Salvatore prize for Cancer Research (2017) and the Ellison-Cliffe Medal, Royal Society of Medicine (2017). Charles was appointed Napier Professor in Cancer by the Royal Society in 2016. Charles was elected EMBO member and was appointed the Cancer Research UK Chief Clinician in 2017 and elected a Fellow of the Royal Society in 2018.
Francoise Mornex, France

Dr. Mornex is a Professor of Oncology at the University Claude Bernard in Lyon, France, and chair of the Radiation Oncology Department at the Centre Hospitalier Lyon Sud, where she practices medical oncology and radiation. Dr. Mornex’s work is focused in the field of combined chemoradiation, where she has assumed a leadership role in the development of multi-modal treatment for lung and digestive tract tumors. Her current research interests include the development of new chemoradiation treatments and the design of phase I, II and III randomized trials.

Dr. Mornex joined the IASLC in 1987 and served on its Board of Directors from 2013-2017. She has organized many national and international meetings, including multiple IASLC lung cancer workshops. She was the co-president of the highly successful first and second European IASLC-ESMO lung cancer conferences in Geneva in 2008 and 2010. She is the general secretary and a member of the French Radiation Oncology Society (SFRO), as well as a member of the American Society for Therapeutic Radiology and Oncology (ASTRO), among others. An accomplished scientist, Dr. Mornex has published over 230 articles, two books and several book chapters on lung cancer.
FADLO KHURI, USA

Fadlo R. Khuri, MD is the 16th president of the American University of Beirut. He was elected in March 2015 and assumed office in September 2015. He was Professor and Chairman of the Department of Hematology and Medical Oncology, Emory University School of Medicine, and held the Roberto C. Goizueta Distinguished Chair for Cancer Research. He also served as Deputy Director for the Winship Cancer Institute of Emory University. Dr. Khuri was also the Executive Associate Dean for Research of the Emory University School of Medicine.

Dr. Khuri was born in Boston, MA and brought up in Beirut, where he attended the American University of Beirut from 1981-82. He moved to the US in 1982, and earned his bachelor’s degree from Yale University, in New Haven, CT, and his MD from Columbia University, College of Physicians and Surgeons, in New York, NY. He completed his residency in Internal Medicine at the Boston City Hospital, Boston, MA, and his fellowship in Hematology and Medical Oncology at the Tufts-New England Medical Center. He was on faculty at the U.T. M.D. Anderson Cancer Center from 1995-2002 prior to joining Emory University and the Winship Cancer Institute (Winship) in 2003.

An accomplished molecular oncologist and translational thought leader, Dr. Khuri’s clinical expertise and research are focused on the development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with lung and aerodigestive cancers. He has conducted seminal research on oncolytic viral therapy, developed approaches to integrate molecularly targeted therapies by combining signal transduction inhibitors with chemotherapy, pioneered novel induction and window of opportunity trials, and led major cooperative group chemoprevention efforts for these cancers. His laboratory group investigates mechanisms of action of signal transduction inhibitors in lung and aerodigestive track cancers based on the selective activation of certain signaling networks.

Dr. Khuri has published over 300 peer reviewed articles, including papers in Nature Medicine, the New England Journal of Medicine, Journal of the National Cancer Institute, Journal of Clinical Oncology, Cancer, Cancer Research, Clinical Cancer Research, Science Signaling, and the Journal of Clinical Investigation. His work has been cited over 15,000 times and his h-factor is 64. He serves as Editor-in-Chief of Cancer, the oldest and one of the most prestigious journals in the field, having served on more than a dozen prior editorial boards of major journals. Dr. Khuri has also served as a permanent member of multiple peer review committees for the American Cancer Society, American Society of Clinical Oncology, and the NCI, including currently serving as the Chair of the NIH’s Clinical Oncology Study Section. He is an active member of the American Association for Cancer Research (AACR), the International Association for the Study of Lung Cancer, the American Society for Clinical Investigation, and the American Society of Clinical Oncology.

Dr. Khuri’s work has been recognized with several major awards, including the 2006 Nagi Sahyoun Award of the Middle East Medical Assembly for “research that has changed the way we think about and treat lung and head and neck cancer”, the 2010 Waun Ki Hong Distinguished Professorship by the University of Texas MD Anderson, and the 2013 Richard and Hinda Rosenthal Memorial Award from the AACR for “his pioneering work in developing oncolytic viruses, signal transduction inhibitors, and biomarker based chemoprevention approaches to lung and aerodigestive cancers.” In 2013, Khuri was also recognized with the Arab American High Achievers (AAHA) Award by the Alif Society, the major Arab Cultural Foundation of Georgia. He is an elected member of the American Society for Clinical Investigation (2007), and a Fellow of the American College of Physicians (2009) and the American Association for the Advancement of Science (2015). He has been listed among America’s Top Doctors by Castle Connolly for the last 8 years.
Nise Yamaguchi is a Brazilian physician who graduated from Faculdade de Medicina da Universidade de São Paulo (FM/USP) in 1982, attended courses and internships in Germany and Switzerland in 1983. After completing her Medical Residency (1984-1986), she participated in scientific exchanges with the Memorial Sloan Kettering Cancer Center in New York and the MD Anderson Cancer Center in Houston. She holds a Master Degree in Immunology (1993) and a Doctor Degree in Clinical Oncology (2002), with specialist titles by the European Society of Allergy and Immunology, and the American Board Certification ECFMGES, European Society of Medical Oncology, Brazilian Society of Clinical Oncology, and Brazilian Medical Association. She is also a member of the Clinical Immunology Society since January 2016. She was certified in 2010 by the Harvard School of Medicine for the Course on Principles and Practices of Clinical Trial.

Dr. Yamaguchi acted as the head of the São Paulo State Office of the Ministry of Health from 2007 until 2011 and as a member of the International Affairs Committee of the American Society of Clinical Oncology between June 2008 through June 2011, developing academic clinical trials and contributing to the “Low and Middle Income Countries Knowledge Working Group.”

She currently participates in the design of research (molecular and clinical studies) projects on tumor pharmacogenomics and genetic diversity of the respiratory tract and works as the Clinical Director of the Instituto Avanços em Medicina. She is a hospital doctor at the Oncology Service of Hospital Israelita Albert Einstein (HIAE) in São Paulo, SP, Brazil, where she also participates in the scientific development and clinical meetings, focusing on assistance and continuing medical education. She is currently the Director of Institutional Relations of the Brazilian Association of Medical Women of the State of São Paulo and Brazil. She was appointed for the tenure 2017 - 2020 as Capital Delegate of the Associação Paulista de Medicina the São Paulo State Section of Associação Médica Brasileira (Brazilian Medical Association).
Mary J. Matthews
Pathology/Translational Research Award

IGNACIO I. WISTUBA, USA

Ignacio I. Wistuba, M.D., is Professor and Chair of the Department of Translational Molecular Pathology, with a joint appointment in Thoracic/Head and Neck Medical Oncology at M.D. Anderson Cancer Center in Houston, TX. He obtained his medical doctor degree in Universidad Austral, Valdivia, Chile (1985), and his surgical pathology training in Catholic University, Santiago, Chile (1989) Dr. Wistuba trained for near five years as post-doctoral research fellow in lung cancer molecular pathology in the Hamon Cancer Center at The University of Texas Southwestern Medical Center under the mentorship of Dr. Adi Gazdar and John Minna (1994-1999). After spending 5 years in Chile as professor of pathology in Catholic University Medical School, he joined MD Anderson Cancer Center in 2003 as associate professor of Pathology and Thoracic/Head and Neck Medical Oncology to lead a lung cancer molecular pathology program. After developing a comprehensive and strong molecular translational pathology for thoracic malignancies at MD Anderson, in 2012 he was named chair of the Department of Translational Molecular Pathology and the Anderson Clinical Faculty Chair for Cancer Treatment and Research.

He is a research surgical and molecular pathologist with a strong record of scientific achievement in lung cancer and other solid tumors, with over 500 peer-reviewed papers and several book chapters. His research interests include the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer, and the identification of novel molecular targets and predictive biomarkers for targeted and immune therapies. He is director of the Thoracic Molecular Pathology Laboratory and UT Lung Molecular Pathology Core, co-director of the TMP Immune-profiling Lab and the pre-CLIA Genomic Test Developmental Lab, and co-leader of the CCSG-supported of the Institutional Tissue Bank and Research Histology Core. Also, he is director of the ECOG-ACRIN Central Biorepository and Pathology Facility, leader of the MD Anderson NIH-funded Center for Immune Monitoring and Analysis for Cancer (CIMAC) and chair of the CIMAC network.

Dr. Wistuba oversees translational studies in a large number of clinical trials for lung cancer and other tumors of the MD Anderson Institutional Strategic Alliances, and he is co-leader of the Moon Shot APOLLO platform. He currently serves as the pathologist of the Lung Cancer Committee for the Southwestern Oncology Group (SWOG), the Lung Cancer Mutation Consortium (LCMC), and chair of the Pathology Committee of the International Association for the Study of Lung Cancer (IASLC). His extramural funding includes contact PI of three NIH U24 grants, and a CPRIT MIRA grant in lung cancer. He serves as senior editor of Cancer Prevention Research (AACR) and Annals of Oncology (ESMO).
## IASLC

### DISTINGUISHED AWARDS

<table>
<thead>
<tr>
<th>Year</th>
<th>IASLC Merit Award</th>
<th>IASLC Mary J. Matthews Pathology/Translational Research Award</th>
<th>IASLC Joseph W. Cullen Prevention/Early Detection Award</th>
<th>IASLC Paul A. Bunn, Jr. Scientific Award (Formerly IASLC Scientific Award)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Clifton Mountain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>Y. Shimosato N. Bleezen</td>
<td>Geno Saccamanno</td>
<td>Jesse Steinfeld</td>
<td>Robert Ginsberg</td>
</tr>
<tr>
<td>1997</td>
<td>Heine H. Hansen</td>
<td>William Travis</td>
<td>Clifford Douglas</td>
<td>John D. Minna</td>
</tr>
<tr>
<td>2000</td>
<td>Desmond Carney</td>
<td>Yokio Shimosato</td>
<td></td>
<td>Daniel C. Ihde</td>
</tr>
<tr>
<td>2003</td>
<td>Paul A. Bunn, Jr.</td>
<td>Adi Gazdar</td>
<td></td>
<td>Paul van Houtte</td>
</tr>
<tr>
<td>2005</td>
<td>Harubumi Kato</td>
<td>Elisabeth Brambilla</td>
<td>Nigel Gray</td>
<td>Thierry LeChevalier</td>
</tr>
<tr>
<td>2007</td>
<td>Peter Goldstraw</td>
<td>Fred R. Hirsch</td>
<td>James Mulshine</td>
<td>Frances Shepherd</td>
</tr>
<tr>
<td>2009</td>
<td>Giorgio V. Scaglotti</td>
<td>Masayuki Noguchi</td>
<td>Stephen Lam</td>
<td>Bruce Johnson Tom Lynch</td>
</tr>
<tr>
<td>2011</td>
<td>David Ball</td>
<td>Philip Hasleton</td>
<td>John Field</td>
<td>Nagahiro Saijo</td>
</tr>
<tr>
<td>2013</td>
<td>James Jett</td>
<td>Tetsuya Mitsudomi</td>
<td>Pieter Postmus</td>
<td>David R. Gandara</td>
</tr>
<tr>
<td>2015</td>
<td>Harvey Pass</td>
<td>Ming Tsao</td>
<td>Jacek Jassem</td>
<td>Yi-Long Wu</td>
</tr>
<tr>
<td>2016</td>
<td>Sumitra Thongprasert Keunchil Park</td>
<td>Keith Kerr</td>
<td>Ugo Pastorino</td>
<td>Roy Herbst</td>
</tr>
<tr>
<td>2017</td>
<td>Ramon Rami-Porta</td>
<td>Yasushi Yatabe</td>
<td>Carolyn Dresler</td>
<td>Tony Mok</td>
</tr>
<tr>
<td>Award Category</td>
<td>Winner</td>
<td>Project Title</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>--------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| IASLC Foundation Fellowship | Dimou Anastasios | University of Colorado, Aurora, CO USA  
Project title: Non-genetic determinants of EGFR TKI resistance in EGFR mutant lung cancer |
| IASLC Foundation Fellowship | Sanghyuk Song   | Kangwon National University Hospital, Chuncheon, Gangwon-do, South Korea  
Project title: Development of advanced stereotactic ablative radiotherapy for early-stage lung cancer; respiratory gating with inflated lung using a high-flow nasal cannula system |
| IASLC Foundation Fellowship | Laura Mezquita  | Institut Gustave Roussy, Villejuif, France  
Project title: European observational study of the indoor radon in non-small cell lung cancer (NSCLC) patients harboring driver molecular alterations |
| IASLC Foundation Young Investigator Award | Benjamin Lok | Princess Margaret Cancer Centre, Toronto, Canada  
Project title: Development of Epigenetic Therapeutics for Small Cell Lung Cancer |
| IASLC Foundation Young Investigator Award | John Charles Rotondo | University of Ferrara, Ferrara, FE Italy  
Project title: A3 and P2X7 receptors as new targets for a potential innovative therapy of the malignant pleural mesothelioma |
| IASLC Foundation Young Investigator Award | Aaron Tan      | National Cancer Centre Singapore, Singapore  
Project title: Minimally-invasive detection of early recurrence with circulating tumour DNA (ctDNA) in patients with resected early stage EGFR mutant non-small lung cancer (NSCLC) |
| Free ME From Lung Cancer (FMFLC) and IASLC Foundation (IASLCF) Joint Fellowship Award for the Early Detection of Lung Cancer | Eva Koziolek | University of California Los Angeles, Los Angeles, CA USA  
Project title: A novel biomarker for diagnosis and treatment of lung pre-malignancy |
| LCFA and IASLC Foundation Lori Monroe Scholarship in Translational Lung Cancer Research | Alice Berger | University of Washington, Seattle, WA USA  
Project title: Genomic Characterization of Lung Cancer in Never-Smokers |
| LCFA and IASLC Foundation Lori Monroe Scholarship in Translational Lung Cancer Research | Christine Lovly | Vanderbilt University School of Medicine, Nashville, TN USA  
Project title: Understanding dynamic somatic genome changes and hereditary predisposition in patients with Small Cell Lung Cancer |
| LCFA-BMS/IASLC Foundation Young Investigator Award | Zoltan Lohinai | National Koranyi Institute of Pulmonology, Budapest, Hungary  
Project title: Interaction of immunotherapy with the mycobiome in lung adenocarcinoma |
| LCFA-BMS/IASLC Foundation Young Investigator Award | Kathryn Beckermann | Vanderbilt University School of Medicine, Nashville, TN USA  
Project title: Single cell analysis to understand the biological response to novel immunotherapy combination in lung cancer |
| Prevent Cancer Foundation and IASLC Foundation Lung Cancer Fellowship | Atiqur Rahman | University of Newcastle, Newcastle, New South Wales, Australia  
Project title: Discovery of efficient and accurate early stage biomarkers is crucial towards the treatment of early stage lung cancer |
IASLC International Mentorship Award Winners

**BANU ATALAR**  
Acibadem University, Turkey  
P2.16-14: Results of Stereotactic Radiation Therapy (SABR) in Early Stage Lung Cancer: Turkish Radiation Oncology Group (TROG) Study

**BROOKLYN MAZURE**  
Cross Cancer Institute, Canada  
MA22.09: Should Stereotactic Radiosurgery be Considered for Salvage of Intracranial Recurrence in Small Cell Lung Cancer?

**NEHEMIYA IGULU BANDESE**  
Uganda Cancer Institute, Uganda  
P2.06-15: Malignant Pleural Mesothelioma in Young Adult People in Uganda

**MANOJ GOWDA**  
All India Institute of Medical Sciences, India  
P3.09-22: Correlation Between Maximum Tumour Diameter Measurement on CT-Scan and Histopathological Specimen: An Indian Experience

**YANGSI LI**  
Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China  
P1.01-55: Unique Genetic Profiles from Cerebrospinal Fluid Could Predict Survival of EGFR-Mutant NSCLC with Leptomeningeal Metastases

**BROOKLYN MAZURE**  
Cross Cancer Institute, Canada  
MA22.09: Should Stereotactic Radiosurgery be Considered for Salvage of Intracranial Recurrence in Small Cell Lung Cancer?

**VALLIAPPAN MUTHU**  
Postgraduate Institute of Medical Education and Research (PGIMER), India  
P1.09-15: Preliminary Experience with Liquid Biopsies in a Resource Constrained Setting and its Impact on Treatment Decision Making

**JULIETA BELÉN PANDOLFI**  
Hospital Italiano de Buenos Aires, Argentina  
P2.01-75: Study of Molecular Alterations in Cytological Smears By FISH In Patients with Advanced Non Small Cell Lung Carcinoma (NSCLC).

**KURUSWAMY THURAI PRASAD**  
Postgraduate Institute of Medical Education and Research (PGIMER), India  
P2.01-77: Interconversion of Two Commonly Used Performance Tools: An Analysis of 5844 Paired Assessments in 1501 Lung Cancer Patients

**JELENA SPASIC**  
Institute for Oncology and Radiology of Serbia, Serbia  
P3.01-92: Blood Test Parameters as Prognostic Factors In EGFR-Mutated Non-Small Cell Lung Cancer Treated With TKIs

**SHUYUAN WANG**  
Shanghai Chest Hospital, China  
MA01.01: Proposal on Incorporating Lymphovascular Invasion as a T-Descriptor for Stage I Non-Small Cell Lung Cancer

**CHAO ZHANG**  
Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China  
MA24.01: Genomic Evolution Trajectory Depicts Invasiveness Acquisition from Pre-invasive to Invasive Adenocarcinoma

**JIA-TAO ZHANG**  
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Southern Medical University., China  
P1.11-18: A Classification-Based Machine Learning Method Reveals Exosomal miRNA Biomarkers for Patients with Pulmonary Ground Glass Nodule
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Presentation Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ARPITA DESAI</strong></td>
<td>The University of Chicago, USA</td>
<td>OA08.03: Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis</td>
</tr>
<tr>
<td><strong>AROOJ FATIMA</strong></td>
<td>Shaukat Khanum Cancer Hospital and Research Centre, Pakistan</td>
<td>MA07.07: Identifying the Severity of Psychosocial Symptoms Among Patients Diagnosed with Lung Cancer. Do We Really Need Emotional Support Groups?</td>
</tr>
<tr>
<td><strong>GIOVANNI FUCÀ</strong></td>
<td>Istituto Nazionale dei Tumori, Italy</td>
<td>MA10.05: Effect of Early Steroids use in Advanced NSCLC Patients Treated with Immunotherapy</td>
</tr>
<tr>
<td><strong>SILVIA GARCIA-ROMAN</strong></td>
<td>Laboratory of Oncology/Pangaea Oncology, Quirón-Dexeus University Hospital, Spain</td>
<td>P1.13-01: Anti-EGF Antibodies Increase the Effect of ALK and MEK Inhibitors in ALK and KRAS NSCLC and CRC Cell Lines</td>
</tr>
<tr>
<td><strong>MARJOLEIN HEUVELMANS</strong></td>
<td>University of Groningen, University Medical Center Groningen, Netherlands</td>
<td>MA03.05: New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial</td>
</tr>
<tr>
<td><strong>FANG HU</strong></td>
<td>Shanghai Chest Hospital, China</td>
<td>OA07.06: Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations</td>
</tr>
<tr>
<td><strong>ADAM JANUSZEWSKI</strong></td>
<td>Imperial College London, UK</td>
<td>MA21.03: Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC</td>
</tr>
<tr>
<td><strong>TAO JIANG</strong></td>
<td>Shanghai Pulmonary Hospital, Tongji University School of Medicine, China</td>
<td>OA07.03: Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprocessive Liver Metastases</td>
</tr>
<tr>
<td><strong>JENNY G. TURCOTT</strong></td>
<td>National Cancer Institute of Mexico, Mexico</td>
<td>MA02.08: The Effect of Nabilone on Appetite, Nutritional Status, and Quality of Life in Lung Cancer Patients: A Randomized, Double-Blind Clinical Trial</td>
</tr>
<tr>
<td><strong>NATALIE VOKES</strong></td>
<td>Dana Farber Cancer Institute, USA</td>
<td>MA19.01: Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes</td>
</tr>
<tr>
<td><strong>ZYANYA LUCIA ZATARAIN-BARRÓN</strong></td>
<td>Instituto Nacional de Cancerología, Mexico</td>
<td>P1.09-21: Circulating Tumor DNA Improves Genotypification and Detection of Targetable Alterations in Selected Lung Cancer Patients</td>
</tr>
</tbody>
</table>
### IASLC WCLC 2018 Developing Nation Award Winners

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUCIENNE BONAN</td>
<td>SCMED/ANVISA, Brazil</td>
<td>MA07.11: Drug Price Comparison in Advanced Lung Cancer – High Cost Prices is Accompanied by Patient Benefits?</td>
</tr>
<tr>
<td>NATALIA KHRANOVSKA</td>
<td>National Cancer Institute of Ukraine, Ukraine</td>
<td>P2.04-22: Dendritic Cell Based Immunotherapy in Stage IIB-IIIA Non-Small Cell Lung Cancer Patients: 10-Years Experience</td>
</tr>
<tr>
<td>DONGRONG SITU</td>
<td>Lung Cancer Research Institute, Sun Yat-sen University, China</td>
<td>OAO6.02: Video-Assisted Thoracoscopic Surgery vs. Thoracotomy for Non-Small Cell Lung Cancer: Oncologic Outcome of a Randomized Trial</td>
</tr>
<tr>
<td>LIANG-LIANG CAI</td>
<td>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China</td>
<td>MA06.07: Genetic and Epigenetic Alterations are Associated with Tumor Mutation Burden in Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td>SHRUTI KATE</td>
<td>Tata Memorial Hospital, India</td>
<td>P1.01-44: Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced NSCLC Patients: A Single-Centre Retrospective Analysis</td>
</tr>
<tr>
<td>TAHIR MEHMOOD</td>
<td>Northwest General Hospital and Research Centre, Pakistan</td>
<td>P2.17-01: Trimodality Therapy (TT) in the Treatment of Stage IIIA Non-Small Cell Lung Cancer (NSCLC)</td>
</tr>
<tr>
<td>ORESTES SANTOS MORALES</td>
<td>CIM, Cuba</td>
<td>P1.01-84: High Basal Serum EGF Levels Predicts Response to CIMAavx-EGF, a Therapeutic Vaccine for Advanced NSCLC</td>
</tr>
</tbody>
</table>

### IASLC WCLC 2018 Patient Advocate Award Winners

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>CALEB EGWUENU</td>
<td>Nigeria</td>
<td></td>
</tr>
<tr>
<td>NABANITA MANDAL</td>
<td>India</td>
<td></td>
</tr>
<tr>
<td>ERIN SARAUER</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>JUANITA SEGURA</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>VIVEK TOMAR</td>
<td>India</td>
<td></td>
</tr>
</tbody>
</table>

### IASLC WCLC 2018 Nurse and Allied Health Professional Award Winners

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLIED HEALTH PROFESSIONAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSABA LÁSZLÓ DÉGI</td>
<td>Babes - Bolyai University, Romania</td>
<td>MA07.05: Psychosocial Needs and Programs of Cancer Patients/Survivors and Their Relatives: Unmet Needs from an International Study</td>
</tr>
<tr>
<td>NURSE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BARBARA GUTIERRES</td>
<td>Universidade Paulista, Brazil</td>
<td>OAO4.01: What is the Cost of a Strong Evidence for the Treatment of Advanced Non-Small Cell Lung Cancer?</td>
</tr>
</tbody>
</table>
The IASLC WCLC 2018 Lectureship Award Recipients will be presented with their awards during the Lectureship Award Session on Wednesday, September 26, 13:30 - 15:00 in Room 105, Level 100.

**IASLC WCLC 2018 Lectureship Awards**

**Clifton F. Mountain Lectureship Award for Staging**
Johan Vansteenkiste, Belgium

**Adi F. Gazdar Lectureship Award for Translational Research**
Matthew Meyerson, USA

**Robert J. Ginsberg Lectureship Award for Surgery**
Valerie Rusch, USA

**IASLC Lectureship Award for Radiation Oncology**
Hak Choy, USA

**Tsuguo Naruke Lectureship Award for Surgery**
Hisao Asamura, Japan

**IASLC Lectureship Award for Nursing and Allied Health**
Kim Rohan, USA

**Heine H. Hansen Lectureship Award for Small Cell Lung Cancer**
Charles Rudin, USA

**Daniel C. Ihde Lectureship Award for Medical Oncology**
David P. Carbone, USA
DO YOU NEED FUNDING?

RESEARCH FUNDING
Coming this Fall!

IASLC Foundation Fellowship Opportunities:
The IASLC Foundation awards support research fellowships across the globe to the next generation of lung cancer physicians, scientists and researchers. IASLC Fellowships and Young Investigator Awards are granted for one year.

IASLC Foundation also offers larger research grants through partnerships with other organizations.

Applications open October 1, 2018.

Don’t miss out on this incredible opportunity!

VISIT www.iaslc.org/fellowship/announcements FOR MORE INFORMATION.
JOIN TODAY!

As an IASLC member, you will receive:

- Collaboration with a multidisciplinary global team of thoracic oncology experts and leaders
- Member access to the Journal of Thoracic Oncology, the premier journal in lung cancer, as well as the latest classification and staging publications
- Multidisciplinary education including the latest in ground-breaking research and treatment of thoracic malignancies

FELLOWS, RESIDENTS AND TRAINEES MAY APPLY FOR A FREE, NON-VOTING FELLOW MEMBERSHIP!

See us in the Exhibit Hall at Booth 100 or at the IASLC Membership Booth at Registration | Apply at iasl.org
SECTION 5
Conference Program

TAKE ACTION
Against Lung Cancer!
PROGRAM
AT A GLANCE

SATURDAY
Sept. 22, 2018

06:30
Registration
(06:30–18:00)

07:00
Young Investigator Session
(08:00–09:30)

08:30
IASLC Foundation Concert
[Ticketed Event]

11:00
Unopposed Industry Symposium
(11:30–13:00)

13:00
Unopposed Industry Symposium
(13:00–14:30)

15:00
Unopposed Industry Symposium
(14:30–16:00)

16:00
Unopposed Industry Supported Symposium
(16:00–17:30)

18:00
IASLC Foundation Concert
[Ticketed Event]

SUNDAY
September 23, 2018

07:00
Meet the Expert Sessions
(07:00–08:00)

08:30
IASLC Foundation Walk
(08:00–09:30)

11:00
Opposed Industry Symposium
(09:45–11:15)

14:00
Oral and Mini Oral Abstract Sessions
(10:30–12:00)

15:00
Oral and Mini Oral Abstract Sessions
(13:30–15:00)

18:00
Poster Viewing Reception
Poster Presenters Present
(16:45–18:00)

MONDAY
September 24, 2018

07:00
Opposed Industry Supported Symposia
(07:00–08:00)

08:30
Plenary Session
(08:15–10:45)

11:00
Oral and Mini Oral Abstract Sessions
(09:45–10:30)

14:00
Educational Sessions
*Includes Mini Symposia, Educational Sessions, Pro-Con Sessions, Grand Rounds Sessions
(10:30–12:00)

15:00
Educational Sessions
*Includes Mini Symposia, Educational Sessions, Pro-Con Sessions, Grand Rounds Sessions
(13:30–15:00)

18:00
Unopposed Industry Supported Symposium
(18:00–19:30)

20:00
Faculty Dinner
(by Invitation Only)
(19:30–22:00)
<table>
<thead>
<tr>
<th>Time</th>
<th>TUESDAY (September 25, 2018)</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:30</td>
<td>Registration (06:30–15:30)</td>
</tr>
<tr>
<td>06:30</td>
<td>Speaker Preview Centre (06:30–16:00)</td>
</tr>
<tr>
<td>06:30</td>
<td>Exhibit Hall (09:30–18:30)</td>
</tr>
<tr>
<td>07:00</td>
<td>Highlights of the Previous Day Sessions (07:00–08:00)</td>
</tr>
<tr>
<td>07:00</td>
<td>Meet the Expert (Ticketed Session) (07:00–08:00)</td>
</tr>
<tr>
<td>07:00</td>
<td>Opposed Industry Supported Symposia (07:00–08:00)</td>
</tr>
<tr>
<td>08:00</td>
<td>Presidential Symposium including Top 5 Rated Abstracts (08:15–09:45)</td>
</tr>
<tr>
<td>08:00</td>
<td>Press Conference (08:45–10:30)</td>
</tr>
<tr>
<td>08:00</td>
<td>Educational Sessions *Includes Mini Symposia, Educational Sessions, Pro-Con Sessions, Grand Rounds Sessions (10:30–12:00)</td>
</tr>
<tr>
<td>09:45</td>
<td>Poster Viewing – Exhibit Hall (09:45–10:30)</td>
</tr>
<tr>
<td>10:30</td>
<td>Oral and Mini Oral Abstract Sessions *Includes Mini Symposia, Educational Sessions, Pro-Con Sessions, Grand Rounds Sessions (10:30–12:00)</td>
</tr>
<tr>
<td>12:00</td>
<td>Unopposed Industry Supported Symposium (12:00–13:30)</td>
</tr>
<tr>
<td>13:30</td>
<td>Oral and Mini Oral Abstract Sessions *Includes Mini Symposia, Educational Sessions, Pro-Con Sessions, Grand Rounds Sessions (13:30–15:00)</td>
</tr>
<tr>
<td>15:15</td>
<td>Educational Sessions *Includes Mini Symposia, Educational Sessions, Pro-Con Sessions, Grand Rounds Sessions (15:15–16:45)</td>
</tr>
<tr>
<td>16:45</td>
<td>Poster Viewing Reception *Poster Presenters Present (16:45–18:00)</td>
</tr>
<tr>
<td>18:00</td>
<td>Unopposed Industry Supported Symposium (18:00–19:30)</td>
</tr>
<tr>
<td>19:00</td>
<td>Conference Dinner [Ticketed Event] (20:00–23:00)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>WEDNESDAY (September 26, 2018)</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:30</td>
<td>Registration (06:30–15:30)</td>
</tr>
<tr>
<td>06:30</td>
<td>Speaker Preview Centre (06:30–16:00)</td>
</tr>
<tr>
<td>06:30</td>
<td>Exhibit Hall (09:30–18:30)</td>
</tr>
<tr>
<td>07:00</td>
<td>Highlights of the Previous Day Sessions (07:00–08:00)</td>
</tr>
<tr>
<td>07:00</td>
<td>Meet the Expert (Ticketed Session) (07:00–08:00)</td>
</tr>
<tr>
<td>07:00</td>
<td>Opposed Industry Supported Symposia (07:00–08:00)</td>
</tr>
<tr>
<td>08:00</td>
<td>Plenary Session (08:15–09:45)</td>
</tr>
<tr>
<td>08:00</td>
<td>Poster Viewing – Exhibit Hall (08:45–10:30)</td>
</tr>
<tr>
<td>10:00</td>
<td>Educational Sessions *Includes Mini Symposia, Educational Sessions, Pro-Con Sessions, Grand Rounds Sessions (10:30–12:00)</td>
</tr>
<tr>
<td>09:45</td>
<td>Media Availability (09:45–10:30)</td>
</tr>
<tr>
<td>12:00</td>
<td>Unopposed Industry Supported Symposia (12:00–13:30)</td>
</tr>
<tr>
<td>13:30</td>
<td>Oral and Mini Oral Abstract Sessions *Includes Mini Symposia, Educational Sessions, Pro-Con Sessions, Grand Rounds Sessions (13:30–15:00)</td>
</tr>
<tr>
<td>15:15</td>
<td>Educational Sessions *Includes Mini Symposia, Educational Sessions, Pro-Con Sessions, Grand Rounds Sessions (15:15–16:45)</td>
</tr>
<tr>
<td>16:45</td>
<td>IASLC Business Meeting (17:00–18:00)</td>
</tr>
<tr>
<td>17:00</td>
<td>Closing Plenary (15:15–16:30)</td>
</tr>
</tbody>
</table>

Program listings are subject to change.
## Advanced NSCLC

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MONDAY, SEPTEMBER 24</strong></td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE9</td>
<td>Management of Advanced Wild-Type Lung Cancer in Special Situations</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td><strong>MONDAY, SEPTEMBER 24</strong></td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA02</td>
<td>Improving Outcomes for Patients with Lung Cancer</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td><strong>MONDAY, SEPTEMBER 24</strong></td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS07</td>
<td>Antibody-Drug Conjugates in Advanced NSCLC</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td><strong>MONDAY, SEPTEMBER 24</strong></td>
<td>13:30 - 15:00</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA05</td>
<td>Clinical Trials in IO</td>
<td>Room 106</td>
</tr>
<tr>
<td><strong>MONDAY, SEPTEMBER 24</strong></td>
<td>15:15 - 16:45</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA08</td>
<td>Clinical Trials in Brain Metastases</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td><strong>TUESDAY, SEPTEMBER 25</strong></td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE18</td>
<td>Case-Based Management of Patients with Inadequate Tissue for Molecular Tests</td>
<td>Room 201 F</td>
</tr>
<tr>
<td><strong>TUESDAY, SEPTEMBER 25</strong></td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA10</td>
<td>Considerations in Immunotherapy / Real World</td>
<td>Room 105</td>
</tr>
<tr>
<td><strong>TUESDAY, SEPTEMBER 25</strong></td>
<td>10:30 - 12:00</td>
<td>PRO-CON SESSION</td>
<td>PC05</td>
<td>Optimizing Clinical Trial Design in NSCLC</td>
<td>Room 205 AC</td>
</tr>
<tr>
<td><strong>TUESDAY, SEPTEMBER 25</strong></td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA16</td>
<td>Novel Mechanisms for Molecular Profiling</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td><strong>TUESDAY, SEPTEMBER 25</strong></td>
<td>13:30 - 15:00</td>
<td>PRO-CON SESSION</td>
<td>PC07</td>
<td>The Future of Cytotoxic Chemotherapy in Advanced NSCLC</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td><strong>WEDNESDAY, SEPTEMBER 26</strong></td>
<td>10:30 - 12:00</td>
<td>PRO-CON SESSION</td>
<td>PC09</td>
<td>Approaches to Management of Advanced NSCLC</td>
<td>Room 107</td>
</tr>
<tr>
<td><strong>WEDNESDAY, SEPTEMBER 26</strong></td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA26</td>
<td>New Therapies and Emerging Data in ALK, EGFR and ROS1</td>
<td>Room 201 BD</td>
</tr>
</tbody>
</table>

## Advocacy

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MONDAY, SEPTEMBER 24</strong></td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS04</td>
<td>Joint GLCC/IASLC Session: Exploring Hot SESSION TYPES for Advocates</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td><strong>MONDAY, SEPTEMBER 24</strong></td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA07</td>
<td>Towards Survivorship: The Landscape, Supports and Barriers</td>
<td>Room 205 AC</td>
</tr>
<tr>
<td><strong>TUESDAY, SEPTEMBER 25</strong></td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE17</td>
<td>Living with and Beyond Lung Cancer: An Education for Advocates</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td><strong>TUESDAY, SEPTEMBER 25</strong></td>
<td>15:15 - 16:45</td>
<td>EDUCATIONAL SESSION</td>
<td>ES05</td>
<td>Collaboration Between Stakeholders to Improve Lung Cancer Research</td>
<td>Room 205 AC</td>
</tr>
</tbody>
</table>

### Session Types
- **ES**: EDUCATIONAL SESSION
- **GR**: GRAND ROUNDS SESSION
- **MA**: MINI ORAL ABSTRACT SESSION
- **MS**: MINI SYMPOSIUM
- **MTE**: MEET THE EXPERT SESSION (TICKETED SESSIONS - CONTINENTAL BREAKFAST PROVIDED)
- **OA**: ORAL ABSTRACT SESSION
- **PC**: PRO-CON SESSION
- **PL**: PLENARY SESSION
- **S**: SYMPOSIUM
- **SH**: HIGHLIGHTS OF THE PREVIOUS DAY
- **WS**: WORKSHOP (TICKETED SESSIONS)
- **YI**: YOUNG INVESTIGATOR SESSION
### Biology

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE01</td>
<td>Preclinical Models of Lung Cancer</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS01</td>
<td>Cancer Pathways, Targeted Therapy and Resistance</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA24</td>
<td>Genomic Evolution, KEAP 3 and More Non-Coding RNA</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA06</td>
<td>PD11, TMB and DNA Repair</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE11</td>
<td>Biology of Small Cell Lung Cancer</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS13</td>
<td>Novel Mediators of Lung Cancer Metastasis</td>
<td>Room 201 F</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>15:15 - 16:45</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA21</td>
<td>Molecular Subtyping, CBL3, and Non Coding RNA</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS22</td>
<td>Biology of the Lung and Lung Cancer</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA25</td>
<td>Oligometastasis: Defining, Treating, and Evaluating</td>
<td>Room 203 BD</td>
</tr>
</tbody>
</table>

### Immunooncology

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS02</td>
<td>The Future of IO</td>
<td>Room 106</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA04</td>
<td>Novel Approaches with IO</td>
<td>Room 107</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE12</td>
<td>IO in the Real World - High Risk Populations And Patient Support</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA11</td>
<td>Biomarkers of IO Response</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS14</td>
<td>IO in Early Stage NSCLC</td>
<td>Room 107</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>15:15 - 16:45</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA19</td>
<td>Genomic Markers of IO Response</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE21</td>
<td>Can I Treat Brain Metastasis with Immunotherapy?</td>
<td>Room 105</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS28</td>
<td>IO Combinations in Advanced NSCLC</td>
<td>Room 106</td>
</tr>
</tbody>
</table>

### Interventional Diagnostics/Pulmonology

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE10</td>
<td>Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>15:15 - 16:45</td>
<td>MINI SYMPOSIUM</td>
<td>MS09</td>
<td>Tumour Board - Tissue Acquisition and Staging</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA13</td>
<td>Interventional Pulmonology</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS19</td>
<td>Pulmonary Dilemmas with Immunotherapy</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE28</td>
<td>Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP</td>
<td>Room 201 F</td>
</tr>
</tbody>
</table>
### Mesothelioma

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE06</td>
<td>Symptom Management in Mesothelioma</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>10:30 - 12:00</td>
<td>PRO-CON SESSION</td>
<td>PC01</td>
<td>Controversies in Mesothelioma</td>
<td>Room 205 AC</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>15:15 - 16:45</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA08</td>
<td>Mesothelioma: Immunotherapy and microRNA for Diagnosis and Treatment</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA12</td>
<td>Mesothelioma Surgery and Novel Targets for Prognosis and Therapy</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>15:15 - 16:45</td>
<td>EDUCATIONAL SESSION</td>
<td>ES03</td>
<td>How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural biopsy</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS25</td>
<td>Genetic and Prognostic Markers in Mesothelioma; Going Beyond the Histology Subtypes</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS31</td>
<td>Clinical Science in Mesothelioma</td>
<td>Room 205 AC</td>
</tr>
</tbody>
</table>

### Nursing and Allied Health Professionals

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE08</td>
<td>Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>10:30 - 12:00</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA04</td>
<td>Improving Access and Outcomes in Lung Cancer Management</td>
<td>Room 201 F</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>EDUCATIONAL SESSION</td>
<td>ES02</td>
<td>Quality Care in Lung Cancer</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA17</td>
<td>New Methods to Improve Lung Cancer Patients Outcomes</td>
<td>Room 205 AC</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE25</td>
<td>Enhancing the Care of Your Older Adult Population with Lung Cancer</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>EDUCATIONAL SESSION</td>
<td>ES07</td>
<td>Beyond the Diagnosis - Collaborative Care for Change</td>
<td>Room 205 BD</td>
</tr>
</tbody>
</table>

### Oligometastatic NSCLC

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS03</td>
<td>New Frontiers in Oligometastases</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS06</td>
<td>Practical Issues in the Management of Oligometastatic NSCLC</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>15:15 - 16:45</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA07</td>
<td>Oligometastasis: What Should Be the State-Of-The-Art?</td>
<td>Room 107</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>13:30 - 15:00</td>
<td>PRO-CON SESSION</td>
<td>PC08</td>
<td>The Great Oligometastatic Debates</td>
<td>Room 105</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>EDUCATIONAL SESSION</td>
<td>ES06</td>
<td>Oligometastatic Disease</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA25</td>
<td>Oligometastasis: Defining, Treating, and Evaluating</td>
<td>Room 203 BD</td>
</tr>
</tbody>
</table>
## Pathology

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE02</td>
<td>Update on WHO Classification and Staging of Lung Cancer</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>10:30 - 12:00</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA03</td>
<td>Advances in Lung Cancer Pathology</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS05</td>
<td>Diagnostic Dilemma in Lung Cancer</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>15:15 - 16:45</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA09</td>
<td>Lung Cancer Surgical and Molecular Pathology</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>13:30 - 15:00</td>
<td>PRO-CON SESSION</td>
<td>PC06</td>
<td>Controversies in Immunobiomarker Testing</td>
<td>Room 106</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE20</td>
<td>Molecular Testing in Small Samples</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>EDUCATIONAL SESSION</td>
<td>ES08</td>
<td>The Pathologist - An Essential Member of the Patient Care Team</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA26</td>
<td>New Therapies and Emerging Data in ALK, EGFR and ROS1</td>
<td>Room 201 BD</td>
</tr>
</tbody>
</table>

## Prevention and Tobacco Control

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>15:15 - 16:45</td>
<td>MINI SYMPOSIUM</td>
<td>MS11</td>
<td>Stigma and Lung Cancer: Unintended Translational Consequences of Effective Tobacco Control</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>15:15 - 16:45</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA09</td>
<td>Prevention and Cessation</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS15</td>
<td>Disruptive Technology and Lung Cancer Risk</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE22</td>
<td>Incorporation of Smoking Cessation in Clinical Care</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS24</td>
<td>Global Perspectives on Tobacco Control</td>
<td>Room 206 BD</td>
</tr>
</tbody>
</table>

## Screening and Early Detection

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUNDAY, SEPTEMBER 23</td>
<td>07:00 - 12:00</td>
<td>SYMPOSIUM</td>
<td>S01</td>
<td>IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>SUNDAY, SEPTEMBER 23</td>
<td>07:30 - 11:15</td>
<td>JOINT IASLC/CSCO/CAALC SESSION</td>
<td>JCSE01</td>
<td>Perspectives for Lung Cancer Early Detection</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE04</td>
<td>Comparison of Various Risk Models</td>
<td>Room 205 AC</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA02</td>
<td>Improving Outcomes for Patients with Lung Cancer</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA03</td>
<td>Lung Cancer Screening - Next Step</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>13:30 - 15:00</td>
<td>EDUCATIONAL SESSION</td>
<td>ES01</td>
<td>Advances in Lung Cancer Screening Through Imaging</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE14</td>
<td>Nodule Management (Pro Con Debate and Case Presentations)</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS16</td>
<td>Implementation of Lung Cancer Screening</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>15:15 - 16:45</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA20</td>
<td>Implementation of Lung Cancer Screening</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS29</td>
<td>Selection into Screening Programs: Interplay of Risk Algorithms, Genetic Markers and Biomarkers</td>
<td>Room 206 F</td>
</tr>
</tbody>
</table>
## Small Cell Lung Cancer/NET

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>13:30 - 15:00</td>
<td>PRO-CON SESSION</td>
<td>PC02</td>
<td>Debate on Local Therapies for Limited Small Cell Lung Cancer? Surgery PRO/CON and BID Radiation PRO/CON</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE16</td>
<td>What Is Changing in the Management of Pulmonary Neuroendocrine Tumours?</td>
<td>Room 205 AC</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS18</td>
<td>Management of SCLC Patients Not Represented in Clinical Trials</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>15:15 - 16:45</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA22</td>
<td>New Therapeutics, Pathology, and Brain Metastases for Small Cell and Neuroendocrine Tumour</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE27</td>
<td>Controversies in Radiotherapy for SCLC</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA13</td>
<td>Therapeutics and Radiation for Small Cell Lung Cancer</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS32</td>
<td>SCLC - From Benchside to Bedside - Clinical Science Session</td>
<td>Room 107</td>
</tr>
</tbody>
</table>

## Targeted Therapy

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE03</td>
<td>Clinical Trial Design With Novel Lung Cancer Therapy</td>
<td>Room 105</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>10:30 - 12:00</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA02</td>
<td>Novel Therapies in ROS1, HER2 and EGFR</td>
<td>Room 105</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>15:15 - 16:45</td>
<td>PRO-CON SESSION</td>
<td>PC04</td>
<td>Targeted Therapy for NSCLC</td>
<td>Room 106</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE13</td>
<td>Clonal Evolution and Targeted Therapy</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA10</td>
<td>Right Patient, Right Target &amp; Right Drug - Novel Treatments and Research Partnerships</td>
<td>Room 106</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA15</td>
<td>Colliding Approaches - EGFR and Immunotherapy</td>
<td>Room 107</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>15:15 - 16:45</td>
<td>EDUCATIONAL SESSION</td>
<td>ES04</td>
<td>Liquid Biopsies in Lung Cancer</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>15:15 - 16:45</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA12</td>
<td>Novel Therapies in MET, RET and BRAF</td>
<td>Room 106</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS23</td>
<td>What's New in Targeted Therapy?</td>
<td>Room 106</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA26</td>
<td>New Therapies and Emerging Data in ALK, EGFR and ROS1</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA27</td>
<td>Novel Drugs and PDX Models</td>
<td>Room 206 BD</td>
</tr>
</tbody>
</table>
### Thymoma/Other Thoracic Malignancies

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED)</td>
<td>MTE07</td>
<td>Management of Pleural Recurrence</td>
<td>Room 201 F</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>15:15 - 16:45</td>
<td>PRO-CON SESSION</td>
<td>PC03</td>
<td>Controversies in Management of Resectable Thymoma</td>
<td>Room 205 AC</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>GRAND ROUNDS SESSION</td>
<td>GR01</td>
<td>Thymic Malignancies Tumor Board</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>13:30 - 15:00</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA11</td>
<td>Thymic and Other Thoracic Tumours: Targeted Therapies, Biomarkers and Neo/Adjuvant Radiotherapy</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED)</td>
<td>MTE19</td>
<td>How I Treat Advanced Stage Thymic Malignancy Patients</td>
<td>Room 205 AC</td>
</tr>
</tbody>
</table>

### Treatment in the Real World - Support, Survivorship, Systems Research

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS08</td>
<td>Lung Cancer in the Real World</td>
<td>Room 201 F</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA10</td>
<td>Considerations in Immunotherapy / Real World</td>
<td>Room 105</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA14</td>
<td>Survivorship, Socioeconomic and End-of-Life Considerations</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA18</td>
<td>Modelling, Decision-Making and Population-Based Outcomes</td>
<td>Room 201 F</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS17</td>
<td>Life After Lung Cancer: Survivorship</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED)</td>
<td>MTE26</td>
<td>New Paradigms in Symptom Management in Lung Cancer</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS26</td>
<td>From Textbook to Practice Around the World</td>
<td>Room 205 AC</td>
</tr>
</tbody>
</table>

### Treatment of Early Stage/Localized Disease

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA01</td>
<td>Early Stage Lung Cancer: Questions and Controversies</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA24</td>
<td>Genomic Evolution, KEAP 3 and More Non-Coding RNA</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>13:30 - 15:00</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA06</td>
<td>Early Stage Lung Cancer: Techniques and Adjuvant Therapies</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>15:15 - 16:45</td>
<td>MINI SYMPOSIUM</td>
<td>MS10</td>
<td>Part Solid Nodules, GGN and STAS</td>
<td>Room 206 F</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED)</td>
<td>MTE15</td>
<td>Who is Too High Risk for a VATS Resection?</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>15:15 - 16:45</td>
<td>MINI SYMPOSIUM</td>
<td>MS20</td>
<td>Innovative and Evolving Strategies in Diagnosis and Management of Stage I NSCLC</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED)</td>
<td>MTE24</td>
<td>Multiple Lung Nodules; Ressect, Radiate or Watch?</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td>MA23</td>
<td>Early Stage Lung Cancer: Present and Future</td>
<td>Room 105</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>10:30 - 12:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS27</td>
<td>Therapeutic Implications of Staging Issues</td>
<td>Room 201 BD</td>
</tr>
</tbody>
</table>
# Treatment of Locoregional Disease - NSCLC

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONDAY, SEPTEMBER 24</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT</td>
<td>MTE05</td>
<td>Role of Pneumonectomy in N2 Disease</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td></td>
<td>10:30 - 12:00</td>
<td>ORAL ABSTRACT SESSION</td>
<td>OA01</td>
<td>Improving Outcomes in Locoregional NSCLC I</td>
<td>Room 107</td>
</tr>
<tr>
<td></td>
<td>13:30 - 15:00</td>
<td>MINI ORAL ABSTRACT</td>
<td>MA05</td>
<td>Improving Outcomes in Locoregional NSCLC II</td>
<td>Room 105</td>
</tr>
<tr>
<td></td>
<td>15:15 - 16:45</td>
<td>MINI SYMPOSIUM</td>
<td>MS12</td>
<td>Immunotherapy and RT</td>
<td>Room 105</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>15:15 - 16:45</td>
<td>GRAND ROUNDS SESSION</td>
<td>GR02</td>
<td>Management of N2 NSCLC - A Case Based Discussion</td>
<td>Room 107</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>MEET THE EXPERT (TICKETED SESSION)</td>
<td>MTE23</td>
<td>Surgical Considerations Following Induction Therapy for Stage IIIA Disease</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>13:30 - 15:00</td>
<td>MINI SYMPOSIUM</td>
<td>MS30</td>
<td>Modern Day RT in LA NSCLC: Where Is the Evidence?</td>
<td>Room 202 BD</td>
</tr>
</tbody>
</table>

# Multi-Track Sessions

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
<th>SESSION TYPE</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>07:00 - 08:00</td>
<td>HIGHLIGHT OF THE</td>
<td>SH01</td>
<td>Highlights of the Previous Day Session</td>
<td>Plenary Hall</td>
</tr>
<tr>
<td></td>
<td>07:00 - 08:00</td>
<td>PREVIOUS DAY SESSION</td>
<td>SH02</td>
<td>Highlights of the Previous Day Session</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td>TUESDAY, SEPTEMBER 25</td>
<td>08:15 - 09:45</td>
<td>PRESIDENTIAL SYMPOSIUM</td>
<td>PLO2</td>
<td>Presidential Symposium - Top 5 Rated Abstracts</td>
<td>Plenary Hall</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>HIGHLIGHT OF THE</td>
<td>SH03</td>
<td>Highlights of the Previous Day Session</td>
<td>Room 107</td>
</tr>
<tr>
<td>WEDNESDAY, SEPTEMBER 26</td>
<td>07:00 - 08:00</td>
<td>PREVIOUS DAY SESSION</td>
<td>SH04</td>
<td>Highlights of the Previous Day Session</td>
<td>Room 106</td>
</tr>
</tbody>
</table>

**Legend:**
- **ES**: EDUCATIONAL SESSION
- **GR**: GRAND ROUNDS SESSION
- **MA**: MINI ORAL ABSTRACT SESSION
- **MS**: MINI SYMPOSIUM
- **MTE**: MEET THE EXPERT SESSION (TICKETED SESSIONS - CONTINENTAL BREAKFAST PROVIDED)
- **OA**: ORAL ABSTRACT SESSION
- **PC**: PRO-CON SESSION
- **PL**: PLENARY SESSION
- **SH**: HIGHLIGHTS OF THE PREVIOUS DAY SESSION
- **WS**: WORKSHOP (TICKETED SESSIONS)
- **YI**: YOUNG INVESTIGATOR SESSION
Membership Lounge: NEW THIS YEAR!

Escape the conference hustle and bustle and take a minute to relax!

Visit the IASLC Membership Lounge in the Exhibit Hall (Level 300) to:

- Network with colleagues
- Learn about IASLC membership if you’re not yet a member
- Relax on a comfy couch and catch up on email
- Grab a cup of coffee and snacks

MEMBERSHIP LOUNGE HOURS:

- Monday: 09:30-18:30
- Tuesday: 09:30-18:30
- Wednesday: 09:30-14:00

COMMITTEE CORNER

Want to make an impact by joining an IASLC member committee?
Just want to find out more information?
Visit our Committee Corner located in the Membership Lounge.

- Talk with committee members and chairs one-on-one
- Find out what it means to be a committee member
- Learn how you can contribute to forwarding the IASLC’s mission

Each day committee members and chairpersons will be available to discuss their specific committees. Look for the daily schedule in the WCLC 2018 Daily News.
# Session Overview | Sunday, September 23, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00-11:00</td>
<td>IASLC Foundation Walk supported by Lung Cancer Canada</td>
<td>MTCC North Building, Room 201 F</td>
</tr>
<tr>
<td></td>
<td>07:00 - 08:00 Registration Open</td>
<td></td>
</tr>
<tr>
<td></td>
<td>08:00 - 09:00 Walk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>09:00 - 09:30 Celebration and Snacks</td>
<td></td>
</tr>
<tr>
<td>07:00-12:00</td>
<td>SO1  🍀 Screening and Early Detection</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td></td>
<td>IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Breakfast and Lunch provided)</td>
<td></td>
</tr>
<tr>
<td>07:30-11:15</td>
<td>JCSE01  🍀 Screening and Early Detection</td>
<td>Room 202 BD</td>
</tr>
<tr>
<td></td>
<td>Joint IASLC - CSCO - CAALC Session: Perspectives for Lung Cancer Early Detection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Breakfast and Lunch provided)</td>
<td></td>
</tr>
<tr>
<td>08:00-11:15</td>
<td>WS01  🍀 Room 201 BD</td>
<td>Cancer Genomics Workshop</td>
</tr>
<tr>
<td>08:00-11:15</td>
<td>WS02  🍀 Room 205 AC</td>
<td>Mesothelioma Workshop</td>
</tr>
<tr>
<td>08:00-11:30</td>
<td>WS03  🍀 Room 205 BD</td>
<td>Endoscopic Diagnosis and Staging of Lung Cancer - Interventional Pulmonology Hands-On Workshop</td>
</tr>
<tr>
<td>08:00-11:30</td>
<td>YI01  Room 106</td>
<td>Young Investigator’s Session (Breakfast and Coffee Break provided)</td>
</tr>
<tr>
<td>12:00-18:00</td>
<td>WS04  Room 206 BD</td>
<td>ITONF Workshop: Excellence in Thoracic Oncology Care (Lunch provided)</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>PR01  Room 202 BD</td>
<td>Press Conference</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>17:45-18:45</td>
<td>IASLC Foundation Concert</td>
<td>Glenn Gould Studio (CBC Building), 250 Front Street W (Across from Metro Toronto Convention Centre)</td>
</tr>
<tr>
<td>19:00-20:30</td>
<td>OC01 Opening Ceremony</td>
<td>Plenary Hall</td>
</tr>
<tr>
<td>20:30-22:00</td>
<td>Welcome Reception</td>
<td>Exhibit Hall (Food and Drinks provided)</td>
</tr>
</tbody>
</table>
## SECTION 5

**SESSION OVERVIEW | MONDAY, SEPTEMBER 24, 2018**

### Parallel Sessions 07:00-08:00

<table>
<thead>
<tr>
<th>MTE01</th>
<th>Biology</th>
<th>Room 206 F</th>
<th>Preclinical Models of Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTE02</td>
<td>Pathology</td>
<td>Room 203 BD</td>
<td>Update on WHO Classification and Staging of Lung Cancer</td>
</tr>
<tr>
<td>MTE03</td>
<td>Targeted Therapy</td>
<td>Room 105</td>
<td>Clinical Trial Design With Novel Lung Cancer Therapy</td>
</tr>
<tr>
<td>MTE04</td>
<td>Screening and Early Detection</td>
<td>Room 205 AC</td>
<td>Comparison of Various Risk Models</td>
</tr>
<tr>
<td>MTE05</td>
<td>Treatment of Locoregional Disease - NSCLC</td>
<td>Room 202 BD</td>
<td>Role of Pneumonectomy in N2 Disease</td>
</tr>
<tr>
<td>MTE06</td>
<td>Mesothelioma</td>
<td>Room 206 BD</td>
<td>Symptom Management in Mesothelioma</td>
</tr>
<tr>
<td>MTE07</td>
<td>Thymoma/Other Thoracic Malignancies</td>
<td>Room 201 F</td>
<td>Management of Pleural Recurrence</td>
</tr>
<tr>
<td>MTE08</td>
<td>Nursing and Allied Professionals</td>
<td>Room 205 BD</td>
<td>Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges</td>
</tr>
<tr>
<td>MTE09</td>
<td>Advanced NSCLC</td>
<td>Room 206 AC</td>
<td>Management of Advanced Wild-Type Lung Cancer in Special Situations</td>
</tr>
<tr>
<td>MTE10</td>
<td>Interventional Diagnostics/Pulmonology</td>
<td>Room 201 BD</td>
<td>Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous</td>
</tr>
</tbody>
</table>

### 08:15-09:45

<table>
<thead>
<tr>
<th>PL01</th>
<th>Patients First</th>
<th>Plenary Hall</th>
</tr>
</thead>
</table>

### 09:45-10:30

<table>
<thead>
<tr>
<th>P1</th>
<th>Poster Viewing Session</th>
<th>Exhibit Hall (Drinks and Snacks provided)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Media Availability</td>
<td>Plenary Hall</td>
<td></td>
</tr>
</tbody>
</table>

### Parallel Sessions 10:30-12:00

<table>
<thead>
<tr>
<th>MS01</th>
<th>Biology</th>
<th>Room 206 F</th>
<th>Cancer Pathways, Targeted Therapy and Resistance</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS02</td>
<td>Immunooncology</td>
<td>Room 106</td>
<td>The Future of IO</td>
</tr>
<tr>
<td>MS03</td>
<td>Oligometastatic NSCLC</td>
<td>Room 203 BD</td>
<td>New Frontiers in Oligometastases</td>
</tr>
<tr>
<td>MS04</td>
<td>Advocacy</td>
<td>Room 206 BD</td>
<td>Joint GLCC/IASLC Session: Exploring Hot Topics for Advocates</td>
</tr>
<tr>
<td>PC01</td>
<td>Mesothelioma</td>
<td>Room 205 AC</td>
<td>Controversies in Mesothelioma</td>
</tr>
<tr>
<td>MA01</td>
<td>Treatment of Early Stage/Localized Disease</td>
<td>Room 202 BD</td>
<td>Early Stage Lung Cancer: Questions and Controversies</td>
</tr>
<tr>
<td>MA02</td>
<td>Advanced NSCLC</td>
<td>Room 201 BD</td>
<td>Improving Outcomes for Patients with Advanced NSCLC</td>
</tr>
<tr>
<td>MA03</td>
<td>Screening and Early Detection</td>
<td>Room 206 AC</td>
<td>Lung Cancer Screening - Next Step</td>
</tr>
<tr>
<td>OA01</td>
<td>Treatment of Locoregional Disease - NSCLC</td>
<td>Room 107</td>
<td>Improving Outcomes in Locoregional NSCLC I</td>
</tr>
<tr>
<td>OA02</td>
<td>Targeted Therapy</td>
<td>Room 105</td>
<td>Novel Therapies in ROS1, HER2 and Rare EGFR Mutations</td>
</tr>
<tr>
<td>OA03</td>
<td>Pathology</td>
<td>Room 205 BD</td>
<td>Advances in Lung Cancer Pathology</td>
</tr>
<tr>
<td>OA04</td>
<td>Nursing and Allied Professionals</td>
<td>Room 201 F</td>
<td>Improving Access and Outcomes in Lung Cancer Management</td>
</tr>
</tbody>
</table>

### 12:00-13:30

<table>
<thead>
<tr>
<th>Meet the JTO Editor</th>
<th>Room 206 BD</th>
<th>TICKETED EVENT</th>
</tr>
</thead>
</table>

**CONTINENTAL BREAKFAST PROVIDED FOR MTE SESSIONS**
### Parallel Sessions 13:30-15:00

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MS05</strong></td>
<td>Pathology</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td></td>
<td>Diagnostic Dilemma in Lung Cancer</td>
<td></td>
</tr>
<tr>
<td><strong>MS06</strong></td>
<td>Oligometastatic NSCLC</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td></td>
<td>Practical issues in the Management of Oligometastatic NSCLC</td>
<td></td>
</tr>
<tr>
<td><strong>MS07</strong></td>
<td>Advanced NSCLC</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td></td>
<td>Antibody-Drug Conjugates in Advanced NSCLC</td>
<td></td>
</tr>
<tr>
<td><strong>MS08</strong></td>
<td>Treatment in the Real World - Support, Survivorship, Systems Research</td>
<td>Room 201 F</td>
</tr>
<tr>
<td></td>
<td>Lung Cancer in the Real World</td>
<td></td>
</tr>
</tbody>
</table>

### Parallel Sessions 15:15-16:45

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MS09</strong></td>
<td>Interventional Diagnostics/Pulmonology</td>
<td>Room 206 BD</td>
</tr>
<tr>
<td></td>
<td>Tumour Board - Tissue Acquisition and Staging</td>
<td></td>
</tr>
<tr>
<td><strong>MS10</strong></td>
<td>Treatment of Early Stage/Localized Disease</td>
<td>Room 206 F</td>
</tr>
<tr>
<td></td>
<td>Part Solid Nodules, GGN and STAS</td>
<td></td>
</tr>
<tr>
<td><strong>MS11</strong></td>
<td>Prevention and Tobacco Control</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td></td>
<td>Stigma and Lung Cancer: Unintended Translational Consequences of Effective Tobacco Control</td>
<td></td>
</tr>
</tbody>
</table>

### 16:45-18:00

**P1** Poster Viewing Session with Presenters Present
Exhibit Hall (Food and Drinks provided)

### 19:30-22:30

**Faculty Dinner (by Invitation Only)**
### SESSION OVERVIEW | TUESDAY, SEPTEMBER 25, 2018

#### Parallel Sessions 07:00-08:00

| MTE11 | Biology | Room 203 BD | Biology of Small Cell Lung Cancer |

| MTE12 | Immunooncology | Room 206 AC | IO in the Real World - High Risk Populations And Patient Support |

| MTE13 | Targeted Therapy | Room 201 BD | Clonal Evolution and Targeted Therapy |

| MTE14 | Screening and Early Detection | Room 206 F | Nodule Management (Pro Con Debate and Case Presentations) |

| MTE15 | Treatment of Early Stage/Localized Disease | Room 205 BD | Who is Too High Risk for a VATS Resection? |

| MTE16 | Small Cell Lung Cancer/NET | Room 205 AC | What Is Changing in the Management of Pulmonary Neuroendocrine Tumours? |

#### Parallel Sessions 08:15-09:45

| PL02 | Presidential Symposium including Top 5 Rated Abstracts | Plenary Hall |

| P2 | Poster Viewing Session | Exhibit Hall (Drinks and Snacks provided) |

| SH01 | Multi-Tracks | Plenary Hall |

| SH02 | Multi-Tracks | Room 202 BD | Highlights of the Previous Day Session |

#### Parallel Sessions 10:30-12:00

| MS13 | Biology | Room 201 F | Novel Mediators of Lung Cancer Metastasis |

| MS14 | Immunooncology | Room 107 | IO in Early Stage NSCLC |

| MS15 | Prevention and Tobacco Control | Room 201 BD | Disruptive Technology and Lung Cancer Risk |

| ES02 | Nursing and Allied Professionals | Room 206 BD | Quality Care in Lung Cancer |

| GR01 | Thymoma/Other Thoracic Malignancies | Room 206 F | Thymic Malignancies Tumor Board |

| MA01 | Advanced NSCLC | Room 206 AC | Treatment in the Real World - Support, Survivorship, Systems Research |

| MA03 | Interventional Diagnostics/Pulmonology | Room 205 BD | Survivorship, Socioeconomic and End-of-Life Considerations |

| MA10 | Immunooncology | Room 105 | Considerations in Immunotherapy |

| MA11 | Immunooncology | Room 203 BD | Biomarkers of IO Response |

| MA12 | Mesothelioma | Room 202 BD | Mesothelioma Surgery and Novel Targets for Prognosis and Therapy |

| PC05 | Advanced NSCLC | Room 205 AC | Optimizing Clinical Trial Design in NSCLC |

| OA10 | Targeted Therapy | Room 106 | Right Patient, Right Target & Right Drug - Novel Treatments and Research Partnerships |
## Parallel Sessions 13:30-15:00

<table>
<thead>
<tr>
<th>Room</th>
<th>Session</th>
<th>Duration</th>
<th>Room</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 206 F</td>
<td>MS16 Screening and Early Detection</td>
<td>13:30-15:00</td>
<td>Room 206 F</td>
<td>Implementation of Lung Cancer Screening</td>
</tr>
<tr>
<td>Room 206 AC</td>
<td>MS17 Treatment in the Real World - Support, Survivorship, Systems Research</td>
<td></td>
<td>Room 206 AC</td>
<td>Life After Lung Cancer: Survivorship</td>
</tr>
<tr>
<td>Room 206 BD</td>
<td>MS18 Small Cell Lung Cancer/NET</td>
<td></td>
<td>Room 206 BD</td>
<td>Management of SCLC Patients Not Represented in Clinical Trials</td>
</tr>
<tr>
<td>Room 201 BD</td>
<td>MS19 Interventional Diagnostics/Pulmonology</td>
<td></td>
<td>Room 201 BD</td>
<td>Pulmonary Dilemmas with Immunotherapy</td>
</tr>
<tr>
<td>Room 206 F</td>
<td>PC06 Pathology</td>
<td></td>
<td>Room 106</td>
<td>Controversies in Immunobiomarker Testing</td>
</tr>
<tr>
<td>Room 202 BD</td>
<td>PC07 Advanced NSCLC</td>
<td></td>
<td>Room 202 BD</td>
<td>The Future of Cytotoxic Chemotherapy in Advanced NSCLC</td>
</tr>
<tr>
<td>Room 105</td>
<td>PC08 Oligometastatic NSCLC</td>
<td></td>
<td>Room 105</td>
<td>The Great Oligometastatic Debates</td>
</tr>
<tr>
<td>Room 202 BD</td>
<td>MA15 Targeted Therapy</td>
<td></td>
<td>Room 107</td>
<td>Colliding Approaches - EGFR and Immunotherapy</td>
</tr>
<tr>
<td>Room 203 BD</td>
<td>MA16 Advanced NSCLC</td>
<td></td>
<td>Room 203 BD</td>
<td>Novel Mechanisms for Molecular Profiling</td>
</tr>
<tr>
<td>Room 205 AC</td>
<td>MA17 Nursing and Allied Professionals</td>
<td></td>
<td>Room 205 AC</td>
<td>New Methods to Improve Lung Cancer Patients Outcomes</td>
</tr>
<tr>
<td>Room 201 F</td>
<td>MA18 Treatment in the Real World - Support, Survivorship, Systems Research</td>
<td></td>
<td>Room 201 F</td>
<td>Modelling, Decision-Making and Population-Based Outcomes</td>
</tr>
<tr>
<td>Room 206 BD</td>
<td>MA19 Immunooncology</td>
<td></td>
<td>Room 106</td>
<td>Novel Therapies in MET, RET and BRAF</td>
</tr>
<tr>
<td>Room 202 BD</td>
<td>MA20 Screening and Early Detection</td>
<td></td>
<td>Room 206 BD</td>
<td>How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural Biopsy</td>
</tr>
<tr>
<td>Room 203 BD</td>
<td>MA21 Biology</td>
<td></td>
<td>Room 205 AC</td>
<td>How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural Biopsy</td>
</tr>
<tr>
<td>Room 205 BD</td>
<td>OA11 Thymoma/Other Thoracic Malignancies</td>
<td></td>
<td>Room 205 AC</td>
<td>New Therapies in MET, RET and BRAF</td>
</tr>
<tr>
<td>Room 205 BD</td>
<td>OA12 Targeted Therapy</td>
<td></td>
<td>Room 106</td>
<td>Novel Therapies in MET, RET and BRAF</td>
</tr>
</tbody>
</table>

## Parallel Sessions 15:15-16:45

<table>
<thead>
<tr>
<th>Room</th>
<th>Session</th>
<th>Duration</th>
<th>Room</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 202 BD</td>
<td>MS20 Treatment of Early Stage/Localized Disease</td>
<td></td>
<td>Room 202 BD</td>
<td>Innovative and Evolving Strategies in Diagnosis and Management of Stage I NSCLC</td>
</tr>
<tr>
<td>Room 105</td>
<td>MS21 Room 105 Giants in Thoracic Oncology</td>
<td></td>
<td>Room 105</td>
<td>Management of N2 NSCLC - A Case Based Discussion</td>
</tr>
<tr>
<td>Room 206 AC</td>
<td>GR02 Treatment of Logoregional Disease - NSCLC</td>
<td></td>
<td>Room 107</td>
<td>Management of N2 NSCLC - A Case Based Discussion</td>
</tr>
<tr>
<td>Room 206 AC</td>
<td>ES03 Mesothelioma</td>
<td></td>
<td>Room 206 AC</td>
<td>How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural Biopsy</td>
</tr>
<tr>
<td>Room 203 BD</td>
<td>ES04 Targeted Therapy</td>
<td></td>
<td>Room 203 BD</td>
<td>Liquid Biopsies in Lung Cancer</td>
</tr>
<tr>
<td>Room 205 AC</td>
<td>ES05 Advocacy</td>
<td></td>
<td>Room 205 AC</td>
<td>Collaboration Between Stakeholders to Improve Lung Cancer Research</td>
</tr>
<tr>
<td>Room 206 AC</td>
<td>MA19 Genomic Markers of IO Response</td>
<td></td>
<td>Room 201 BD</td>
<td>Novel Therapies in MET, RET and BRAF</td>
</tr>
<tr>
<td>Room 206 BD</td>
<td>MA20 Genomic Markers of IO Response</td>
<td></td>
<td>Room 206 BD</td>
<td>How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural Biopsy</td>
</tr>
<tr>
<td>Room 205 BD</td>
<td>OA12 Targeted Therapy</td>
<td></td>
<td>Room 205 BD</td>
<td>New Therapies in MET, RET and BRAF</td>
</tr>
</tbody>
</table>

## 16:45-18:00

- **IASLC Business Meeting (17:00-18:00)**
  - Room 202 BD
- **P2 Poster Viewing Session with Presenters Present**
  - Exhibit Hall (Food and Drinks provided)

## 20:00-23:30

- **Conference Dinner**
  - Plenary Hall
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00-08:00</td>
<td><strong>Parallel Sessions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MTE19 Thymoma/Other Thoracic Malignancies</td>
<td>Room 205 AC</td>
<td>How I Treat Advanced Stage Thymic Malignancy Patients</td>
</tr>
<tr>
<td></td>
<td>MTE20 Pathology</td>
<td>Room 202 BD</td>
<td>Molecular Testing in Small Samples</td>
</tr>
<tr>
<td></td>
<td>MTE21 Immunooncology</td>
<td>Room 105</td>
<td>Can I Treat Brain Metastasis with Immunotherapy?</td>
</tr>
<tr>
<td></td>
<td>MTE22 Prevention and Tobacco Control</td>
<td>Room 206 BD</td>
<td>Incorporation of Smoking Cessation in Clinical Care</td>
</tr>
<tr>
<td></td>
<td>MTE23 Treatment of Logoregional Disease - NSCLC</td>
<td>Room 201 BD</td>
<td>Surgical Considerations Following Induction Therapy for Stage IIIA Disease</td>
</tr>
<tr>
<td></td>
<td>MTE24 Treatment of Early Stage/Localized Disease</td>
<td>Room 203 BD</td>
<td>Multiple Lung Nodules; Resect, Radiate or Watch?</td>
</tr>
<tr>
<td></td>
<td>MTE25 Nursing and Allied Professionals</td>
<td>Room 205 BD</td>
<td>Enhancing the Care of Your Older Adult Population with Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>MTE26 Treatment in the Real World - Support, Survivorship, Systems Research</td>
<td>Room 206 AC</td>
<td>New Paradigms in Symptom Management in Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>MTE27 Small Cell Lung Cancer/NET</td>
<td>Room 206 F</td>
<td>Controversies in Radiotherapy for SCLC</td>
</tr>
<tr>
<td></td>
<td>MTE28 Interventional Diagnostics/Pulmonology</td>
<td>Room 201 F</td>
<td>From Textbook to Practice Around the World</td>
</tr>
<tr>
<td></td>
<td>SH03 Multi-Tracks</td>
<td>Room 107</td>
<td>Highlights of the Previous Day Session</td>
</tr>
<tr>
<td></td>
<td>SH04 Multi-Tracks</td>
<td>Room 106</td>
<td>Highlights of the Previous Day Session</td>
</tr>
<tr>
<td>08:15-09:45</td>
<td><strong>PL03 Call to Action - Challenges Ahead</strong></td>
<td>Plenary Hall</td>
<td></td>
</tr>
<tr>
<td>09:45-10:30</td>
<td><strong>P3 Poster Viewing Session</strong> (Drinks and Snacks provided)</td>
<td>Exhibit Hall</td>
<td>Media Availability</td>
</tr>
<tr>
<td></td>
<td><strong>Parallel Sessions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-12:00</td>
<td>MS22 Biology</td>
<td>Room 206 F</td>
<td>Biology of the Lung and Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>MS23 Targeted Therapy</td>
<td>Room 106</td>
<td>What’s New in Targeted Therapy?</td>
</tr>
<tr>
<td></td>
<td>MS24 Prevention and Tobacco Control</td>
<td>Room 206 BD</td>
<td>Global Perspectives on Tobacco Control</td>
</tr>
<tr>
<td></td>
<td>MS25 Mesothelioma</td>
<td>Room 206 AC</td>
<td>Genetic and Prognostic Markers in Mesothelioma; Going Beyond the Histology Subtypes</td>
</tr>
<tr>
<td></td>
<td>MS26 Treatment in the Real World - Support, Survivorship, Systems Research</td>
<td>Room 205 AC</td>
<td>From Textbook to Practice Around the World</td>
</tr>
<tr>
<td></td>
<td>MS27 Treatment of Early Stage/Localized Disease</td>
<td>Room 201 BD</td>
<td>Therapeutic Implications of Staging Issues</td>
</tr>
<tr>
<td></td>
<td>ES06 Oligometastatic NSCLC</td>
<td>Room 202 BD</td>
<td>Oligometastatic Disease</td>
</tr>
<tr>
<td></td>
<td>PC09 Advanced NSCLC</td>
<td>Room 107</td>
<td>Approaches to Management of Advanced NSCLC</td>
</tr>
<tr>
<td></td>
<td>MA23 Treatment of Early Stage/Localized Disease</td>
<td>Room 105</td>
<td>Early Stage Lung Cancer: Present and Future</td>
</tr>
<tr>
<td></td>
<td>MA24 Biology</td>
<td>Room 107</td>
<td>Treatment of Early Stage/Localized Disease</td>
</tr>
<tr>
<td></td>
<td>OA13 Small Cell Lung Cancer/NET</td>
<td>Room 203 BD</td>
<td>Genomic Evolution, KEAP 3 and More Non-Coding RNA</td>
</tr>
</tbody>
</table>

**Continental Breakfast Provided for MTE Sessions**
### Onsite Program

**IASLC 19th World Conference on Lung Cancer**

**www.iarsc.org**

#### 12:00-13:30

**P3**  
**Poster Viewing Session with Presenters Present**  
Exhibit Hall (Food and Drinks provided)

#### Parallel Sessions 13:30-15:00

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
</table>
| **12:00-13:30** | **P3** | Poster Viewing Session with Presenters Present  
Exhibit Hall (Food and Drinks provided) |
| **13:30-15:00** | **MS28** | Immunooncology  
Room 106  
IO Combinations in Advanced NSCLC |
|          | **MS29** | Screening and Early Detection  
Room 206 F  
Selection into Screening Programs: Interplay of Risk Algorithms, Genetic Markers and Biomarkers |
|          | **MS30** | Treatment of Logoregional Disease - NSCLC  
Room 202 BD  
Modern Day RT in LA NSCLC: Where Is the Evidence? |
|          | **MS31** | Mesothelioma  
Room 205 AC  
Clinical Science in Mesothelioma |
|          | **MS32** | Small Cell Lung Cancer/NET  
Room 107  
SCLC - From Benchside to Bedside - Clinical Science Session |
|          | **ES07** | Nursing and Allied Professionals  
Room 205 BD  
Beyond the Diagnosis - Collaborative Care for Change |
|          | **ES08** | Pathology  
Room 206 AC  
The Pathologist - An Essential Member of the Patient Care Team |
|          | **LA01** | IASLC Lectureship Award Session  
Room 105 |
|          | **MA25** | Oligometastatic NSCLC  
Biology  
Room 203 BD  
Oligometastasis: Defining, Treating, and Evaluating |
|          | **MA26** | Targeted Therapy  
Advanced NSCLC  
Pathology  
Room 201 BD  
New Therapies and Emerging Data in ALK, EGFR and ROS1 |
|          | **MA27** | Targeted Therapy  
Room 206 BD  
Novel Drugs and PDX Models |

#### 15:15-16:30

**PLO4**  
**Take Action - Key Messages from WCLC 2018 and Goals for 2019**  
Plenary Hall

---

**ES** Educational Session  
**GR** Grand Rounds Session  
**MA** Mini Oral Abstract Session  
**MS** Mini Symposium  
**MTE** Meet The Expert Session (ticketed sessions - continental breakfast provided)  
**OA** Oral Abstract Session  
**PC** Pro-Con Session  
**PL** Plenary Session  
**S** Symposium  
**SH** Highlights of the Previous Day  
**WS** Workshop (ticketed sessions)  
**YI** Young Investigator Session
Learn today’s best approaches to lung cancer diagnosis, treatment, and follow-up from global experts in conjunction with the IASLC.

IASLC Thoracic Oncology, 2nd Edition

Harvey I. Pass, MD, Executive Editor
David Ball, MD, FRANZCR, Editor
and Giorgio V. Scagliotti, MD, PhD, Editor
2018 • ISBN: 978-0-323-52357-8

FREE DIGITAL VERSION included with print purchase!
SECTION 6

Daily Scientific Program

TAKE ACTION
Against Lung Cancer!
DAILY SCIENTIFIC PROGRAM
SATURDAY, SEPTEMBER 22 / SUNDAY SEPTEMBER 23, 2018

SUNDAY, SEPTEMBER 23, 2018

06:30 – 20:00  Registration Open
Level 200
06:30 – 20:00  Speaker Preview Centre Open
Room 204
08:00 – 19:00  Media Room Open
Exhibit Hall (Behind Posters)
20:30 – 22:00  Exhibits Open – Welcome Reception
(Drinks and Food provided)
Exhibit Hall

Session II: Future Integration of Biomarkers in the Selection of High Risk Individuals for Lung Cancer Screening

08:00  S01.07: The U19 Plans for Integration of Biomarkers into Future Lung Cancer Screening
Christopher Amos, The Geisel School of Medicine at Dartmouth, USA
Rayjean Hung, Lunenfeld-Tanenbaum Research Institute, University of Toronto, Canada
Paul Brennan, International Agency for Research on Cancer, France

08:50  S01.08: Discussion

Session III: European Strategy for the Implementation of Lung Cancer Screening

09:00  S01.10: EU Position Statement on Lung Cancer Screening
Matthijs Oudkerk, University of Groningen, University Medical Center Groningen, Netherlands

09:20  S01.11: Discussion
09:30  Coffee Break

Session IV: Lung Cancer Screening Requires Infra-Structural Organisation and an Integrated Smoking Cessation Plan

09:50  S01.14: Coordination of the Lung Cancer CT Screening Experience
Joelle Fathi, University of Washington, USA

10:05  S01.15: Integration of Smoking Cessation into Lung Cancer Screening
Kate Brain, Cardiff University School of Medicine, UK

10:20  S01.16: Discussion

Session V: Panel Discussion: Next Steps for Lung Screening?

10:30  Andrea Borody Kitts, Lahey Hospital & Medical Center, USA
Claudia Henschke, Icahn School of Medicine, USA
Kwun M. Fong, University of Queensland Thoracic Research Centre at The Prince Charles Hospital, Australia
Motoyasu Sagawa, Tohoku Medical and Pharmaceutical University, Japan
Matthew Callister, Leeds Teaching Hospitals, UK
Nasser Altorki, Cornell University, USA
Bruce Pyenson, Miliman, Inc., USA

11:30 S01.18: IASLC Leads the International Collaboration on Data Sharing (IASLC-ELIC-CCTRR)
John Field, The University of Liverpool, UK
Jim Mulshine, Rush University, USA

11:50 S01.19: Discussion

12:00 Networking Lunch

07:30 – 11:15 JCSE01: JOINT IASLC/CSCO/CAALC SESSION - PERSPECTIVES FOR LUNG CANCER EARLY DETECTION
ROOM: 202 BD
CHAIRS: FRED R. HIRSCH, USA; YI-LONG WU, CHINA & TONY MOK, HONG KONG

BREAKFAST AND COFFEE BREAK PROVIDED

07:30 Breakfast and Poster Viewing

08:00 JCSE01.02: Necessity for Early Detection in Lung Cancer and Initial Attempts for Early Detection
Annette McWilliams, Fiona Stanley Hospital, Australia

08:20 JCSE01.03: CT Screening for Early Detection (NLST, UKLS, NELSON, ITALUNG, DANTE, Others)
Matthijs Oudkerk, University of Groningen, University Medical Center Groningen, Netherlands

08:40 JCSE01.04: Risk Modeling for the Early Detection of Tin Miner Lung Cancer in China
You-lin Qiao, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, China

09:00 JCSE01.05: Biomarkers and Liquid biopsy for Early Detection of Lung Cancer
K.C. Allen Chan, The Chinese University of Hong Kong, China

09:20 JCSE01.06: Incorporating Artificial Intelligence for Early Detection of Lung Cancer
Jie Hu, Zhongshan Hospital Fudan University, China

09:40 JCSE01.07: Discussion

09:50 JCSE01.08: Coffee Break and Poster Viewing

10:15 JCSE01.09: Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advanced NSCLC
Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

10:25 JCSE01.10: A Ph3 Study of Niraparib as Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients
Shun Lu, Shanghai Lung Cancer Center, China

10:35 JCSE01.11: Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients
Jianhua Chang, Fudan University Shanghai Cancer Center, China

10:45 JCSE01.12: Discussant Oral Abstracts
Daniel W. Tan, National Cancer Centre Singapore, Singapore

11:00 JCSE01.13: Discussant Poster Abstracts
Bob T. Li, Memorial Sloan Kettering Cancer Center, USA

11:15 JCSE01.23: Closing Remarks

07:30 – 11:15 Posters on Display

JCSE01.14: Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand-1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues
Xu Wang, The First Hospital of Jinlin University, China

JCSE01.15: Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients
Chunwei Xu, Fujian Cancer Hospital, China

JCSE01.16: Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma
Zheng Wang, Beijing Hospital, China

JCSE01.17: Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study
Changli Wang, Tianjin Medical University Cancer Institute and Hospital, China

JCSE01.18: A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Non-squamous Non-Small Cell Lung Cancer (CTONG1506)
Qing Zhou, Guangdong General Hospital, China

JCSE01.19: ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line
Baohui Han, Shanghai Chest Hospital, China

JCSE01.20: Outcome in Small Cell Lung Cancer Patients with Cerebral Recurrence After Prior Prophylactic Cranial Irradiation
Lei Zhao, Shanghai Chest Hospita, Shanghai Jiaotong University, China

JCSE01.21: Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients
Shuyuan Wang, Shanghai Chest Hospital, China
08:00 – 11:30 YI01: YOUNG INVESTIGATORS SESSION

ROOM: 106

CHAIRS: JONATHON YEUNG, CANADA & KATY CLARKE, UK

BREAKFAST AND COFFEE BREAK PROVIDED

07:30 Breakfast

08:00 YI01.01: Introduction to the IASLC - Why You Should be a Member
Clarissa Mathias, NOB/Oncoclinicas, Brazil

08:10 YI01.02: Planning a Career in Lung Cancer - Clinical Trials
Roy S. Herbst, Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven, USA

08:20 YI01.03: Planning a Career in Lung Cancer - Science
Yolonda Colson, Brigham and Women’s Hospital, USA

08:30 YI01.04: Planning a Career in Lung Cancer - Bench to Beside
Pasi A. Jänne, Dana-Farber Cancer Institute, USA

08:40 YI01.05: Planning a Career in Lung Cancer - Education
Barbara Melosky, British Columbia Cancer Agency, Canada

08:50 YI01.06: Community Oncology
Parneet K. Cheema, Sunnybrook Odette Cancer Centre, Canada

09:00 YI01.07: Making the Most of Your Cooperative Group
Rolf A. Stahel, University Hospital Zurich, Switzerland

09:10 YI01.08: Panel Discussion

09:30 Break

09:45 YI01.10: Knowing Your Statistics
Mary W. Redman, Fred Hutchinson Cancer Research Center, USA

10:00 YI01.11: How to Get Your Paper Published
Alex Adjei, Roswell Park Cancer Institute, USA

10:15 YI01.12: Writing a Successful Abstract
Michael Boyer, Chris O’Brien Lifehouse, Australia

10:30 YI01.13: How to Give a Great Presentation
Tony S. Mok, The Chinese University of Hong Kong, Hong Kong

10:45 YI01.14: How to Write a Successful Grant Application
Dean A. Fennell, University of Leicester & Leicester University Hospitals, UK

11:00 YI01.15: Panel Discussion

11:15 YI01.16: Young Investigator Experience
Fabio Y. Moraes, Hospital Sirio Libanes, Brazil

11:20 YI01.17: Getting the Most Out of WCLC 2018
Natasha B. Leighl, Princess Margaret Cancer Centre, Canada
Andrea Bezjak, Princess Margaret Cancer Centre, Canada
Gail Darling, Princess Margaret Cancer Centre, Canada

08:00 – 11:15 WS01: CANCER GENOMICS WORKSHOP

ROOM: 201 BD

CHAIRS: RAMASWAMY GOVINDAN, USA & RICHARD HASPEL, USA

08:00 WS01.01: Introduction to the Workshop

08:15 WS01.02: Exercise 1: Cancer Gene Panels: Methods and Application
08:00 – 11:15 WS02: MESOTHELIOMA WORKSHOP

TRACK: MESOTHELIOMA
ROOM: 205 AC
CHAIR: MICHELE CARBONE, USA

Session I: Surgery for Mesothelioma

CHAIR: HARVEY PASS, USA
08:00 WS02.02: What Are the Most Important Unmet Needs in the Surgical Management of Mesothelioma?
Valerie W. Rusch, Memorial Sloan-Kettering Cancer Center, USA
08:15 WS02.03: Who Are the High Risk Patients for Surgical Failure in Mesothelioma?
Harvey Pass, NYU Langone Medical Center, USA
08:30 WS02.04: SMART, Where It is Going
Marc De Perrot, University Health Network, Canada
08:45 WS02.05: Reliability of MM Diagnosis and Role of BAP1 Staining
Francoise Galateau-Salle, Centre Leon Berard, France
09:00 WS02.06: Q&A

Session II: Immunotherapy in Mesothelioma

CHAIR: PAUL BAAS, NETHERLANDS
09:05 WS02.08: The Microenvironment and Mesothelioma
Prasad S. Adusumilli, MSKCC, USA
09:20 WS02.09: PDL-1 and Mesothelioma
Raphael Bueno, Brigham and Women’s Hospital, USA
09:35 WS02.10: An Overview of Present and Future Immunotherapy Trials in Mesothelioma: Progress and Problems
Aaron S. Mansfield, Mayo Clinic, USA
09:50 WS02.11: Window of Opportunity Immunotherapy Trials in Mesothelioma: Design and Translation
Anne S. Tsao, University of Texas M.D. Anderson Cancer Center, USA
10:05 WS02.12: Q&A

Session III: Transcriptome Changes and Mutations in Mesothelioma – Somatic, Germline, BAP1 and more

CHAIR: DAVID M. JABLONS, USA
10:10 WS02.14: BAP1 Mutations: Mechanisms and Significance
Michele Carbone, University of Hawaii Cancer Center, USA
10:25 WS02.15: Novel Approaches for Targeting BAP1
Marjorie G. Zauderer, MSKCC, USA
10:40 WS02.16: Genome-wide Silencing Screen in Mesothelioma Cells Reveals that Loss of Function of BAP1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition: Implication for Therapy
Emanuela Felley-Bosco, Zurich University Hospital, Switzerland
10:55 WS02.17: A Subset of Mesotheliomas with Improved Survival Occurring in Carriers of BAP1 and of other Germline Mutations
Haining Yang, University of Hawaii Cancer Center, USA
11:10 WS02.18: Q&A

08:00 – 11:30 WS03: ENDOSCOPIC DIAGNOSIS AND STAGING OF LUNG CANCER – INTERVENTIONAL PULMONOLOGY HANDS-ON WORKSHOP

TRACK: INTERVENTIONAL DIAGNOSTICS/PULMONOLOGY
ROOM: 205 BD
CHAIR: KAZUHIRO YASUFUKU, CANADA
08:00 WS03.01: Welcome and Introduction
08:35 WS03.02: EBUS-TBNA – Role in Invasive Mediastinal Staging
09:10 WS03.03: Combined EBUS/EUS Mediastinal Staging
09:45 WS03.04: Radial Probe EBUS – Methods and Results
10:20 WS03.05: Navigational Bronchoscopy
10:55 WS03.06: Hands-On Session on 6 Stations
12:00 - 18:00  WS04: ITONF WORKSHOP: EXCELLENCE IN THORACIC ONCOLOGY CARE

**TRACK:** NURSING AND ALLIED PROFESSIONALS  
**ROOM:** 206 BD

**LUNCH PROVIDED**

12:00  ITONF Membership Meeting & Luncheon  
Melissa Culligan, University of Maryland Medical Center – Thoracic Surgery, USA

12:30  WS04.02: Keynote Speaker: Lung Cancer and Mesothelioma Nursing Care in Canada  
Massey Nematollahi, Southlake Regional Cancer Center, Canada

13:00  WS04.03: Panel Discussion: Managing Hope and Expectations in Thoracic Oncology  
**Moderator:** Maria Guerin, University Hospital Aintree, UK  
Beth Eaby-Sandy, University of Pennsylvania Health System, USA  
Bethany Taylor, The University of Sheffield, UK

13:30  WS04.04: Tag, Tweet or Follow: Top Tips for Using Social Media in Your Clinical Practice  
Liz Darlison, University Hospitals of Leicester NHS Trust, UK

13:50  WS04.05: UPDATE: Immunotherapy, Targeted Therapy and Combination Therapy Clinical Trials in Lung Cancer and Mesothelioma  
**Lung Cancer:** Rebecca Lau, Peter MacCallum Cancer Center, Australia  
**Mesothelioma:** Beurkley Rose, University of Chicago, USA

14:15  Break

14:30  WS04.07: Global Issues in Lung Cancer and Mesothelioma in 2018  
**Mesothelioma:** Lorraine Creech, University Hospitals of Leicester, UK  
**Lung Cancer:** Andrea Serena, Centre Hospitalier Universitaire Vaudois, Switzerland

15:00  WS04.08: UPDATE: Advances in Local Treatments for Lung Cancer and Mesothelioma (Radiation and Surgery)  
**Surgery - Meso:** Anastasia Bykova, Toronto General Hospital, University Health Network, Canada  
**XRT Lung Cancer-MESO:** Mary Duffy, Peter MacCallum Cancer Centre, Australia  
**Surgery - Lung Cancer:** Jenny Mitchell, Oxford University Hospitals NHS Trust, UK

15:45  Break

16:00  WS04.10: Nurse-led TeleHealth in Thoracic Oncology  
John McPhelim, Hairmyres Hospital, UK  
Sarah Cubbin, Clatterbridge Cancer Centre, UK

16:30  WS04.11: UPDATE: Toxicity Management of Immunotherapy Treatments in Lung Cancer and Mesothelioma  
**Moderator:** Kathleen Gamblin, Northside Hospital Cancer Institute, USA  
Marianne Davies, Yale Cancer Center, USA  
John McPhelim, Hairmyres Hospital, UK  
Anne Fraser, Auckland City Hospital, New Zealand

17:00  WS04.12: 2017-18 Year in Review: Scientific Poster Session  
Maria Guerin, University Hospital Aintree, UK
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 – 17:30</td>
<td><strong>PRO1: PRESS CONFERENCE</strong></td>
</tr>
<tr>
<td></td>
<td>Location: 202 BD</td>
</tr>
<tr>
<td></td>
<td>Chairs: Natasha Leigh, Canada; Andrea Beziak, Canada &amp; Gail Darling, Canada</td>
</tr>
<tr>
<td></td>
<td>For information on topics and speakers, please visit the Press &amp; Media page on the Conference website at: <a href="https://wclc2018.iaslc.org/press-media/">https://wclc2018.iaslc.org/press-media/</a></td>
</tr>
<tr>
<td>17:45 – 18:45</td>
<td><strong>IASLC FOUNDATION CONCERT</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Ticketed Event</strong></td>
</tr>
<tr>
<td></td>
<td>Venue: Glenn Gould Studio (CBC Building), 250 Front Street W (Across from Metro Toronto Convention Centre)</td>
</tr>
<tr>
<td></td>
<td>Toronto Symphony Orchestra Chamber Members playing Copland Appalachian Spring &amp; Vivaldi’s Seasons: Spring and Autumn</td>
</tr>
<tr>
<td>19:00 – 20:30</td>
<td><strong>OPENING CEREMONY</strong></td>
</tr>
<tr>
<td></td>
<td>Location: Plenary Hall</td>
</tr>
<tr>
<td></td>
<td>• Official Welcome to Canada</td>
</tr>
<tr>
<td></td>
<td>• Welcome Addresses</td>
</tr>
<tr>
<td></td>
<td>• IASLC Distinguished Award Presentations</td>
</tr>
<tr>
<td></td>
<td>• Eradicating Lung Cancer Prabat Jha, Centre for Global Health Research, St. Michael’s Hospital, University of Toronto, Canada</td>
</tr>
<tr>
<td>20:30 – 22:00</td>
<td><strong>WELCOME RECEPTION</strong></td>
</tr>
<tr>
<td></td>
<td>Location: Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Drinks and Food will be provided</td>
</tr>
</tbody>
</table>
07:30 MTE02.02: Update on WHO Classification and Staging of Lung Cancer
Teh-Ying Chou, Taipei Veterans General Hospital, Taiwan

07:00 – 08:00 MTE03: CLINICAL TRIAL DESIGN WITH NOVEL LUNG CANCER THERAPY  
TRACK: TARGETED THERAPY
ROOM: 105
07:00 MTE03.01: Inclusion/Exclusion Updates (CNS Mets, Multiple Prior Cancers, Organ Dysfunction)
Peter M. Ellis, Juravinski Cancer Centre, Canada
07:30 MTE03.02: Novel Trial Design for Precision Medicine
Fiona Blackhall, Manchester University and The Christie Hospital NHS Foundation Trust, UK

07:00 – 08:00 MTE04: COMPARISON OF VARIOUS RISK MODELS  
TRACK: SCREENING AND EARLY DETECTION
ROOM: 205 AC
07:00 MTE04.01: Comparisons of Risk Models
Christine Berg, US National Cancer Institute, USA
07:30 MTE04.02: Where Should Health Programs Set Threshold for Tailored Screening?
James L. Mulshine, Rush University, USA

07:00 – 08:00 MTE05: ROLE OF PNEUMONECTOMY IN N2 DISEASE  
TRACK: TREATMENT OF LOCOREGIONAL DISEASE – NSCLC
ROOM: 202 BD
07:00 MTE05.01: Role of Pneumonectomy in N2 Disease
Jessica Donington, University of Chicago, USA
07:30 MTE05.02: Role of Pneumonectomy in N2 Disease
Paula Ugalde, Institut Universitaire de Cardiologie et Pneumologie de Quebec, Canada

07:00 – 08:00 MTE01: PRECLINICAL MODELS OF LUNG CANCER  
TRACK: BIOLOGY
ROOM: 206 F
07:00 MTE01.01: GEMM of Lung Cancer
Sarah A. Best, The Walter and Eliza Hall Institute of Medical Research, Australia
07:30 MTE01.02: Lung Patient Derived Xenograft and Organoid
Nadeem Moghal, Princess Margaret Cancer Centre, University Health Network, Canada

07:00 – 08:00 MTE02: UPDATE ON WHO CLASSIFICATION AND STAGING OF LUNG CANCER  
TRACK: PATHOLOGY
ROOM: 203 BD
07:00 MTE02.01: Update on WHO Classification and Staging of Lung Cancer
Sanja Dacic, University of Pittsburgh, USA
07:30 MTE02.02: Update on WHO Classification and Staging of Lung Cancer
Sanja Dacic, University of Pittsburgh, USA
07:00 – 08:00  MTE06: SYMPTOM MANAGEMENT IN MESOTHELIOMA  
**TICKETED SESSION**

**TRACK:**  MESOTHELIOMA  
**ROOM:**  206 BD

07:00  MTE06.01: Role of Pleurectomy in Palliation of Symptoms  
John G. Edwards, Sheffield Teaching Hospitals NHS Foundation Trust, UK

07:30  MTE06.02: How to Register Toxicity and Guide Patients  
Liz Darlison, University Hospitals of Leicester NHS Trust, UK

07:00 – 08:00  MTE07: MANAGEMENT OF PLEURAL RECURRANCE  
**TICKETED SESSION**

**TRACK:**  THYMOMA/OTHER THORACIC MALIGNANCIES  
**ROOM:**  201 F

07:00  MTE07.01: From Radiation Oncology Perspective  
Andreas Rimner, Memorial Sloan Kettering Cancer Center, USA

07:30  MTE07.02: From Surgical Perspective  
Robert J. Korst, Mount Sinai Health System, USA

07:00 – 08:00  MTE08: ENHANCING THE NURSE’S ROLE IN TOBACCO PREVENTION AND CESSATION: NEW CHALLENGES  
**TICKETED SESSION**

**TRACK:**  NURSING AND ALLIED PROFESSIONALS  
**ROOM:**  205 BD

07:00  MTE08.01: Enhancing the Nurse’s Role in Tobacco Prevention and Cessation: New Challenges  
Linda Sarna, University of California, Los Angeles, USA

07:00 – 08:00  MTE09: MANAGEMENT OF ADVANCED WILD-TYPE LUNG CANCER IN SPECIAL SITUATIONS  
**TICKETED SESSION**

**TRACK:**  ADVANCED NSCLC  
**ROOM:**  206 AC

07:00  MTE09.01: Evidence Based Management of the Patient over 80  
Elisabeth Quoix, University Hospital, France

07:30  MTE09.02: Management of the PS 2 Patient  
Joan Schiller, Inova Schar Cancer Institute, USA

07:00 – 08:00  MTE10: EMERGING TECHNOLOGIES FOR SMALL AND SMALLER LESIONS – UPDATE ON ABLATION VIA ENDOSCOPY VS PERCUTANEOUS  
**TICKETED SESSION**

**TRACK:**  INTERVENTIONAL DIAGNOSTICS/PULMONOLOGY  
**ROOM:**  201 BD

07:00  MTE10.01: Emerging Technologies for Small and Smaller Lesions – Update on Ablation via Endoscopy vs Percutaneous  
Felix J. F. Herth, Thoraxklinik at Heidelberg University Hospital, Germany

08:15 – 09:45  PL01: PATIENTS FIRST  
**ROOM:**  PLENARY HALL

**CHAIRS:**  ANDREA BEZJAK, CANADA & PAUL A. BUNN JR., USA

08:15  PL01.01: When Breath Becomes Air  
Lucy Kalanithi, USA

08:25  PL01.02: Science that Matters  
David P. Carbone, The Ohio State Wexner Medical Center, USA

08:40  PL01.03: Trials that Matter!  
Tony S. Mok, The Chinese University of Hong Kong, Hong Kong

08:55  PL01.04: Getting Drugs to Patients Faster: A Global View  
Solange Peters, Lausanne University Hospital CHUV, Switzerland

09:10  PL01.05: Conquering Lung Cancer - The IASLC Vision  
Giorgio V. Scagliotti, University of Torino, Italy

09:25  PL01.06: Patients First  
Tish Vigna, Canada

08:15 – 09:45  PL01: PATIENTS FIRST  
**ROOM:**  PLENARY HALL

**CHAIRS:**  ANDREA BEZJAK, CANADA & PAUL A. BUNN JR., USA

08:15  PL01.01: When Breath Becomes Air  
Lucy Kalanithi, USA

08:25  PL01.02: Science that Matters  
David P. Carbone, The Ohio State Wexner Medical Center, USA

08:40  PL01.03: Trials that Matter!  
Tony S. Mok, The Chinese University of Hong Kong, Hong Kong

08:55  PL01.04: Getting Drugs to Patients Faster: A Global View  
Solange Peters, Lausanne University Hospital CHUV, Switzerland

09:10  PL01.05: Conquering Lung Cancer - The IASLC Vision  
Giorgio V. Scagliotti, University of Torino, Italy

09:25  PL01.06: Patients First  
Tish Vigna, Canada

09:45 – 10:30  MEDIA AVAILABILITY  
Plenary Hall

09:45 – 10:30  Coffee Break and Poster Viewing - Poster Session 1  
Exhibit Hall

Refreshments provided
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>MA01: EARLY STAGE LUNG CANCER: QUESTIONS AND CONTROVERSIES</td>
<td></td>
</tr>
<tr>
<td>10:30-10:40</td>
<td><strong>MA01.01</strong>: Proposal on Incorporating Lymphovascular Invasion as a T-Descriptor for Stage I Non-Small Cell Lung Cancer</td>
<td>Shuyuan Wang, Shanghai Chest Hospital, China</td>
</tr>
<tr>
<td>10:35-10:45</td>
<td><strong>MA01.02</strong>: Histologic Subtyping in Pathologic Stage I Lung Adenocarcinoma Provides Risk-Based Stratification for Surveillance</td>
<td>Yusuke Takahashi, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>10:40-10:45</td>
<td><strong>MA01.03</strong>: An Externally Validated Nomogram for Predicting Distant Metastasis After SBRT for Early Stage Non-Small Cell Lung Cancer</td>
<td>Aditya Juloori, Cleveland Clinic, USA</td>
</tr>
<tr>
<td>10:45-10:50</td>
<td><strong>MA01.04</strong>: Discussant - MA01.01, MA01.02, MA01.03</td>
<td>Deepali Jain, All India Institute of Medical Sciences, India</td>
</tr>
<tr>
<td>11:00-11:05</td>
<td><strong>MA01.05</strong>: Opioids and Sleep Medication Use After Surgery for Early Stage Lung Cancer: A SEER-Medicare Analysis</td>
<td>Stephanie Tumiello, Icahn School of Medicine at Mount Sinai, USA</td>
</tr>
<tr>
<td>11:05-11:10</td>
<td><strong>MA01.06</strong>: Evaluation of Safety and Efficacy in Surgical Treatment for Octogenarian Lung Cancer Patients by Multicenter Prospective Study: JACS1303</td>
<td>Tomohiro Haruki, Tottori University, Japan</td>
</tr>
<tr>
<td>11:10-11:15</td>
<td><strong>MA01.07</strong>: Validation of RTOG 0813 Normal Tissue Constraints for Pulmonary Toxicity in SBRT for Central Non-Small Cell Lung Cancer</td>
<td>Kyle Verdecchia, Cleveland Clinic, USA</td>
</tr>
<tr>
<td>11:15-11:20</td>
<td><strong>MA01.08</strong>: Discussant - MA01.05, MA01.06, MA01.07</td>
<td>Biniam Kidane, University of Manitoba, Canada</td>
</tr>
<tr>
<td>11:20-11:25</td>
<td><strong>MA01.09</strong>: Risk Factors of Radiation-Induced Lymphopenia (RLI) and Its Prognostic Significance in Small Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy</td>
<td>Jian He, Zhongshan Hospital, Fudan University, China</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>MA01.10</strong>: Toxicity and Local Control in “Ultra-Central” Lung Tumors Treated with SBRT or High-Dose Hypofractionated RT</td>
<td>Chunyu Wang, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>11:40</td>
<td><strong>MA01.11</strong>: Salvage SBRT for Local Recurrence After Primary Surgical Resection of Early Stage Non-Small Cell Lung Cancer</td>
<td>Sarah Sittenfeld, Cleveland Clinic, USA</td>
</tr>
<tr>
<td>11:45</td>
<td><strong>MA01.12</strong>: Discussant - MA01.09, MA01.10, MA01.11</td>
<td>Drew Moghanaki, Hunter Holmes McGuire Veterans Affairs Medical Center, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-12:00</td>
<td>MA02: IMPROVING OUTCOMES FOR PATIENTS WITH LUNG CANCER</td>
<td></td>
</tr>
<tr>
<td>10:30-10:35</td>
<td><strong>MA02.01</strong>: ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events</td>
<td>Terry L. Ng, University of Colorado Cancer Center, USA</td>
</tr>
<tr>
<td>10:35-10:40</td>
<td><strong>MA02.02</strong>: Multistate Healthcare Network Underutilizes Valuable End-of-Life Resources in Stage IV Non-Small Cell Lung Cancer</td>
<td>Candice L. Wilshire, Swedish Cancer Institute, USA</td>
</tr>
<tr>
<td>10:40-10:45</td>
<td><strong>MA02.03</strong>: ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC</td>
<td>Yi-Long Wu, Guangdong General Hospital &amp; Guangdong Academy of Medical Sciences, China</td>
</tr>
<tr>
<td>10:45-10:50</td>
<td><strong>MA02.04</strong>: Discussant - MA02.01, MA02.02, MA02.03</td>
<td>Alona Zer, Rabin Medical Center, Israel</td>
</tr>
<tr>
<td>11:00-11:05</td>
<td><strong>MA02.05</strong>: Opioids and Sleep Medication Use After Surgery for Early Stage Lung Cancer: A SEER-Medicare Analysis</td>
<td>Stephanie Tuminello, Icahn School of Medicine at Mount Sinai, USA</td>
</tr>
<tr>
<td>11:05-11:10</td>
<td><strong>MA02.06</strong>: Evaluation of Safety and Efficacy in Surgical Treatment for Octogenarian Lung Cancer Patients by Multicenter Prospective Study: JACS1303</td>
<td>Tomohiro Haruki, Tottori University, Japan</td>
</tr>
<tr>
<td>11:10-11:15</td>
<td><strong>MA02.07</strong>: Validation of RTOG 0813 Normal Tissue Constraints for Pulmonary Toxicity in SBRT for Central Non-Small Cell Lung Cancer</td>
<td>Kyle Verdecchia, Cleveland Clinic, USA</td>
</tr>
<tr>
<td>11:15-11:20</td>
<td><strong>MA02.08</strong>: Discussant - MA02.05, MA02.06, MA02.07</td>
<td>Biniam Kidane, University of Manitoba, Canada</td>
</tr>
<tr>
<td>11:20-11:25</td>
<td><strong>MA02.09</strong>: Risk Factors of Radiation-Induced Lymphopenia (RLI) and Its Prognostic Significance in Small Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy</td>
<td>Jian He, Zhongshan Hospital, Fudan University, China</td>
</tr>
<tr>
<td>11:30</td>
<td><strong>MA02.10</strong>: Toxicity and Local Control in “Ultra-Central” Lung Tumors Treated with SBRT or High-Dose Hypofractionated RT</td>
<td>Chunyu Wang, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>11:40</td>
<td><strong>MA02.11</strong>: Salvage SBRT for Local Recurrence After Primary Surgical Resection of Early Stage Non-Small Cell Lung Cancer</td>
<td>Sarah Sittenfeld, Cleveland Clinic, USA</td>
</tr>
<tr>
<td>11:45</td>
<td><strong>MA02.12</strong>: Discussant - MA02.09, MA02.10, MA02.11</td>
<td>Drew Moghanaki, Hunter Holmes McGuire Veterans Affairs Medical Center, USA</td>
</tr>
</tbody>
</table>
11:10 MA02.07: Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial
Kumar Prabhash, Department of Medical Oncology, Tata Memorial Hospital, India

11:15 MA02.08: The Effect of Nabilone on Appetite, Nutritional Status, and Quality of Life in Lung Cancer Patients: A Randomized, Double-Blind Clinical Trial
Jenny G. Turcott, National Cancer Institute of Mexico, Mexico

11:20 MA02.09: Discussant - MA02.05, MA02.06, MA02.07, MA02.08
Paul Wheatley-Price, Ottawa Hospital Cancer Center, Canada

11:35 MA02.10: The First Year of Implementing a Lung Cancer Screening Program in an Urban Safety-Net Health System
Heidi Hamann, University of Arizona, USA

11:40 MA02.11: Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE)
Doreen A. Ezeife, University Health Network, Canada

11:45 MA02.12: Discussant - MA02.10, MA02.11
William K. Evans, McMaster University, Canada

10:30 - 12:00 MA03: LUNG CANCER SCREENING - NEXT STEP
ROOM: 206 AC
CHAIRS: ALAIN TREMBLAY, CANADA & SAM M. JANES, UK

10:30 MA03.01: Manchester Lung Cancer Screening: Results of the First Incidence Screening Round
Haval Balata, Manchester University NHS Foundation Trust, UK

10:35 MA03.02: Prospective Evaluation of the Clinical Utility of the International Lung Screen Trial Lung Nodule Management Protocol
Stephen Lam, British Columbia Cancer Agency, Canada

10:40 MA03.03: Prolonged Low-DoseComputed Tomography (LDCT) Screening Beyond 5 Years Reduces Overall and Lung Cancer Specific Mortality
Ugo Pastorino, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

10:45 MA03.04: Discussant - MA03.01, MA03.02, MA03.03
Denise Aberle, UCLA, USA

11:00 MA03.05: New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial
Marjolein A. Heuvelmans, University of Groningen, University Medical Center Groningen, Netherlands

11:05 MA03.06: Descriptive Epidemiology of Significant Incidental Findings in a Large Clinical Lung Cancer Screening Program
Shawn M. Regis, Lahey Hospital & Medical Center, USA

11:10 MA03.07: Development and Validation of Deep Learning Model for Recognition of Histologic Subtype of Lung Adenocarcinoma from CT Images
Yunlang She, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

11:15 MA03.08: Discussant - MA03.05, MA03.06, MA03.07
Richard Booton, Manchester University NHS Foundation Trust, UK

11:30 MA03.09: Transcriptome-Wide Association Study Reveals Candidate Causal Genes for Lung Cancer
Alisson Clemenceau, Institut universitaire de cardiologie et de pneumologie de Québec, Canada

11:35 MA03.10: Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer
Shamus R. Carr, University of Maryland School of Medicine, USA

11:40 MA03.11: Trained Dogs Can Identify Malignant Pulmonary Nodules in Exhaled Gas
Angela Guirao, Hospital Clinic Barcelona, Spain

11:45 MA03.12: Discussant - MA03.09, MA03.10, MA03.11
Luis M. Montuenga, CIMA. University of Navarra, Spain

10:30 - 12:00 MS01: CANCER PATHWAYS, TARGETED THERAPY AND RESISTANCE
TRACK: BIOLOGY
ROOM: 206 F
CHAIRS: GREG RIELY, USA & WAN LAM, CANADA

10:30 MS01.01: Defects of the SWI/SNF OR MYC/MAX Pathways: Effects in Cell Differentiation and Therapeutic Opportunities
Montse Sanchez-Cespedes, Bellvitge Biomedical Research Institute, Spain

10:50 MS01.02: Targeting Negative Feedback Regulators to Hyperactivate Oncogenic Signaling
William Lockwood, British Columbia Cancer Agency, Canada

11:00 MS01.03: Stimulating Anti-Tumor Immunity Through Enhancing T-Cell Activation
Kwok-Kin Wong, NYU Langone Health Perlmutter Cancer Center, USA
MONDAY, SEPTEMBER 24, 2018

SECTION 6

11:00 MS03.03: Investigations into Alternative Clinical Endpoints for OM Beyond Survival
Alexander Louie, Sunnybrook Health Sciences Centre, Canada

11:15 MS03.04: Treatment of Oligoprogression: Real Progress or False Hope?
Fiona McDonald, Institute of Cancer Research & Royal Marsden Hospital, UK

11:30 MS03.05: Integration of Immunotherapy in the Oligometastatic Paradigm
Shankar Siva, Peter MacCallum Cancer Center, Australia

11:45 MS03.06: Q&A

10:30 – 12:00 MS04: JOINT GLCC/IASLC SESSION: EXPLORING HOT TOPICS FOR ADVOCATES

TRACK: ADVOCACY
ROOM: 206 BD
CHAIRS: CAROLYN ALDIGE, USA & CRISTINA SIT, CANADA

10:30 MS04.01: Collecting Data in the Real World - How Can Patient Groups Work with Researchers in Defining and Collecting Real-World Evidence?
Taofeek Owonikoko, Emory Winship Cancer Institute, USA

10:45 MS04.02: How is Lung Cancer Screening Evolving to Be More Efficient and Effective?
David R. Baldwin, Nottingham University Hospitals, UK

11:00 MS04.03: Exploring Smoking Stigma, Negativity and Lung Cancer – What Can Be Done?
Stefania Vallone, WALCE Onlus, Italy

11:15 MS04.04: E-Cigarettes - What Do Lung Cancer Advocates Need to Know?
Matthew Peters, Macquarie University, Australia

11:30 MS04.05: Panel Discussion

10:30 – 12:00 MS03: NEW FRONTIERS IN OLIGOMETASTASES

TRACK: OLIGOMETASTATIC NSCLC
ROOM: 203 BD
CHAIRS: JYOTI PATEL, USA & ERIC LIM, UK

10:30 MS03.01: The Biology of Oligometastases: What Have We learned?
David Palma, University of Western Ontario, Canada

10:45 MS03.02: Biomarkers in Oligometastatic Patients: Monitoring Diseases Response - Imaging vs Serum
Max Diehn, Stanford University, USA

10:30 – 12:00 OA01: IMPROVING OUTCOMES IN LOCOREGIONAL NSCLC I

TRACK: TREATMENT OF LOCOREGIONAL DISEASE - NSCLC
ROOM: 107
CHAIRS: GAETANO ROCCO, ITALY & RYAN CARLSON, CANADA

10:30 OA01.01: 10-Year Updated Analysis of NRG Oncology/RTOG 0214: A Phase III Comparison of PCI vs. Observation in Patients with LA-NSCLC
Alexander Sun, Princess Margaret Cancer Centre, Canada
10:40  OA01.02: The Estimate of Shrinking Field and SIB Radiotherapy Guided by 18F-FDG PET/CT in Locally Advanced NSCLC Patients: A Phase 2 Randomized Clinical Yaping Xu, Shanghai Pulmonary Hospital, China

10:50  OA01.03: Interaction Between Dose and Calcifications is a Predictor for Overall Survival in Lung Cancer Patients Receiving Radiotherapy Alan McWilliam, University of Manchester, UK

11:00  OA01.04: Discussant - OA01.01, OA01.02, OA01.03 John Armstrong, St. Luke’s Hospital, Ireland

11:15  OA01.05: Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCG Mariano Provencio, Hospital Puerta de Hierro, Spain

11:25  OA01.06: DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer Steven H. Lin, The University of Texas MD Anderson Cancer Center, USA

11:35  OA01.07: Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC Greg Durm, Indiana University School of Medicine, USA

11:45  OA01.08: Discussant - OA01.05, OA01.06, OA01.07 Corey J. Langer, University of Pennsylvania, USA

10:30 – 12:00  OA02: NOVEL THERAPIES IN ROS1, HER2 AND EGFR

10:30  OA02.01: Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) Robert C. Doebele, University of Colorado, USA

10:40  OA02.02: Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC Jessica J. Lin, Massachusetts General Hospital, USA

10:50  OA02.03: Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6 Sai-Hong I. Ou, University of California Irvine, USA

10:15  OA02.04: Discussant - OA02.01, OA02.02, OA02.03 Shengxiang Ren, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, China

11:15  OA02.05: CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial Melissa L. Johnson, Sarah Cannon Research Institute, USA

11:25  OA02.06: A Phase II Trial of Pozitinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) John V. Heymach, The University of Texas MD Anderson Cancer Center, USA

11:35  OA02.07: Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or -Mutated Advanced Non-Small-Cell Lung Cancer Junji Tsurutani, Kindai University Faculty of Medicine, Japan

11:45  OA02.08: Discussant - OA02.05, OA02.06, OA02.07 Daniel B Costa, Beth Israel Deaconess Medical Center, USA

10:30 – 12:00  OA03: ADVANCES IN LUNG CANCER PATHOLOGY

10:30  OA03.01: The Immunophenotyping and Genomic Characteristics of Pulmonary Sarcomatoid Carcinoma: Pleomorphic, Spindle Cell and Giant Cell Carcinoma Chunyan Wu, Shanghai Pulmonary Hospital, China

10:40  OA03.02: Nationwide Comparative Study of PD-L1 IHC Assays on Lung Cancer: Initial Report of LC-SCRUM-IBIS Project Noriko Motoi, National Cancer Center Hospital, Tokyo, Japan

10:40  OA03.02: Nationwide Comparative Study of PD-L1 IHC Assays on Lung Cancer: Initial Report of LC-SCRUM-IBIS Project Noriko Motoi, National Cancer Center Hospital, Tokyo, Japan

10:50  OA03.03: Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study Keith M. Kerr, Aberdeen Royal Infirmary, Aberdeen University Medical School, UK

11:00  OA03.04: Discussant - OA03.01, OA03.02, OA03.03 Julien Adam, Gustave Roussy, France
11:15 OA03.05: Characterization of the Immunologic Intra-Tumor Heterogeneity in Early Stages of Non-Small Cell Lung Cancer by Multiplex Immunofluorescence
Alejandro Francisco Cruz, The University of Texas MD Anderson Cancer Center, USA

11:25 OA03.06: Extraction of Radiomic Values from Lung Adenocarcinoma with Near-Pure Histological Subtypes
Mong-Wei Lin, National Taiwan University Hospital, Taiwan

11:35 OA03.07: Three-Dimensional Immunofluorescence Analysis of Dynamic Vessel Co-Option of Spread Through Air Spaces (STAS) in Lung Cancer
Yukako Yagi, Memorial Sloan Kettering Cancer Center, USA

11:45 OA03.08: Discussant - OA03.05, OA03.06, OA03.07
David L. Rimm, Yale University School of Medicine, USA

10:30 – 12:00 PC01: CONTROVERSIES IN MESOTHELIOMA
TRACK: MESOTHELIOMA
ROOM: 205 AC
CHAIRS: NICOLE BOUCHARD, CANADA & NICO VAN ZANDWIJK, AUSTRALIA

10:30 PC01.01: PRO Intrapleural Chemotherapy Is It the Future?
Isabelle Opitz, University Hospital of Zurich, Switzerland

10:45 PC01.02: CON Intrapleural Chemotherapy Is It the Future?
David Rice, MD Anderson Cancer Center, USA

11:00 PC01.03: PRO IO in Mesothelioma Should Only Be Given on Clinical Trials
Penelope Bradbury, Princess Margaret Cancer Centre and University of Toronto, Canada

11:15 PC01.04: CON in Mesothelioma Should Only Be Given on Clinical Trials
Evan Alley, University of Pennsylvania, USA

11:30 PC01.05: PRO Radiation Options: Are We SMART Enough?
John Cho, University Hospital Network, Princess Margaret Cancer Centre, Canada

11:45 PC01.06: CON Radiation Options: Are We SMART Enough?
Charles B. Simone, University of Maryland Medical Center, USA
12:00 – 13:30  **JTO: MEET THE JTO EDITOR**
ROOM: 206 BD

**12:00**  **JTO.01: Meet the JTO Editor**
Alex Adjei, Roswell Park Cancer Institute, USA

13:30 – 15:00  **ES01: ADVANCES IN LUNG CANCER SCREENING THROUGH IMAGING**

**TRACK:** SCREENING AND EARLY DETECTION
**ROOM:** 206 F
**CHAIRS:** HEIDI SCHMIDT, CANADA & DENISE Aberle, USA

**13:30**  **ES01.01: Image Quality Characteristics and Nodule Growth Measurement, Medical Physics and Machine Parameters**
Ricardo S. Avila, Accumetra, LLC, USA

**13:50**  **ES01.02: Image Interpretation and Advances from the Perspective of the Radiologist**
David F. Yankelevitz, Icahn School of Medicine at Mount Sinai, USA

**14:10**  **ES01.03: Deep Machine Learning for Screening LDCT**
Bram Van Ginneken, Radboud University Medical Center, Netherlands

**14:30**  **ES01.04: Multi-Phasic Screening – Can We Address Competing Causes of Morbidity & Mortality Such as Coronary Artery Disease and COPD**
Rozemarijn Vliegenthart, UMCG, Netherlands

**14:50**  **ES01.05: Q&A**

13:30 – 15:00  **MA04: NOVEL APPROACHES WITH IO**

**TRACK:** IMMUNOONCOLOGY
**ROOM:** 107
**CHAIRS:** TATIANE C. MONTELLA, BRAZIL & RANDEEP SANGHA, CANADA

**13:30**  **MA04.01: Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts**
Victor Moreno, START MADRID-FJD, Hospital Fundación Jiménez Díaz, Spain

**13:35**  **MA04.02: Responses and Durability in NSCLC Treated with Pegilodecakin and Anti-PD-1**
Edward B. Garon, University of California Los Angeles (UCLA), USA

**13:40**  **MA04.03: Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry**
Oliver Gautschi, Lucerne Cantonal Hospital, Switzerland

**13:45**  **MA04.04: Discussant**
- MA04.01, MA04.02, MA04.03
Jose Pacheco, University of Colorado Anschutz Medical, USA

**14:00**  **MA04.05: Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%**
Mark M. Awad, Dana-Farber Cancer Institute, USA

**14:05**  **MA04.06: PD-1 Blockade Promotes Hyperprogressive Disease in NSCLC Through Macrophages Activation via Antibody-Fc/FcR Interaction**
Gabriella Sozzi, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

**14:10**  **MA04.07: MicroRNA-Based Liquid Biopsy Combines with PD-L1 Tumor Expression to Predict Response to Immunotherapy in Advance NSCLC Patients**
Mattia Boeri, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

**14:15**  **MA04.08: Discussant**
- MA04.05, MA04.06, MA04.07
Patrick M. Forde, Johns Hopkins University, USA

**14:30**  **MA04.09: Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)**
Valerie W. Rusch, Memorial Sloan Kettering Cancer Center, USA

**14:35**  **MA04.10: Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC**
Filiz Oezkan, The Ohio State University, USA

**14:40**  **MA04.11: Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD-1 Blockade**
Kellie N. Smith, Johns Hopkins University School of Medicine, USA

**14:45**  **MA04.12: Discussant**
- MA04.09, MA04.10, MA04.11
Alex Adjei, Roswell Park Cancer Institute, USA
13:30 - 15:00  MA05: IMPROVING OUTCOMES IN LOCOREGIONAL NSCLC II

**TRACK:** TREATMENT OF LOCOREGIONAL DISEASE - NSCLC

**ROOM:** 105

**CHAIRS:** JOCELYNE MARTIN, CANADA & DEVIN SCHELLENBERG, CANADA

13:30  MA05.01: E6508: Phase II Study of Immunotherapy with Tecomotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC
Jyoti Patel, University of Chicago Comprehensive Cancer Center, USA

13:35  MA05.02: PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT
Johan F. Vansteenkiste, University Hospitals KU Leuven, Belgium

13:40  MA05.03: Immune Microenvironment and its Association with Adjuvant Chemotherapy Benefit in Locoregionally Advanced Lung Adenocarcinoma
Raj G. Vaghjiani, Memorial Sloan Kettering Cancer Center, USA

13:45  MA05.04: Discussant - MA05.01, MA05.02, MA05.03
Scott N. Gettinger, Yale Cancer Center, USA

14:00  MA05.05: Photon-Based Cardiac Sparing Via Volumetric Modulated Arc Therapy in Thoracic Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
Matthew J. Ferris, Winship Cancer Institute at Emory University, USA

14:05  MA05.06: Locally Advanced Lung Cancer Radiotherapy in Deep Inspiration Breath Hold: Dosimetric Benefits from a Prospective Trial
Mirjana Josipovic, Rigshospitalet Copenhagen University Hospital, Denmark

14:10  MA05.07: Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial
Jan Nyman, Sahlgrenska University Hospital, Sweden

14:15  MA05.08: Discussant - MA05.05, MA05.06, MA05.07
Benjamin H. Lok, Princess Margaret Cancer Centre, Canada

14:30  MA05.09: PFS and Cardiac-Toxicity-Adjusted-PFS as Predictors of OS in Locally Advanced NSCLC Treated with Concurrent Chemoradiation
Chen Hu, NRG Oncology Statistics and Data Management Center, USA

14:35  MA05.10: The Pathologic Response of Locally Advanced NSCLC Treated with Concomitant Chemoradiation to 60 Gy in Image Guided Radiation Therapy (IGRT)
Sarit Appel, Chaim Sheba Medical Center Tel Hashomer, Israel

14:40  MA05.11: Radiomics Analysis Using SVM Predicts Mediastinal Lymph Nodes Status of Squamous Cell Lung Cancer by Pre-Treatment Chest CT Scan
Wu Nan, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

14:45  MA05.12: Discussant - MA05.09, MA05.10, MA05.11
Matthew Hatton, Weston Park Hospital, UK

13:30 – 15:00  MA06: PDL1, TMB AND DNA REPAIR

**TRACK:** BIOLOGY

**ROOM:** 206 AC

**CHAIRS:** NORIKO MOTOI, JAPAN & JULIEN ADAM, FRANCE

13:30  MA06.01: The Intrinsic PD-L1 Promotes Cellular Invasiveness Via their PD-1 Receptor in Lung Adenocarcinoma Cells
Wen-Pin Su, National Cheng Kung University, Taiwan

13:35  MA06.02: Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer: Genomic and Immune Profiling Updates from Project ICON
Marcelo V. Negrao, UT MD Anderson Cancer Center, USA

13:40  MA06.03: PD-1 and Id-1 Combined Blockade Impacts Tumor Growth and Survival Through PD-L1 Expression and Tumor Infiltration by Immune-Related Cells
Ignacio Gil-Bazo, Clinica Universidad de Navarra, Spain

13:45  MA06.04: Discussant - MA06.01, MA06.02, MA06.03
Akihiko Yoshida, National Cancer Center Hospital, Japan

14:00  MA06.05: Photon-Based Cardiac Sparing Via Volumetric Modulated Arc Therapy in Thoracic Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
Matthew J. Ferris, Winship Cancer Institute at Emory University, USA

14:05  MA06.06: Locally Advanced Lung Cancer Radiotherapy in Deep Inspiration Breath Hold: Dosimetric Benefits from a Prospective Trial
Mirjana Josipovic, Rigshospitalet Copenhagen University Hospital, Denmark

14:10  MA06.07: Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial
Jan Nyman, Sahlgrenska University Hospital, Sweden

14:15  MA06.08: Discussant - MA06.05, MA06.06, MA06.07
Benjamin H. Lok, Princess Margaret Cancer Centre, Canada
14:00 MA06.05: The Micro-Environmental Cross Talk Between Mast Cells and Lung Cancer Cells Through Cell-to-Cell Contact
Rachel Shemesh, Sackler Faculty of Medicine, Tel Aviv University, Israel

14:05 MA06.06: An Ex-Vivo Patient-Derived, Immunocompetent (PDI) Culture System to Evaluate Immunotherapeutic Agents’ Anti-Tumor Efficacy
Zachary E. Tano, Memorial Sloan Kettering Cancer Center, USA

14:10 MA06.07: Genetic and Epigenetic Alterations are Associated with Tumor Mutation Burden in Non-Small Cell Lung Cancer
Liang-Liang Cai, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

14:15 MA06.08: Discussant - MA06.05, MA06.06, MA06.07
Jyoti Patel, University of Chicago, USA

14:30 MA06.09: XRCC6BP1: A DNA Repair Gene in Cisplatin Resistant Lung Cancer Stem Cells That May Predict Survival Outcomes in Patients
Martin P. Barr, St. James’s Hospital & Trinity College Dublin, Ireland

14:35 MA06.10: Germline Mutation in ATM Affect Lung Cancer Risk with High Effect
Xuemei Ji, Geisel School of Medicine at Dartmouth, USA

14:40 MA06.11: Distinct Origins of Lymphatic and Brain Metastasis in Lung Cancer
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

14:45 MA06.12: Discussant - MA06.09, MA06.10, MA06.11
Rebecca Heist, Massachusetts General Hospital, USA

13:30 – 15:00 MA07: TOWARDS SURVIVORSHIP: THE LANDSCAPE, SUPPORTS AND BARRIERS

13:30 MA07.01: No Longer Outliers: Understanding the Needs of Long-Term Lung Cancer Survivors
Maureen Rigney, Lung Cancer Alliance, USA

13:35 MA07.02: Line of Therapy and Patient Preferences Treating Lung Cancer: A Discrete-Choice Experiment
Andrea Ferris, LUNGevity Foundation, USA

13:40 MA07.03: Attitudes to Lung Cancer in Europe: Findings from a Global Consumer Survey
Jesme Fox, Roy Castle Lung Cancer Foundation, UK

13:45 MA07.04: Discussant - MA07.01, MA07.02, MA07.03
Govind Babu Kanakasetty, Kidwai Memorial Institute of Oncology, India

14:00 MA07.05: Psychosocial Needs and Programs of Cancer Patients/Survivors and Their Relatives: Unmet Needs from an International Study
Csaba L. Dégi, Romania

14:05 MA07.06: Telephonic Communication in Palliative Care for Better Management of Terminal Cancer Patients in Rural India - An NGO Based Approach.
Nabanita Mandal, Narikeldaha Prayas, India

14:10 MA07.07: Identifying the Severity of Psychosocial Symptoms Among Patients Diagnosed with Lung Cancer. Do We Really Need Emotional Support Groups?
Arooj Fatima, Shaukat Khanum Cancer Hospital and Research Centre, Pakistan

13:30 – 15:00 MS05: DIAGNOSTIC DILEMMA IN LUNG CANCER

13:30 MS05.01: Staging and Pathology of Multiple Lung Nodules
Alain C. Borczuk, Weill Cornell Medicine, USA

13:35 MS05.02: Defining Invasion in Minimally Invasive Adenocarcinoma
Masayuki Noguchi, University of Tsukuba, Japan
### MS05: Tumor Heterogeneity in Lung Cancer
Elisabeth Brambilla, Institut Albert Bonnnot, Hopital Albert Michallon, France

### MS04: Diagnosis and Classification in Biopsies
Andre Moreira, New York University Langone Health, USA

### MS05: Q&A

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:10</td>
<td>MS07.03: Clinical Data</td>
<td>Thomas E. Stinchcombe, Duke Cancer Insitute, USA</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>MS07.04: Future Directions</td>
<td>Silvia Novello, University of Turin, Italy</td>
<td></td>
</tr>
<tr>
<td>14:50</td>
<td>MS07.05: Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 13:30 – 15:00 MS06: PRACTICAL ISSUES IN THE MANAGEMENT OF OLIGOMETASTATIC NSCLC

**Track:** Oligometastatic NSCLC  
**Room:** 206 BD  
**Chairs:** Mary MacNeil, Canada & Ugo Pastorino, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>MS06.01: The Role of Radiation in Treating the Mets</td>
<td>Hak Choy, UT Southwestern, USA</td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td>MS06.02: The Role of Interventional Pulmonology and Radiology</td>
<td>Kwun M. Fong, University of Queensland Thoracic Research Centre at The Prince Charles Hospital, Australia</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>MS06.03: The Role of Surgical Resection</td>
<td>Boris Sepesi, MD Anderson Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td>MS06.04: Systemic Therapy for Oligomets: Before, During, or After Local Therapies?</td>
<td>Ross Camidge, University of Colorado Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>MS06.05: The Special Case of Brain Metastases: Systemic Therapy, Radiation or Both?</td>
<td>Laurie Gaspar, University of Colorado Denver Health Science Center, USA</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>MS06.06: Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 13:30 – 15:00 MS07: ANTIBODY-DRUG CONJUGATES IN ADVANCED NSCLC

**Track:** Advanced NSCLC  
**Room:** 205 BD  
**Chairs:** Normand Blais, Canada & Edgaro Santos, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>MS07.01: Basic Science</td>
<td>David E. Gerber, UT Southwestern, USA</td>
<td></td>
</tr>
<tr>
<td>13:50</td>
<td>MS07.02: Pharmacology</td>
<td>Christian Rolfo, Antwerp University Hospital, Belgium</td>
<td></td>
</tr>
</tbody>
</table>

### 13:30 – 15:00 MS08: LUNG CANCER IN THE REAL WORLD

**Track:** Treatment in the Real World  
**Room:** 201F  
**Chairs:** Antoinette Wozniak, USA & Ronan Kelly, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>MS08.01: How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies – European Perspective</td>
<td>Yolande Lievens, UZ Ghent, Belgium</td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td>MS08.02: How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies – US Perspective</td>
<td>Gideon Blumenthal, Member – National Navy Medical Center, USA</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>MS08.03: Sources of Real World Data: Research Designs, Statistical Modelling and Quality Assurance Requirements</td>
<td>Mary W. Redman, Fred Hutchinson Cancer Research Center, USA</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td>MS08.04: The ASCO Perspective</td>
<td>Bruce E. Johnson, Dana-Farber Cancer Institute, USA</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>MS08.05: The ESTRO Perspective</td>
<td>Umberto Ricardi, Univeristy of Turin, Italy</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>MS08.06: Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 13:30 – 15:00 OA05: CLINICAL TRIALS IN IO

**Track:** Advanced NSCLC  
**Room:** 106  
**Chairs:** Scott Owen, Canada & Denis Moro-Sibilot, France

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>OA05.01: Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy</td>
<td>Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, USA</td>
<td></td>
</tr>
</tbody>
</table>
13:40 OA05.02: Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037
Liza Villaruz, University of Pittsburgh, USA

13:50 OA05.03: Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC
Ben C. Creeлан, H. Lee Moffitt Cancer Center and Research Institute, Inc, USA

14:00 OA05.04: Discussant
- OA05.01, OA05.02, OA05.03
Martin J. Edelman, Fox Chase Cancer Center, USA

14:15 OA05.05: Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Phase 3 JAVELIN Lung 200 Trial
Fabrice Barlesi, Aix-Marseille University, France

14:25 OA05.06: CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC
Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center at John Hopkins, USA

14:35 OA05.07: IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
Vassiliki A. Papadimitrakopoulou, The University of Texas MD Anderson Cancer Center, USA

14:45 OA05.08: Discussant
- OA05.05, OA05.06, OA05.07
Hossein Borghaei, Fox Chase Cancer Center, USA

13:30 – 15:00 OA06: EARLY STAGE LUNG CANCER: OUTCOMES AND INTERVENTIONS
TRACK: TREATMENT OF EARLY STAGE/LOCALIZED DISEASE
ROOM: 202 BD
CHAIRS: PAUL VAN SCHIL, BELGIUM & HARUBUMI KATO, JAPAN

13:30 OA06.01: Case-Series Study in Ever- and Never-Smoking Females and Males with NSCLC: Exposures, Tumor Factors, Biology and Survival (SWOG S0424)
Kathy S. Albain, Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center, USA

13:40 OA06.02: Video-Assisted Thoracoscopic Surgery vs. Thoracotomy for Non-Small Cell Lung Cancer: Oncologic Outcome of a Randomized Trial
Dongrong Situ, Lung Cancer Research Institute, Sun Yat-sen University, China

13:50 OA06.03: Sublobar Resection is Equivalent to Lobectomy for Screen Detected Lung Cancer
Brendon M. Stiles, Weill Cornell Medicine, USA

14:00 OA06.04: Discussant
- OA06.01, OA06.02, OA06.03
Valerie W. Rusch, Memorial Sloan-Kettering Cancer Center, USA

14:15 OA06.05: Do SBRT Planning and Delivery Factors Influence Local Control for Early Stage Non-Small Cell Lung Cancer (e-NSCLC)?
Gregory M. M. Videtic, Cleveland Clinic, USA

14:25 OA06.06: MISSILE-NSCLC: A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early-Stage Non-Small Cell Lung Cancer
David Palma, London Health Sciences Centre, Canada

14:35 OA06.07: Predictors and Consequences of Refusing Surgery for Clinical Stage I NSCLC: A National Cancer Database Analysis
Brendon Stiles, Weill Cornell Medicine/New York Presbyterian Hospital, USA

14:45 OA06.08: Discussant
- OA06.05, OA06.06, OA06.07
Steven H. Lin, The University of Texas MD Anderson Cancer Center, USA
15:15 – 16:45  **MA08: CLINICAL TRIALS IN BRAIN METASTASES**

**TRACK:** ADVANCED NSCLC  
**ROOM:** 203 BD

**CHAIRS:** EDITH FILION, CANADA & BARBARA MELOSKY, CANADA

15:15  **MA08.01:** Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER)  
Zhenn Zhou Yang, Daping Hospital, Third Military Medical University, China

15:20  **MA08.02:** Prophylactic Cranial Irradiation Reduces the Risk of Brain Metastases in High-Risk Lung Cancer Patients: EGFR and ALK Mutations  
Oscar Arrieta, National Cancer Institute, Mexico

15:25  **MA08.03:** EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis  
Wenhua Liang, the First Affiliated Hospital of Guangzhou Medical University, China

15:30  **MA08.04:** Discussant  
- MA08.01, MA08.02, MA08.03  
Nasser Hanna, Indiana University, USA

15:45  **MA08.05:** Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study  
Todd M. Bauer, Sarah Cannon Cancer Research Institute/Tennessee Oncology, PLLC, USA

15:50  **MA08.06:** Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases  
Janet L. Espirito, McKesson Specialty Health, USA

15:55  **MA08.07:** Real World Data of Osimertinib in Patients with Central Nervous System (CNS) Metastasis in ASTRIS Korean Subset.  
Jin-Hyoun Kang, Department of Medical Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea

16:00  **MA08.08:** Discussant  
- MA08.05, MA08.06, MA08.07  
Myung-Ju Ahn, Samsung Medical Center Sungkyunkwan University, Korea

16:15  **MA08.09:** Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients  
Lizza Hendriks, Maastricht University Medical Center, Netherlands

16:20  **MA08.10:** Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases  
Margaux Geier, CHRU Morvan, University Hospital of Brest, France

16:25  **MA08.11:** Early Safety Data of a Phase I/II Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients with NSCLC  
Raafat Alameddine, Centre Hospitalier de l’Université de Montréal, Canada

16:30  **MA08.12:** Discussant  
- MA08.09, MA08.10, MA08.11  
Arjun Sahgal, Sunnybrook Research Institute, Canada

15:15 – 16:45  **MA09: LUNG CANCER SURGICAL AND MOLECULAR PATHOLOGY**

**TRACK:** PATHOLOGY  
**ROOM:** 202 BD

**CHAIRS:** DEEPALI JAIN, INDIA & DOGNMEI LIN, CHINA

15:15  **MA09.01:** Correlation of Pre-Operative Cancer Imaging Techniques with Post-Operative Macro and Microscopic Lung Pathology Images  
Stephen J. Harrow, Beatson West of Scotland Cancer Centre, UK

15:20  **MA09.02:** Tumor Size and Frozen Section Should Be Considered Jointly to Predict the Final Pathology for Lung Adenocarcinoma  
Erjia Zhu, Shanghai Pulmonary Hospital, China

15:25  **MA09.03:** Multiple Pathological Variables Predict Efficacy of Adjuvant Chemotherapy in Primary Lung Adenocarcinoma  
John Le Quesne, University of Leicester, UK

15:30  **MA09.04:** Discussant  
- MA09.01, MA09.02, MA09.03  
Natasha Rekhtman, Memorial Sloan Kettering Cancer Center, USA

15:45  **MA09.05:** Can We Predict Radiosensitivity in Non-Small Cell Lung Cancer?  
Juvenal Baena, University of Leicester, UK

15:50  **MA09.06:** The Newly Recognized Filigree Pattern of Micropapillary (MIP) Lung Adenocarcinoma (LADC) is as Clinically Important as the Classical Pattern  
Katsura Emoto, Memorial Sloan Kettering Cancer Center, USA

15:15 – 16:45  **MA08: CLINICAL TRIALS IN BRAIN METASTASES**

**TRACK:** ADVANCED NSCLC  
**ROOM:** 203 BD

**CHAIRS:** EDITH FILION, CANADA & BARBARA MELOSKY, CANADA

15:15  **MA08.01:** Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER)  
Zhenn Zhou Yang, Daping Hospital, Third Military Medical University, China

15:20  **MA08.02:** Prophylactic Cranial Irradiation Reduces the Risk of Brain Metastases in High-Risk Lung Cancer Patients: EGFR and ALK Mutations  
Oscar Arrieta, National Cancer Institute, Mexico

15:25  **MA08.03:** EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis  
Wenhua Liang, the First Affiliated Hospital of Guangzhou Medical University, China

15:30  **MA08.04:** Discussant  
- MA08.01, MA08.02, MA08.03  
Nasser Hanna, Indiana University, USA

15:45  **MA08.05:** Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study  
Todd M. Bauer, Sarah Cannon Cancer Research Institute/Tennessee Oncology, PLLC, USA

15:50  **MA08.06:** Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases  
Janet L. Espirito, McKesson Specialty Health, USA

15:55  **MA08.07:** Real World Data of Osimertinib in Patients with Central Nervous System (CNS) Metastasis in ASTRIS Korean Subset.  
Jin-Hyoun Kang, Department of Medical Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea

16:00  **MA08.08:** Discussant  
- MA08.05, MA08.06, MA08.07  
Myung-Ju Ahn, Samsung Medical Center Sungkyunkwan University, Korea

16:15  **MA08.09:** Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients  
Lizza Hendriks, Maastricht University Medical Center, Netherlands

16:20  **MA08.10:** Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases  
Margaux Geier, CHRU Morvan, University Hospital of Brest, France

16:25  **MA08.11:** Early Safety Data of a Phase I/II Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients with NSCLC  
Raafat Alameddine, Centre Hospitalier de l’Université de Montréal, Canada

16:30  **MA08.12:** Discussant  
- MA08.09, MA08.10, MA08.11  
Arjun Sahgal, Sunnybrook Research Institute, Canada
15:15-16:45 MS10: PART SOLID NODULES, GGN AND STAS

**TRACK:** TREATMENT OF EARLY STAGE/LOCALIZED DISEASE  
**ROOM:** 206 F

**CHAIRS:** PAUL VAN SCHIL, BELGIUM & NIR PELED, ISRAEL

**15:15** MS10.01: Radiographic Differences Between Presumed AIS and MIA  
Mini Pakkal, Toronto General Hospital, Canada

**15:30** MS10.02: Importance of CT in the Pathologic Assessment of Tumor Sized in Subsolid and Part-Solid Adenocarcinoma  
Erik Thunnissen, Amsterdam UMC, VU University Medical Center, Netherlands

**15:45** MS10.03: CT Versus Needle Biopsy Assessment Before Resection of Part Solid Nodules  
Young Tae Kim, Seoul National University Hospital, Korea

**16:00** MS10.04: Therapeutic Implications of Spread Through Air Spaces (STAS)  
William D. Travis, Memorial Sloan Kettering Cancer Center, USA

**16:15** MS10.05: Should We Resect GGNs  
Kenji Suzuki, Juntendo University Hospital, Japan

**16:30** MS10.06: Q&A

---

15:15 - 16:45 MS09: TUMOUR BOARD - TISSUE ACQUISITION AND STAGING

**TRACK:** INTERVENTIONAL DIAGNOSTICS/PULMONOLOGY  
**ROOM:** 206 BD

**CHAIRS:** SEPTIMIU MURGU, USA & ERIC EDELL, USA

**15:15** MS09.01: Cases Prepared by Drs. Edell/Murgu  
Neal Navani, University College London, UK

**15:35** MS09.02: Cases Prepared by Drs. Edell/Murgu  
Karin Steinke, Royal Brisbane and Women’s Hospital, Australia

**15:55** MS09.03: Cases Prepared by Drs. Edell/Murgu  
Kazuhiro Yasufuku, Toronto General Hospital, University of Toronto, Canada

**16:15** MS09.04: Cases Prepared by Drs. Edell/Murgu  
David Hwang, Sunnybrook Health Sciences Centre, Canada

**16:35** MS09.05: Q&A
### 15:15 – 16:45  MS12: IMMUNOTHERAPY AND RT

**Track:** TREATMENT OF LOCOREGIONAL DISEASE – NSCLC  
**Room:** 105  
**Chairs:** YI-LONG WU, CHINA & SALAMA JOSEPH, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>MS12.01: Biology IO+RT</td>
<td>Dirk De Ruysscher, Maastricht University Medical Centre, Netherlands</td>
</tr>
<tr>
<td>15:35</td>
<td>MS12.02: Clinical Data Available</td>
<td>Feng-Ming (Spring) Kong, Case Western Reserve University, USA</td>
</tr>
<tr>
<td>15:55</td>
<td>MS12.03: Ongoing Studies</td>
<td>Francoise Mornex, Hopital Lyon Sud, France</td>
</tr>
<tr>
<td>16:15</td>
<td>MS12.04: Implications for Routine Practice</td>
<td>Paul Mitchell, Olivia Newton-John Cancer, Wellness and Research Centre, Australia</td>
</tr>
<tr>
<td>16:35</td>
<td>MS12.05: Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### 15:15 – 16:45  OA07: OLIGOMETASTASIS: WHAT SHOULD BE THE STATE-OF-THE-ART?

**Track:** OLIGOMETASTATIC NSCLC  
**Room:** 107  
**Chairs:** YEE UNG, CANADA & PAULA MULVENNA, UK

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>OA07.01: Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT)</td>
<td>Joshua M. Baum, Perelman School of Medicine at the University of Pennsylvania, USA</td>
</tr>
<tr>
<td>15:25</td>
<td>OA07.02: ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI</td>
<td>Oscar S.H. Chan, Hong Kong Integrated Oncology Centre, China</td>
</tr>
<tr>
<td>15:35</td>
<td>OA07.03: Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver Metastases</td>
<td>Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China</td>
</tr>
<tr>
<td>15:45</td>
<td>OA07.04: Discussant - OA07.01, OA07.02, OA07.03</td>
<td>Gregory M. M. Videtic, Cleveland Clinic, USA</td>
</tr>
<tr>
<td>16:00</td>
<td>OA07.05: Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated with EGFR-TKIs</td>
<td>Yaping Xu, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China</td>
</tr>
<tr>
<td>16:10</td>
<td>OA07.06: Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.</td>
<td>Fang Hu, Shanghai Chest Hospital, China</td>
</tr>
<tr>
<td>16:20</td>
<td>OA07.07: PFS and OS Beyond 5 years of NSCLC Patients with Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)</td>
<td>Dirk De Ruysscher, Maastricht University Medical Centre, Netherlands</td>
</tr>
<tr>
<td>16:30</td>
<td>OA07.08: Discussant - OA07.05, OA07.06, OA07.07</td>
<td>Sue S. Yom, UCSF, USA</td>
</tr>
</tbody>
</table>

### 15:15 – 16:45  MS12: IMMUNOTHERAPY AND RT

**Track:** TREATMENT OF LOCOREGIONAL DISEASE – NSCLC  
**Room:** 105  
**Chairs:** YI-LONG WU, CHINA & SALAMA JOSEPH, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>OA08.01: Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)</td>
<td>Takashi Nakano, Otemae Hospital, Japan</td>
</tr>
<tr>
<td>15:25</td>
<td>OA08.02: DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result</td>
<td>Anna K. Nowak, University of Western Australia, Australia</td>
</tr>
<tr>
<td>15:35</td>
<td>OA08.03: Phase II Trial of Pembrolizumab (NCT02399371) in Previously-Treated Malignant Mesothelioma (MM): Final Analysis</td>
<td>Arpita Desai, The University of Chicago, USA</td>
</tr>
<tr>
<td>15:45</td>
<td>OA08.04: Discussant - OA08.01, OA08.02, OA08.03</td>
<td>Thomas John, Olivia Newton-John Cancer Centre, Australia</td>
</tr>
<tr>
<td>16:00</td>
<td>OA08.05: Quantifying Tumour Infiltrating Lymphocytes (TILs) in Malignant Pleural Mesothelioma (MPM) -Defining the Hot, the Warm and the Cold Tumours.</td>
<td>Bibhushal Thapa, Olivia Newton John Cancer Research Institute, Australia</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>OA09: PREVENTION AND CESSATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TRACK: PREVENTION AND TOBACCO CONTROL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ROOM: 205 BD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHAIRS: JAMES JETT, USA &amp; PAULA UGALDE, CANADA</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>OA09.01: 5As to 3As: Evolution of the Systematic Approach to Smoking Cessation in Ontario's Regional Cancer Centres</td>
<td></td>
</tr>
<tr>
<td></td>
<td>William K. Evans, McMaster University, Canada</td>
<td></td>
</tr>
<tr>
<td>15:25</td>
<td>OA09.02: Acceptance of Smoking Cessation Services in Cancer Care Ontario's Lung Cancer Screening Pilot for People at High Risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>William K. Evans, Cancer Care Ontario, Canada</td>
<td></td>
</tr>
<tr>
<td>15:35</td>
<td>OA09.03: Discussions Between Health Professionals and Smokers About E-Cigarettes: Results from the ITC Policy Evaluation Project</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shannon Gravely, University of Waterloo (International Tobacco Control Policy Evaluation Project), Canada</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>OA09.04: Discussant - OA09.01, OA09.02, OA09.03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Betty Tong, Duke Health, USA</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>OA09.05: Potential Reduction in Lung Cancer Mortality in the US from 2015-2065: A Comparative Modeling Approach</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jihyun Jeon, University of Michigan, USA</td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td>OA09.06: Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Laura Mezquita, Gustave Rouissy, France</td>
<td></td>
</tr>
<tr>
<td>16:20</td>
<td>OA09.07: Association Between Outdoor Air Pollution and Lung Cancer in Female Never Smokers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renelle L. Myers, British Columbia Cancer Agency, Canada</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>OA09.08: Discussant - OA09.05, OA09.06, OA09.07</td>
</tr>
<tr>
<td></td>
<td>Doug A. Arenberg, University of Michigan, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>PC03: CONTROVERSIES IN MANAGEMENT OF RESECTABLE THYMOMA</td>
</tr>
<tr>
<td></td>
<td>TRACK: THYMOMA/OTHER THORACIC MALIGNANCIES</td>
</tr>
<tr>
<td></td>
<td>ROOM: 205 AC</td>
</tr>
<tr>
<td></td>
<td>CHAIRS: NORIHIKO IKEDA, JAPAN &amp; ANDREA BEZJAK, CANADA</td>
</tr>
<tr>
<td>15:15</td>
<td>PC03.01: Post-Operative Radiation Therapy or NOT: PRO</td>
</tr>
<tr>
<td></td>
<td>Conrad B. Falkson, Queen's University and CCSEO at KHSC, Canada</td>
</tr>
<tr>
<td>15:25</td>
<td>PC03.02: Post-Operative Radiation Therapy or NOT: CON</td>
</tr>
<tr>
<td></td>
<td>Daniel Gomez, University of Texas MD Anderson Cancer Center, USA</td>
</tr>
<tr>
<td>15:35</td>
<td>PC03.03: Discussión</td>
</tr>
<tr>
<td>15:45</td>
<td>PC03.04: Debate on Standard Surgical Approaches – Minimally Invasive Thymectomy</td>
</tr>
<tr>
<td></td>
<td>Shaf Keshavjee, Toronto General Hospital, Canada</td>
</tr>
<tr>
<td>15:55</td>
<td>PC03.05: Debate on Standard Surgical Approaches – Open Thymectomy</td>
</tr>
<tr>
<td></td>
<td>Meinoshin Okumura, Toneyama National Hospital, Japan</td>
</tr>
<tr>
<td>16:05</td>
<td>PC03.06: Discussion</td>
</tr>
<tr>
<td>16:15</td>
<td>PC03.07: Adjuvant Chemotherapy for Thymic Carcinoma – YES</td>
</tr>
<tr>
<td></td>
<td>Giulia Pasello, Istituto Oncologico Veneto IRCCS, Italy</td>
</tr>
<tr>
<td>16:25</td>
<td>PC03.08: Adjuvant Chemotherapy for Thymic Carcinoma – NO</td>
</tr>
<tr>
<td></td>
<td>Sukhmani K. Padda, Stanford Cancer Institute/Stanford University School of Medicine, USA</td>
</tr>
<tr>
<td>16:35</td>
<td>PC03.09: Discussion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>PC04: TARGETED THERAPY FOR NSCLC</td>
</tr>
<tr>
<td></td>
<td>TRACK: TARGETED THERAPY</td>
</tr>
<tr>
<td></td>
<td>ROOM: 106</td>
</tr>
<tr>
<td></td>
<td>CHAIRS: ZOFIA PIOTROWSKA, USA &amp; BEN SOLOMON, AUSTRALIA</td>
</tr>
<tr>
<td>15:15</td>
<td>PC04.01: Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First versus Osimertinib First)</td>
</tr>
<tr>
<td></td>
<td>James Chih-Hsin Yang, Graduate Institute of Oncology &amp; Cancer Research Center, National Taiwan University, Taiwan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:10</td>
<td>OA08.07: in Silico Discovery of Unannotated miRNAs in Malignant Pleural Mesothelioma Reveals Novel Tissue-Origin Markers</td>
</tr>
<tr>
<td></td>
<td>Brenda C. Minatel, British Columbia Cancer Research Centre, Canada</td>
</tr>
<tr>
<td>16:30</td>
<td>OA08.06: Tumour Suppressor MicroRNAs Modulate Drug Resistance by Targeting Anti-Apoptotic Pathways in Malignant Pleural Mesothelioma (PM)</td>
</tr>
<tr>
<td></td>
<td>Yuen Yee Cheng, Asbestos Diseases Research Institute, Australia</td>
</tr>
</tbody>
</table>
15:27  PC04.02: Optimal Sequencing of EGFR TKI Therapy – 3rd Generation First
Karen L. Reckamp, City of Hope Comprehensive Cancer Center, USA

15:39  PC04.03: Adjuvant Targeted Therapy for pts with Genomic Alterations - Yes
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

15:51  PC04.04: Adjuvant Targeted Therapy for pts with Genomic Alterations - No
Lecia Sequist, Massachusetts General Hospital, USA

16:03  PC04.05: NGS/Whole Exome Sequencing for Routine Use
Daniel S. W. Tan, National Cancer Centre Singapore, Singapore

16:15  PC04.06: Focused Panels for Molecular Profiling for Routine Use
Fernando Lopez-Rios, Hospital Universitario HM Sanchinarro, Spain

16:27  PC04.07: Q&A

16:45 – 18:00  Poster Viewing Reception with Poster Presenters Present – Poster Session 1
Exhibit Hall
Drinks and Snacks provided

P1.01  Advanced NSCLC
P1.02  Advocacy
P1.03  Biology
P1.04  Immunoooncology
P1.05  Interventional Diagnostics/Pulmonology
P1.09  Pathology
P1.11  Screening and Early Detection
P1.12  Small Cell Lung Cancer/NET
P1.13  Targeted Therapy
P1.14  Thymoma/Other Thoracic Malignancies
P1.15  Treatment in the Real World - Support, Survivorship, Systems Research
P1.16  Treatment of Early Stage/Localized Disease
P1.17  Treatment of Locoregional Disease – NSCLC
## Daily Scientific Program

**Tuesday, September 25, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:30 – 15:30</td>
<td>Registration Open</td>
<td>Street Level 200</td>
<td></td>
</tr>
<tr>
<td>06:30 – 16:00</td>
<td>Speaker Preview Centre Open</td>
<td>Room 204</td>
<td></td>
</tr>
<tr>
<td>08:00 – 18:00</td>
<td>Poster Pick Up Open</td>
<td>Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>08:00 – 18:30</td>
<td>Media Room Open</td>
<td>Exhibit Hall (Behind Posters)</td>
<td></td>
</tr>
<tr>
<td>09:30 – 18:30</td>
<td>Exhibits Open</td>
<td>Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td>MTE11: Biology of Small Cell Lung Cancer</td>
<td>Ticketed Session</td>
<td>Room 203 BD</td>
</tr>
<tr>
<td></td>
<td>TRACK: Biology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ROOM: 203 BD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>MTE11.01: Novel Therapeutic Targets in SCLC</td>
<td>Julien Sage, Stanford University, USA</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MTE11.02: Biological Subsets of SCLC</td>
<td>Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td>MTE12: IO in the Real World – High Risk Populations and Patient Support</td>
<td>Ticketed Session</td>
<td>Room 206 AC</td>
</tr>
<tr>
<td></td>
<td>TRACK: Immunooncology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ROOM: 206 AC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>MTE12.01: is IO an Option for Patients with Contraindications (Auto-immune Disease, Pulmonary Fibrosis, HIV, Hepatitis, Transplant etc)</td>
<td>Andrew G. Robinson, Queens University, Canada</td>
<td></td>
</tr>
<tr>
<td>07:40</td>
<td>MTE12.02: How can we Minimize Toxicity for our High Risk Patients?</td>
<td>Massey Nematollahi, William Osler Health Center, Canada</td>
<td></td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td>MTE13: Clonal Evolution and Targeted Therapy</td>
<td>Ticketed Session</td>
<td>Room 201 BD</td>
</tr>
<tr>
<td></td>
<td>TRACK: Targeted Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ROOM: 201 BD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>MTE13.01: Clonal Evolution and Targeted Therapy</td>
<td>Ramaswamy Govindan, Washington University School of Medicine, USA</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MTE13.02: Clonal Evolution and Targeted Therapy</td>
<td>Janessa Laskin, BC Cancer Agency, Canada</td>
<td></td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td>MTE14: Nodule Management (Pro Con Debate and Case Presentations)</td>
<td>Ticketed Session</td>
<td>Room 206 F</td>
</tr>
<tr>
<td></td>
<td>TRACK: Screening and Early Detection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ROOM: 206 F</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>MTE14.01: Nodule Management (Pro Con Debate and Case Presentations)</td>
<td>Stephen Lam, BC Cancer &amp; University of British Columbia, Canada</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MTE14.02: Nodule Management (Pro Con Debate and Case Presentations)</td>
<td>Matthijs Oudkerk, University of Groningen, University Medical Center Groningen, Netherlands</td>
<td></td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td>MTE15: Who is Too High Risk for a VATS Resection?</td>
<td>Ticketed Session</td>
<td>Room 205 BD</td>
</tr>
<tr>
<td></td>
<td>TRACK: Treatment of Early Stage/Localized Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ROOM: 205 BD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>MTE15.01: Identifying High Risk Patients: What Makes a Patient Too High Risk for Surgery and Who Decides?</td>
<td>Hisao Asamura, Keio University School of Medicine, Japan</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MTE15.02: Who is Too High Risk for a VATS Resection?</td>
<td>Pieter E. Postmus, Lified University Medical Centre, Netherlands</td>
<td></td>
</tr>
</tbody>
</table>

Snacks and Beverages provided complimentary during morning break and afternoon poster viewing reception.

Food available for purchase during opening hours.
### 07:00 – 08:00 SH01: HIGHLIGHTS OF THE PREVIOUS DAY SESSION

**ROOM:** PLenary HALL

**CHAIR:** WILFRIED EBERHARDT, GERMANY & RINA HUI, AUSTRALIA

- **07:00 SH01.01:** Advances in Radiation Therapy
  Robert Macrae, The Ottawa Hospital - Cancer Centre, Canada

- **07:12 SH01.02:** Surgery
  TBC

- **07:24 SH01.03:** Access, Outcomes, Survivorship
  Viola Zhu, Chao Family Comprehensive Cancer Center, UC Irvine, USA

- **07:36 SH01.04:** Advanced Lung Cancer
  Luis Raez, Memorial Cancer Institute, USA

- **07:48 SH01.05:** Q&A

### 07:00 – 08:00 SH02: HIGHLIGHTS OF THE PREVIOUS DAY SESSION

**ROOM:** 202 BD

**CHAIRS:** BARBARA MELOSKY, CANADA & NICO VAN ZANDWIJK, AUSTRALIA

- **07:00 SH02.01 - Targeted tx**
  TBC

- **07:12 SH02.02 - Mesothelioma**
  Anne Tsao, University of Texas M.D. Anderson Cancer Center, United States of America

- **07:24 SH02.03 - IO**
  Gregory Riely, Memorial Sloan Kettering Cancer Center, United States of America

- **07:36 SH02.04 - Pathology/Biology/Diagnostics**
  Rafael Rosell, Catalan Institute of Oncology, Spain

- **07:48 SH02.05:** Q&A

### 07:00 – 08:00 MTE16: WHAT IS CHANGING IN THE MANAGEMENT OF PULMONARY NEUROENDOCRINE TUMOURS?

**TRACK:** SMALL CELL LUNG CANCER/NET
**ROOM:** 205 AC

- **07:00 MTE16.01:** Proper Treatment of LCNEC; Chemotherapy or Targeted Therapy
  Sumitra Thongprasert, Bangkok Hospital Chiang Mai, Thailand

- **07:30 MTE16.02:** The Management of Small Cell Lung Cancer following First Line Treatment Failure
  Glenwood Goss, Division of Medical Oncology, University of Ottawa, Canada

### 07:00 – 08:00 MTE17: LIVING WITH AND BEYOND LUNG CANCER: AN EDUCATION FOR ADVOCATES

**TRACK:** ADVOCACY
**ROOM:** 206 BD

- **07:00 MTE17.01:** Living With and Beyond Lung Cancer: An Education for Advocates
  Maureen Rigney, Lung Cancer Alliance, USA
  Winfield Boerckel, CancerCare, USA

### 07:00 – 08:00 MTE18: CASE-BASED MANAGEMENT OF PATIENTS WITH INADEQUATE TISSUE FOR MOLECULAR TESTS

**TRACK:** ADVANCED NSCLC
**ROOM:** 201 F

- **07:00 MTE18.01:** Case-Based Management of Patients with Inadequate Tissue for Molecular Tests
  Adrian Sacher, Princess Margaret Cancer Centre and University of Toronto, Canada
  Benjamin Levy, Johns Hopkins Sidney Kimmel Cancer Center, USA

### ES Educational Session
### GR Grand Rounds Session
### MA Mini Oral Abstract Session
### MS Mini Symposium
### MTE Meet the Expert Session (Ticketed sessions - continental breakfast provided)
### OA Oral Abstract Session
### PC Pro-Con Session
### PL Plenary Session
### S Symposium
### SH Highlights of the Previous Day Session
### WS Workshop (Ticketed Sessions)
### YI Young Investigator Session
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 – 09:45</td>
<td><strong>PLO2: PRESIDENTIAL SYMPOSIUM</strong> - TOP 5 ABSTRACTS</td>
<td></td>
<td>TRACKS: ADVANCED NSCLC, MESOTHELIOMA, SCREENING AND EARLY DETECTION, SMALL CELL LUNG CANCER/NET, TREATMENT OF EARLY STAGE/LOCALIZED DISEASE</td>
</tr>
<tr>
<td></td>
<td>CHAIRS: FRANCES SHEPHERD, CANADA; GIORGIO V. SCAGLIOTTI, ITALY &amp; MING TSAO, CANADA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:25</td>
<td>PLO2.02: Discussant – PLO2.01</td>
<td></td>
<td>Everett E. Vokes, University of Chicago, USA</td>
</tr>
<tr>
<td>08:30</td>
<td>PLO2.03: Brigatinib vs Crizotinib in Patients with ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)</td>
<td></td>
<td>Ross Camidge, University of Colorado Cancer Center, USA</td>
</tr>
<tr>
<td>08:40</td>
<td>PLO2.04: Discussant – PLO2.03</td>
<td></td>
<td>Fiona Blackhall, Manchester University and The Christie Hospital NHS Foundation Trust, USA</td>
</tr>
<tr>
<td>08:45</td>
<td>PLO2.05: Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial</td>
<td></td>
<td>Harry J. De Koning, Erasmus MC, Netherlands</td>
</tr>
<tr>
<td>08:55</td>
<td>PLO2.06: Discussant – PLO2.05</td>
<td></td>
<td>John K. Field, The University of Liverpool, UK</td>
</tr>
<tr>
<td>09:00</td>
<td>PLO2.07: IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC</td>
<td></td>
<td>Stephen V. Liu, Georgetown University, USA</td>
</tr>
<tr>
<td>09:10</td>
<td>PLO2.08: Discussant – PLO2.07</td>
<td></td>
<td>Natasha B. Leigh, Princess Margaret Cancer Centre, Canada</td>
</tr>
<tr>
<td>09:15</td>
<td>PLO2.09: Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial</td>
<td></td>
<td>Giorgio V. Scagliotti, University of Turin, Department of Oncology, S. Luigi Hospital, Italy</td>
</tr>
<tr>
<td>09:25</td>
<td>PLO2.10: Discussant – PLO2.09</td>
<td></td>
<td>Ross Soo, National University Hospital, Singapore</td>
</tr>
<tr>
<td>09:30</td>
<td>PLO2.11: Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45 – 10:30</td>
<td><strong>PR02: PRESS CONFERENCE</strong></td>
<td><strong>Plenary Hall</strong></td>
<td>For information on topics and speakers, please visit the Press &amp; Media page on the Conference website at: <a href="https://wclc2018.iaslc.org/press-media/">https://wclc2018.iaslc.org/press-media/</a></td>
</tr>
<tr>
<td>09:45 – 10:30</td>
<td>Coffee Break and <strong>Poster Viewing – Poster Session 2</strong></td>
<td><strong>Exhibit Hall</strong></td>
<td>Refreshments provided</td>
</tr>
<tr>
<td>10:30 – 12:00</td>
<td><strong>ES02: QUALITY CARE IN LUNG CANCER</strong></td>
<td><strong>ROOM: 206 BD</strong></td>
<td>TRACK: NURSING AND ALLIED PROFESSIONALS</td>
</tr>
<tr>
<td>10:30</td>
<td>ES02.01: Expanding PROs in Daily Practice</td>
<td></td>
<td>Kathen White, Private Practice, Australia</td>
</tr>
<tr>
<td>10:45</td>
<td>ES02.02: PRO: to Medicate: Managing Breathlessness</td>
<td></td>
<td>Alexandre Chan, National Cancer Centre Singapore, Singapore</td>
</tr>
<tr>
<td>11:00</td>
<td>ES02.03: CON: Not to Medicate: Managing Breathlessness</td>
<td></td>
<td>Catherine L. Granger, The University of Melbourne, Australia</td>
</tr>
<tr>
<td>11:15</td>
<td>ES02.04: Molecular Testing 101 for Nurses</td>
<td></td>
<td>Beth Eaby-Sandy, University of Pennsylvania Health System, USA</td>
</tr>
<tr>
<td>11:30</td>
<td>ES02.05: Structured Approach for Developing and Implementing and Advanced Practice Nursing Role in Lung Cancer</td>
<td></td>
<td>Andrea Serena, Lausanne University Hospital, Switzerland</td>
</tr>
<tr>
<td>11:45</td>
<td>ES02.06: Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
11:00 MA10.05: Effect of Early Steroids use in Advanced NSCLC Patients Treated with Immunotherapy
Giovanni Fucà, Istituto Nazionale dei Tumori, Italy

11:05 MA10.06: Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
Biagio Ricciuti, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy

11:10 MA10.07: Discussant – MA10.05, MA10.06
Kenneth O’Byrne, Princess Alexandra Hospital, Australia

11:25 MA10.08: Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC
Balazs Halmos, Albert Einstein College of Medicine/Montefiore Medical Center, USA

11:30 MA10.09: NECPAL 2: A Multicentre Descriptive Study of Primary and Continuous Attention in Palliative Care in Argentina: Lung Cancer Cohort
Carolina Gabay, Instituto de Oncología Angel H.Roffo, University of Buenos Aires, Argentina

11:35 MA10.10: Lung Cancer Stigma: A Ten-Year View of Patient, Provider, and Public Attitudes About Lung Cancer
Jennifer C. King, Lung Cancer Alliance, USA

11:40 MA10.11: Discussant – MA10.08, MA10.09, MA10.10
Antoinette Wozniak, Barbara Ann Karmanos Cancer Institute, Wayne State University, USA

11:55 MA10.12: Q&A

10:30 – 12:00 MA10: CONSIDERATIONS IN IMMUNOTHERAPY / REAL WORLD
TRACKS: ADVANCED NSCLC, TREATMENT IN THE REAL WORLD - SUPPORT, SURVIVORSHIP, SYSTEMS RESEARCH
ROOM: 105

CHAIRS: KEVIN JAO, CANADA & ROSALYN JUERGENS, CANADA

10:30 MA10.01: Antibiotic Use and PD-1 Inhibitors: Shorter Survival in Lung Cancer, Especially When Given Intravenously. Type of Infection Also Matters
Xabier Mielgo-Rubio, Hospital Universitario Fundación Alcorcón, Spain

10:35 MA10.02: Impact of Antibiotics on Outcome of Metastatic Non Small Cell Lung Cancer Patients Treated with Immunotherapy
Giulia Galli, Istituto Nazionale dei Tumori, Italy

10:40 MA10.03: Plasmatic Evaluation of the Intestinal Barrier and Blood Microbiota, and Antibiotic Use in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Etienne Giroux Leprieur, APHP – Hôpital Ambroise Paré, France

10:45 MA10.04: Discussant - MA10.01, MA10.02, MA10.03
Bertrand Routy, University of Montreal, Canada

10:30 – 12:00 MA11: BIOMARKERS OF IO RESPONSE
TRACK: IMMUNOONCOLOGY
ROOM: 203 BD

CHAIRS: GOVIND BABU KANAKASSETTY, INDIA & SHIRISH GADGEEL, USA

10:30 MA11.01: Comparative Efficacy of T-Cell Intrinsic Versus Extrinsic PD-1 Blockade to Overcome PD-L1+ Tumor-Mediated Exhaustion
Jordan Dozier, Memorial Sloan Kettering Cancer Center, USA
10:35 MA11.02: Increased CD3+ TIL Infiltration and Low FOXP3+/CD8+ TIL Ratio Can Predict Anti-PD-1 Therapeutic Response in Non-Small Cell Lung Cancer Patients
Hyojin Kim, Seoul National University Bundang Hospital, Korea

10:40 MA11.03: Interaction of Tumor Infiltrating Lymphocytes and Cancer Nuclei Predicts Response to Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
Xiangxue Wang, Case Western Reserve University, USA

10:45 MA11.04: Discussant - MA11.01, MA11.02, MA11.03
Donald Morris, Tom Baker Cancer Centre, Canada

11:00 MA11.05: Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact
Francesco Agustoni, University of Colorado Anschutz Medical Campus, USA

11:05 MA11.06: Prognostic Value of Complement System in NSCLC and its Association with PD-1 and PD-L1 Expression
Luis M. Montuenga, CIMA, Spain

11:10 MA11.07: Expression of LAG-3 and NY-ESO-1 in Tumor Cells is Promising Biomarker Predicting Durable Clinical Benefit of PD-1 Blockade in Advanced NSCLC
Hee Ryeong Jang, Kangwon National University Hospital, Korea

11:15 MA11.08: Discussant - MA11.05, MA11.06, MA11.07
Erin Schenk, Mayo Clinic, USA

11:30 MA11.09: Single-Cell Characterization of the Immunologic Microenvironment in Advanced-Stage, Oncogene-Driven NSCLC
Julia Rotow, University of California, San Francisco, USA

11:35 MA11.10: Identification of Mismatch Repair Deficient Lung Adenocarcinomas Using Targeted Next-Generation Sequencing
Navin R. Mahadevan, Brigham and Women’s Hospital, USA

11:40 MA11.11: Discrepancy of Tumor Neoantigen Burden Between Primary Lesions and Matched Metastases in Lung Cancer
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

11:45 MA11.12: Discussant - MA11.09, MA11.10, MA11.11
Ignacio Gil-Bazo, Clinica Universidad de Navarra, Spain
11:35 MA12.10: Long-Term Impact of Radiotherapy Before Surgery for Mesothelioma on the Distribution of Memory T Cell Subsets
Junichi Murakami, Toronto General Research Institute, Canada

11:40 MA12.11: Analysis of Angiogenic and Stromal Biomarkers in a Large Malignant Mesothelioma Cohort
Puey Ling Chia, Olivia Newton-John Cancer Research Institute, Australia

Masaki Anraku, The University of Tokyo Hospital, Japan

10:30 – 12:00 MA13: INTERVENTIONAL PULMONOLOGY

10:30 MA13.01: CT-Guided Transthoracic Needle Biopsy for Evaluation of PD-L1 Expression: Comparison of 22C3 and SP263 Assays
Kyongmin S. Beck, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea

10:35 MA13.02: PD-L1 Expression in EBUS-Guided Cytology Specimens of Non-Small Cell Lung Cancer is Not Affected by Type of Fixation: A Study of Matched Pairs
Alexander Haragan, University of Liverpool, UK

10:40 MA13.03: Heterogeneity Analysis of EBUS-TBNA-Derived Specimens for Evaluation of PD-L1 Expression and Copy Number Alterations in Patients with NSCLC
Katsuhiro Yoshimura, Hamamatsu University School of Medicine, Japan

10:45 MA13.04: Discussant - MA13.01, MA13.02, MA13.03
John R. Gosney, Royal Liverpool University Hospital, UK

11:00 MA13.05: The Canada Lymph Node Sonographic Score: National Validation of a Sonographic Score to Determine Mediastinal Lymph Node Malignancy
Danielle A. Hylton, McMaster University, Canada

11:05 MA13.06: Endosonography with Lymph Nodes Sampling for Restaging the Mediastinum in Lung Cancer: A Systematic Review and Pooled-Data Analysis
Long Jiang, The First Affiliated Hospital of Guangzhou Medical University, China

11:10 MA13.07: Diagnostic Yield of N3 Hilar Staging by Endobronchial Ultrasonography (EBUS) in Lung Cancer
Antoni Rosell, Hospital Universitari de Bellvitge, Spain

11:15 MA13.08: Discussant - MA13.05, MA13.06, MA13.07
Nicole Bouchard, Centre Hospitalier Universitaire De Sherbrooke, Canada

11:30 MA13.09: Electromagnetic Navigation Bronchoscopy as an Integrated Approach to Aid in Diagnosis and Treatment of Pulmonary Lesions
Sanddeep Khandhar, Inova Health System, USA

11:35 MA13.10: Comparison of Pulmonary Nodule Location Between Preprocedural CT and Intra-Procedural Cone-Beam CT During Guided Bronchoscopy
Michael A. Pritchett, Pinehurst Medical Clinic and FirstHealth Moore Regional Hospital, USA

11:40 MA13.11: Photodynamic Therapy for Peripheral-Type Lung Cancer in a Multi-Center Clinical Trial
Jitsuo Usuda, Nippon Medical School, Japan

Antoni Rosell, Hospital Universitari de Bellvitge, Spain

10:30 – 12:00 MA14: SURVIVORSHIP, SOCIOECONOMIC AND END-OF-LIFE CONSIDERATIONS

Jinwook Hwang, Korea University Ansan Hospital, Korea

10:35 MA14.02: Long-Term Impact of Radiotherapy Before Surgery for Mesothelioma on the Distribution of Memory T Cell Subsets
Junichi Murakami, Toronto General Research Institute, Canada

10:40 MA14.03: Analysis of Angiogenic and Stromal Biomarkers in a Large Malignant Mesothelioma Cohort
Puey Ling Chia, Olivia Newton-John Cancer Research Institute, Australia

10:45 MA14.04: Discussant - MA14.01, MA14.02, MA14.03
John R. Gosney, Royal Liverpool University Hospital, UK

11:00 MA14.05: The Canada Lymph Node Sonographic Score: National Validation of a Sonographic Score to Determine Mediastinal Lymph Node Malignancy
Danielle A. Hylton, McMaster University, Canada

11:05 MA14.06: Endosonography with Lymph Nodes Sampling for Restaging the Mediastinum in Lung Cancer: A Systematic Review and Pooled-Data Analysis
Long Jiang, The First Affiliated Hospital of Guangzhou Medical University, China

11:10 MA14.07: Diagnostic Yield of N3 Hilar Staging by Endobronchial Ultrasonography (EBUS) in Lung Cancer
Antoni Rosell, Hospital Universitari de Bellvitge, Spain

11:15 MA14.08: Discussant - MA14.05, MA14.06, MA14.07
Nicole Bouchard, Centre Hospitalier Universitaire De Sherbrooke, Canada

11:30 MA14.09: Electromagnetic Navigation Bronchoscopy as an Integrated Approach to Aid in Diagnosis and Treatment of Pulmonary Lesions
Sanddeep Khandhar, Inova Health System, USA

11:35 MA14.10: Comparison of Pulmonary Nodule Location Between Preprocedural CT and Intra-Procedural Cone-Beam CT During Guided Bronchoscopy
Michael A. Pritchett, Pinehurst Medical Clinic and FirstHealth Moore Regional Hospital, USA

11:40 MA14.11: Photodynamic Therapy for Peripheral-Type Lung Cancer in a Multi-Center Clinical Trial
Jitsuo Usuda, Nippon Medical School, Japan

Antoni Rosell, Hospital Universitari de Bellvitge, Spain

10:30 – 12:00 MA15: INTERVENTIONAL PULMONOLOGY

10:30 MA15.01: CT-Guided Transthoracic Needle Biopsy for Evaluation of PD-L1 Expression: Comparison of 22C3 and SP263 Assays
Kyongmin S. Beck, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea

10:35 MA15.02: PD-L1 Expression in EBUS-Guided Cytology Specimens of Non-Small Cell Lung Cancer is Not Affected by Type of Fixation: A Study of Matched Pairs
Alexander Haragan, University of Liverpool, UK

10:40 MA15.03: Heterogeneity Analysis of EBUS-TBNA-Derived Specimens for Evaluation of PD-L1 Expression and Copy Number Alterations in Patients with NSCLC
Katsuhiro Yoshimura, Hamamatsu University School of Medicine, Japan

10:45 MA15.04: Discussant - MA15.01, MA15.02, MA15.03
John R. Gosney, Royal Liverpool University Hospital, UK

11:00 MA15.05: The Canada Lymph Node Sonographic Score: National Validation of a Sonographic Score to Determine Mediastinal Lymph Node Malignancy
Danielle A. Hylton, McMaster University, Canada

11:05 MA15.06: Endosonography with Lymph Nodes Sampling for Restaging the Mediastinum in Lung Cancer: A Systematic Review and Pooled-Data Analysis
Long Jiang, The First Affiliated Hospital of Guangzhou Medical University, China

11:10 MA15.07: Diagnostic Yield of N3 Hilar Staging by Endobronchial Ultrasonography (EBUS) in Lung Cancer
Antoni Rosell, Hospital Universitari de Bellvitge, Spain

11:15 MA15.08: Discussant - MA15.05, MA15.06, MA15.07
Nicole Bouchard, Centre Hospitalier Universitaire De Sherbrooke, Canada

11:30 MA15.09: Electromagnetic Navigation Bronchoscopy as an Integrated Approach to Aid in Diagnosis and Treatment of Pulmonary Lesions
Sanddeep Khandhar, Inova Health System, USA

11:35 MA15.10: Comparison of Pulmonary Nodule Location Between Preprocedural CT and Intra-Procedural Cone-Beam CT During Guided Bronchoscopy
Michael A. Pritchett, Pinehurst Medical Clinic and FirstHealth Moore Regional Hospital, USA

11:40 MA15.11: Photodynamic Therapy for Peripheral-Type Lung Cancer in a Multi-Center Clinical Trial
Jitsuo Usuda, Nippon Medical School, Japan

11:45 MA15.12: Discussant - MA15.09, MA15.10, MA15.11
Antoni Rosell, Hospital Universitari de Bellvitge, Spain
10:30 – 12:00  MS13: NOVEL MEDIATORS OF LUNG CANCER METASTASIS

**TRACK:** BIOLOGY  
**ROOM:** 201 F  
**CHAIRS:** OSCAR ARRIETA, MEXICO & KWOK-KIN WONG, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>MS13.01: Liquid Biopsy-mediated Identification of Metastatic Variants</td>
</tr>
<tr>
<td></td>
<td>Philip C. Mack, UC Davis Comprehensive Cancer Center, USA</td>
</tr>
<tr>
<td>10:45</td>
<td>MS13.02: Capicua Inactivation Drives Lung Cancer Metastasis</td>
</tr>
<tr>
<td></td>
<td>Trever G. Bivona, UCSF, USA</td>
</tr>
<tr>
<td>11:00</td>
<td>MS13.03: Ubiquilin as a Novel Mediator of Lung Cancer Invasion and Metastasis</td>
</tr>
<tr>
<td></td>
<td>Levi J. Beverly, University of Louisville, USA</td>
</tr>
<tr>
<td>11:15</td>
<td>MS13.04: Tracking the Evolution of Non-Small-Cell Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>Charles Swanton, Francis Crick Institute, UK</td>
</tr>
<tr>
<td>11:30</td>
<td>MS13.05: Discussant</td>
</tr>
<tr>
<td></td>
<td>David Beer, University of Michigan, USA</td>
</tr>
<tr>
<td>11:45</td>
<td>MS13.06: Q&amp;A</td>
</tr>
</tbody>
</table>

---

10:30 – 12:00  MS14: IO IN EARLY STAGE NSCLC

**TRACK:** IMMUNOONCOLOGY  
**ROOM:** 107  
**CHAIR:** MARK KRIS, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>MS14.01: Basic Science Rationale of IO in Early Stage NSCLC?</td>
</tr>
<tr>
<td></td>
<td>Johan F. Vansteenkiste, University Hospital KU Leuven, Belgium</td>
</tr>
<tr>
<td>10:45</td>
<td>MS14.02: Adjuvant / Neoadjuvant IO Therapy</td>
</tr>
<tr>
<td></td>
<td>Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center, USA</td>
</tr>
<tr>
<td>11:00</td>
<td>MS14.03: Concerns About IO for the Thoracic Surgeon?</td>
</tr>
<tr>
<td></td>
<td>Bernward Passlick, Medical Center – University of Freiburg, Germany</td>
</tr>
<tr>
<td>11:15</td>
<td>MS14.04: IO – New Standards in Stage III NSCLC</td>
</tr>
<tr>
<td></td>
<td>Rafał Dziadziuszko, Medical University of Gdansk, Poland</td>
</tr>
<tr>
<td>11:30</td>
<td>MS14.05: Do Biomarkers used in Metastatic Setting Apply in Earlier Stages</td>
</tr>
<tr>
<td></td>
<td>Naiyer A. Rizvi, Columbia University Medical Center, USA</td>
</tr>
<tr>
<td>11:45</td>
<td>MS14.06: Q&amp;A</td>
</tr>
</tbody>
</table>
10:30 – 12:00  MS15: DISRUPTIVE TECHNOLOGY AND LUNG CANCER RISK

TRACK: PREVENTION AND TOBACCO CONTROL
ROOM: 201 BD

CHAIRS: ERIC BEDARD, CANADA & DOUG ARENBERG, USA

10:30  MS15.01: Just Water Vapor? Toxicology Perspectives on Electronic Cigarettes
Maciej L. Goniewicz, Roswell Park Comprehensive Cancer Center, USA

10:45  MS15.02: PRO- Electronic Cigarettes: A Cessation Tool
K. Michael Cummings, Medical University of South Carolina, USA

11:00  MS15.03: CON- Electronic Cigarettes: Not Evidence Based Cessation
Alison Wallace, University Health Network-University of Toronto, Canada

Junji Yoshida, Tokyo Midtown Clinic, Japan

11:30  MS15.05: Heat-Not-Burn Tobacco: Real Risk Reduction or Industry’s Next Promise
Carolyn Dresler, Human Rights and Tobacco Control Network, USA

11:45  MS15.06: Q&A

10:30 – 12:00  OA10: RIGHT PATIENT, RIGHT TARGET & RIGHT DRUG – NOVEL TREATMENTS AND RESEARCH PARTNERSHIPS

TRACK: TARGETED THERAPY
ROOM: 106

CHAIRS: HOWARD (JACK) WEST, USA & JYOTI PATEL, USA

10:30  OA10.01: Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC
John F. P. Bridges, Department of Biomedical Informatics, The Ohio State University College of Medicine, USA

10:40  OA10.02: Oncogene-Driven Patient Groups: A New Era for Research Partnerships
Janet Freeman-Daily, The ROS1ders, USA

10:50  OA10.03: Discussant - OA10.01, OA10.02
Zofia Piotrowska, Massachusetts General Hospital, USA

11:05  OA10.04: Afatinib with or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403
Sarah B. Goldberg, Yale School of Medicine, USA

11:15  OA10.05: An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09)
Jang Ho Cho, Samsung Medical Center, Korea

11:25  OA10.06: A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Keunchil Park, Samsung Medical Center, Korea

Caicun Zhou, Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, China

11:45  OA10.08: Discussant - OA 10.04, OA 10.05, OA 10.06, OA 10.07
Linda Coate, University Hospital Limerick, Ireland

10:30 – 12:00  PC05: OPTIMIZING CLINICAL TRIAL DESIGN IN NSCLC

TRACK: ADVANCED NSCLC
ROOM: 205 AC

CHAIRS: PILAR GARRIDO, SPAIN & LUIS UBILOS, URUGUAY

10:30  PC05.01: Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS – Point of View: PFS
Mary O’Brien, Royal Marsden Hospital, UK

10:45  PC05.02: Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS – Point of View: OS
Yu Shyr, Vanderbilt University School of Medicine, USA

11:00  PC05.03: Discussion

11:05  PC05.04: Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting – YES
Maurice Pérol, Centre Leon Berard, France

11:20  PC05.05: Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting – NO
Rathi N. Pillai, Winship Cancer Institute, Emory University, USA

11:35  PC05.06: Discussion
11:40 PC05.07: Let's Not Forget Chemo-Regret
Patricia J. Hollen, University of Virginia, USA

11:50 PC05.08: Discussion

13:30 - 15:00 MA15: COLLIDING APPROACHES – EGFR AND IMMUNOTHERAPY

TRACK: TARGETED THERAPY
ROOM: 107
CHAIRS: HEATHER WAKELEE, USA & NAJEEB R. RIZVI, USA

13:30 MA15.01: Strong PD-L1 Expression Predicts Poor Response and de Novo Resistance to EGFR TKIs Among Non-Small Cell Lung Cancer Patients with EGFR Mutation
Shan Su, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

13:35 MA15.02: Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC
Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA

13:40 MA15.03: PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial
Suresh S. Ramalingam, Emory University School of Medicine, Winship Cancer Institute, USA

13:45 MA15.04: Discussant
- MA15.01, MA15.02, MA15.03
Adrian Sacher, Princess Margaret Cancer Centre & University of Toronto, Canada

14:00 MA15.05: The Mutational Profiles of EGFR 19 Exon Deletion and 21 Exon L858R Mutation and Their Association with Primary Response to EGFR-TKIs
Wenhuai Liang, The First Affiliated Hospital of Guangzhou Medical University, China

14:05 MA15.06: Circulating Tumor DNA Portrays the Resistance Landscape to a Novel Third Generation EGFR Inhibitor, AC0010
Yi-Chen Zhang, Southern Medical University, China

14:10 MA15.07: Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients
Shuyuan Wang, Shanghai Chest Hospital, China

14:15 MA15.08: Discussant
- MA15.05, MA15.06, MA15.07
Charu Aggarwal, University of Pennsylvania, USA

14:30 MA15.09: Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs
Chunxiao Su, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

14:35 MA15.10: Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
Sha Zhao, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, China

14:40 MA15.11: Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs
Anne Chiang, Yale University School of Medicine, USA

14:45 MA15.12: Discussant
- MA15.09, MA15.10, MA15.11
Joel W. Neal, Stanford Cancer Institute/Stanford University, USA

13:30 – 15:00 MA16: NOVEL MECHANISMS FOR MOLECULAR PROFILING

TRACK: ADVANCED NSCLC
ROOM: 203 BD
CHAIRS: MUSTAPHA TEHFE, CANADA & MAKOTO NISHIO, JAPAN

13:30 MA16.01: Frequency and Genomic Context of Emerging Markers for Molecular Testing in Lung Adenocarcinoma in Cell-Free DNA NGS Analysis
Vincent K. Lam, The University of Texas MD Anderson Cancer Center, USA

13:35 MA16.02: Prospective Clinical Validation of the InVisionFirst™ ctDNA Assay for Molecular Profiling of Patients with Advanced NSCLC
Ramaswamy Govindan, Washington University School of Medicine, USA

13:40 MA16.03: Discussant
- MA16.01, MA16.02
Geoffrey R. Oxnard, Dana-Farber Cancer Institute, USA

Michael Offin, Memorial Sloan Kettering Cancer Center, USA

14:00 MA16.05: MET Kinase Domain Rearrangements (KDR) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP)
Sai-Hong I. Ou, University of California at Irvine, USA

14:05 MA16.06: EGFR Clonality and Tumor Mutation Burden (TMB) by Circulating Tumor DNA (ctDNA) Sequencing in Advanced Non-Small Cell Lung Cancer (NSCLC)
Xinghao Ai, Shanghai Chest Hospital, Shanghai Jiao Tong University, China
### Section 6

**TUESDAY, SEPTEMBER 25, 2018**

#### ES Educational Session
- **MA16.07**: Discussant - MA16.04, MA16.05, MA16.06  
  Ben J. Solomon, Peter MacCallum Cancer Centre, Australia

#### GR Grand Rounds Session
- **MA16.08**: Clinical Utility of Detecting ROS1 Genetic Alterations in Plasma  
  Ibiyi Dagogo-Jack, Massachusetts General Hospital, USA

#### MA Mini Oral Abstract Session
- **MA16.09**: Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer  
  Aurélie Swalduz, Centre Léon Bérard / Cancer Research Center of Lyon, France

#### MS Mini Symposium
- **MA16.10**: Clinical Utility of Cerebrospinal Fluid Cell-Free DNA for Clarifying Genetic Features of Leptomeningeal Metastases in ALK Rearrangement NSCLC  
  Meimei Zheng, Guangdong Lung Cancer Institute, China

#### MTE Meet the Expert Session
- **MA16.11**: Discussant - MA16.08, MA16.09, MA16.10  
  Robert C. Doebele, University of Colorado, USA

#### OA Oral Abstract Session
- **MA16.12**: Q&A

---

#### MA17: New Methods to Improve Lung Cancer Patients Outcomes

**Track:** Nursing and Allied Professionals  
**Room:** 205 AC  
**Chairs:** Massey Nematollahi, Canada & Rossie Navon, Israel

**13:30** MA17.01: A Sense of Understanding and Belonging When Life is at Stake – Operable Lung Cancer Patients’ Lived Experiences of Participation in Exercise  
Malene Misset, University Hospital of Copenhagen, Denmark

**13:35** MA17.02: Early Accrual to a Precision Lung Cancer Survivorship Intervention: The Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program  
Jamie L. Studts, University of Kentucky College of Medicine, USA

**13:40** MA17.03: Shared Decision-Making for Patients with Advanced Non-Small Cell Lung Cancer  
Mette K. Jensen, Copenhagen University Hospital, Rigshospitalet, Denmark

**13:45** MA17.04: Discussant - MA17.01, MA17.02, MA17.03  
Anne Fraser, Auckland City Hospital, New Zealand

**14:00** MA17.05: Development of a Telephone Clinic for Patients Undergoing Long Term Follow-Up After Thoracic Surgery  
Jenny Mitchell, Oxford University Hospitals NHS Trust, UK

**14:05** MA17.06: The Specialist Lung Cancer Nurse and Self-Management for People Living with Lung Cancer: A Model of Engagement  
Vanessa N. Brunelli, Queensland University of Technology, Australia

**14:10** MA17.07: Nurse-Led Telehealth Clinic in Treatment Monitoring and Follow Up  
Sarah L. Cubbin, Clatterbridge Cancer Centre NHS Foundation Trust, UK

**14:15** MA17.08: Discussant - MA17.05, MA17.06, MA17.07  
Melissa Culligan, University of Maryland Medical Center – Thoracic Surgery, USA

**14:30** MA17.09: Remote Symptom Reporting for Tele-Nursing Team in Thoracic Oncology Clinics: Environmental Scan and Stakeholder Engagement  
Simranjit Koener, Princess Margaret Cancer Centre, Canada

**14:35** MA17.10: The Use of Technology in the Delivery of Supportive Care of Lung Cancer Patients After Treatment  
Pamela Rose, NHS Lanarkshire, UK

**14:40** MA17.11: Multi-Centred, Prospective, Audit to Identify Readmission Causes and Complications Within 30 of Primary Lung Cancer Surgery  
Amy Kerr, Heartlands Hospital, UK

**14:45** MA17.12: Discussant - MA17.09, MA17.10, MA17.11  
Mary Duffy, Peter MacCallum Cancer Centre, Australia
13:30 – 15:00  MA18: MODELLING, DECISION-MAKING AND POPULATION-BASED OUTCOMES

<table>
<thead>
<tr>
<th>TRACK:</th>
<th>ROOM:</th>
</tr>
</thead>
<tbody>
<tr>
<td>TREATMENT IN THE REAL WORLD</td>
<td>201F</td>
</tr>
<tr>
<td>- SUPPORT, SURVIVORSHIP, SYSTEMS RESEARCH</td>
<td></td>
</tr>
</tbody>
</table>

CHAIRS: FABIO Y. MORAES, BRAZIL & ALEXANDER LOUIE, CANADA

13:30  MA18.01: Non-Small Cell Lung Cancer Risk Assessment with Artificial Neural Networks
       Tafadzwa L. Chaunzwa, Howard Hughes Medical Institute, USA

13:35  MA18.02: The Impact of Treatment Evolution in NSCLC (ITEN) Model: Development and Validation
       Manjusha Hurry, Astrazeneca Canada, Canada

13:40  MA18.03: How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience
       William K. Evans, McMaster University, Canada

13:45  MA18.04: Discussant - MA18.01, MA18.02, MA18.03
       Shalini K. Vinod, Liverpool Hospital, Australia

14:00  MA18.05: Characteristics and Long-Term OS of Non-Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment
       Michael Bergqvist, Umeå University, Sweden

14:05  MA18.06: Patterns of Lung Cancer Care in the United States: Developments and Disparities
       Erik F. Blom, Erasmus MC, Netherlands

14:10  MA18.07: Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors
       Lawson Eng, Princess Margaret Cancer Centre and University of Toronto, Canada

14:15  MA18.08: Discussant - MA18.05, MA18.06, MA18.07
       Vera Hirsh, McGill University, Royal Victoria Hospital, Canada

14:30  MA18.09: Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC
       Shirley X. Jiang, Princess Margaret Cancer Centre, Canada

14:35  MA18.10: Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool
       David R. Gandara, UC Davis Comprehensive Cancer Center, USA

14:40  MA18.11: Implementing a Comprehensive National Audit of Lung Cancer Surgery: The English Lung Cancer Clinical Outcomes Publication (LCCOP) Project
       Doug West, The Society for Cardiothoracic Surgery, UK

14:45  MA18.12: Discussant - MA18.09, MA18.10, MA18.11
       Martin R. Stockler, Clinical Trials Centre, University of Sydney, Australia

---

13:30 – 15:00  MS16: IMPLEMENTATION OF LUNG CANCER SCREENING

<table>
<thead>
<tr>
<th>TRACK:</th>
<th>ROOM:</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCREENING AND EARLY DETECTION</td>
<td>206F</td>
</tr>
</tbody>
</table>

CHAIRS: GARTH NICHOLAS, CANADA & HARRY GROEN, NETHERLANDS

13:30  MS16.01: CMS Approved ACR Lung Cancer Screening Registry in the United States
       Ella Kazerooni, University of Michigan, USA

13:45  MS16.02: NELCIN B3 Screening Program in China
       Qinghua Zhou, West China Hospital, Sichuan University, China

14:00  MS16.03: Recruitment Strategies for the Lung Cancer Screening
       Gail E. Darling, University Health Network, Canada

14:15  MS16.04: National Lung Screening Program in Taiwan
       Pan-Chyr Yang, National Taiwan University Hospital, Taiwan

14:45  MS16.06: Q&A

13:30 – 15:00  MS17: LIFE AFTER LUNG CANCER: SURVIVORSHIP

<table>
<thead>
<tr>
<th>TRACK:</th>
<th>ROOM:</th>
</tr>
</thead>
<tbody>
<tr>
<td>TREATMENT IN THE REAL WORLD</td>
<td>206 AC</td>
</tr>
<tr>
<td>- SUPPORT, SURVIVORSHIP, SYSTEMS RESEARCH</td>
<td></td>
</tr>
</tbody>
</table>

CHAIRS: DAVID DAWE, CANADA & JHANELLE GRAY, USA

13:30  MS17.01: Unmet Needs and QOL of Lung Cancer Survivors
       Meredith Giuliani, University of Toronto and Princess Margaret Cancer Center, Canada

14:15  MS17.04: How Important is Tobacco Cessation as Part of Lung Cancer Treatment?
       Clarissa Baldotto, Instituto Nacional de Cancer, Brazil

14:30  MS17.05: Discussion
13:30 – 15:00 | MS18: MANAGEMENT OF SCLC PATIENTS NOT REPRESENTED IN CLINICAL TRIALS

**TRACK:** SMALL CELL LUNG CANCER/NET  
**ROOM:** 206 BD

**CHAIRS:** JIE WANG, CHINA & EVERETT VOKES, USA

13:30 | MS18.01: Treatment of Patients with Poor Performance Status (ECOG 3-4)  
Luiz H. Araujo, Instituto Nacional de Cancer (INCA), Brazil

13:50 | MS18.02: Treatment of Elderly Patients with SCLC  
Karen Kelly, University of California Davis Comprehensive Cancer Center, USA

14:10 | MS18.03: Treatment of SCLC Transformed from EGFR Mutant Adenocarcinoma  
Nicolas Marcoux, CHU de Quebec, Canada

14:30 | MS18.04: Retreatment with Platinum and Etoposide and Treatment Beyond Second Line  
Charles Butts, Cross Cancer Institute, Canada

14:50 | MS18.05: Q&A

13:30 – 15:00 | MS19: PULMONARY DILEMMAS WITH IMMUNOTHERAPY

**TRACK:** INTERVENTIONAL DIAGNOSTICS/PULMONOLOGY  
**ROOM:** 201 BD

**CHAIRS:** SITA ANDARINI, INDONESIA & Luis RAEZ, USA

13:30 | MS19.01: Drug-Induced Pneumonitis with IO: How Worried Should we be for our Lung Cancer Patients  
Desiree Hao, University of Calgary & Tom Baker Cancer Centre, Canada

13:50 | MS19.02: What Are the Clinical Features of IO Progression/Pseudoprogression and Radiation Fibrosis vs Recurrence  
Chong-Kin Liam, University of Malaya, Malaysia

14:10 | MS19.03: Diagnostic Approaches Suspected IO Progression/Pseudoprogression and What/When to Rebiopsy for TT Progression  
Kasia Czarnecka-Kujawa, Toronto General Hospital, Canada

14:30 | MS19.04: Q&A

13:30 – 15:00 | OA11: THYMIC AND OTHER THORACIC TUMOURS: TARGETED THERAPIES, BIOMARKERS AND NEO/ADJUVANT RADIOThERAPY

**TRACK:** THYMOMA/OTHER THORACIC MALIGNANCIES  
**ROOM:** 205 BD

**CHAIRS:** MOJGAN TAREMI, CANADA & YARON SHARGALL, CANADA

13:30 | OA11.01: Role of Post-Operative Radiation in Different Histologic Subgroups of Thymoma: Result Based on National Cancer Data Base (NCDB)  
Tithi Biswas, Sideman Cancer Center, Case Medical Center, USA

13:40 | OA11.02: A Population-Based Study of Incidence and Survival Trends of 1,588 Thymic Malignancies: Results from the California Cancer Registry  
David J. Benjamin, University of California, Davis, USA

13:50 | OA11.03: Discussant  
– OA11.01, OA11.02  
Andrew Hope, Princess Margaret Cancer Centre, Canada

14:05 | OA11.04: A Comparative Study of PD-L1 Immunohistochemical Assays with Four Reliable Antibodies in Thymic Carcinoma  
Tadashi Sakane, Nagoya City University Graduate School of Medical Sciences, Japan

14:25 | OA11.05: Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum-Based Chemotherapy (KOSMIC Trial)  
Se Hyun Kim, Seoul National University Bundang Hospital, Korea

14:35 | OA11.07: Discussant  
– OA11.04, OA11.05, OA11.06  
Giuseppe Giaccone, Georgetown University, USA

14:50 | OA11.08: Q&A
13:30 - 15:00  PC06: CONTROVERSIES IN IMMUNOBIOMARKER TESTING  
**TRACK:** PATHOLOGY  
**ROOM:** 106  
**CHAIRS:** CHRISTIAN COUTURE, CANADA & ERIK THUNNISSSEN, NETHERLANDS  
13:30 PC06.01: Laboratory Developed Test - PRO  
Dara L. Aisner, University of Colorado SOM, USA  
13:50 PC06.02: Laboratory Developed Test - CON  
Mari Mino-Kenudson, Massachusetts General Hospital, USA  
14:10 PC06.03: Tumor Mutation Burden - PRO  
Lynette M. Sholl, Brigham and Women's Hospital, USA  
14:30 PC06.04: Tumor Mutation Burden - CON  
Lukas Bubendorf, University Hospital Basel, Switzerland  
14:50 PC06.05: Q&A

13:30 - 15:00  PC07: THE FUTURE OF CYTOTOXIC CHEMOTHERAPY IN ADVANCED NSCLC  
**TRACK:** ADVANCED NSCLC  
**ROOM:** 202 BD  
**CHAIRS:** STEPHANIE BRULE, CANADA & TEREFUMI KATO, JAPAN  
13:30 PC07.01: Debate 1: Chemotherapy Will Become a Thing of the Past in the Management of Advanced NSCLC – For  
Suresh S. Ramalingam, Emory University Winship Cancer Institute, USA  
13:50 PC07.02: Debate 1: Chemotherapy Will Become a Thing of the Past in the Management of Advanced NSCLC – Against  
Keunchil Park, Samsung Medical Center, Korea  
14:10 PC07.03: Debate 2: for Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO Alone versus Chemo + IO – IO Alone  
Leora Horn, Vanderbilt-Ingram Cancer Center, USA  
14:30 PC07.04: Debate 2: for Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO Alone versus Chemo + IO – Chemo + IO  
Federico Cappuzzo, AUSL Romagna, Italy  
14:50 PC07.05: Q&A

15:15 - 16:45  ES03: HOW TO MANAGE PLEURAL PLAQUES AND PLEURAL EFFUSION WITH NEGATIVE PLEURAL BIOPSY  
**TRACK:** MESOTHELIOMA  
**ROOM:** 206 AC  
**CHAIRS:** ROLF STAHEL, SWITZERLAND & MARC DE PERROT, CANADA  
15:15 ES03.01: Diagnosis of Mesothelioma Based on Cytology Alone  
Jennifer Sauter, Memorial Sloan Kettering Cancer Center, USA  
15:30 ES03.02: Role of CT Scan to Follow Pleural Plaques  
Demetris Patiassos, Toronto General Hospital, Canada
15:45  ES03.03: When to Repeat Pleural Biopsies
Catherine Labbe, Division of Respirology and Thoracic Surgery, Canada

16:00  ES03.04: Role of Chemotherapy in Mesothelioma with Minimal Bulk Disease
Christopher W. Lee, BC Cancer, Canada

16:15  ES03.05: Role of Surgery in T0 Mesothelioma
Seiki Hasegawa, Hyogo College of Medicine, Japan

16:30  ES03.06: Q&A

15:15 – 16:45 GR02: MANAGEMENT OF N2 NSCLC – A CASE BASED DISCUSSION

15:45 ES03.03: When to Repeat Pleural Biopsies
Catherine Labbe, Division of Respirology and Thoracic Surgery, Canada

16:00  ES03.04: Role of Chemotherapy in Mesothelioma with Minimal Bulk Disease
Christopher W. Lee, BC Cancer, Canada

16:15  ES03.05: Role of Surgery in T0 Mesothelioma
Seiki Hasegawa, Hyogo College of Medicine, Japan

16:30  ES03.06: Q&A

15:15 – 16:45 ES04: LIQUID BIOPSIES IN LUNG CANCER

15:15 ES04.01: Liquid Biopsies in Lung Cancer
Ming S. Tsao, University Health Network, Princess Margaret Cancer Centre and University of Toronto, Canada

15:35 ES04.02: Mechanisms of Resistance to Targeted Therapy
Christine Lovly, Vanderbilt University School of Medicine, USA

15:55 ES04.03: Overcoming Resistance by Improving Treatment Compliance
Felipe Gomes, Nucleo de Oncologia da Bahia, Brazil

16:15 ES04.04: Guiding Second Line Treatment in ALK + Patients (Sequence of Drugs, Rebiopsy?)
Enriqueta Felip, Vall D’Hebron University Hospital, Spain

16:35 ES04.05: Q&A

15:15 – 16:45 ES05: COLLABORATION BETWEEN STAKEHOLDERS TO IMPROVE LUNG CANCER RESEARCH

15:15 ES05.01: Linking the Stakeholders: Can Patient Groups, Clinical Researchers and the Pharmaceutical Industry Collaborate to Accelerate Research?
Janet Freeman-Daily, The ROS1ders, USA

15:35 ES05.02: Can Patient Groups and Regulatory Bodies Work Together to Make Clinical Research Easier?
Andrea Ferris, LUNGevity Foundation, USA

15:55 ES05.03: Discrepancies and Sustainable Access to Innovative Therapies: Transforming Patient Experience in to Patient Voice
Jesme Fox, Roy Castle Lung Cancer Foundation, UK

16:15 ES05.04: Challenges and Solutions in Engaging with the Health Technology Assessment Process in Canada
Christina Sit, Lung Cancer Canada, Canada

16:35 ES05.05: Q&A

15:15 – 16:45 MTE

15:30 MTE01.01: Meet the Experts Sessions (Continental Breakfast Provided)

15:35 MTE01.03: The Role of Molecular Tests and the Importance of Testing Patient DNA
Hana Seidman, National Comprehensive Cancer Network, USA

16:00 MTE01.04: The Role of Genomic Testing in NSCLC
Tali Lapidot, Sheba Medical Center, Israel

16:30 MTE01.05: Genomic Testing in Non-Small Cell Lung Cancer
Mary L. Eberhardt, University of California, San Francisco, USA

15:15 – 16:45 OA

15:15 OA01.01: Oral Abstract Session 1

15:45 OA01.02: Oral Abstract Session 2

16:15 OA01.03: Oral Abstract Session 3

16:45 OA01.04: Oral Abstract Session 4

15:15 – 16:45 PC

15:15 PC01.01: Pro-Con Session 1

15:45 PC01.02: Pro-Con Session 2

16:15 PC01.03: Pro-Con Session 3

16:45 PC01.04: Pro-Con Session 4

15:15 – 16:45 SH

15:15 SH01.01: Highlights of the Previous Day

15:45 SH01.02: Highlights of the Previous Day

16:15 SH01.03: Highlights of the Previous Day

16:45 SH01.04: Highlights of the Previous Day

15:15 – 16:45 WS

15:15 WS01.01: Workshop (Continental Breakfast Provided)

15:45 WS01.02: Workshop (Continental Breakfast Provided)

16:15 WS01.03: Workshop (Continental Breakfast Provided)

16:45 WS01.04: Workshop (Continental Breakfast Provided)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>MA19: GENOMIC MARKERS OF IO RESPONSE</td>
<td>CHAIRS: RAFAEL ROSELL, SPAIN &amp; PARNEET K. CHEEMA, CANADA</td>
</tr>
<tr>
<td></td>
<td>Track: IMMUNOONCOLOGY</td>
<td>Room: 201 BD</td>
</tr>
<tr>
<td>15:15</td>
<td>MA19.01: Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes</td>
<td>Natalie Vokes, Dana Farber Cancer Institute, USA</td>
</tr>
<tr>
<td>15:20</td>
<td>MA19.02: Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples</td>
<td>Anne-Marie Boothman, AstraZeneca, UK</td>
</tr>
<tr>
<td>15:25</td>
<td>MA19.03: Discussant – MA19.01, MA19.02</td>
<td>Jonathan W. Goldman, UCLA, USA</td>
</tr>
<tr>
<td>15:40</td>
<td>MA19.04: The Clinical Implication of Frameshift Indel Mutation Burden in Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Young Kwang Chae, Northwestern University, USA</td>
</tr>
<tr>
<td>15:45</td>
<td>MA19.05: Difference of Tumor Mutational Burden is Associated with Distinct Immune Microenvironment in the T Cell-Inflamed Lung Adenocarcinoma</td>
<td>Takahiro Karasaki, Graduate School of Medicine, The University of Tokyo, Japan</td>
</tr>
<tr>
<td>15:50</td>
<td>MA19.06: Blood Based Biomarkers: RNA, KRAS and PD-L1 Strongly Matching with Tissue and Showing Correlation with Clinical Responses in NSCLC Patient’s</td>
<td>Luis E. Raez, Memorial Cancer Institute/Florida International University, USA</td>
</tr>
<tr>
<td>15:55</td>
<td>MA19.07: Discussant - MA19.04, MA19.05, MA19.06</td>
<td>Claudia Poleri, Private Practice, Argentina</td>
</tr>
<tr>
<td>16:10</td>
<td>MA19.08: Detection of Primary Immunotherapy Resistance to PD-1 Checkpoint Inhibitors (PD1CI) in 2nd Line NSCLC</td>
<td>Joachim G. J. V. Aerts, Erasmus MC, Netherlands</td>
</tr>
<tr>
<td>16:15</td>
<td>MA19.09: Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB</td>
<td>Kathryn C. Arbour, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>16:20</td>
<td>MA19.10: Impact of STK11/LKB1 Genomic Alterations on Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC</td>
<td>Ferdinandas Skoulidis, The University of Texas M. D. Anderson Cancer Center, USA</td>
</tr>
<tr>
<td>16:25</td>
<td>MA19.11: Discussant - MA19.08, MA19.09, MA19.10</td>
<td>Lynette M. Sholl, Brigham and Women's Hospital, USA</td>
</tr>
<tr>
<td>16:40</td>
<td>MA19.12: Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>MA20: IMPLEMENTATION OF LUNG CANCER SCREENING</td>
<td>CHAIRS: STEPHEN LAM, CANADA &amp; CHRISTINE BERG, USA</td>
</tr>
<tr>
<td></td>
<td>Track: SCREENING AND EARLY DETECTION</td>
<td>Room: 206 F</td>
</tr>
<tr>
<td>15:15</td>
<td>MA20.01: Lung Cancer Screenee Selection by USPSTF versus PLCoM2012 Criteria – Preliminary ILST Findings</td>
<td>Martin Tammemägi, Brock University, Canada</td>
</tr>
<tr>
<td>15:20</td>
<td>MA20.02: “Reduced” HUNT Lung Cancer Model for Predicting Lung Cancer in the Prospective Danish Lung Cancer Screening Study - Comparison with the NLST.</td>
<td>Oluf D. Røe, Norwegian University of Science and Technology, Norway</td>
</tr>
<tr>
<td>15:25</td>
<td>MA20.03: Surprising Implications of Proposed Risk-Thresholds for Selecting US Ever-Smokers into CT Lung-Cancer Screening</td>
<td>Hormuzd Katki, US National Cancer Institute, USA</td>
</tr>
<tr>
<td>15:30</td>
<td>MA20.04: Discussant - MA20.01, MA20.02, MA20.03</td>
<td>Amanda Tufman, Ludwig Maximilian University of Munich, Germany</td>
</tr>
<tr>
<td>15:45</td>
<td>MA20.05: Who Gets Screened for Lung Cancer? A Simple Adjustment to Current Guidelines to Reduce Racial Disparities</td>
<td>Melinda Aldrich, Vanderbilt University Medical Center, USA</td>
</tr>
<tr>
<td>15:50</td>
<td>MA20.06: Lung Cancer Screening Pilot for People at High Risk: Early Results on Cancer Detection and Staging</td>
<td>Martin Tammemagi, Cancer Care Ontario, Canada</td>
</tr>
<tr>
<td>15:55</td>
<td>MA20.07: Lung Cancer Screening for Limited-Resource Patients: Preliminary Findings from a Low-dose CT Pilot Program</td>
<td>Lesley Watson, American Cancer Society, USA</td>
</tr>
<tr>
<td>16:00</td>
<td>MA20.08: Discussant - MA20.05, MA20.06, MA20.07</td>
<td>Annette M. McWilliams, Fiona Stanley Hospital, Australia</td>
</tr>
<tr>
<td>16:15</td>
<td>MA20.09: Improved Lung Cancer and Mortality Prediction Accuracy Using Survival Models Based on Semi-Automatic CT Image Measurements</td>
<td>Anton Schreuder, Radboudumc, Netherlands</td>
</tr>
<tr>
<td>16:20</td>
<td>MA20.10: Lung Cancer Prediction Using Deep Learning Software: Validation on Independent Multi-Centre Data</td>
<td>Heiko Peschl, Oxford University Hospitals NHS Foundation Trust, UK</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker/Institution</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>16:25</td>
<td>MA20.11: Automatic Nodule Size Measurements Can Improve Prediction Accuracy Within a Brock Risk Model</td>
<td>Timor Kadir, Optellum Ltd., UK</td>
</tr>
<tr>
<td>16:30</td>
<td>MA20.12: Discussant - MA20.09, MA20.10, MA20.11</td>
<td>Heidi Schmidt, Women’s College Hospital, Canada</td>
</tr>
</tbody>
</table>

### MA21: MOLECULAR SUBTYPING, CBL3, AND NON CODING RNA

**Track:** Biology  
**Room:** 205 BD  
**Chairs:** Luis M. Montuenga, Spain & Yuko Minami, Japan

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>MA21.01: Cbl Mutations (mt) as Important Mediators of Oncogenic RTK Signaling in NSCLC</td>
<td>Rebecca Feldman, Caris Life Sciences, USA</td>
</tr>
<tr>
<td>15:20</td>
<td>MA21.02: Identification of an E2 Ubiquitin Conjugase CDC34 That Competes with E3 Ligase c-Cbl to Stabilize EGFR and Promotes Lung Carcinogenesis</td>
<td>Guangbiao Zhou, Institute of Zoology, Chinese Academy of Sciences, China</td>
</tr>
<tr>
<td>15:25</td>
<td>MA21.03: Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC</td>
<td>Adam Januszewski, Imperial College London, UK</td>
</tr>
<tr>
<td>15:30</td>
<td>MA21.04: Discussant - MA21.01, MA21.02, MA21.03</td>
<td>Ravi Salgia, City of Hope, USA</td>
</tr>
<tr>
<td>15:45</td>
<td>MA21.05: Comprehensive Genomic Characterization and Prognostic Nomogram Developed by 295-Gene Panel Targeted Sequencing</td>
<td>Bin Zhang, Tianjin Medical University Cancer Institute and Hospital, China</td>
</tr>
<tr>
<td>15:50</td>
<td>MA21.06: Proteins Associated with Survival Differ Depending on Molecular Subtypes, and Mutational- and Smoking-Status in NSCLC Biopsies</td>
<td>Ann R. Halvorsen, Oslo University Hospital – The Norwegian Radium Hospital, Norway</td>
</tr>
<tr>
<td>15:55</td>
<td>MA21.07: A Nation-Wide Population-Based Mapping of Targetable Alterations in Smoking-Independent Lung Cancer</td>
<td>Maria Planck, Lund University, Sweden</td>
</tr>
</tbody>
</table>

### MA22: NEW THERAPEUTICS, PATHOLOGY, AND BRAIN METASTASES FOR SMALL CELL AND NEUROENDOCRINE TUMOUR

**Track:** Small Cell Lung Cancer/NET  
**Room:** 206 BD  
**Chairs:** Eduardo Richardet, Argentina & Medhat El-Mallah, Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>MA22.01: PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency</td>
<td>Benjamin H. Lok, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>15:20</td>
<td>MA22.02: Activation of MAPK Suppresses Neuroendocrine Transcription Factors and Causes Transdifferentiation of Small Cell Lung Cancer</td>
<td>Yusuke Inoue, British Columbia Cancer Research Centre, Canada</td>
</tr>
<tr>
<td>15:30</td>
<td>MA22.04: Discussant - MA22.01, MA22.02, MA22.03</td>
<td>Céline Mascaux, Université Aix-Marseille, France</td>
</tr>
</tbody>
</table>
15:45 MA22.05: Impact of Tumor Spread Through Air Spaces (STAS) in Lung Neuroendocrine Tumors (NETs)
Rania G. Aly, Memorial Sloan Kettering Cancer Center, USA

15:50 MA22.06: Preinvasive Multifocal Neuroendocrine Lesions with Primary Typical Carcinoid Lung Tumors: A Negative Prognostic Factor?
Niccolo Daddi, University of Bologna, Italy

15:55 MA22.07: Prognostic Value of Distant Organ-Specific Metastases in Newly Diagnosed Lung Neuroendocrine Tumors: A Population-Based Study
Min Fan, Fudan University Shanghai Cancer Center, China

16:00 MA22.08: Discussant - MA22.05, MA22.06, MA22.07
Giuseppe Pelosi, University of Milan, Italy

16:15 MA22.09: Should Stereotactic Radiosurgery be Considered for Salvage of Intracranial Recurrence in Small Cell Lung Cancer?
Brooklyn Mazure, Cross Cancer Institute, Canada

16:20 MA22.10: Prevalence and Risk Factors of Brain Metastases in Limited Stage Small Cell Lung Cancer Immediately Before Prophylactic Cranial Irradiation
Zhengfei Zhu, Fudan University Shanghai Cancer Center, China

16:25 MA22.11: Risk of Hippocampal Metastases in Small Cell Lung Cancer: Implications for Hippocampal Sparing Cranial Irradiation
Rachel Effeney, Princess Alexandra Hospital, Australia

16:30 MA22.12: Discussant - MA22.09, MA22.10, MA22.11
Houda Bahig, Centre Hospitalier de l’Université de Montréal, Canada

15:15 – 16:45 MS20: INNOVATIVE AND EVOLVING STRATEGIES IN DIAGNOSIS AND MANAGEMENT OF STAGE I NSCLC

15:15 MS20.01: Robotic and Innovative Surgery
Waël C. Hanna, McMaster University, Canada

15:30 MS20.02: The Future of Stereotactic Ablative Radiotherapy (SABR)
Billy W. Loo, Stanford University, USA

15:45 MS20.03: Immunotherapy and Surgery: Neoadjuvant or Adjuvant? Is It Safe?
Jamie E. Chaft, Memorial Sloan Kettering Cancer Center, USA

16:00 MS20.04: Prediction of Clinical Outcome in NSCLC Using Integrative Genomics: Implications for Adjuvant Chemotherapy
Philippe Broet, University of Montreal, France

16:15 MS20.05: Beyond Surgery - Support of the Surgical Patient
Kate Kuhns, Penn Presbyterian Medical Center, USA

16:30 MS20.06: Less is More: Segmentectomy in the Management of Early Stage NSCLC
Shun-ichi Watanabe, National Cancer Center Hospital, Japan

15:15 – 16:45 OA12: NOVEL THERAPIES IN MET, RET AND BRAF

15:15 OA12.01: Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14-Skipping Mutations
Enriqueta Felip, Vall d’Hebron University Hospital, Spain

15:25 OA12.02: Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
Alexander Drilon, Memorial Sloan Kettering Cancer Center, USA

15:35 OA12.03: Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial
Denis Moro-Sibilot, Centre Hospitalier Universitaire de Grenoble, Hôpital Michallon, France

15:45 OA12.04: Discussant - OA12.01, OA12.02, OA12.03
Mark M. Awad, Dana-Farber Cancer Institute, USA

16:00 OA12.05: Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial
Julien Mazieres, Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, France

16:15 OA12.06: Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure
Anastasios Dimou, University of Colorado Cancer Center, USA

16:25 OA12.07: Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer
Geoffrey R. Oxnard, Dana-Farber Cancer, USA
15:15 – 17:00  MS21: GIANTS IN THORACIC ONCOLOGY

ROOM: 105

CHAIRS: RONALD FELD, CANADA & MIYAKO SATOUCHI, JAPAN

15:15 MS21.01: Surgery and Its Evolution
Paul E. Van Schil, Antwerp University Hospital, Belgium

15:25 MS21.02: Chemotherapy Through the 21st Century
David H. Johnson, UT Southwestern Medical School, USA

15:35 MS21.03: Revolution in Radiation
Ben Slotman, Amsterdam UMC, Netherlands

15:45 MS21.04: Targeted Therapy
- The Second Revolution
Frances A. Shepherd, Princess Margaret Cancer Centre, Canada

15:55 MS21.05: Quality of Life
- Are We Paying Enough Attention?
Richard J. Gralla, Albert Einstein College of Medicine, USA

16:05 MS21.06: Immunotherapy
- Sequence or Combination?
Roy S. Herbst, Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven, USA

Fred R. Hirsch, University of Colorado Cancer Center, USA

16:25 MS21.08: Where Will We be in 10 Years?
Paul A. Bunn, Jr., University of Colorado Cancer Center, USA

16:35 MS21.09: Discussion

16:30  OA12.08: Discussant
- OA12.05, OA12.06, OA12.07
Thomas Newsom-Davis, Chelsea & Westminster Hospital, UK

17:00 – 18:00  IASLC BUSINESS MEETING
(INCLUDING TRAVEL AWARD CEREMONY)
Room: 202 BD
Light Refreshments will be provided

16:45 – 18:00  Poster Viewing Reception with Poster Presenters Present – Poster Session 2
Exhibit Hall
Drinks and Snacks provided

P2.01 Advanced NSCLC
P2.03 Biology
P2.04 Immunooncology
P2.06 Mesothelioma
P2.09 Pathology
P2.10 Prevention and Tobacco Control
P2.11 Screening and Early Detection
P2.12 Small Cell Lung Cancer/NET
P2.13 Targeted Therapy
P2.15 Treatment in the Real World
- Support, Survivorship, Systems Research
P2.16 Treatment of Early Stage/Localized Disease
P2.17 Treatment of Locoregional Disease – NSCLC

20:00 – 23:00  CONFERENCE DINNER – TICKETED EVENT
Room: Plenary Hall
DAILY SCIENTIFIC PROGRAM
WEDNESDAY, SEPTEMBER 26, 2018

07:00 – 08:00  MTE21: CAN I TREAT BRAIN METASTASIS WITH IMMUNOTHERAPY? TICKETED SESSION
TRACK: IMMUNOONCOLOGY
ROOM: 105

07:00  MTE21.01: Can I Treat Brain Metastasis with Immunotherapy?
Sarah Goldberg, Massachusetts General Hospital, USA

07:30  MTE21.02: Can I Treat Brain Metastasis with Immunotherapy?
Caroline Chung, The University of Texas MD Anderson Cancer Center, USA

07:00 – 08:00  MTE22: INCORPORATION OF SMOKING CESSATION IN CLINICAL CARE TICKETED SESSION
TRACK: PREVENTION AND TOBACCO CONTROL
ROOM: 206 BD

07:00  MTE22.01: Integration of Cessation and Lung Cancer Screening
Matthew A. Steliga, University of Arkansas for Medical Sciences, USA

07:30  MTE22.02: Cessation and Clinical Lung Cancer Care
Jamie Ostroff, Memorial Sloan Kettering Cancer Center, USA

07:00 – 08:00  MTE23: SURGICAL CONSIDERATIONS FOLLOWING INDUCTION THERAPY FOR STAGE IIIA DISEASE TICKETED SESSION
TRACK: TREATMENT OF LOCOREGIONAL DISEASE – NSCLC
ROOM: 201 BD

07:00  MTE23.01: Surgical Considerations Following Induction Therapy for Stage IIIA Disease
Eric Vallieres, Swedish Cancer Institute, USA

07:30  MTE23.02: Surgical Considerations Following Induction Therapy for Stage IIIA Disease
Jonathan D. Spicer, McGill University, Canada

Snacks and Beverages Exhibit Hall provided complimentary during morning break and afternoon poster viewing reception
Food available for purchase during opening hours
07:00 – 08:00 MTE24: MULTIPLE LUNG NODULES; RESECT, RADIATE OR WATCH? TRACK: TREATMENT OF EARLY STAGE/LOCALIZED DISEASE ROOM: 203 BD
07:00 MTE24.01: Surgery vs SABR for Early NSCLC Thomas A. D’Amico, Duke Cancer Institute, USA
07:30 MTE24.02: Small Lung Tumours: High Risk Lesions and Contraindications to Stereotactic Ablative Body Radiotherapy (SABR) David L. Ball, Peter MacCallum Cancer Centre, Australia

07:00 – 08:00 MTE25: ENHANCING THE CARE OF YOUR OLDER ADULT POPULATION WITH LUNG CANCER TRACK: NURSING AND ALLIED PROFESSIONALS ROOM: 205 BD
07:00 MTE25.01: Enhancing the Care of Your Older Adult Population with Lung Cancer Martine Puts, University of Toronto, Canada

07:00 – 08:00 MTE26: NEW PARADIGMS IN SYMPTOM MANAGEMENT IN LUNG CANCER TRACK: TREATMENT IN THE REAL WORLD - SUPPORT, SURVIVORSHIP, SYSTEMS RESEARCH ROOM: 206 AC
07:00 MTE26.01: Treatment of Cancer Related Symptoms Patricia Rivera, University of North Carolina at Chapel Hill, USA
07:30 MTE26.02: Symptoms and IO Toxicity Management Jarushka Naidoo, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, USA

07:00 – 08:00 MTE27: CONTROVERSIES IN RADIOTHERAPY FOR SCLC TRACK: SMALL CELL LUNG CANCER/NET ROOM: 206 F
07:00 MTE27.01: Radiotherapy in ES-SCLC Elizabeth Gore, Medical College of Wisconsin, USA

07:00 – 08:00 MTE28: LESSONS FROM THE PAST-WHAT I WOULDN’T DO AGAIN IN DIAGNOSTIC AND THERAPEUTIC IP TRACK: INTERVENTIONAL DIAGNOSTICS/PULMONOLOGY ROOM: 201 F
07:00 MTE28.01: Lessons from the Past—What I Would Not Do Again in Diagnostic and Therapeutic IP Navneet Singh, Postgraduate Institute of Medical Education and Research (PGIMER), India
07:30 MTE28.02: Lessons from the Past—What I Would Not do Again in Diagnostic and Therapeutic IP Jason Agulnik, Jewish General Hospital / McGill University, Canada

07:00 – 08:00 SH03: HIGHLIGHTS OF THE PREVIOUS DAY SESSION
07:00 SH03.01: Thymoma & Outcomes Shirish Gadgeel, Karmanos Cancer Institute, United States of America
07:12 SH03.02: Targeted Alice T. Shaw, Massachusetts General Hospital, USA
07:24 SH03.03: Biology Glen Reid, Asbestos Diseases Research Institute, Australia
07:36 SH03.04: Screening Stephen Lam, BC Cancer Agency, Canada
07:48 SH03.05 - Q&A

07:00 – 08:00 SH04: HIGHLIGHTS OF THE PREVIOUS DAY SESSION
07:00 SH04.01 - SCLC/NET TBC
07:12 SH04.02 - Surgery TBC
07:24 SH04.03 - Locally Advanced/IO Edgardo Santos, Lynn Cancer Institute/Florida Atlantic University, USA
07:36  SH04.04 - Survivorship & Radiation
Chad Rusthoven, University of Colorado - Denver, USA

07:48  SH04.05 - Q&A

08:15 – 09:45  PL03: CALL TO ACTION - CHALLENGES AHEAD

ROOM:  PLENARY HALL
CHAIRS:  GAIL DARLING, CANADA & NAGAHIRO SAJO, JAPAN

08:15  PL03.01: From Bench to Bedside
Charles Swanton, Francis Crick Institute, UK

08:30  PL03.02: Host Immunity - No Longer a Passive Bystander
Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center, USA

08:45  PL03.03: Beaming Into the Future
David Palma, University of Western Ontario, Canada

09:00  PL03.04: A Cut Above
Yolonda Colson, Brigham and Women’s Hospital, USA

09:15  PL03.05: It’s All in the Tissue
Keith M. Kerr, University of Aberdeen, School of Medicine and Dentistry, UK

09:30  PL03.06: The Future of Targeted Therapy
Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Japan

09:45 – 10:30  MEDIA AVAILABILITY
Plenary Hall

09:45 – 10:30  Coffee Break and Poster Viewing - Poster Session 3
Exhibit Hall
Refreshments provided

10:30 – 12:00  ES06: OLIGOMETASTATIC DISEASE

TRACK: OLIGOMETASTATIC NSCLC
ROOM:  202 BD
CHAIRS: RENATO MARTINS, USA & GAETANO ROCCO, ITALY

10:30  ES06.01: Current Clinical Trials in Oligometastases
Anne-Marie C. Dingemans, Maastricht University Medical Centre, Netherlands

10:50  ES06.02: Integrating New Systemic Therapy into Trials in OMD
Sanjay Popat, Royal Marsden Hospital, UK

11:10  ES06.03: Developments in SBRT in the Oligometastatic Paradigm in NSCLC
Patrick Cheung, Sunnybrook Odette Cancer Centre, Canada

11:30  ES06.04: Surgical Considerations in OMD
Jessica Donington, University of Chicago, USA

11:50  ES06.05: Q&A
11:30  MA23.09: Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy, a Comparison Utilizing the National Cancer Database  
Mark Hennon, Roswell Park Comprehensive Cancer Center, USA

11:35  MA23.10: Cone-Beam Computed Tomography-Guided Microcoil Localization of Pulmonary Nodules During Video-Assisted Thoracic Surgery  
Hideki Ujiie, Toronto General Hospital, University Health Network, University of Toronto, Canada

11:40  MA23.11: Lobe-Specific Nodal Dissection for Clinical Stage I and II Non-Small Cell Lung Cancer: Japanese Multi-Institutional Retrospective Study  
Tomoyuki Hishida, Keio University School of Medicine, Japan

11:45  MA23.12: Discussant - MA23.09, MA23.10, MA23.11  
Giulia Veronesi, Humanitas Research Hospital, Italy

10:30 – 12:00  MA24: GENOMIC EVOLUTION, KEAP 3 AND MORE NON-CODING RNA

TRACK:  BIOLOGY, TREATMENT OF EARLY STAGE/LOCALIZED DISEASE  
ROOM:  205 BD  
CHAIRS:  PING YANG, USA & RAVI SALGIA, USA

10:30  MA24.01: Genomic Evolution Trajectory Depicts Invasiveness Acquisition from Pre-invasive to Invasive Adenocarcinoma  
Chao Zhang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

10:35  MA24.02: Genomic Alterations in Lung Adenocarcinoma Precursor Lesions  
Dennis Wigle, Mayo Clinic, USA

10:40  MA24.03: Biologic Profiling of Pre-Metastatic Niche in Completely Resected Pathological Stage I Non-Small Cell Lung Cancer  
Tomohito Saito, Kansai Medical University, Japan

10:45  MA24.04: Discussant - MA24.01, MA24.02, MA24.03  
Udayan Guha, Center for Cancer Research, NCI, NIH, USA

11:00  MA24.05: Baseline Spatial Heterogeneity of T790M in Tyrosine Kinase Inhibitor Naïve EGFR-Mutant Lung Adenocarcinomas  
Michael Cabanero, University of Toronto, University Health Network, Canada

11:05  MA24.06: Long Non-Coding Rna Expression Patterns Delineate Infiltrating Immune Cells in the Lung Tumour Microenvironment  
Adam P. Sage, British Columbia Cancer Research Centre, Canada

11:10  MA24.07: A Novel cis-Acting IncRNA Controls HMGA1 Expression in Lung Adenocarcinoma  
Adam P. Sage, British Columbia Cancer Research Centre, Canada

11:15  MA24.08: Discussant - MA24.05, MA24.06, MA24.07  
Alice Berger, Fred Hutchinson Cancer Research Center, USA

11:30  MA24.09: Synergy Between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small Cell Lung Cancer with an Altered Metabolism  
Sarah A. Best, The Walter and Eliza Hall Institute of Medical Research, Australia

11:35  MA24.10: Interrogating the Metabolic Effects of Keap1 Inactivation in Adenocarcinoma  
Sarah A. Best, The Walter and Eliza Hall Institute of Medical Research, Australia

11:40  MA24.11: Loss of Tumour Suppressors is Adequate and Sufficient to Drive Lung Cancer in CRISPR/Cas9 Mice  
Paola A. Marignani, Dalhousie University Tupper Medical Building 9F1, Canada

Vladmir C. Cordeiro De Lima, A C Camargo Cancer Center, Brazil

10:30 – 12:00  MS22: BIOLOGY OF THE LUNG AND LUNG CANCER

TRACK:  BIOLOGY  
ROOM:  206 F  
CHAIRS:  MATTHEW MEYERSON, USA & GEOFFREY LIU, CANADA

10:30  MS22.01: Lung Development and Stem Cells  
Carla Kim, Boston Children’s Hospital, USA

10:45  MS22.02: Epigenetic Alterations in Lung Cancer Development  
Wan Lam, BC Cancer Research Centre, Canada

11:00  MS22.03: Non-Coding RNA in Lung Cancer  
Sven Diederichs, Medical Center - University of Freiburg, Germany
11:15 MS22.04: Genomics of Resistance and Response in Lung Cancer
Marc Ladanyi, MSKCC, USA

11:30 MS22.05: Inflammation in Lung Cancer
Katerina Politi, Yale University, USA

11:45 MS22.06: Transcriptomic-Metabolomic Reprograming as Resistant Mechanism
Patrick Ma, WVU Cancer Institute, West Virginia University, USA

10:30 – 12:00 MS23: WHAT’S NEW IN TARGETED THERAPY?

TRACK: TARGETED THERAPY
ROOM: 106

CHAIRS: VERA HIRSH, CANADA & ALEXANDER DRILLON, USA

10:30 MS23.01: Novel Combinations of Targeted Therapies
Pasi A. Jänne, Dana-Farber Cancer Institute, USA

10:45 MS23.02: Emerging or Rare Targets - Fusions, Mutational Burden Etc
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

11:00 MS23.03: Management of CNS Mets in the Era of CNS-Penetrant TKIs (Med Onc and Rad Onco Perspectives)
Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

11:15 MS23.04: Targeting Driver Oncogenes in Stage 1-3 NSCLC
Helena Yu, Memorial Sloan Kettering Cancer Center, USA

11:30 MS23.05: Role of Immunotherapy in Patients with Molecular Driven NSCLC
Benjamin Besse, Gustave Roussy, France

11:45 MS23.06: Q&A

10:30 – 12:00 MS24: GLOBAL PERSPECTIVES ON TOBACCO CONTROL

TRACK: PREVENTION AND TOBACCO CONTROL
ROOM: 206 BD

CHAIRS: RUI HADDAD, BRAZIL & DESMOND CARNEY, IRELAND

10:30 MS24.01: Tobacco Control Impacting the Effectiveness and Cost of Cancer Care
Graham Warren, Medical University of South Carolina, USA

10:45 MS24.02: Legal Action Against the Tobacco Industry in Europe
Paul Baas, The Netherlands Cancer Institute, Netherlands

11:00 MS24.03: The Importance of Physician Involvement in Tobacco Control
Jacek Jassem, Medical University of Gdansk, Poland

11:15 MS24.04: Challenges of Tobacco Control in China
Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University, China

11:30 MS24.05: Q&A

10:30 – 12:00 MS25: GENETIC AND PROGNOSTIC MARKERS IN MESOTHELIOMA; GOING BEYOND THE HISTOLOGY SUBTYPES

TRACK: MESOTHELIOMA
ROOM: 206 AC

CHAIRS: DEAN A. FENNELL, UK & AARON MANSFIELD, USA

10:30 MS25.01: Impact of Tumor Volume on Outcome: What Are the Limitations?
Anna K. Nowak, University of Western Australia, Australia

10:45 MS25.02: How Should P16, BAP1, and NF2 Mutations Be Integrated in Therapeutic Algorithms?
Francoise Galateau-Salle, Centre Leon Berard, France

11:00 MS25.03: Impact of Innate and Adaptive Tumor Infiltrating Cells on Prognosis
Thomas John, Olivia Newton-John Cancer Centre, Australia

10:30 – 12:00 MS26: FROM TEXTBOOK TO PRACTICE AROUND THE WORLD

TRACK: TREATMENT IN THE REAL WORLD - SUPPORT, SURVIVORSHIP, SYSTEMS RESEARCH
ROOM: 205 AC

CHAIRS: JARUSHKA NAIDDO, USA & FABIO MORAES, BRAZIL

10:30 MS26.01: Translation of Clinical Data to Real World – Asia
Dae Ho Lee, University of Ulsan College of Medicine, Asan Medical Center, Korea

10:45 MS26.02: Translation of Clinical Data to Real World – North America
Cheryl Ho, BC Cancer, Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40</td>
<td>OA13.02: Two Novel Immunotherapy Agents Targeting DLL3 in SCLC: Trials in Progress of AMG 757 and AMG 119</td>
<td>Taoee Owonikoko, Department of Hematology and Medical Oncology, Emory University School of Medicine, USA</td>
</tr>
<tr>
<td>10:50</td>
<td>OA13.03: Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC; A Multicentre, Randomized, Double-Blind Phase 2 Trial</td>
<td>Ying Cheng, Jilin Cancer Hospital, China</td>
</tr>
<tr>
<td>11:00</td>
<td>OA13.04: Discussant - OA13.01, OA13.02, OA13.03</td>
<td>Normand Blais, Hospital Notre-Dame – CHUM, Canada</td>
</tr>
<tr>
<td>11:15</td>
<td>OA13.05: Prophylactic Cranial Irradiation (PCI) for Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 CONVERT Trial</td>
<td>Cecile Le Pechoux, Gustave Roussy, France</td>
</tr>
<tr>
<td>11:25</td>
<td>OA13.06: Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volumes with Radiation Dosimetric and Pathologic Analyses</td>
<td>Xiao Hu, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, China</td>
</tr>
<tr>
<td>11:35</td>
<td>OA13.07: Survival Outcomes After Whole Brain Radiotherapy for Brain Metastases in Elderly Patients with Newly Diagnosed Metastatic Small Cell Carcinoma</td>
<td>Paul Renz, Allegheny Health Network, USA</td>
</tr>
<tr>
<td>11:45</td>
<td>OA13.08: Discussant - OA13.05, OA13.06, OA13.07</td>
<td>Inga Grills, Beaumont Health Royal Oak, USA</td>
</tr>
</tbody>
</table>

**PC09: APPROACHES TO MANAGEMENT OF ADVANCED NSCLC**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>PC09.01: Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild-Type NSCLC – Early</td>
<td>Qing Zhou, Guangdong Lung Cancer Institute, Guangdong General Hospital &amp; Guangdong Academy of Medical Sciences, China</td>
</tr>
<tr>
<td>10:45</td>
<td>PC09.02: Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild-Type NSCLC – Delayed</td>
<td>Walter Curran Jr., Emory University, USA</td>
</tr>
</tbody>
</table>
11:00  PC09.03: Discussion

11:15  PC09.04: Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - NSCLC
Noemi Reguart, Hospital Clinic of Barcelona, Spain

11:30  PC09.05: Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - SCLC
Scott A. Laurie, The Ottawa Hospital Cancer Centre, Canada

11:45  PC09.06: Discussion

12:00 – 13:30  Poster Viewing Reception with Poster Presenters Present – Poster Session 3
Exhibit Hall
Drinks and Snacks provided

P3.01 Advanced NSCLC
P3.03 Biology
P3.04 Immunooncology
P3.07 Nursing and Allied Professionals
P3.08 Oligometastatic NSCLC
P3.09 Pathology
P3.11 Screening and Early Detection
P3.12 Small Cell Lung Cancer/NET
P3.13 Targeted Therapy
P3.15 Treatment in the Real World - Support, Survivorship, Systems Research
P3.16 Treatment of Early Stage/Localized Disease
P3.17 Treatment of Locoregional Disease – NSCLC
P3.CR Case Reports

13:30 – 15:00  ES07: BEYOND THE DIAGNOSIS – COLLABORATIVE CARE FOR CHANGE

TRACK:  NURSING AND ALLIED PROFESSIONALS
ROOM:  205 BD

CHAIRS:  MARIA GUERIN, UK & DIANE ZAWISZA, CANADA

13:30  ES07.01: A Moment in Time for the Unplanned Conversations
Kelly McGuigan, Princess Margaret Cancer Centre, Canada

13:50  ES07.02: Special Needs and Wellness in Lung Cancer Patients – Australian Perspective
Maria Ftanou, Peter MacCallum Cancer Insititue, Australia

14:00  ES07.03: Special Needs and Wellness in Lung Cancer Patients – European Perspective
Rossie Navon, Sheba Medical Center, Israel

14:10  ES07.04: Leveraging Social Media to Change the Public Conversation on Lung Cancer Stigma
Lisa Carter-Harris, Indiana University School of Nursing, USA

14:30  ES07.05: Research Update: Patient’s Perspective on Living with Malignant Pleural Mesothelioma
Angela M. Tod, University of Sheffield, UK

14:50  ES07.06: Q&A

13:30 – 15:00  ES08: THE PATHOLOGIST – AN ESSENTIAL MEMBER OF THE PATIENT CARE TEAM

TRACK:  PATHOLOGY
ROOM:  206 AC

CHAIRS:  CLAUDIA POLERI, ARGENTINA & PRODIPTO PAL, CANADA

13:30  ES08.01: Targeted Therapy
Yasushi Yatabe, Aichi Cancer Center, Japan

13:50  ES08.02: Immunotherapy
Sylvie Lantuejoul, Centre Léon Bérard UNICANCER and Grenoble Alpes University, France

14:10  ES08.03: Mesothelioma, Thymic Epithelial Tumors and Others
Andrew G. Nicholson, Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, UK

14:30  ES08.04: Neoadjuvant Therapy
Ignacio I. Wistuba, The University of Texas MD Anderson Cancer Center, USA

14:50  ES08.05: Q&A

13:30 – 15:00  LA01: IASLC LECTURESHIP AWARD SESSION

ROOM:  105

CHAIRS:  GIORGIO SCAGLIOTTI, ITALY; FRED R. HIRSCH, USA & TETSUYA MITSUDOMI, JAPAN

13:30  LA01.01: Clifton F. Mountain Lectureship Award for Staging: Is There Still a Stage for Improvements in Staging?
Johan F. Vansteenkiste, University Hospital KU Leuven, Belgium

13:50  LA01.02: IASLC Lectureship Award for Radiation Oncology: Defining the Role of Radiotherapy for Lung Cancer: Past, Present and Future
Hak Choy, UT Southwestern, USA

14:00  LA01.03: Heine H. Hansen Lectureship Award for Small Cell Lung Cancer: New Opportunities in Small Cell Lung Cancer
Charles M. Rudin, Memorial Sloan Kettering, USA

14:10  LA01.04: Adi F. Gazdar Lectureship Award for Translational Research: Genomic Alterations in Human Lung Cancers
Matthew Meyerson, Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute, USA

11:00  PC09.03: Discussion

11:15  PC09.04: Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - NSCLC
Noemi Reguart, Hospital Clinic of Barcelona, Spain

11:30  PC09.05: Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - SCLC
Scott A. Laurie, The Ottawa Hospital Cancer Centre, Canada

11:45  PC09.06: Discussion

12:00 – 13:30  Poster Viewing Reception with Poster Presenters Present – Poster Session 3
Exhibit Hall
Drinks and Snacks provided

P3.01 Advanced NSCLC
P3.03 Biology
P3.04 Immunooncology
P3.07 Nursing and Allied Professionals
P3.08 Oligometastatic NSCLC
P3.09 Pathology
P3.11 Screening and Early Detection
P3.12 Small Cell Lung Cancer/NET
P3.13 Targeted Therapy
P3.15 Treatment in the Real World - Support, Survivorship, Systems Research
P3.16 Treatment of Early Stage/Localized Disease
P3.17 Treatment of Locoregional Disease – NSCLC
P3.CR Case Reports

13:30 – 15:00  ES07: BEYOND THE DIAGNOSIS – COLLABORATIVE CARE FOR CHANGE

TRACK:  NURSING AND ALLIED PROFESSIONALS
ROOM:  205 BD

CHAIRS:  MARIA GUERIN, UK & DIANE ZAWISZA, CANADA

13:30  ES07.01: A Moment in Time for the Unplanned Conversations
Kelly McGuigan, Princess Margaret Cancer Centre, Canada

13:50  ES07.02: Special Needs and Wellness in Lung Cancer Patients – Australian Perspective
Maria Ftanou, Peter MacCallum Cancer Insititue, Australia

14:00  ES07.03: Special Needs and Wellness in Lung Cancer Patients – European Perspective
Rossie Navon, Sheba Medical Center, Israel

14:10  ES07.04: Leveraging Social Media to Change the Public Conversation on Lung Cancer Stigma
Lisa Carter-Harris, Indiana University School of Nursing, USA

14:30  ES07.05: Research Update: Patient’s Perspective on Living with Malignant Pleural Mesothelioma
Angela M. Tod, University of Sheffield, UK

14:50  ES07.06: Q&A

13:30 – 15:00  ES08: THE PATHOLOGIST – AN ESSENTIAL MEMBER OF THE PATIENT CARE TEAM

TRACK:  PATHOLOGY
ROOM:  206 AC

CHAIRS:  CLAUDIA POLERI, ARGENTINA & PRODIPTO PAL, CANADA

13:30  ES08.01: Targeted Therapy
Yasushi Yatabe, Aichi Cancer Center, Japan

13:50  ES08.02: Immunotherapy
Sylvie Lantuejoul, Centre Léon Bérard UNICANCER and Grenoble Alpes University, France

14:10  ES08.03: Mesothelioma, Thymic Epithelial Tumors and Others
Andrew G. Nicholson, Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, UK

14:30  ES08.04: Neoadjuvant Therapy
Ignacio I. Wistuba, The University of Texas MD Anderson Cancer Center, USA

14:50  ES08.05: Q&A

13:30 – 15:00  LA01: IASLC LECTURESHIP AWARD SESSION

ROOM:  105

CHAIRS:  GIORGIO SCAGLIOTTI, ITALY; FRED R. HIRSCH, USA & TETSUYA MITSUDOMI, JAPAN

13:30  LA01.01: Clifton F. Mountain Lectureship Award for Staging: Is There Still a Stage for Improvements in Staging?
Johan F. Vansteenkiste, University Hospital KU Leuven, Belgium

13:50  LA01.02: IASLC Lectureship Award for Radiation Oncology: Defining the Role of Radiotherapy for Lung Cancer: Past, Present and Future
Hak Choy, UT Southwestern, USA

14:00  LA01.03: Heine H. Hansen Lectureship Award for Small Cell Lung Cancer: New Opportunities in Small Cell Lung Cancer
Charles M. Rudin, Memorial Sloan Kettering, USA

14:10  LA01.04: Adi F. Gazdar Lectureship Award for Translational Research: Genomic Alterations in Human Lung Cancers
Matthew Meyerson, Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute, USA
14:10 LA01.05: Tsuguo Naruke Lectureship Award for Surgery: The Value of Naruke Lymph Node Chart and the Creation of IASLC Chart in Lung Cancer
Hisao Asamura, Keio University School of Medicine, Japan

14:20 LA01.06: Daniel C. Ihde Lectureship Award for Medical Oncology: The Intersection of Science and Medicine
David P. Carbone, The Ohio State Wexner Medical Center, USA

14:30 LA01.07: Robert J. Ginsberg Lectureship Award for Surgery: Honoring the Tradition of Surgically-Based Clinical Trials
Valerie W. Rusch, Memorial Sloan-Kettering Cancer Center, USA

14:40 LA01.08: IASLC Lectureship Award for Nursing and Allied Health Professionals: The Right Hand: The Art of Collaboration
Kimberly A. Rohan, Edward Cancer Center, USA

14:50 LA01.09: Q&A

13:30 – 15:00 MA25: OLIGOMETASTASIS: DEFINING, TREATING, AND EVALUATING

13:30 MA25.01: EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC
Lizza Hendriks, MUMC, Netherlands

13:35 MA25.02: Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts
Anne-Marie C. Dingemans, Maastricht University Medical Center, Netherlands

13:40 MA25.03: Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion
Lizza Hendriks, Maastricht University Medical Center, Netherlands

13:45 MA25.04: Discussant - MA25.01, MA25.02, MA25.03
Abraham J. Wu, Memorial Sloan Kettering Cancer Center, USA

14:00 MA25.05: Characteristics & Survival of Resected Stage IV Non-Small Cell Lung Cancer (NSCLC) in the Mid-South Quality of Surgical Resection Cohort
Nicholas R. Faris, Baptist Cancer Center, USA

14:05 MA25.06: RPA Analysis for Oligometastatic Non-Small Cell Lung Cancer: Smoking Combine T3/4 Patients May Not Be Benefit from Local Consolidative Treatment
Jia-Tao Zhang, Guangdong Lung Cancer Institute, China

14:10 MA25.07: Effectiveness of Systemic Therapy Combined with Thoracic Radiotherapy for Patients with Oligometastatic NSCLC: A Pooled Analysis
Jingbo Wang, Cancer Hospital, Chinese Academy of Medical Sciences, China

14:15 MA25.08: Discussant - MA25.05, MA25.06, MA25.07
Alysa Fairchild, Cross Cancer Institute, Canada

14:30 MA25.09: M1b Disease in the 8th Edition of IASLC Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome
Hyesun Park, Dana Farber Cancer Institute, USA

14:35 MA25.10: Complete Response by PET-CT After Radical Treatment in Oligometastatic Non-Small Cell Lung Cancer Predicts Longer Survival
Oscar Arrieta, National Cancer Institute, Mexico

14:40 MA25.11: Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT
Fabio Y. Moraes, Princess Margaret Cancer Centre, Canada

14:45 MA25.12: Discussant - MA25.09, MA25.10, MA25.11
Michael MacManus, Peter MacCallum Cancer Centre, Australia

13:30 – 15:00 MA26: NEW THERAPIES AND EMERGING DATA IN ALK, EGFR AND ROS1

13:30 MA26.01: Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

Elisa Gobbini, Department of Oncology, University of Turin, AOU San Luigi, Italy

13:30 – 15:00 MA26: NEW THERAPIES AND EMERGING DATA IN ALK, EGFR AND ROS1

13:30 MA26.01: Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

Elisa Gobbini, Department of Oncology, University of Turin, AOU San Luigi, Italy
13:40 MA26.03: Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement
Zosia Piotrowska, Massachusetts General Hospital, USA

13:45 MA26.04: Discussant - MA26.01, MA26.02, MA26.03
Caroline McCoach, University of California, San Francisco, USA

14:00 MA26.05: Comprehensive Analysis of Treatment Response and Progression Pattern in Chinese Patients with Different ALK Fusion-Variants
Meng Qiao, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

14:05 MA26.06: Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative
Erik Thunnissen, VU University Medical Center, Netherlands

14:10 MA26.07: ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists
Keith M. Kerr, University of Aberdeen, School of Medicine and Dentistry, UK

14:15 MA26.08: Discussant - MA26.05, MA26.06, MA26.07
Dong-Wan Kim, Seoul National University Hospital, Korea

14:30 MA26.09: Lazertinib, a Third Generation EGFR-TKI, in Patients with EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/II Study
Byoung Chul Cho, Yonsei Cancer Center, Yonsei University College of Medicine, Korea

14:35 MA26.10: CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

14:40 MA26.11: Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC
Yi-Long Wu, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

Liza Villaruz, University of Pittsburgh, USA
13:30 – 15:00 MS28: IO COMBINATIONS IN ADVANCED NSCLC

TRACK: IMMUNOONCOLOGY
ROOM: 106
CHAIRS: COREY LANGER, USA & EDGARDO SANTOS, USA

13:30 MS28.01: Understanding the Rationale for Combining IO Agents
Edward B. Garon, UCLA, USA

13:45 MS28.02: Combination IO+IO
Myung-Ju Ahn, Samsung Medical Center Sungkyunkwan University, Korea

14:00 MS28.03: Combinatorial IO + Chemo
Rosalyn Juergens, Juravinski Cancer Centre, Canada

14:15 MS28.04: Combination with Targeted Therapies
Ross Soo, National University Hospital, Singapore

14:30 MS28.05: Combining IO with Radiation
Corinne Faivre-Finn, The University of Manchester and, The Christie NHS F'dation Trust, UK

14:45 MS28.06: Q&A

13:30 – 15:00 MS29: SELECTION INTO SCREENING PROGRAMS: INTERPLAY OF RISK ALGORITHMS, GENETIC MARKERS AND BIOMARKERS

TRACK: SCREENING AND EARLY DETECTION
ROOM: 206 F
CHAIRS: JOHN GOFFIN, CANADA & BETTY TONG, USA

13:30 MS29.01: Assessment of Risk Prediction Algorithms for Entry into Screening Programs
Martin Tammemagi, Brock University, Canada

13:45 MS29.02: Defining Screening Frequency & Duration Using Risk Prediction Algorithms and CT Image Findings
Kevin Ten Haaf, Erasmus MC, Netherlands

14:00 MS29.03: Polygenic Risk Score for Risk Assessment
Rayjean J. Hung, University of Toronto, Canada

14:15 MS29.04: LuCID Exhaled Breath Analysis
Marc P. Van Der Schee, Owlstone Medical Ltd, UK

14:30 MS29.05: Early Detection Biomarker Development: is Success on the Horizon?
Peter Mazzone, Cleveland Clinic, USA

14:45 MS29.06: Q&A

13:30 – 15:00 MS30: MODERN DAY RT IN LA NSCLC: WHERE IS THE EVIDENCE?

TRACK: TREATMENT OF LOCOREGIONAL DISEASE - NSCLC
ROOM: 202 BD
CHAIRS: FIONA HEGI-JOHNSON, AUSTRALIA & YUKO NAKAYAMA, JAPAN

13:30 MS30.01: Overview of RT Technology in LA NSCLC (IMRT, VMAT, IGRT)
Gerard G. Hanna, Queen’s University of Belfast, UK

13:45 MS30.02: What Evidence is Available to Support RT Technology in LA NSCLC (including Protons)?:
Yong Chan Ahn, Samsung Medical Center, Korea

14:00 MS30.03: What Evidence is Available to Support RT Treatment Intensification in LA NSCLC?
Jeffrey Bradley, Washington University School of Medicine, USA

14:15 MS30.04: Perspective
Maria Werner-Wasik, Thomas Jefferson University Hospital, USA
14:30 MS30.05: Nutritional Management During Radical Radiotherapy
Rhys White, Guys and St Thomas’ NHS Foundation Trust, UK

14:45 MS30.06: Q&A

13:30 – 15:00 MS31: CLINICAL SCIENCE IN MESOTHELIOMA

TRACK: MESOTHELIOMA
ROOM: 205 AC
CHAIRS: HAINING YANG, USA & MARC DE PERROT, CANADA

13:30 MS31.01: Mechanisms and Targets for BAP1 Activity
Michele Carbone, University of Hawaii Cancer Center, USA

13:45 MS31.02: Clinical Implementation of BAP1 Inhibitors
Paul Baas, Netherlands Cancer Institute, Netherlands

14:00 MS31.03: Targeting the Hippo Pathway
David M. Jablons, University of California, San Francisco, USA

14:15 MS31.04: CAR-T and ADC’s in MPM
Prasad S. Adusumilli, Memorial Sloan-Kettering Cancer Center, USA

14:30 MS31.05: Vaccination and Antibody-Based Therapy in Mesothelioma
Joachim G. J. V. Aerts, Erasmus MC, Netherlands

14:45 MS31.06: Q&A

13:30 – 15:00 MS32: SCLC – FROM BENCHSIDE TO BEDSIDE – CLINICAL SCIENCE SESSION

TRACK: SMALL CELL LUNG CANCER/NET
ROOM: 107
CHAIRS: ALEX ADJEI, USA & JASON PANTAROTTO, CANADA

13:30 MS32.01: Genetic Mouse Models (GEMMS)
Trudy G. Oliver, University of Utah & Huntsman Cancer Institute, USA

13:45 MS32.02: Patient Derived Models (PDX & CTC-Derived)
Anna F. Farago, Massachusets General Hospital, USA

14:00 MS32.03: Liquid Biopsies for Drug Development in SCLC
Caroline Dive, Cancer Research UK Manchester Institute, UK

14:15 MS32.04: Molecular Phenotypes of SCLC
Adi Gazdar, UT Southwestern Medical Center, USA

14:30 MS32.05: Targeting DNA Damage and Repair
Lauren Byers, UT MD Anderson Cancer Center, USA

14:45 MS32.06: Epigenetic Targets
John Poirier, Memorial Sloan Kettering Cancer Center, USA

15:15 – 16:30 PLO4: TAKE ACTION – KEY MESSAGES FROM WCLC 2018 AND GOALS FOR 2019

ROOM: PLENARY HALL
CHAIRS: NATASHA B. LEIGHL, CANADA & ROBERT PIRKER, AUSTRIA

15:15 PLO4.01: Medical Oncology
David R. Gandara, UC Davis Comprehensive Cancer Center, USA

15:20 PLO4.02: Pathology
Fred R. Hirsch, University of Colorado Cancer Center, USA

15:25 PLO4.03: Surgery
Ramon Rami-Porta, Hospital Universitari Mutua Terrassa, Spain

15:30 PLO4.04: Radiation Oncology
Jose Belderbos, The Netherlands Cancer Institute, Netherlands

15:35 PLO4.05: Americas
Clarissa Mathias, NOB/Oncoclinicas, Brazil

15:40 PLO4.06: Asia Pacific
Michael Boyer, Chris O’Brien Lifehouse, Australia

15:45 PLO4.07: Discussion and Q&A

16:25 PLO4.08: Invitation to WCLC 2019
Barcelona, Spain
End of the official IASLC CME accredited Scientific Program
All sessions listed on the following pages are not part of the IASLC CME accredited scientific program.

SECTION 7

Poster Sessions

TAKE ACTION
Against Lung Cancer!
POSTERS AT A GLANCE
MONDAY SEPTEMBER 24, 2018 | POSTER SESSION 1

P1.01 ADVANCED NSCLC

P1.02 ADVOCACY

P1.03 BIOLOGY
- P1.03-01 - P1.03-12 Characterization
- P1.03-13 - P1.03-22 In vitro
- P1.03-23 - P1.03-34 Prognosis

P1.04 IMMUNOONCOLOGY
- P1.04-01 - P1.04-10 Biology
- P1.04-11 - P1.04-25 Biomarkers
- P1.04-26 - P1.04-30 Outcomes
- P1.04-31 - P1.04-36 Trials

P1.05 INTERVENTIONAL DIAGNOSTICS/PULMONOLOGY

P1.06 PATHOLOGY
- P1.09-01 - P1.09-07 IO
- P1.09-08 - P1.09-23 Molecular
- P1.09-24 - P1.09-40 Pathology

P1.07 SCREENING AND EARLY DETECTION

P1.12 SMALL CELL LUNG CANCER/NET
- P1.12-01 - P1.12-06b Clinical Trial/Therapeutics
- P1.12-07 - P1.12-21 Outcome

P1.13 TARGETED THERAPY
- P1.13-01 - P1.13-08 ALK
- P1.13-09 - P1.13-28 EGFR
- P1.13-29 - P1.13-39 General
- P1.13-40 - P1.13-45 Rare Targets

P1.14 THYMOMA/OTHER THORACIC MALIGNANCIES

P1.15 TREATMENT IN THE REAL WORLD - SUPPORT, SURVIVORSHIP, SYSTEMS RESEARCH
- P1.15-01 - P1.15-36 Population/Real World Outcomes

P1.16 TREATMENT OF EARLY STAGE/LOCALIZED DISEASE
- P1.16-01 - P1.16-10 Advanced
- P1.16-11 - P1.16-19 Other
- P1.16-20 - P1.16-29 Radiation Oncology
- P1.16-30 - P1.16-64 Surgery

P1.17 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC
P1.01 ADVANCED NSCLC

P1.01-01: ROC1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea
Beung Chul Ahn
Yonsei Cancer Center, Korea

P1.01-02: Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
Scott Antonia
H. Lee Moffitt Cancer Center and Research Institute, USA

P1.01-03: Effect of Prophylactic Cranial Irradiation on Cognitive Function and QoL in NSCLC Patients at High Risk of Brain Metastases
Oscar Arrieta
National Cancer Institute, Mexico

P1.01-04: Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients
Fabrice Barlesi
Assistance Publique-Hôpitaux de Marseille, Aix Marseille University, France

P1.01-05: Metformin in Combination with Crizotinib for the Treatment of EML4-ALK+ Lung Cancer
Abigail Bland
University of Otago, New Zealand

P1.01-06: Plinabulin, a Novel Immunooncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients
Douglas Blayney
Stanford Cancer Institute, USA

P1.01-07: Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy
Angela Botticella
KU Leuven, Belgium

P1.01-08: Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-PD-1/PD-L1
Nicole Bouchard
Chris O’Brien Lifehouse, Australia

P1.01-10: Stage III Non-Small Cell Lung Cancer Clinical Outcomes with Surgical Resection After Definitive Neoadjuvant Chemoradiotherapy
Ilaria Caturegli
University of Maryland School of Medicine, USA

P1.01-11: Named Patient Use Program for Afatinib in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers
Keunchil Park
Samsung Medical Center, Azienda Ospedaliera di Perugia, Italy

P1.01-12: SWitch Maintenance Pembozilumab in Patients with Metastatic Non Small Cell Lung Cancer (SWIPE)
Haris Charalambous
Bank of Cyprus Oncology Centre, Cyprus

P1.01-13: A Study of S-1 Plus Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer
Yuh-Min Chen
Taipei Veterans General Hospital, Taiwan

P1.01-14: Immunotherapy (I) for Advanced, Pre-Treated, Non-Squamous NSCLC (APNS-NSCLC): Preliminary Data of a Pooled Analysis
Lorenza Landi
Department of Oncology, City Hospital, AUSL Romagna, Italy

P1.01-15: ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial
Biagio Ricciuti
Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy

P1.01-16: First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 positive NSCLC: A Network Meta-Analysis of Randomized Trials
Mark Doherty
Sunnybrook Odette Cancer Centre, Canada

P1.01-17: Immune-Related Adverse Events in Patients with Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy
Narjust Duma
Mayo Clinic, USA

P1.01-18: Immunosenesence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
Roberto Ferrara
Gustave Roussy, France

P1.01-19: Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases
Ronan Flippot
Gustave Roussy, France

P1.01-20: Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)
Tatsuro Fukuhara
Miyagi Cancer Center, Japan

P1.01-21: Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control in ATLANTIC
Marina Garassino
Fondazione IRCCS Istituto Nazionale dei Tumori, Italy
P1.01-22: Effect of Basal Lymphopenia on Outcome of Non Small Cell Lung Cancer Patients Treated with Immunotherapy
Giulia Galli
Istituto Nazionale dei Tumori, Italy

P1.01-23: High PD-L1 Expression is Less Common Than Expected Among Advanced NSCLC in Brazil. Are We Missing the Target?
Ana Gelatti
Hospital do Câncer Mãe de Deus, Brazil

P1.01-24: Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy
Daniel Glick
BC Cancer- Victoria, Canada

P1.01-25: Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)
Yasuhiro Goto
Fujita Health University, Japan

P1.01-26: Single-Centre Experience of Clinical Outcomes for Advanced Lung Cancer Patients in Phase I Clinical Trials
Donna Graham
The Christie NHS Foundation Trust, UK

P1.01-27: Influence of EGFR-TKIs Treatment Lines and PFS on the Emergence of T790M Mutation
Xiaorong Dong
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, China

P1.01-28: Impact of Afinatinib Dosing on Safety and Efficacy Real-World in Patients with EGFR Mutation-Positive Advanced NSCLC
Balazs Halmos
Montefiore/Albert Einstein Cancer Center, USA

P1.01-29: Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?
BaoHui Han
Shanghai Chest Hospital, China

P1.01-30: Crizotinib in Advanced Non-Adenocarcinoma NSCLC (NA-NSCLC) Patients with ALK Rearrangement: A Retrospective Study and Literature Review
BaoHui Han
Shanghai Chest Hospital, China

P1.01-31: Weekly Regimen of PAXUS-PM, a Novel Cremophor-Free, with Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer in Vietnam
Mi-Ryung Jin
Samyang Biopharmaceutical Corporation, Korea

P1.01-32: A Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease
Masaki Hanibuchi
Shikoku Central Hospital of the Mutual Aid Association of Public School Teachers, Japan

P1.01-33: Randomized Phase 2 Study Comparing CBDDA+PTX+BEV and CDDP+MEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)
Toshiyuki Harada
JCHO Hokkaido Hospital, Japan

P1.01-34: Docetaxel Plus Ramucirumab with Prophylactic PEG-G-CSF Support for Chemo-Naïve Elderly NSCLC Patients: A Phase II Study (WJOG9416L)
Akito Hata
Kobe City Medical Center General Hospital, Japan

P1.01-35: Tumor Volume Analysis In ALK-Rearranged NSCLC Treated with Crizotinib: Identifying an Early Marker for Clinical Outcome
Tomoyuki Hida
Brigham and Women’s Hospital, USA

P1.01-36: Thoracic Surgery in Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy
Chen-Hao Hsiao
Cheng Hsin General Hospital, Taiwan

P1.01-37: BPI-9016M, a Novel c-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results from a First-In-Human, Phase 1, Dose-Escalation Study
Xingsheng Hu
Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, China

P1.01-38: A Phase II With a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC
Yiqing Huang
National University Cancer Institute Singapore, Singapore

P1.01-39: Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study
Meijuan Huang
Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China

P1.01-40: Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly pts with Untreated Advanced NSCLC: TORG1323
Kentaro Ito
Matsusaka Municipal Hospital, Japan

P1.01-41: A Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer
Pasi Jänne
Dana-Farber Cancer Institute and the Belfer Center for Applied Cancer Science, USA

P1.01-42: Real-World Evaluation of Tolerability in Older Adult Patients (U75 Years Old) with EGFR-mutated NSCLC
Shirley Jiang
Princess Margaret Cancer Centre, Canada

P1.01-43: Next-Generation Sequencing in the Exploration of Genetic Heterogeneity for Lung Adenocarcinoma Patients with EGFR Activating Mutations
Ying Jin
Zhejiang Cancer Hospital, China

P1.01-44: Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced NSCLC Patients: A Single-Centre Retrospective Analysis
Shrutí Kate
Tata Memorial Hospital, India

P1.01-45: Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
Saadettin Kılıçkap
Hacettepe University Faculty of Medicine, Turkey

P1.01-46: Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer
Chul Kim
Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, NCI, NIH, USA

P1.01-47: Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Chul Kim
Georgetown University, USA
P1.01-48: Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Cavelonil-1 Expression
Tatsunori Kiriu
Kobe University Graduate School of Medicine, Japan

P1.01-49: irAE, Possible Predictive Markers for Immune Checkpoint Inhibitors
Kazutoshi Komiya
Saga University, Japan

P1.01-50: Real World Experience of Nivolumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)
Doran Ksienksi
BC Cancer Victoria, Canada

P1.01-51: Real World Experience of Pembrolizumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)
Doran Ksienksi
BC Cancer Victoria, Canada

P1.01-52: BR-34- Randomized Trial of Durvalumab & Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC
Swati Kulkarni
Windsor Regional Cancer Program, Canada

P1.01-53: Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Lorenza Landi
AUSL della Romagna, Italy

P1.01-54: A Phase I/IIb Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC
Natasha Leighl
Princess Margaret Cancer Centre, Canada

P1.01-55: Unique Genetic Profiles from Cerebrospinal Fluid Could Predict Survival of EGFR-Mutant NSCLC with Leptomeningeal Metastases
Yangsi Li
Guangdong Lung Cancer Institute, Guangdong Provinical Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P1.01-56: Concurrent Mutations in Chinese Lung Cancer Patients Carrying HER2 Genomic Aberrations
Xuefeng Xia
Geneplus-Beijing Institute, China

P1.01-57: The Role of EGFR Mutation as a Prognostic Factor in Survival After Diagnosis of Brain Metastasis in NSCLC: A Systematic Review and Meta-Analysis
Wenya Li
First Hospital of China Medical University, China

P1.01-58: Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers
Naixin Liang
Peking Union Medical College Hospital, China

P1.01-59: A Better Real World Practice for ROS1 Positive NSCLC Patients, Driven by the Targeted Next Generation Sequencing (NGS) and the Targeted TKI
Yongchang Zhang
Hunan Cancer Hospital, China

P1.01-60: Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC
Chien-Chung Lin
National Cheng Kung University Hospital, Taiwan

P1.01-61: Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers
Zhefeng Liu
General Hospital of Chinese PLA, China

P1.01-62: The Third Generation Irreversible EGFR Inhibitor HS-10296 in Advanced Non-Small Cell Lung Cancer Patients
Shun Lu
Shanghai Chest Hospital, China

P1.01-63: Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer
Margarita Majem Tarruella
Hospital de la Santa Creu i Sant Pau, Spain

P1.01-64: Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLC
Melina Marmarelis
University of Pennsylvania, USA

P1.01-65: PI1 of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIKi201)
Riichiro Maruyama
Social Insurance Omuta Tenryo Hospital, Japan

P1.01-66: Randomized Phase II Evaluating EGFR-TKI Associated with Anti-Estrogen in Women with Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial
Julien Mazieres
University Hospital, France

P1.01-67: Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients
Laura Mezquita
Gustave Roussy, France

P1.01-68: Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients
Laura Mezquita
Gustave Roussy, France

P1.01-69: Validation of the Lung Immune Prognostic Index (LIPI): Useful to Identify Resistance to PD-1 Checkpoint Inhibitors in Pretreated Lung Cancer
Xabier Mielgo-Rubio
Hospital Universitario Fundación Alcorcón, Spain

P1.01-70: Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
Daniel Morgensztern
Washington University School of Medicine, USA

P1.01-71: Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center
Nathaniel Myall
Stanford Cancer Institute/Stanford University, USA

P1.01-72: FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and Translocated Squamous NSCLC
Jürgen Wolf
Lung Cancer Group Cologne, Germany

P1.01-73: Preliminary Results of the SENeCA (Second Line Nintedanib in Non-Small Cell Lung Cancer) Trial: An Italian Experience
Silvia Novello
AOU San Luigi, Department of Oncology, University of Turin, Italy
P1.01-74: MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition
Michael Offin
Memorial Sloan Kettering Cancer Center, USA

P1.01-75: Utility of cfDNA Testing for Acquired Resistance: The Memorial Sloan Kettering Experience with Plasma EGFR T790M Clinical Testing
Michael Offin
Memorial Sloan Kettering Cancer Center, USA

P1.01-76: A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
Paul Paik
Memorial Sloan Kettering Cancer Center, USA

P1.01-77: Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation from Circulating Tumor DNA
Cheol-Kyu Park
Chonnam National University Hwasun Hospital, Korea

P1.01-78: The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib
Tejas Patil
University of Colorado, USA

P1.01-79: CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line (1L) Treatment of Advanced NSCLC
Luis Paz-Ares
Hospital Universitario Doce de Octubre, CNIO, Universidad Complutense & CiberOnc, Spain

P1.01-80: ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients with EGFRm and NSCLC Treated with Osimertinib
Zosia Piotrowska
Department of Medicine, Massachusetts General Hospital, USA

P1.01-81: Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789
Gregory Riely
Memorial Sloan Kettering Cancer Center, USA

P1.01-82: Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts
Julia Rooper
Pius Hospital Oldenburg, Germany

P1.01-83: IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab
Jeffrey Rothenstein
R.S. McLaughlin Durham Regional Cancer Centre, Canada

P1.01-84: High Basal Serum EGF Levels Predicts Response to CIMAvax-EGF, a Therapeutic Vaccine for Advanced NSCLC
Orestes Santos Morales
CIM, Cuba

P1.01-85: The Prevalence of Different EGFR exon20 Mutations in 12,833 Chinese Lung Cancer Patients
Yang W. Shao
School of Public Health, Nanjing Medical University, China

P1.01-86: BTCRC-LUN15-017: Phase-Ib Integrated Study of Single Agent Alpelisib, Durvalumab: ABOUND.2L+
Santiago Ponce Aix
Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO, Spain

P1.01-87: A Phase 1b Study of TRC105 In Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients with Stage 4 Non-Squamous Cell Lung Cancer
Garrett Sherwood
University of Alabama - Birmingham, USA

P1.01-88: Osimertinib Maintenance After Definitive Chemoradiation in Patients with Unresectable EGFRm-Positive Stage III NSCLC (LAURA)
Lu Shun
Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.01-89: Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM
Veena Singh
Biocept, Inc., USA

P1.01-90: A Pilot Trial Assessing Apatinib Combined with Docetaxel (DTX) as Second-Line Chemotherapy for EGFR Negative Advanced NSCLC
Yong Song
Jinling Hospital, Nanjing University School of Medicine, China

P1.01-91: A Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer
Julian Surujballi
Schulich School of Medicine and Dentistry, Canada

P1.01-92: A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations
Kensuke Suzuki
Toyama Pefectural Central Hospital, Japan

P1.01-93: Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+
Jialei Wang
Fudan University Shanghai Cancer Center, China

P1.01-94: Phase I Trial to Establish Maximum Tolerated Dose Safety and Pharmacokinetic Profile of Oral Paclitaxel
Satheesh Thungappa
Spandana Oncology Centre, India

P1.01-95: Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients with ROS1 Rearrangement——A Single Chinese Cancer Institute Experience
Jialei Wang
Fudan University Shanghai Cancer Center, China

P1.01-96: Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy
Da Wu
Peking University Shenzhen Hospital, China

P1.01-97: Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC
Yi-Long Wu
Guangdong Lung Cancer Institute; Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences, China

P1.01-98: A Phase IIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients with Brain Metastases or Dose Reductions
Yi-Long Wu
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China
P1.01-99: Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China
Chong-Rui Xu
Guangdong Lung Cancer Institute; Guangdong General Hospital(GGH) & Guangdong Academy of Medical Sciences, China

P1.01-100: Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC
Yaping Xu
Shanghai Pulmonary Hospital, China

P1.01-101: Survival Benefit of Sequential Therapy in ALK Positive Oligoprogressive NSCLC Patients After Crizotinib Resistance
Haiyan Xu
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P1.01-102: Retrospective Analysis of Immune Checkpoint Inhibitors in Patients with EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort
Tadaaki Yamada
Kyoto Prefectural University of Medicine, Japan

P1.01-103: Leukocyte Telomere Length as a Novel Biomarker in Advanced Lung Adenocarcinoma Patients Treated with Gefitinib
Ming Yang
Shandong Cancer Hospital Affiliated to Shandong University, China

P1.01-104: Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women with Metastatic Non-Squamous NSCLC
Patricia Young
University of California, USA

P1.01-105: Lung Cancer Patients with Concurrent EGFR and MET Mutations: A Retrospective Analysis of 29 Cases
Zhaoxia Wang
The Second Affiliated Hospital of Nanjing Medical University, China

P1.01-106: Pembrolizumab Randomized, Phase I Study in Chinese Patients with Advanced NSCLC: KEYNOTE-032
Li Zhang
Sun Yat-sen University Cancer Center, China

P1.01-107: The Impact of Anlotinib on Quality of Life in Patients with Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)
Li Zhang
Peking Union Medical College Hospital, China

P1.01-108: Management of Anlotinib-Related Adverse Events: Data From ALTER0303
Li Zhang
Peking Union Medical College Hospital, China

P1.01-109: Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Hongyun Zhao
Sun Yat-sen University Cancer Center, China

P1.01-110: Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated with Afinitinib
Shen Zhao
Sun Yat-sen University Cancer Center, China

P1.01-111: EGFR exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer
Chao Zhao
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P1.01-112: Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
Caicun Zhou
Tongji University, China

P1.01-113: Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer
Youcai Zhu
Zhejiang Rongjun Hospital, China

P1.02 ADVOCACY

P1.02-01: Imaging of Lung Cancer at the University College Hospital, Ibadan, Nigeria: Does Nuclear Medicine Have Anything to Offer?
Olusegun Ayeni
University College Hospital, Nigeria

P1.02-02: ‘Listen To Your Lungs’ – An Awareness Campaign from The Marie Keating Foundation
Anne-Marie Baird
Lung Cancer Europe, Ireland

P1.02-03: The Role of Lung Cancer Advocacy Organizations in Biomarker Testing
Winfield Boerckel
CancerCare, USA

P1.02-04: The EGFR Resisters Lung Cancer Group: A Patient-Driven Initiative to Understand & Improve Treatments for EGFR+ Lung Cancer
Jill Feldman
EGFR Resisters, USA

P1.02-05: ALK Positive Lung Cancer: Patient Engagement and Partnership
Shelly Engfer-Triebenbach
ALK Positive, USA

P1.02-06: Usefulness of Workshop to Promote Communication Between Patient and Family
Kazuo Hasegawa
Patient Network ONESTEP, Japan

P1.02-07: The Role of Volunteers in Quality Palliative Care Delivery for Advance Lung Cancer
Aditya Manna
Narikeldaha Prayas, India

P1.02-08: Hope for People Living with Metastatic Lung Cancer
Aditya Manna
Narikeldaha Prayas, India

P1.02-09: Identifying Gaps in Messaging for Biomarker Testing in the Lung Cancer Community: Need for Consistent and Actionable Messaging
Upal Basu Roy
LUNGevery, USA

P1.02-10: “We Are Ambassadors for Survivors:” Experiences of Lung Cancer Support Group Attendees and Facilitators
Maureen Rigney
Lung Cancer Alliance, USA

P1.02-11: Lung Cancer Symptom Awareness: Findings from a Global Consumer Survey
Maureen Rigney
Lung Cancer Alliance, USA

P1.03 BIOLOGY

P1.03-01 - P1.03-12 Characterization

P1.03-01: Association of APC Mutations with Chinese Patients Molecular Spectrum in Non-Small-Cell Lung Cancer
Shuitu Feng
Xiamen Haicang Hospital, China
POSTERS 1
MONDAY, SEPTEMBER 24, 2018

142

China Xiangya Hospital, Central South University, China
Min Li
Microenviroment
Benign and Malignant Solitary Pulmonary
P1.03-11: Analysis of T-Cell Repertoires in
Fujian Cancer Hospital, China
Quxia Zhang
Cancer Patients
Variants in Chinese Non-Small-Cell Lung
P1.03-09: Molecular Landscape of FGFR1
Point Mutations in Chinese Non-Small-Cell
Lung Cancer Patients: A Retrospective
Study
Quxia Zhang
Fujian Cancer Hospital, China
P1.03-06: Molecular Landscape of FGF1
Point Mutations in Chinese Non-Small-Cell
Lung Cancer Patients: A Retrospective
Study
Quxia Zhang
Fujian Cancer Hospital, China
P1.03-05: Transcriptome Landscape of
Lung Adenocarcinoma Patients Revealed
Distinct Trajectory Patterns
Yuqing Lou
Shanghai Chest Hospital, Shanghai Jiaotong
University, China
P1.03-04: Molecular Characteristics of
ALK Primary Point Mutations Non-Small-
Cell Lung Cancer in Chinese Patients
Chunwei Xu
Fujian Cancer Hospital, China
P1.03-03: Molecular Characteristics of
Chinese Patients with TSC2-Mutated Non-
Small-Cell Lung Cancer: A Retrospective
Study
Zhangzhou Huang
Fujian Cancer Hospital, China
P1.03-02: Analysis of SMAD4 Aberrations
in Chinese Patients with Non-Small-Cell
Lung Cancer
Jianhui Huang
Lishui Hospital of Zhejiang University, China

P1.03-12: PD-L1 Expression is Predominant
in CD68+ Tumor-Associated Macrophages
in Stage I-III Non-Small Cell Lung Cancers
Boris Sepesi
MD Anderson Cancer Center, USA

P1.03-13 - P1.03-022 In vitro

P1.03-13: elF2α, A Subunit of Translation-
Initiation Factor elf2, as a Potential
Therapeutic Target for Non-Small Cell Lung
Cancer
Daiki Goto
Nagoya University Graduate School of
Medicine, Japan

P1.03-14: Interaction Between Celecoxib
and Cisplatin is Dependent on the p53
Status in Human NSCLC Cell Lines
Weiying Li
Beijing Chest Hospital, Capital Medical
University / Beijing Tuberculosis and
Thoracic Tumor Research Institute, China

P1.03-15: TMS Reduced Gefitinib
Resistance In NSCLCs Via Suppressing
MAPK/Akt/Bcl-2 Pathway by Upregulation
of miR-345 and miR-498
Ping Liu
The Second Xiangya Hospital, Central
South University, China

P1.03-16: Anlotinib Inhibits Angiogenesis
of Refractory Advanced Non-Small Cell
Lung Cancer via Blocking CCL2 Expression
Baohui Han
Shanghai Chest Hospital, Shanghai Jiao
Tong University, China

P1.03-17: Functional Mechanism of GLDC
Gene Alternative Splicing in Non-Small Cell
Lung Cancer
Kewei Ma
The First Hospital of Jinlin University, China

P1.03-18: Mechanobiology of Lung Cancer
Cells: Regulation of PD-L1 Expression by
Matrix Stiffness
Ayako Miyazawa
Nagoya University Graduate School of
Medicine, Japan

P1.03-19: Antibody Blockade of Integrin
Alpha-V-Beta-6 (avb6) as a Novel
Therapeutic Target for Non-Small Cell Lung
Cancer
Banu Rudran
Barts Cancer Institute, UK

P1.03-20: The Novel SFN Inhibitors
Aprepitant and Ticagrelor Exert Anti-
Tumor Effects Through Blocking of
Oncoprotein Ubiquitination
Aya Shiba
University of Tsukuba, Japan

P1.03-21: Huaier Aqueous Extract Induces
Lung Adenocarcinoma Cell Apoptosis
Through Excessive Activation Of MEK/
ERK Signaling Pathway
Zhao Shilei
The First Affiliated Hospital of Dalian
Medical University, China

P1.03-22: MiR-125b Plays a Tumor
Suppressor Role in Inflammation-Related
Non-Small Cell Lung Cancer via Repressing
IGF-1 Signal Pathway
Yanwei Zhang
Shanghai Jiaotong University Affiliated
Shanghai Chest Hospital, China

P1.03-23 – P1.03-34 Prognosis

P1.03-23: The Molecular Landscape and
Outcome of Chinese Patients with Non-
Small Cell Lung Cancer Harboring NTRK1
Point Mutations: A Retrospective Study
Xiaohui Chen
Fujian Cancer Hospital, China

P1.03-24: TMPRSS4: A Novel Prognostic
Biomarker and Therapeutic Target in
NSCLC
Francisco Expósito
Center for Applied Medical Research
(CIMA), University of Navarra, Spain

P1.03-25: The Frequency and Prognosis of
ATM Mutations in Chinese Non-Small-Cell
Lung Cancer Patients
Quxia Zhang
Fujian Cancer Hospital, China

P1.03-26: Analysis of DDR2 Gene
Aberrations in Chinese Non-Small-Cell
Lung Cancer Patients and Evaluation of
Their Prognosis
Chunwei Xu
Fujian Cancer Hospital, China

P1.03-27: Somatic Mutations in BRCA2
Genes Are Associated with Prognosis
in Chinese Non-Small-Cell Lung Cancer
Patients
Chunwei Xu
Fujian Cancer Hospital, China

P1.03-28: Association Between Molecular
Characteristics of CTNNB1 Mutations and
Prognosis in Patients with Nsclc in Chinese
Patients
Chunwei Xu
Fujian Cancer Hospital, China

P1.03-29: An Intronic Variant in EGFR
Regulates GBAS Expression and Predicts
Survival in Early-Stage Non-Small Cell Lung
Cancer
Eungbae Lee
Kyungpook National University Chilgok
Hospital, Korea
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.03-30</td>
<td>The Number of Mutated Repair Genes as Predictor for Tumor Mutation Burden of Lung Adenocarcinoma</td>
<td>Yuqing Lou Shanghai Chest Hospital, Shanghai Jiaotong University, China</td>
<td></td>
</tr>
<tr>
<td>P1.03-31</td>
<td>Periostin is a Negative Prognostic Factor and Promotes Cancer Cell Proliferation in Non-Small Cell Lung Cancer</td>
<td>Toshimasa Okazaki Miyagi Cancer Center, Japan</td>
<td></td>
</tr>
<tr>
<td>P1.03-32</td>
<td>Molecular Characteristics and Prognosis FBXW7 Mutations in Chinese Non-Small-Cell Lung Cancer Patients</td>
<td>Chunwei Xu Fujian Cancer Hospital, China</td>
<td></td>
</tr>
<tr>
<td>P1.03-33</td>
<td>Mutational Spectrum and Prognosis of Non-Small-Cell Lung Cancer Harboring MTOR Mutations in Chinese Population</td>
<td>Chunwei Xu Fujian Cancer Hospital, China</td>
<td></td>
</tr>
<tr>
<td>P1.03-34</td>
<td>Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI</td>
<td>Yi-Chen Zhang Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China</td>
<td></td>
</tr>
<tr>
<td>P1.03-30</td>
<td>The Number of Mutated Repair Genes as Predictor for Tumor Mutation Burden of Lung Adenocarcinoma</td>
<td>Yuqing Lou Shanghai Chest Hospital, Shanghai Jiaotong University, China</td>
<td></td>
</tr>
<tr>
<td>P1.03-31</td>
<td>Periostin is a Negative Prognostic Factor and Promotes Cancer Cell Proliferation in Non-Small Cell Lung Cancer</td>
<td>Toshimasa Okazaki Miyagi Cancer Center, Japan</td>
<td></td>
</tr>
<tr>
<td>P1.03-32</td>
<td>Molecular Characteristics and Prognosis FBXW7 Mutations in Chinese Non-Small-Cell Lung Cancer Patients</td>
<td>Chunwei Xu Fujian Cancer Hospital, China</td>
<td></td>
</tr>
<tr>
<td>P1.03-33</td>
<td>Mutational Spectrum and Prognosis of Non-Small-Cell Lung Cancer Harboring MTOR Mutations in Chinese Population</td>
<td>Chunwei Xu Fujian Cancer Hospital, China</td>
<td></td>
</tr>
<tr>
<td>P1.03-34</td>
<td>Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI</td>
<td>Yi-Chen Zhang Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China</td>
<td></td>
</tr>
<tr>
<td>P1.04-01</td>
<td>Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity</td>
<td>Chih-Hsiang Leng National Health Research Institutes, Taiwan</td>
<td></td>
</tr>
<tr>
<td>P1.04-02</td>
<td>Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients with NSCLC by Whole Genome Sequencing</td>
<td>Megan Barnet Garvan Institute of Medical Research, Australia</td>
<td></td>
</tr>
<tr>
<td>P1.04-03</td>
<td>Mass Spectrometry-Based Serum Proteomic Signature as a Potential Biomarker for Survival in NSCLC Patients with Immunotherapy</td>
<td>Young Chae Northwestern University, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-04</td>
<td>Elucidating the Role of Leukocyte-Associated Immunoglobulin-Like Receptor 2 (LAIR2) in Lung Cancer Development</td>
<td>Dalam Ly University Health Network, Canada</td>
<td></td>
</tr>
<tr>
<td>P1.04-05</td>
<td>Plants as a Biomarker of Antitumor Activity in Patients with Metastatic NSCLC</td>
<td>Junhong Li Shanghai Jiaotong University, China</td>
<td></td>
</tr>
<tr>
<td>P1.04-06</td>
<td>Clinicopathological Analysis of Pulmonary Pleomorphic Carcinoma</td>
<td>Misa Noguchi Graduate School of Medicine, Kyoto University, Japan</td>
<td></td>
</tr>
<tr>
<td>P1.04-07</td>
<td>Pemetrexed Enhances Anti-Tumor Efficacy of PD-L1 blockade by Promoting Intra-Tumor Immune Response via Tumor and T Cell-Intrinsic Mechanisms</td>
<td>Neelam Amaladas Eli Lilly, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-08</td>
<td>Co-Residence of Patient-Derived Immune Cells in Patient-Derived Xenografts from Lung Cancer Patients</td>
<td>Xingxiang Pu The University of Texas MD Anderson Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-09</td>
<td>Immunomodulatory Effects of Aflatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI</td>
<td>Jonathan Riess UC Davis Comprehensive Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-10</td>
<td>The Importance of Suppressor and Cytotoxic T Lymphocyte Subsets and Cytotoxic Mechanisms in Non-Small Cell Lung Cancer</td>
<td>Akif Turna Istanbul University, Cerrahpasa Medical Faculty, Turkey</td>
<td></td>
</tr>
<tr>
<td>P1.04-11</td>
<td>Neutrophil-to-Lymphocyte Ratio as a Biomarker for Survival After Immunotherapy in Non-Small Cell Lung Cancer</td>
<td>Young Chae Northwestern University, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-12</td>
<td>Mass Spectrometry-Based Serum Proteomic Signature as a Potential Biomarker for Survival in NSCLC Patients with Immunotherapy</td>
<td>Young Chae Northwestern University, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-13</td>
<td>Combining Clinical and Genomic Data for Predicting Response to Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer</td>
<td>Michelle Chiu Case Western Reserve University School of Medicine, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-14</td>
<td>HLA B44 Supertype Associated with Less Favorable Neoantigen Binding in Non-Small Cell Lung Cancer Treated with Immunotherapy</td>
<td>Amy Cummings University of California, Los Angeles, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-15</td>
<td>Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer</td>
<td>Carlo Genova Ospedale Policlinico San Martino, Italy</td>
<td></td>
</tr>
<tr>
<td>P1.04-16</td>
<td>Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC with High PD-L1 Expression Tested on Cytology Versus Biopsy Samples</td>
<td>Katie Guo Jewish General Hospital, Canada</td>
<td></td>
</tr>
<tr>
<td>P1.04-17</td>
<td>Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICD) in Patients with Metastatic Non-Small-Cell Lung Cancer</td>
<td>Oded Icht Thoracic Cancer Unit, Davidoff Cancer Institute, Rabin Medical Center, Affiliated to the Sackler Faculty of Medicine, Israel</td>
<td></td>
</tr>
<tr>
<td>P1.04-18</td>
<td>PD-L1 Expression and its Correlation with Tumor TNM Stage in Patients with Non-Small Cell Lung Cancer</td>
<td>Taewon Jang Kosin University Gosepel Hospital, Korea</td>
<td></td>
</tr>
<tr>
<td>P1.04-19</td>
<td>Combining Clinical and Genomic Data for Predicting Response to Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer</td>
<td>Michelle Chiu Case Western Reserve University School of Medicine, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-20</td>
<td>Computational Biological Model Prediction of PD-L1 Expression and Immunotherapy Response for KRAS Mutated Lung Cancer Based on Co-Mutations</td>
<td>Sukhmani Padha Stanford Cancer Institute/Stanford University School of Medicine, USA</td>
<td></td>
</tr>
</tbody>
</table>
P1.04-21: The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
Mari Mino-Kenudson
Massachusetts General Hospital, USA

P1.04-22: CD73 Immunohistochemical Expression in Malignant Cells and Correlation with Immune Infiltrate in Non-Small Cell Lung Carcinoma (NSCLC)
Ignacio I. Wistuba
The University of Texas MD Anderson Cancer Center, USA

P1.04-23: Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma
Hui Yu
University of Colorado Anschutz Medical Campus, USA

P1.04-24: Digital Core Needle-Biopsy to Assess PD-L1 Expression in Non-Small Cell Lung Cancer: Optimal Sampling and Need for Re-Biopsy
Alexander Haragan
University of Liverpool, UK

P1.04-25: The Implication of Frameshift Mutation Burden in Neoadtigent and Immune Cell Landscape in Non-Small Cell Lung Cancer (NSCLC)
Young Chae
Northwestern University Feinberg School of Medicine, USA

P1.04-26: Prospective Immuno-Biobank in NSCLC
Alfredo Addeo
HUG, Switzerland

Maria Bluthgen
Hospital Aleman, Argentina

P1.04-28: Baseline Markers of Inflammation and Outcome with Nivolumab in Pretreated Non Small Cell Lung Cancers: A Retrospective Study
Alessandro Russo
Medical Oncology Unit A.O. Papardo & Department of Human Pathology University of Messina, Italy

P1.04-29: Second or Third Line Nivolumab Versus First Line Nivolumab in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Antonio Irigoyen Medina
Hospital Virgen De La Salud. Toledo, Spain

P1.04-30: A Potential Effect of Diabetes Mellitus and Metformin Use on Efficacy of Immune Checkpoint Inhibitors (ICI)
Oded Jacobi
Davidoff Cancer Institute, Rabin Medical Center, Israel

P1.04-31 - P1.04-36 Trials

P1.04-31: Efficacy and Tolerance of Immune-Checkpoint Inhibitors in EGFR, ALK/ROS 1 Non-Small-Cell-Lung-Cancer (NSCLC): GFPC 03-2016 IMAD Study
Olivier Bylicki
Hia Percy, France

P1.04-32: Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC
Alberto Chiappori
H. Lee Moffitt Cancer Center and Research Institute, Inc, USA

P1.04-33: Retrospective Descriptive Analysis of Metformin with Atezolizumab in Advanced Non-Small Cell Lung Cancer in The OAK Trial
Richard Pietras
UCLA Division of Hematology-Oncology and Jonsson Comprehensive Cancer Center, USA

P1.04-34: Study on Treatment of Stage IV Solid Tumors with Mutant Neoadtigent Specific T Cells
Qi Song
The General Hospital of People’s Liberation Army, China

P1.04-35: Quick Progression (QP) in Patients Treated by Nivolumab (IO) in 2nd Line or More for Non-Small Cell Lung Cancer: ERORECI Study (GFPC 2016-04)
Alain Vergnenegre
CHU Dupuytren, France

P1.04-36: Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer
Jie Wang
Chinese Academy of Medical Sciences Tumor Hospital, China

P1.05-01: Incidence and Clinical Relevance of NSCLC Lymph Node Micro-Metastasis Detected by Staging EBUS-TBNA
Adam Belanger
University of North Carolina, USA

P1.05-02: Endobronchial Ultrasound-Transbronchial Needle Aspiration for Lymphoma in Patients With Mediastinal Lymphadenopathy
Yu-Deok Choi
Chonnam National University Medical School, Korea

P1.05-03: Significance of Lymph Node SUVmax In Predicting Nodal Metastasis By EBUS in Lung Cancer Patients
Michael Gulak
University of Ottawa, Canada

P1.05-04: Cone-Beam CT Confirms the Status of Transbronchial Biopsy Under Virtual Bronchoscopic Navigation for Peripheral Lung Lesions
Naoya Kawakita
Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

P1.05-05: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Suspected Malignancy; Current Status and Issues
Hidenao Kayawake
Kyoto University, Japan

P1.05-06: Bronchoscopic Image-Guided Microwave Ablation of Peripheral Lung Tumours – Early Results
Kelvin Lau
St Bartholomew’s Hospital, UK

P1.05-07: Clinical Significance of Pleural Indentation of Lung Adenocarcinoma Presented as Ground Glass Opacities
Choon-Taek Lee
Seoul National University Bundang Hospital, Korea

P1.05-08: Spread Through Air Spaces (STAS) in Invasive Mucinous Adenocarcinoma of the Lung: Incidence, Prognostic Impact, and Predictive Factors
Min A Lee
Samsung Medical Center, Korea

P1.05-09: Dielectric Property Test for the Rapid Differential Diagnosis of Lung Nodules/Mass
Di Lu
Nanfang Hospital, China

P1.05-10: Usefulness of Respiratory Dilatation Balloon in Tracheobronchial Stenosis Requiring Silicone Y-Stent Treatment
Shinjiro Mizuguchi
Osaka City General Hospital, Japan

P1.05-11: Role of EBUS-TBNA in Evaluation of Mediastinal Lymphadenopathy and Masses in Patients with Known or Suspected Extra-Pulmonary Malignancies
Deepali Jain
All India Institute of Medical Sciences, India
P1.05-12: 18F-FDG PET/CT Findings May Predict Postoperative Acute Exacerbation of Interstitial Pneumonia in Lung Cancer Patients
Hisashi Oishi
Institute of Development, Aging and Cancer, Tohoku University, Japan

P1.05-13: The Demonstration of the Possibility of the Pleura Cryo Biopsy – A Preliminary Report
Jaroslav Pierog
Pomeranian Medical University, Poland

P1.05-14: Autofluorescence Mode of Thoracoscopy Improves Visceral Pleural Invasion Diagnosis in Non-Small Cell Lung Cancer
Toru Sawada
Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

P1.05-15: Benign Lung Nodule Resections in the Era of Advanced Imaging and Clinical Guidelines: Imaging Features and How We Can Reduce the Resection Rate
Mohamed Sayyouch
University of Michigan, USA

P1.05-16: Clinical Utility of Electromagnetic Navigation Bronchoscopy in the Diagnosis of Lung Cancer
Navneet Singh
SUNY Downstate Medical Center, USA

P1.05-17: Clinicopathological Characteristics of Primary Lung Cancers Associated with Emphysematous Bullae
Mikito Suzuki
Keio University, School of Medicine, Japan

P1.05-18: Predictive Performance of Semi-Quantitative Metabolic Metrics on FDG-PET/CT for the Identification of EGFR Mutations
Taimei Tachibana
Tokyo Medical University Hospital, Japan

P1.05-19: CT and PET/CT Parameters of Lepidic Predominant Pattern Lung Adenocarcinoma and Invasiveness on Pathology
Hiromitsu Takizawa
Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

P1.05-20: Therapeutic Condition of Photodynamic Therapy Using Taraporfin Sodium for Central Airway Stenosis
Takaaki Tsuchida
National Cancer Center Hospital, Japan

P1.05-21: CT-Guided Biopsy of Lung Lesions with Outer Cannula Washing Cytology
Fumiyasu Tsushima
Hirosaki University Graduate School of Medicine, Japan

P1.05-22: New Methods of Brachytherapy Catheter Stabilization in the Airways
Jiri Votruba
Charles University Hospital, Czech Republic

P1.05-23: Evaluation of the 8th Edition of the TNM Classification for Lung Cancer at a Single Institution
Jia Wang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

P1.05-24: Clinical Characteristics and Prognostic Analysis of Multiple Primary Malignant Neoplasms in Patients with Lung Cancer
Huijuan Wang
Henan Cancer Hospital, China

P1.09-01 – P1.09-07 IO
P1.09-01: PD-L1 Testing On NSCLC Cytology Samples in a UK Teaching Hospital
Haider Al-Najjar
Central Manchester University Hospitals NHS Foundation Trust, UK

Dominique Arpin
Hopital Nord Ouest, France

P1.09-03: Challenges in PD-L1 Immunohistochemistry in Lung Adenocarcinoma: A Retrospective Study of Conventional Type of Lung Adenocarcinoma
Deepali Jain
All India Institute of Medical Sciences, India

P1.09-04: Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region
Rosalyn Juergens
McMaster University, Canada

P1.09-05: Why Does PD-L1 (22C3) Expression Rate Show Difference Among Regional Hospitals?
Yuko Minami
Hospital Universitario HM Sanchinarro-CIBERONC, Spain

P1.09-06: The Incidence of PD-L1 in NSCLC and its Correlation with Driver Mutations in Turkish Patients; A Single Center Experience.
Buge Oz
Istanbul University, Cerrahpasa Medical Faculty, Turkey

P1.09-08: Integrating NGS Information for Staging Multiple Lung Adenocarcinoma: A McGill University Health Centre Retrospective Study.
Ayesha Baig
McGill University Health Center and McGill University, Canada

P1.09-09: Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients
Esther Conde
Hospital Universitario HM Sanchinarro-CIBERONC, Spain

P1.09-10: Targeted Sequencing of Pulmonary Enteric Adenocarcinoma Reveals Distinctive Mutation Profile from Conventional Type of Lung Adenocarcinoma
Likun Hou
Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P1.09-11: Immunohistochemical Assessment of BRCA1 Associated Protein-1 (BAP1) in Pulmonary Mucoepidermoid Carcinomas
Deepali Jain
All India Institute of Medical Sciences, India

P1.09-12: Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients with NSCLC Highlights Correlation of ROS1 and PD-L1 Expression
Tae-Jung Kim
Department of Hospital Pathology, The Catholic University of Korea, Korea
P1.09-13: Detection of Actionable Mutations in Plasma cfDNA Samples From NSCLC Patients Using a Novel Amplicon-Based Firefly NGS Assay
Jiaotao Lou
Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.09-14: Analysis of Real-Word Mutations of Lung Cancer Driver Genes in 3081 Patients from China
Ye Guo
The First Hospital of Jinlin University, China

P1.09-15: Preliminary Experience with Liquid Biopsies in a Resource Constrained Setting and its Impact on Treatment Decision Making
Valliappan Muthu
Postgraduate Institute of Medical Education and Research (PGIMER), India

P1.09-16: Novel Somatic Gene Mutation of SLC17A9, Detected in Early-Stage Lung Adenocarcinoma
Shingo Sakashita
University of Tsukuba, Japan

P1.09-17: CTNNB1 (Beta-Catenin) Mutations in Non-Small Cell Lung Carcinoma: A Clinicopathological Study of 18 Cases
Vincent Thomas De Montpréville
Marie Lannelongue Hospital, France

P1.09-18: 15 Cases of Clinical and Molecular Features Analysis in Pulmonary Adenoid Cystic Carcinoma
Chunwei Xu
Fujian Cancer Hospital, China

P1.09-19: Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma
Zheng Wang
Beijing Hospital, China

P1.09-20: Correlation Between Whole Genomic Copy Number Variant Scoring and Pathological Classification, Staging in Lung Non-Mucinous Adenocarcinoma
Zheng Wang
Beijing Hospital, China

P1.09-21: Circulating Tumor DNA Improves Genotyping and Detection of Targetable Alterations in Selected Lung Cancer Patients
Zyanya Zatarain-Barrón
Instituto Nacional de Cancerología, Mexico

P1.09-22: Detection of ALK Gene Rearrangement in FFPE Tissues of Non-Small Cell Lung Cancer Using in Situ RNA Hybridization
Xuan Zeng
Peking Union Medical College Hospital, China

P1.09-23: Effect of Plasma Input on the Clinical Sensitivity of a Real-Time PCR Assay for the Detection of EGFR Mutation in Plasma ctDNA From NSCLC Patients
Guanshan Zhu
Amoy Diagnostics Co., Ltd., China

P1.09-24 - P1.09-40 Pathology

P1.09-24: The Effects of NLR and PLR of Effect on Prognosis in Patients with the Lung Cancer
Fazil Aydin
Karadeniz Technical University, Turkey

P1.09-25: Invasive Size (Not Total Size) Predicts Overall Survival in Invasive Mucinous Adenocarcinomas
Wei-Chin Chang
MacKay Memorial Hospital, Taiwan

P1.09-26: A Case Report of Discordant Markers of Lung Cancer Tumor Cells: An Unusual Immunophenotype of Uncertain Significance
Lisa Giscombe
Roger Williams Medical Center, USA

P1.09-27: Clear Cell Adenocarcinoma Subtype is an Independent Predictor of Better Survival in Patients with Lung Adenocarcinoma
Takefumi Komiya
Tulane University School of Medicine, USA

P1.09-28: Clinical Utility of Rapid Immunohistochemistry for Differentiation of Solitary Pulmonary Adenocarcinomas
Hayato Konno
Shizuoka Cancer Center, Japan

P1.09-29: In Situ Growth Pattern in Lung Adenocarcinoma Is Divisible into Distinct Categories with Divergent Biological and Survival Implications
John Le Quesne
MRC Toxicology Institute, UK

P1.09-30: Heterotopic Expression of Ceruloplasmin in Lung Adenocarcinoma and its Possible Clinical Use as a Tumor Biomarker
Roja Matsuo
University of Tsukuba Hospital, Japan

P1.09-31: Preliminary Experience with Liquid Biopsies in a Resource Constrained Setting and Its Impact on Treatment Decision Making
Valliappan Muthu
Postgraduate Institute of Medical Education and Research (PGIMER), India

P1.09-32: Classification and Mutation Prediction from Non-Small Cell Lung Cancer Histopathology Images Using Deep Learning
Paolo Ocampo
New York University School of Medicine, USA

P1.09-33: Validation of Non-Small Cell Lung Cancer Not Otherwise Specified to Use Immunohistochemistry on Treatment Outcome
Takahiro Ota
National Cancer Center Hospital East, Japan

P1.09-34: Prognostic Impact of Invasive Size, Actual Tumor Size, and Mucinous Tumor Size in Invasive Mucinous Adenocarcinoma of the Lung
Tomohito Saito
Kansai Medical University, Japan

P1.09-35: Clinical Impact of Systemic Inflammation and Histologic Grade in Non-Small Cell Lung Carcinoma (NSCLC)
Nikolaos Tsoukalas
Veterans Hospital (417 NIMTS), Greece

P1.09-36: Clinical Significance of Cannabinoid Receptor CB2 Expression in Non Small Cell Lung Cancer (NSCLC)
Nikolaos Tsoukalas
Veterans Hospital (417 NIMTS), Greece

P1.09-37: Tumor Spread Through Air Spaces (STAS) in Stage I Lung Squamous Cell
Hironori Uruga
Toranomom Hospital, Japan

P1.09-38: Pulmonary Epithelioid Hemangioendothelioma (EHE) with Von Recklinghausen Disease
Satoshi Yamamoto
Medical Kouhoukai Takagi Hospital, Japan

P1.09-39: Spread Through Air Spaces Predicts a Worse Survival in Patients with Stage I Adenocarcinomas > 2.0cm After Radical Lobectomy
Lin Yang
Cancer Hospital, National Cancer Center/Chinese Academy of Medical Sciences, China

P1.09-40: Metastatic Endometrial Sarcoma Presenting as a Spontaneous Pneumothorax and Masquerading as a Pulmonary Blastoema
Giselle Suero-Abreu
Rutgers University New Jersey Medical School, USA
P1.11-01: The NELSON Triage Algorithm 
Applied to a Chinese Biopsied Population: A Pilot Study
Hubert Beaumont
Median Technologies, France

P1.11-02: Pathologic Comparison of Prevalent vs. Incident CT Lung Screen Detected Cancer in NCCN High-Risk Subjects: Are They Different?
Eric Burks
Lahey Hospital & Medical Center, USA

P1.11-03: MicroRNA with Ability to Reciprocal Regulation of Dicer and Drosha – Plasma Expression Status and Diagnostic Value in Non-Small Cell Lung Cancer
Pawel Krawczyk
Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland

P1.11-04: Size Measurement Variability of Solid Component of Lung Adenocarcinoma
Kazutoshi Hamanaka
Shinshu University School of Medicine, Japan

P1.11-05: Metabolomic Profiling for Second Primary Lung Cancer Among Lung Cancer Survivors
Summer Han
Stanford University School of Medicine, USA

P1.11-06: Lung Cancer Probability in New Perifissural Nodules Detected in a Lung Cancer Screening Study
Marjolein Heuvelmans
University of Groningen, University Medical Center Groningen, Netherlands

P1.11-07: Utility of the Maximum CT Value in Predicting Invasiveness of Pure GGNs
Junji Ichinose
The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan

P1.11-08: AI Based Malignancy Prediction of Indeterminate Pulmonary Nodules: Robustness to CT Contrast Media
Timor Kadir
Optellum Ltd., UK

P1.11-09: The Delay of Lung Cancer Diagnosis Due to Misdiagnosing as Pulmonary Tuberculosis
Ana Rima
Medical Faculty Sebelas Maret University, Indonesia

P1.11-10: Optimizing Radiomics Features by Minimizing Boundary Effects and Normalizing with Opposite Lung Tissue Characteristics
Saeed Seyyedi
British Columbia Cancer Agency Research Centre, Canada

P1.11-11: Comparing Lung Cancer Diagnosed by Low Dose CT (LDCT), Incidental Lung Nodule Program (ILNP), and Non-Program-Based Detection
Matthew Smeltzer
University of Memphis School of Public Health, USA

P1.11-12: Interrogation of an Exhaled MicroRNA Panel for Lung Cancer Risk Assessment
Simon Spivack
Albert Einstein College of Medicine, USA

P1.11-13: Noninvasive Detection of Early Stage NSCLC EGFR Mutations Using Electric Field Induced Release and Measurement (EFIRM)
Charles Strom
UCLA, USA

P1.11-14: Radiological Pleura-Tumor Proximity in Pure-Solid Clinical Stage I Lung Cancer: Its Influence on Lymph Node Metastasis and Recurrence
Tosiki Tanaka
Yamaguchi University Graduate School of Medicine, Japan

P1.11-15: Application of Lung-RADS vs. PAN-CAN Nodule Risk Calculation in the Alberta Lung Cancer Screening Study
Alain Tremblay
University of Calgary Cumming School of Medicine, Canada

P1.11-16: Optimizing Radiomics Features by Minimizing Boundary Effects and Normalizing with Opposite Lung Tissue Characteristics
Saeed Seyyedi
British Columbia Cancer Agency Research Centre, Canada

P1.11-17: Discriminating Less Invasive Lesions of Early-Stage Lung Adenocarcinoma by Three-Dimensional Computed Tomography Analysis
Nobuyuki Yoshiyasu
St. Luke’s International Hospital, Japan

P1.11-18: A Classification-Based Machine Learning Method Reveals Exosomal miRNA Biomarkers for Patients with Pulmonary Ground Glass Nodule
Jia-Tao Zhang
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Southern Medical University,, China

P1.11-19: Expression of TNFRII in Serum is Correlated with the Significant Risk of Subcentimeter Lung Adenocarcinoma
Yanwei Zhang
Shanghai Chest Hospital, Shanghai Jiaotong University, China

P1.11-01 – P1.12-06b Clinical Trial/Therapeutics

Yun Fan
Zhejiang Cancer Hospital, China

P1.12-02: Phase II Study of Amrubicin Monotherapy in Elderly or Poor-Risk Patients with Extensive Disease of Small Cell Lung Cancer
Satoshi Iigawa
Kitasato University School of Medicine, Japan

P1.12-03: A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy
Yutao Liu
Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, China

P1.12-04: A Phase Study of Niraparib as Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients
Shun Lu
Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.12-05: Efficacy of Perioperative Chemotherapy for High-Grade Neuroendocrine Tumors
Hiroyuki Ogawa
Hyogo Cancer Center, Japan

P1.12-06: Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus
Simron Singh
Sunnybrook Health Sciences Centre, Odette Cancer Centre, Canada

P1.12-06a: RovaPituzumab Tesirine Maintenance Therapy Following 1st Line Platinum-Based Chemotherapy in Small Cell Lung Cancer
Ho-Jin Lee
AbbVie Inc., USA
P1.12-06b: Rovalpitzumab Tesirine vs Topotecan in Patients with Advanced Small Cell Lung Cancer Following 1st Line Chemotherapy
Ho-Jin Lee
AbbVie Inc., USA

P1.12-07 - P1.12-21 Outcome

P1.12-07: Time to the End of Thoracic Radiotherapy Affects to Survival Outcomes Greater than Radiation Dose in Limited Stage Small Cell Lung Cancer
Sung-Ja Ahn
Chonnam National University Hwasun Hospital, Korea

P1.12-08: The Effect of Cisplatin Versus Carboplatin on Cancer Outcomes for Small Cell Lung Cancer Patients in a Population-Based Cohort
David Dawe
CancerCare Manitoba, Canada

P1.12-09: The Effect of Site of First Chemotherapy on Small Cell Lung Cancer Patient Outcomes
David Dawe
CancerCare Manitoba, Canada

P1.12-10: Patterns of Curative Chemoradiotherapy Regimen and Impacts on the Outcome of Limited Stage SCLC in a Canadian Institution: 2010 – 2015 Diagnoses
Anifat Elegbede
University of Calgary, Canada

Anifat Elegbede
University of Calgary, Canada

P1.12-12: A Systematic Review and Meta-Analysis of Early and Late Survival Following Anti-Cancer Therapies for Small Cell Lung Cancer
Gavin Jones
University of Nottingham, UK

P1.12-13: Impact of Chronic Obstructive Pulmonary Disease on the Survival of Patients with Extensive-Disease Small Cell Lung Cancer
Eun Joo Kang
Korea University Guro Hospital, Korea

P1.12-14: Survival of Patients with Small-Cell Lung Cancer Undergoing Surgical Resection
Shinji Kikuchi
University of Tsukuba, Japan

P1.12-15: Distinctive Clinical Characteristics of SCLC in Never-Smokers
Idrees Mian
National Cancer Institute, USA

P1.12-16: Management of Elderly Small-Cell Lung Cancer Patients in a Romanian Tertiary Care Center
Lucian Miron
Regional Institute of Oncology, Romania

P1.12-17: Overall Survival and Recurrence After Surgical Resection of Pure and Mixed Large Cell Neuroendocrine Tumors.
Brooks Udelsman
Massachusetts General Hospital, USA

P1.12-18: Outcome in Small Cell Lung Cancer Patients with Cerebral Recurrence After Prior Prophylactic Cranial Irradiation
Lei Zhao
Shanghai Chest Hospital, Shanghai Jiaotong University, China

P1.12-19: Clinico-Pathological Characteristics and Treatment Outcome in Small Cell Lung Cancer: A Single Institutional Experience
Sandip Ganguly
Tata Medical Center, India

P1.12-20: Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial.
Martin Forster
University College of London Hospital and UCL Cancer Institute, UK

P1.12-21: Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC)
Lee Schwartzberg
University of Tennessee, USA

P1.13 TARGETED THERAPY

P1.13-01 - P1.13-08 ALK

P1.13-01: Anti-EGF Antibodies Increase the Effect of ALK and MEK Inhibitors in ALK and KRAS NSCLC and CRC Cell Lines
Silvia Garcia - Roman
Laboratory of Oncology/Pangaea Oncology, Quirón-Dexeus University Hospital, Spain

P1.13-02: eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients
Leora Horn
Vanderbilt- Ingram Cancer Center, USA

P1.13-03: Ensartinib Treatment Beyond Disease Progression in Stage IV ALK+ Non-Small Cell Lung Cancer
Leora Horn
Vanderbilt University Medical Center, USA

P1.13-04: Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK Rearranged NSCLC
Mi-Sook Lee
Sungkyunkwan University School of Medicine, Korea

P1.13-05: Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in Alk rearranged NSCLC
Mi-Sook Lee
Sungkyunkwan University School of Medicine, Korea

P1.13-06: First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer
Alice Shaw
Massachusetts General Hospital, USA

P1.13-07: Epithelial-Mesenchymal Transition Induced the Acquired Resistance to ALK Inhibitor Brigatinib in Lung Cancer Cells Harboring with ALK Fusions
Keiko Tanimura
Department of Pulmonary Medicine, Kyoto Prefectural University, Japan

Xuefeng Xia
Geneplus-Beijing Institute, China

P1.13-09 - P1.13-28 EGFR

P1.13-09: Efficacy and Tolerance of Osimertinib in Real Word Setting: Results of the French Early Access Program (EXPLORE T790M GFPC Study).
Jean Bernard Auliac
Oncology, Quirón-Dexeus University Hospital, Spain

P1.13-10: Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer
Sourav Bandyopadhyay
UC San Francisco, USA

P1.13-11: PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A Real World Assessment
Silvia Garcia - Roman
Laboratory of Oncology/Pangaea Oncology, Quirón-Dexeus University Hospital, Spain

P1.13-12: EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma
Farhad Kosari
Mayo Clinic, USA
P1.13-39: Epidermal Growth Factor Receptor Mutation Among Non-Small Cell Lung Cancer Patients in Trinidad and Tobago: Frequency and Trends
Aaron Haralsingh
Eric Williams Medical Sciences Complex, Trinidad and Tobago

P1.13-40: Rapid, Robust and Durable Responses to Larotrectinib in Patients with TRK Fusion Non-Small Cell Lung Cancer
Anna Farago
Cancer Center, Massachusetts General Hospital, USA

P1.13-41: In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping
Toshio Fujino
Kinda University Faculty of Medicine, Japan

P1.13-42: Activity of Novel HER2 Inhibitor, Pozotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance
Takamas Koga
Kinda University Faculty of Medicine, Japan

P1.13-43: Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial
Bob Li
Memorial Sloan Kettering Cancer Center, USA

P1.13-44: Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
Joel Neal
Stanford Cancer Institute/Stanford University, USA

P1.13-45: Coexistence of Activating BRAF and KRAS Mutations in Lung Cancer Patients
Yingyi Wang
Peking Union Medical College Hospital, China

P1.14-02: Predicting Stent Failure in Malignant Esophageal Obstruction
Tommi Järvinen
Helsinki University Hospital, Finland

P1.14-03: Phase II Trial of Amrubicin and Cisplatin Chemotherapy for Invasive Thymoma: WJOGSS09L
Keita Kudo
National Hospital Organization Osaka Minami Medical Center, Japan

P1.14-04: Stereotactic Body Radiation Therapy for Pleural Recurrences of Thymoma
Cécile Le Pechoux
Gustave Roussy, France

P1.14-05: The Association of Pulmonary Function with Survival After Treatment in Patients with Esophageal Cancer
Hsien-Chi Liao
National Taiwan University Hospital, Taiwan

P1.14-06: Treatment Outcomes of Patients with Thymic Carcinoma: A Monocentric Experience of Sequential Regimens Modality
Margaret Ottaviano
University of Naples Federico II, Italy

P1.14-07: Intraoperative Detection of Circulating Tumor Cells in Pulmonary Venous Blood During Metastasectomy for Colorectal Lung Metastases
Severin Schmid
Medical Center - University of Freiburg, Germany

P1.14-08: The Usefulness of the Hemiclamshell Thoracotomy in Thoracic Surgery
Masanori Tsuchida
Niigata University Graduate School of Medical and Dental Sciences, Japan

P1.14-09: Outcome After Lung Resection for Primary Lung Carcinomas/Metastasis in Patients with Performed Total Laryngectomy for Laryngeal Carcinoma
Huseyn Melek
Uludag University, Turkey

P1.14-10: Surgical Treatment of a Rare Case of Clear Cell Carcinomatous Transformation of a Diaphragmatic Endometriosis Focus
Angela De Palma
University of Bari “Aldo Moro”, Italy

P1.14-11: The Expression Pattern of Programmed Death-Ligand 1 According to the Pathological Type of Malignant Thymic Epithelial Tumors
Shunta Ishihara
Kyoto Prefectural University of Medicine, Japan

P1.14-12: GTF2I Mutation in Thymomas: Indian and German Study
Deepali Jain
All India Institute of Medical Sciences, India

P1.14-13: PD-L1 Immuno-Expression Assay in Thymomas: A Study from India
Deepali Jain
All India Institute of Medical Sciences, India

P1.14-14: Histotyping of Indian Thymomas: A Comprehensive Clinicopathologic Study
Deepali Jain
All India Institute of Medical Sciences, India

P1.14-15: Prevalence of Mediastinal Tumors Using Low-Dose Spiral Computed Tomography in Healthy Population
Ikuma Kasuga
Shinjuku Oiwake Clinic and Ladies Branch, Japan

P1.14-16: DNA Methylation of GNG4, GH KSR, HOXD9 and SALL3 Genes Predict Malignant Behavior of Thymic Epithelial Tumors
Reina Kishibuchi
Graduate School of Biomedical Sciences, Tokushima University, Japan

P1.14-17: Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model
Sukhmani Padda
Stanford Cancer Institute/Stanford University School of Medicine, USA

P1.14-18: The Promising Role of Sunitinib Rechallenge in Heavily Pre-Treated Thymic Carcinoma: A Case Report
Giovannella Palmieri
University of Naples Federico II, Italy

P1.14-19: Hemagglutinating Virus of Japan Envelope (HVJ-E: Inactivated Viral Nanoparticles) Against Chemotherapy-Resistant Pleural Mesothelioma
Kazuma Sakura
Osaka University Graduate School of Medicine, Japan

P1.14-20: The Expression of DNA Methylation of GAD1 Gene is an Indicator of Malignant Behavior in Thymic Epithelial Tumor.
Kazuya Kondo
Graduate School of Biomedical Sciences, Tokushima University, Japan

P1.14-21: Circulating Biomarkers in Thymic Epithelial Tumors
Clemens Aigner
University Clinic Essen, Germany
P1.14-22: The Prognostic Role of the Suppressor of Cytokine Signaling-5 (SOCS5) in Esophageal Squamous Cell Carcinoma
Pei-Wen Yang
National Taiwan University Hospital, Taiwan

Sanjaya Acharya
National Academy of Medical Sciences, BIR Hospital, Nepal

P1.14-24: External Radiotherapy Concurrent with Cisplatin Plus 5-Flourouracil in Locally Advanced Carcinoma of Esophagus
Rashmey Pun
Nepal Medical College and Teaching Hospital, Nepal

P1.14-25: Pulmonary Metastasis from Oral Cancer - Who Survive Without Recurrence After Pulmonary Metasectomy?
Chihiro Takasaki
Musashino Red Cross Hospital, Japan

P1.14-26: Long Term Outcome and Clinicopathological Features of Thymic Carcinoma - A Retrospective Study of 25 Cases at a Single Institution
Hirotu Tanaka
Keio University, School of Medicine, Japan

P1.14-27: Differentiation Between Each Thymic Epithelial Tumor According to WHO Classification Scheme by Using MDCT Findings
Yutthaphan Wannasopha
Chiang Mai University, Thailand

P1.14-28: Frequent Genetic Alterations and Their Clinical Significance in Patients with Thymic Epithelial Tumors
Song Xu
Tianjin Medical University General Hospital, China

P1.14-29: Surgical Treatment for Metastatic Lung Tumors from Various Sarcomas
Hiromasa Yamamoto
Okayama University Hospital, Japan

P1.14-30: Prognostic Factors for Sarcoma Patients with Lung Metastasis Who Underwent Extended Pulmonary Resection
Haruchika Yamamoto
Okayama University Hospital, Japan

P1.14-31: Assessing the Prognostic Significance of Extended Pulmonary Resection for Patients with Lung Metastasis
Haruchika Yamamoto
Okayama University Hospital, Japan

P1.14-32: Prognostic Factors for Sarcoma Patients with Lung Metastasis Who Underwent Extended Pulmonary Resection
Haruchika Yamamoto
Okayama University Hospital, Japan

P1.14-33: Prognostic Factors for Sarcoma Patients with Lung Metastasis Who Underwent Extended Pulmonary Resection
Haruchika Yamamoto
Okayama University Hospital, Japan

P1.14-34: Prognostic Factors for Sarcoma Patients with Lung Metastasis Who Underwent Extended Pulmonary Resection
Haruchika Yamamoto
Okayama University Hospital, Japan

P1.14-35: Prognostic Factors for Sarcoma Patients with Lung Metastasis Who Underwent Extended Pulmonary Resection
Haruchika Yamamoto
Okayama University Hospital, Japan

P1.14-36: Prognostic Factors for Sarcoma Patients with Lung Metastasis Who Underwent Extended Pulmonary Resection
Haruchika Yamamoto
Okayama University Hospital, Japan

P1.15-01: Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience
Biagio Ricciuti
Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy

P1.15-02: Migration Differences in Small Cell vs Non-Small Cell Lung Cancer
Shruti Bhandari
James Graham Brown Cancer Center, University of Louisville, USA

P1.15-03: Clinical Characteristics of Long-Term Survivors With Nivolumab in Pretreated Advanced NSCLC from Real-World Data (RWD)
Antonio Calles
Hospital Gregorio Marañón, Spain

P1.15-04: Practice Patterns Regarding Multidisciplinary Cancer Management for NSCLC and Implemetantion: Results of National Survey in México
Saúl Campos-Gómez
Centro Oncologico Estatal ISSEMYM, Mexico

P1.15-05: The Frequency and Spectrum of EGFR Exon 20 Insertions in NSCLC: A Global Literature Review
Victoria Crossland
Takeda International-UK Branch, UK

P1.15-06: Integrative Quality Improvement for Management of Lung Cancer in Uganda
Semujuu David
African Federation of Hospital Associations (AFHA), Uganda

P1.15-07: Geriatric Oncology - Lung Cancer in Elderly Patients and Palliative Treatment: Prospective Analysis of A. C. Camargo Cancer Center
Mauro DS Donadio
A.C. Camargo Cancer Center, Brazil

P1.15-08: Implementation and Feasibility of the Assessment of EGFR Mutation in NSCLC Using Liquid Biopsy at an Argentinean University Hospital
Carolina Gabay
Instituto de Oncología Angel H.Roffo, University of Buenos Aires, Argentina

P1.15-09: Trends in Lung Cancer Survival in Lithuania
Vaida Gedvilaité
National Cancer Institute, Lithuania

P1.15-10: Comparison of Selected Colombian National Administrative Cancer Registry (NACR) Data in Lung Cancer with the U.S.
Robert Hsu
University of Miami/Jackson Memorial Hospital, USA

P1.15-11: Lung Cancer as One of Multiple Cancers: A Population-Based Study in Estonia 1995-2015
Jana Jaal
Tartu University Hospital, Estonia

P1.15-12: Real World Applications of Next-Generation Sequencing of Non-Small Cell Lung Cancer in the Veteran Population
Jeremy Kratz
University of Wisconsin-Madison, USA

P1.15-13: Wait Times for Diagnosis and Treatment of Lung Cancer Across the Province of Quebec, Canada
Catherine Labbe
Division of Respiratory and Thoracic Surgery, Canada

P1.15-14: Pneumonia in Patients with Lung Cancer of South Korea: A Nationwide Population Based Study
Hyun Woo Lee
Ajou University School of Medicine, Korea

P1.15-15: Real-World Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
Chong-Kin Liam
University of Malaya, Malaysia

Huamao Lin
Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, USA

P1.15-17: Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study
Hui Liu
Sun Yat-sen University Cancer Center, China
P1.15-18: The Impact of Patient Age on Clinical Outcomes in NSCLC: A National Study
Yanyan Lou
Mayo Clinic, USA

P1.15-19: Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real World Data
Shun Lu
Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.15-20: Diagnosis and Treatment Delay Among Patients with Lung Cancer in Mexican Population
Omar Macedo-Pérez
Instituto Nacional de Cancerologí, Mexico

P1.15-21: Creating an Optimal Care Coordination Model to Improve Multidisciplinary Care for Lung Cancer Patients on Medicaid
Amanda Kramar
Association of Community Cancer Centers, USA

P1.15-22: Patterns of Palliative and Psychosocial Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients
Tahir Mehmood
Northwest General Hospital and Research Centre, Pakistan

P1.15-23: Factors Affecting Treatment in Non-Small Cell Lung Cancer Patients
Phuong Ngo
James Graham Brown Cancer Center, University of Louisville, USA

P1.15-24: Small Cell Lung Cancer: Clinical Characteristics and Survival of a Spanish Cohort of 221 Patients
Virginia Calvo
Hospital Puerta de Hierro, Spain

P1.15-25: Has Lung Cancer Radiotherapy Utilisation Changed over Time in New South Wales, Australia? Sharlini Vinod
Liverpool and Macarthur Cancer Therapy Centres, Australia

P1.15-26: A Review of Colombian National Administrative Cancer Registry (NACR) Data to Evaluate Healthcare Delivery and Biologics Use
Brian Pico
University of Miami / Jackson Memorial Hospital, USA

P1.15-27: Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada.
So Jin Seung
Sunnybrook Health Sciences Centre, Canada

P1.15-28: Real World Treatment Patterns and Survival of Stage IV Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada.
So Jin Seung
Sunnybrook Health Sciences Centre, Canada

P1.15-29: Impact of Radiation Therapy Quality Assurance on Progression-Free and Overall Survival in Randomized Trials of Lung Cancer
Yu Yang Soon
National University Hospital, Singapore, Singapore

P1.15-30: Survival of Patients with Advanced NSCLC Treated with First-Generation EGFR-TKIs at a Cancer Hospital in Thailand, 2011-2016
Sithi Sukauchai
Chonburi Cancer Hospital, Thailand

P1.15-31: Survival and Patterns of Care Comparing Black and White Patients With All Stages of NSCLC: An NCDB Analysis
Melissa Vyfhuis
University of Maryland Medical Center, USA

P1.15-32: Real World EGFR Mutation Profile from 1699 Non-Small Cell Lung Cancer Patients in Eastern China
Wei Wang
Taizhou Hospital, China

P1.15-33: Real-World Data on Prognostic Factors for Overall Survival in NSCLC Patients Treated with Bevacizumab Combination Therapy
Shang-Gin Wu
National Taiwan University Hospital, Taiwan

P1.15-34: Treatment Patterns and Outcomes of Stage III Non-Small Cell Lung Cancer (NSCLC): Real World Evidence of How our Patients Fare
Dimas Yusuf
Cross Cancer Institute, Canada

P1.15-35: Real World Outcome of Different Administrations Endostar Combined With Chemotherapy in Driver Gene Mutation Negative Advanced NSCLC
Yongchang Zhang
Hunan Cancer Hospital, China

P1.15-36: A Better Real World Practice for Pemetrexed in First-Line Treatment of Advanced Mon-Squamous Non-Small Cell Lung Cancer
Yongchang Zhang
Hunan Cancer Hospital, China

P1.16-01: Prognostic Variables Associated with Improved Outcomes in Stage III NSCLC Patients Treated with Consolidation Pembrolizumab
Bilal Anouti
Indiana University Melvin and Bren Simon Cancer Center, USA

P1.16-02: Support and Information Needs for Patients with NSCLC Receiving Concurrent Chemo-Radiotherapy: Findings from the INSIGHT Study.
Jackie Fenemore
The Christie Hospital NHS Trust, UK

P1.16-03: Prognostic Significance of PD-L1 in Stage II/III Non-Small Cell Lung Cancer
Mustafa Karaca
Antalya Education and Research Hospital, Turkey

P1.16-04: Outcomes of Patients <70 or U70 Years of Age in PACIFIC
Mark Socinski
Florida Hospital Cancer Institute, USA

P1.16-05: Effect of Induction Chemotherapy in the PACIFIC Study
David Spigel
Sarah Cannon Research Institute, USA

P1.16-06: Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%
Alexander Spira
Virginia Cancer Specialists, USA

P1.16-07: Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
Wan Ling Tan
Singapore National Cancer Centre Singapore, Singapore

P1.16-08: Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study
Changli Wang
Tianjin Medical University Cancer Institute and Hospital, China
P1.16-09: Surgical Result of Pathologic Stage III a Non Small Cell Lung Cancer: Have We Improved?
Ching-Yang Wu
Chang Gung Memorial Hospital, Linkou, Taiwan

P1.16-10: Marginal Features Analyses of Lung Adenocarcinoma for Survival Prediction
Geewon Lee
Pusan National University Hospital, Korea

P1.16-11: Monitoring of Early Stage Lung Cancer Using Liquid Biopsies.
Alexander Dobrovic
Olivia Newton-John Cancer Research Institute, Australia

P1.16-12: Identification of a Biomarker Panel in Resected NSCLC That Predicts Patient Outcomes and Benefit from Adjuvant Chemotherapy
Stacy Grieve
University of New Brunswick, Canada

P1.16-13: Photo Dynamic Therapy (PDT) in Our Hospital
Fumihiko Hoshi
Development, Aging and Cancer, Tohoku University, Japan

P1.16-14: Impact of Smoking on Treatment Outcome in Early Squamous Cell Lung Cancer (TINO)
Junghee Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

P1.16-15: Evaluation of Emphysema Severity by 3D-CT for Predicting Postoperative Respiratory Complications and Prognosis of Lung Cancer
Yojiro Makino
Tokyo Medical University Hospital, Japan

P1.16-16: Automatic Intratumor Segmentation in CT of NSCLC: An Alternative to PET Metabolic Subregions
Qintao Qiu
Shandong Cancer Hospital Affiliated to Shandong University, China

P1.16-17: The Role of Quantitative Metabolic Metrics on FDG-PET/CT in Predicting Pathological Invasive Factors in cNO Lung Adenocarcinoma
Takehiko Tanaka
Tokyo Medical University, Japan

P1.16-18: Role of ERCC1/2 Single Nucleotide Polymorphism (SNP) on Treatment Response in Patients with Lung Cancer Undergoing Radiation Therapy
Yaping Xu
Shanghai Pulmonary Hospital, China

P1.16-19: Neither Maximum Tumor Size nor Solid Component Size Was the Best Prognosticator for Subsolid Nodule
Erjia Zhu
Shanghai Pulmonary Hospital, China

P1.16-20: A Systematic Review and Meta-Analysis of Stereotactic Body Radiation Therapy Versus Surgery for Patients with Non Small Cell Lung Cancer
Christopher Cao
Memorial Sloan Kettering Cancer Center, USA

P1.16-21: Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients with Locally Advanced NSCLC
Yuko Kawano
Graduate School of Medical Sciences, Kyushu University, Japan

Janusz Kowalewski
Department of Thoracic Surgery and Tumors. Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru, Poland

P1.16-23: Long-Term Survival Analysis of Surgery in Potential Stereotactic Ablative Radiotherapy Candidates of Non-Small Cell Lung Cancer
Shaolei Li
Peking University Cancer Hospital & Institute, China

P1.16-24: Impact of Tumor Location & Dosimetric Predictors for Chest Wall Toxicity in Single Fraction SBRT for Stage I Non-Small Cell Lung Cancer
Gregory Videtic
USA

P1.16-25: A Propensity Score Model for Appropriate Treatment Selection (Sublobar Resection vs. SBRT) In Patients With cStage I NSCLC
Yukinori Matsuo
Kyoto University Graduate School of Medicine, Japan

P1.16-26: Safety of SABR (Stereotactic Ablative Body Radiotherapy) for Central Non-Small Cell Lung Cancers (cNSCLC) with 50 Gray in 5 Fractions (50Gy/5f)
Robert Rulach
The Beatson West of Scotland Cancer Centre, UK

P1.16-27: Using Rates of Clinical Brachial Plexopathy after Lung SBRT to Better Characterize the Tolerance of the Brachial Plexus
Kyle Verdechecia
Cleveland Clinic, USA

P1.16-28: The Impact of Spironolactone on the Lung Injury Induced by Concomitant Trastuzumab and Thoracic Radiotherapy
Guler Yavas
Selcuk University, Turkey

P1.16-29: Accelerated Hypofractionated Radiotherapy for Central Lung Tumors Unsuitable for Stereotactic Body Radiotherapy Or Concurrent CRT
K. Liang Zeng
Sunnybrook Odette Cancer Centre, Canada

P1.16-30: Quality of Lymphadenectomy During Lobectomy for Non-small Cell Lung Cancer: VATS Versus Thoracotomy
Raquel Alves
Institut Universitaire de Cardiologie et de Pneumologie du Quebec (IUCPQ), Canada

P1.16-31: Surgically Resected Acinar Adenocarcinoma of the Lung: Analysis of Different Prognostic Groups.
Pietro Bertoglio
Sacro Cuore-Don Calabria Research Centre, Italy

P1.16-32: Lung Cancer Completeness of Resection in Uniportal Versus Multiportal Video-Assisted Thoracoscopic Surgery Lobectomy
Etienne Bourdages-Pageau
Institut Universitaire de Cardiologie et de Pneumologie du Quebec (IUCPQ), Canada

P1.16-33: Occult Lymph Node Metastases in Early Stage NSCLC Patients: Where Do We Stand Now? A Proposal for a Preoperative Risk Model
Giuseppe Cipollone
G.d’Annunzio Chieti University, Italy
P1.16-34: The Impact of Pathology, Staging and Operative Resection on Survival and CT Evidence of Recurrence of Early NSCLC
Richard Finley
University of British Columbia, Canada

P1.16-35: Sleeve Lobectomy Versus Pneumonectomy for Non-Small Cell Lung Cancer, a Cumulative Updated Meta-Analysis
Zhihua Guo
The First Affiliated Hospital of Guangzhou Medical University, China

P1.16-36: Real-Time Ct Guided Video Assisted Thoracoscopic Partial Resection of Peripheral Small-Sized Lung Tumors.
Taisuke Kaho
Chiba University Graduate School of Medicine, Japan

P1.16-37: Clinicopathological Characteristics and Prognostic Factors of Operable Non-Small Cell Lung Cancer Patients with the Diabetes Mellitus
Kaoru Kaseda
Keio University School of Medicine, Japan

P1.16-38: Meta-Analysis of Unplanned Readmissions Following Thoracoscopic Versus Open Lung Cancer Resection
Janusz Kowalewski
Department of Thoracic Surgery and Tumors. Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland

P1.16-39: A Nomogram for Predicting Survival Of TNM8 Stage I Non-Small Cell Lung Cancer Patients to Tailor Potential Chemotherapy Candidates
Wenhua Liang
The First Affiliated Hospital of Guangzhou Medical University, China

P1.16-40: Evaluating the Tumor Heterogeneity in Lung Cancer by Constructing Tumor Heterogeneity Index (THI) from Magnetic Resonance Imaging
Hui Liu
Sun Yat-sen University Cancer Center, China

P1.16-41: The Role of Surgery in Pulmonary Large Cell Neuroendocrine Carcinoma: A Propensity-Score Matching Analysis of SEER Database
Zhichao Liu
The First Affiliated Hospital of Guangzhou Medical University, China

P1.16-42: Indocyanine Green Intersegmental Visualization During Fluorescence Imaging of Thoracoscopic Anatomic Segmentectomy: A Novel Approach
Takuya Matsui
Aichi Cancer Center Hospital, Japan

P1.16-43: Analyses of Long-Term Outcomes and Prognostic Factors in Surgically Resected ALK-Rearranged Lung Adenocarcinoma
Yosuke Matsuura
The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan

P1.16-44: Minute Ventilation-To-Carbon Dioxide Slope is Associated with Early and Long Term Survival After Anatomical Pulmonary Resection
Takuro Miyazaki
St. James’s University Hospital, UK

P1.16-45: Thoracoscopic Stapler-Based Complex Segmentectomy Assisted by Virtual Assisted Lung Mapping
Jun-ichi Nitadori
The University of Tokyo Hospital, Japan

P1.16-46: A Population-Based Validation Study of the Proposed ‘R-Factor’ Classification in a Lung Cancer-Endemic Region of the US.
Raymond Osarogiagbon
Baptist Cancer Center, USA

P1.16-47: Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216)
Geoffrey Oxnard
Dana-Farber Cancer Institute, USA

P1.16-48: The Impact of Segmentectomy Versus Lobectomy on Pulmonary Function of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis
Guoping Qiu
The First Affiliated Hospital of Guangzhou Medical University, China

P1.16-49: Treatment of NSCLC Patients with Clinical N1 Disease: Is There an Advantage to Neoadjuvant Therapy?
Brendon Stiles
Weill Cornell Medicine/New York Presbyterian Hospital, USA

P1.16-50: The Role of Adjuvant Therapy for Patients with Early Stage Large Cell Neuroendocrine Lung Cancer: A National Analysis
Vignesh Raman
Duke University Medical Center, USA

Lary Robinson
Moffitt Cancer Center, USA

P1.16-52: Long-Term Impact of Postoperative Complications Following Lung Resection Among Patients with Non-Small Cell Lung Cancer
Shuichi Shinohara
Chubu Rosai Hospital, Japan

P1.16-53: County-Level Variations and Contributing Factors in Receipt of Surgery for Early-Stage Non-Small Cell Lung Cancer in the US
Raymond Osarogiagbon
Baptist Cancer Center, USA

P1.16-54: The Significance of Multiple Lung Cancer Occurrence in Surgically-Treated Clinical Stage I Lung Cancer
Hiroshi Sugimura
Kameda Medical Center, Japan

P1.16-55: Surgical Treatment for Lung Cancer. Subaortic (Para-Aortic) Lymph Nodes Involvement - N1 or N2 Disease?
Magdalena Szczepna
National Research Institute of Tuberculosis and Lung Diseases, Poland

P1.16-56: Prognostic Ability of New T1 Descriptors in the TNM Classification of Surgically Treated Non-Small Cell Lung Cancer
Tomoyoshi Takenaka
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Japan

P1.16-57: Outcomes of Pulmonary Resection in Elderly Non-Small Cell Lung Cancer Patient
Apichat Tantraworasin
Chiang Mai University, Thailand

P1.16-58: Hospital Lung Surgery Volume and Patient Outcomes in Victoria
Alesha Thai
Austin Health, Australia

P1.16-59: A Phase II Study of Adjuvant Chemotherapy with Tegafur-Uracil for Vessel Invasion Positive Stage IA Non-Small Cell Lung Cancer (LOGIK0602)
Tomoshi Tsuchiya
Nagasaki University Graduate School of Biomedical Sciences, Japan

P1.16-60: A High Risk of Recurrence After the Resection of Lower Lobe Adenocarcinoma
Kazuhiro Ueda
Yamaguchi University Graduate School of Medicine, Japan
P1.17-01: Robustness of an Image-Based Data Mining Approach in Lung Cancer Patients
Alan McWilliam
University of Manchester, UK

P1.17-02: Low Prognostic Nutritional Index Predicts Poor Survival in Stage IIB Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy
Ali Besen
Baskent University, Turkey

P1.17-03: Potential Associated SNPs by GWAS with Radiation Pneumonitis (RP) in Patients with Lung Cancer Treated with Radiotherapy
Lehui Du
Chinese PLA General Hospital, China

P1.17-04: Curative Intent Treatment for Stage III NSCLC in England
Susan Harden
Royal College of Physicians of London, UK

P1.17-05: Accelerated Radiotherapy for Non-Small Cell Lung Cancer: A 12 Year Retrospective Review of Two Dose Fractionation Schedules
Matthew Hatton
Weston Park Hospital, UK

P1.17-06: Salvage Surgery After Chemotherapy and/or Radiotherapy Including SBRT and Proton: Consecutive Analysis of 46 Patients
Aki Kobayashi
National Cancer Center Hospital, Japan

P1.17-07: The Prognostic Value of Volumetric Changes of the GTV Measured on CBCT During Radiotherapy for CCRT in NSCLC Patients
Jose Belderbos
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Netherlands

P1.17-08: Genetic Predictors of Response to Chemoradiation in Stage III Non-Small-Cell Lung Cancer
Leo Luo
Memorial Sloan Kettering Cancer Center, USA

P1.17-09: V30 May Better Predict Radiation Pneumonitis After Intensity-Modulated Radiation Therapy for Lung Cancer
Yinnan Meng
Taizhou Hospital, China

P1.17-10: Consolidation Chemotherapy in Stage III Non-Small-Cell Lung Cancer: Still a Critical Piece of the Puzzle
Pranshu Mohindra
University of Maryland School of Medicine, USA

P1.17-11: Pattern and Survival Impact of Neoadjuvant Treatment of Non-Small Cell Lung Cancer (NSCLC) in a Prospective Lung Resection Cohort
Meredith Ray
University of Memphis School of Public Health, USA

P1.17-12: Colleague Peer Review of Radical Lung Radiotherapy Treatment Plans: The Impact on Interval from Decision to Treat to Treatment Delivery
Gerard Walls
Northern Ireland Cancer Centre, UK

P1.17-13: The Role of Post-Operative Radiation Therapy in Patients with Locally Advanced NSCLC after Nodal Downstaging with Systemic Chemotherapy
Annemarie Shepherd
Memorial Sloan Kettering Cancer Center, USA

P1.17-14: Outcomes of Hypofractionated Radiation Therapy (HFRT) with Concurrent Chemotherapy in Patients with Stage III Non Small Cell Lung Cancer (NSCLC)
Annemarie Shepherd
Memorial Sloan Kettering Cancer Center, USA

P1.17-15: Perioperative Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non-Small Lung Cancers
Junichi Soh
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P1.17-16: Correlation of Tumor Volume Reduction During Neoadjuvant Chemoradiotherapy with Pathological Complete Response of Lung Cancer
Shigeo Takahashi
Kagawa University Hospital, Japan

P1.17-17: The Impact of Induction Chemoradiotherapy Followed by Surgery for N1 Involved Non-Small Cell Lung Cancer
Yuta Takahashi
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan

P1.17-18: Treatment for Patients with T4 Superior Sulcus Non-Small Cell Lung Cancer: A Propensity-Matched Analysis of SEER Database
Min Fan
Fudan University Shanghai Cancer Center, China

P1.17-19: Correlation of Dosimetric and Clinical Factors with Radiation Pneumonitis in Lung Cancer Patients Received Involved-Field IMRT
Lehui Du
Chinese PLA General Hospital, China

P1.17-20: Excluding PTV From Lung Volume May Better Predict Radiation Pneumonitis For IMRT Treated Lung Cancer Patients
Yinnan Meng
Taizhou Hospital, China
### POSTERS AT A GLANCE

#### TUESDAY SEPTEMBER 25, 2018 | POSTER SESSION 2

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Subsections</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P2.01</strong></td>
<td>ADVANCED NSCLC</td>
<td></td>
</tr>
<tr>
<td><strong>P2.03</strong></td>
<td>BIOLOGY</td>
<td>P2.03-01 – P2.03-12 Characterization, P2.03-13 – P2.03-24 In vitro, P2.03-25 – P2.03-37 Prognosis</td>
</tr>
<tr>
<td><strong>P2.04</strong></td>
<td>IMMUNOONCOLOGY</td>
<td>P2.04-01 – P2.04-19 Biomarkers, P2.04-20 – P2.04-24 Outcomes, P2.04-25 – P2.04-30 Trials</td>
</tr>
<tr>
<td><strong>P2.06</strong></td>
<td>MESOTHELIOMA</td>
<td></td>
</tr>
<tr>
<td><strong>P2.09</strong></td>
<td>PATHOLOGY</td>
<td>P2.09-01 – P2.09-08 IO, P2.09-09 – P2.09-16 Molecular, P2.09-17 – P2.09-32 Pathology</td>
</tr>
<tr>
<td><strong>P2.10</strong></td>
<td>PREVENTION AND TOBACCO CONTROL</td>
<td></td>
</tr>
<tr>
<td><strong>P2.11</strong></td>
<td>SCREENING AND EARLY DETECTION</td>
<td></td>
</tr>
<tr>
<td><strong>P2.12</strong></td>
<td>SMALL CELL LUNG CANCER/NET</td>
<td>P2.12-01 – P2.12-09 Clinical Trial/Therapeutics, P2.12-10 – P2.12-12 Prognostic Model, P2.12-13 – P2.12-19 Radiation</td>
</tr>
<tr>
<td><strong>P2.15</strong></td>
<td>TREATMENT IN THE REAL WORLD - SUPPORT, SURVIVORSHIP, SYSTEMS RESEARCH</td>
<td>P2.15-01 – P2.15-33 Costs, Disparities</td>
</tr>
<tr>
<td><strong>P2.16</strong></td>
<td>TREATMENT OF EARLY STAGE/LOCALIZED DISEASE</td>
<td>P2.16-01 – P2.16-13 Other, P2.16-14 – P2.16-24 Radiation Oncology, P2.16-25 – P2.16-51 Surgery</td>
</tr>
<tr>
<td><strong>P2.17</strong></td>
<td>TREATMENT OF LOCOREGIONAL DISEASE - NSCLC</td>
<td></td>
</tr>
</tbody>
</table>
P2.01-01: The Impact of Anlotinib on Brain Metastases of NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)
Wenhua Liang
The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, China

P2.01-02: Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study
Nir Peled
Soroka University Medical Center, Israel

P2.01-03: Quality of Life Outcomes for FDA-Approved Agents in Advanced Non-Small Cell Lung Cancer
Hamzeh Albaba
Princess Margaret Cancer Centre, Canada

P2.01-04: Reducing Time to Molecular Diagnosis for Advanced NSCLC in the Context of a Reference Testing Center
Alla’a Ali
Rossy Cancer Network, Canada

P2.01-05: Adenocarcinoma of the Lung: The Woman’s Cancer?
Noor Alsaadoun
Department of Oncology, Cumming School of Medicine, University of Calgary, Canada

P2.01-06: HSP72 Expression Associates with Survival in EGFR Mutated NSCLC
Idoroeniyi Amanam
City of Hope, USA

P2.01-07: Safety and Efficacy of LATTICE Radiotherapy in Voluminous Non-Small Cell Lung Cancer: A Retrospective Study of 10 Patients Over 7 Year Period
James Melotek
Innovative Cancer Institute, USA

P2.01-08: Conversion Surgery for Locally Advanced Lung Adenocarcinoma Harboring Driver Gene Mutation After TKI Followed by Cytotoxic Agent
Masaya Aoki
Kagoshima University, Japan

P2.01-09: Targetable Genomic Alterations in KRAS Mutant Lung Adenocarcinoma by Targeted Next Generation Sequencing
Edurne Arriola
Hospital del Mar, Spain

P2.01-10: Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer
So Hyeon Bak
Kangwon National University Hospital, Korea

P2.01-11: Characteristics of Non-Small Cell Lung Cancer: Differences by Sex and Hormonal Status in a Hispanic Population
Feliciano Barron
Instituto Nacional de Cancerología, Mexico

P2.01-12: Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients
Marta Batus
Rush University Medical Center, USA

P2.01-13: Number, Rather Than Location of Metastases, Dictates Outcome in Stage IV, M1b, Non-Small Cell Lung Cancer
Amanda Gibson
University of Calgary, Canada

P2.01-14: Preferred and Achieved Goals of Patients with Metastatic Lung Cancer and Their Oncologists in End-of-Life Therapy
Annemarie Becker
VUmc, Netherlands

P2.01-15: A Radiologist-Led Training Workshop for MR Based Normal Tissue and Tumour Delineation for Lung Cancer Radiotherapy
Sean Brown
The Christie NHS Foundation Trust, UK

P2.01-16: Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients
Jianhua Chang
Fudan University Shanghai Cancer Center, China

P2.01-17: MALAT1-Mir-101-SOX9 Feedback Loop Modulates the Chemoresistance of Lung Cancer Cell to DDP via Wnt Signaling Pathway
Wei Chen
Huaian No.1 People’s Hospital, China

P2.01-18: Differential Molecular Mechanisms Associated with Dramatic and Gradual Progression in NSCLC Patients with Intrathoracic Dissemination
Ying Chen
Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P2.01-19: Radiomics Features of Contrast Enhanced CT as Prognostic Factors in Resectable Adenocarcinoma of Lung
Jooae Choe
Asan Medical Center, Korea

P2.01-20: FLT-PET for Detection of Relapse Following Radiotherapy for Lung Cancer. Preliminary Results
Tine Christensen
Rigshospitalet, Copenhagen University Hospital, Denmark

P2.01-21: Antigen Cascade Triggering Correlates with Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade with Nivolumab
Pierpaolo Correale
Metropolitan Grand Hospital “Bianchi-Melacrin-Morelli”, Italy

Guilherme Costa
Instituto Medicina Integral Porf Fernando Figueira, Brazil
P2.01-23: Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC)  
Doreen Ezife  
University Health Network, Canada

P2.01-24: MLPH Activates CDC42/PAK1 Signaling to Promote Epithelial-Mesenchymal Transition via TGF-β in Non-Small Cell Lung Cancer  
Xiaorong Dong  
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

P2.01-25: MicroRNA-330-3p Promotes Brain Metastasis of Non-Small Cell Lung Cancer by Activating MAPK/MEK/ERK Signaling Through GRIA3  
Xiaorong Dong  
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

P2.01-26: Association of Base Excision Repair Gene Polymorphisms with Response to Chemotherapy of Advanced Non-Small-Cell Lung Cancer  
Xu Wang  
The First Hospital of Jilin University, China

P2.01-27: MR, CT and Cone-Beam CT for Lymph Node Visualisation in Locally-Advanced Lung Cancer  
Sean Brown  
University of Manchester, UK

P2.01-28: Gender and Systemic Treatment Patterns: Impacts on the Overall Survival of Stage IV NSCLC 2010 – 2014 Diagnoses  
Anifat Elegbede  
University of Calgary, Canada

P2.01-29: Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer  
Yun Fan  
Zhejiang Cancer Hospital, China

P2.01-30: Applicability of Lung-molGPA Index in Non-Small Cell Lung Cancer Patients with Different Gene Alterations and Brain Metastases  
Carlos Gil Ferreira  
Neotorax Oncologia D’or, Brazil

P2.01-31: Updated EGFR Mutation Frequency in 1,689 NSCLC Brazilian Patients – A National-Wide Study  
Carlos Gil Ferreira  
Neotorax Oncologia D’or, Brazil

P2.01-32: Economic Evaluation of Diagnostic Platforms for T790M Detection in Post EGFR-TKI NSCLC in Brazil  
Qisen Guo  
Shandong Cancer Hospital, China

P2.01-33: Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1 Containing Therapy (HUDSON)  
Patrick Forde  
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, USA

P2.01-34: Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated with Immunotherapy and Ramucirumab Plus Docetaxel  
Marta Batus  
Rush University Medical Center, USA

P2.01-35: Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Patients with Advanced Lung Cancer  
Apar Kishor Ganti  
VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center/Fred & Pamela Buffett Cancer Center, USA

P2.01-36: Real-World Treatment Patterns in Treatment-Naive Advanced NSCLC Patients in North America: A Systematic Literature Review  
Yong He  
Daping Hospital, The Third Military Medical University, China

P2.01-37: A Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) with Docetaxel in pts with Previously Treated NSCLC  
Matthew Hatton  
Weston Park Hospital, UK

P2.01-38: Sarcopenia is Associated with Metastatic Burden and is a Negative Prognostic Factor in Metastatic Non-Small Cell Lung Cancer  
Chad Glisch  
Medical College of Wisconsin, USA

P2.01-39: Can Benefit or Futility in Treating Advanced NSCLC Be Determined Early Using the LCSS 3-Item Global Index (3-IGI) PRO?  
Richard Gralla  
Albert Einstein College of Medicine, USA

P2.01-40: Prognostic Importance of Sarcopenia and Inflammatory Statements in Stage III Non Small Cell Lung Carcinoma  
Serap Akyürek  
Ankara University School of Medicine, Turkey

P2.01-41: The Role and Mechanism of FBW7 Deficiency in Advanced Non-Small Cell Lung Cancer with Docetaxel Resistance  
Qisen Guo  
Shandong Cancer Hospital, China

P2.01-42: Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy  
Martin Gutierrez  
John Theurer Cancer Center, Hackensack University Medical Center, USA

P2.01-43: ADSCaN: A Randomised Phase II Study of Accelerated, Dose Escalated, Sequential Chemo-Radiotherapy in Non-Small Cell Lung Cancer (NSCLC)  
Serap Akyürek  
Oncologia D’or, Brazil

P2.01-44: Prognostic Value of TP53 Hot Exon Mutation in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)  
Nick Pavlakis  
University of Sydney, Australia

P2.01-45: Mutational and Inflammatory Biomarkers for Lung Cancer Patients with Pleural Effusions  
Balazs Hegedus  
University Clinic Essen, Germany

P2.01-46: Investigating the Effects of Prior Malignancy on NSCLC Trial Eligibility  
Michael Herman  
Princess Margaret Cancer Centre, Canada

P2.01-47: Clinical Outcome After Surgical Resection Of Clinical Single-station N2 Non-Small Cell Lung Cancer  
Kwan-yong Hyun  
Seoul St. Mary’s Hospital, Catholic University of Korea, Korea

P2.01-48: Predictive Factors in NSCLC Patients with Stage IIIB/IV Treated with First Line Platinum-Doublet Chemotherapy  
Sofi Isaksson  
Lund University, Sweden

P2.01-49: Comparision of Radiotherapy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer  
Abdurrahman İskidogan  
Dicle University, Turkey

P2.01-50: Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer  
Nik Pavičak  
Royal North Shore Hospital, Australia
P2.01-51: Study of CD26/DPP4 Expression in a Large Series of Non-Small Cell Lung Cancer Patients  
Sven Hillinger  
University Hospital Zurich, Switzerland

P2.01-52: Identification of Leptomeningeal Metastasis-Specific Exosomal miRNA Signatures in Cerebrospinal Fluids of NSCLC Patients  
Yang W. Shao  Nanjing Medical University, China

P2.01-53: Local Treatment for Oligoprogression/Oligometastases After Failure to Crizotinib for ALK-Rearranged Stage IV Lung Cancer  
Tsz Yeung Kam  
Pamela Youde Nethersole Eastern Hospital, Hong Kong

P2.01-54: Predictive Factors for Thromboembolism in Advanced Lung Cancer Patients on Platinum Chemotherapy: A Prospective Study  
Shruti Kate  
Tata Memorial Hospital, India

P2.01-55: Dual-Energy CT Scan to Evaluate Sarcopenia in Lung Cancer in Comparison with Conventional CT Scan  
Eun Young Kim  
Gachon University Gil Medical Center, Korea

P2.01-56: Metastases in Residual PET Uptake of Lymph Nodes After Treatment: Added Value of CT Radiomic Approach for Prediction  
Chu Hyun Kim  
Samsung Medical Center, Korea

P2.01-57: Prognostic Implication of Clinical, Imaging, and Pathologic Parameters in N2(+) Stage IIIA Lung Cancer Patients  
Yong Chan Ahn  
Samsung Medical Center, Korea

P2.01-58: Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A CancerLink Cohort  
Alyssa Klein  
Astra Zeneca, USA

P2.01-59: The Cost of Lung Cancer in the County of Gävleborg – Sweden  
Harsh Koyi  
Gävle Hospital, Sweden

P2.01-60: Clinical Utility of Circulating Tumor Cell (CTC) Analysis Using Target Selector™ in Metastatic NSCLC Chemotherapy Patients  
Lara Kujtan  
University of Missouri at Kansas City, USA

P2.01-61: Body Mass Index over Time is Associated with Overall Survival in Advanced NSCLC Patients Treated with Immunotherapy  
Stephanie Labomascus  
Rush University Medical Center, USA

P2.01-62: Extracellular Vesicle-Based Egfr Genotyping in Bronchoalveolar Lavage Fluid from Non-Small Cell Lung Cancer Patients  
Jong Sik Lee  Konkuk University Medical Center, Korea

P2.01-63: Are Heart Doses Associated with Survival in NSCLC Treated with Post-Operative Radiotherapy? A National Population-Based Study  
Chia Ching Lee  National University Cancer Institute Singapore, Singapore

P2.01-64: Prognostic Value of PET-CT after Induction Chemoradiotherapy and Curative Surgery in IIIA-N2 NSCLC: A Multi-Institutional Analysis  
Jong Hoon Lee  St. Vincent’s Hospital, The Catholic University of Korea, Korea

P2.01-65: Assessment of Individual and Combined of Five Serum Tumor Markers for Lung Cancer  
Yaping Li  Department of Respiratory, The First Affiliated Hospital of Wenzhou Medical University, China

P2.01-66: Comparison of EGFR Mutation Status in Tissue and Plasma Cell-Free DNA Detected by ARMS in Advanced Lung Adenocarcinoma Patients  
Yaping Li  Department of Respiratory, The First Affiliated Hospital of Wenzhou Medical University, China

P2.01-67: The Prognostic Analysis of Lung Cancer Patients with Occult Malignant Pleural Disease at Thoracotomy  
Shaolei Li  Peking University Cancer Hospital & Institute, China

P2.01-68: Capture-Based Sequencing Depicts Evolution Characteristics of Pulmonary Sarcomatoid Carcinoma  
Xuewen Liu  Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, China

P2.01-69: EZH2-Mediated Epigenetic Suppression Of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small Cell Lung Cancer  
Xiyi Lu  Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China

P2.01-70: Tumor Treating Fields and Radiosurgery for Supra- and/or Infratentorial Brain Metastases (1-10) from NSCLC in the Phase 3 METIS Study  
Uri Weinberg  Novocure GmbH, Switzerland

P2.01-71: Clinical Outcome of Induction Chemoradiotherapy Followed by Surgery for the Patients with cN2 Non-Small Cell Lung Cancer  
Akihiro Miura  Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Japan

P2.01-72: Bronchial Sleeve vs Pneumonectomy: Complications, Recurrences and Survival  
Marc Boada  Hospital Clinic de Barcelona, Spain

P2.01-73: Automated Image Analysis Tool for Tumor Volume Growth Rate to Guide Precision Cancer Therapy: EGFR-Mutant NSCLC as a Paradigm  
Mizuki Nishino  Dana-Farber Cancer Institute, USA

P2.01-74: Docetaxel-Related Febrile Neutropenia (FN) And Patient Reported Symptoms/ QOL (PROs) in East Asian (EA) and Non-EA Patients  
Sotaro Enatsu  Eli Lilly Japan K.K., Japan

P2.01-75: Study of Molecular Alterations in Cytological Smears By FISH In Patients with Advanced Non Small Cell Lung Carcinoma (NSCLC)  
Julieta Pandolfi  Hospital Italiano de Buenos Aires, Argentina

P2.01-76: The Impact of Concordance with a Lung Cancer Diagnosis Pathway Guideline on Treatment Access in Patients with Stage IV Lung Cancer  
Luke Jeagal  University of Toronto, Canada

P2.01-77: Interconversion of Two Commonly Used Performance Tools: An Analysis of 5844 Paired Assessments in 1501 Lung Cancer Patients  
Kuruswamy Prasad  Postgraduate Institute of Medical Education and Research (PGIMER), India
P2.01-78: Validation of InVisionFirst ctDNA NGS Profiling via ddPCR Testing in Patients with Non-Small Cell Lung Cancer (NSCLC)
Michael Pritchett
Pinehurst Medical Clinic and FirstHealth Moore Regional Hospital, USA

P2.01-79: Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer
Matthew Ramotar
Princess Margaret Cancer Centre, Canada

P2.01-80: Performance Status and Resource Utilization in Patients Receiving Palliative Care with Stage IV Non-Small Cell Lung Cancer
Candice Wilshire
Swedish Cancer Institute, USA

P2.01-81: Treatment of Superior Sulcus Tumor: A Twelve-Year Single-Center Experience
Witold Rzyman
Medical University of Gdańsk, Poland

P2.01-82: Neutrophil-to-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors
Diana Saravia
University of Miami, USA

P2.01-83: Evaluation of Dynamic Thiol/Disulphide Homeostasis in Advance Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Mehmet Ali Sendur
Ankara Yıldırım Beyazıt University, Turkey

P2.01-84: Patterns of Central Nervous System Metastases in EGFR Mutated or ALK Rearranged Non Small Cell Lung Cancer Patients
Mansi Sharma
RGIRC, India

P2.01-85: The Efficacy of the Traditional Chinese Medicine as Maintenance Therapy for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
Peng Shen
The First Affiliated Hospital, College of Medicine, Zhejiang University, China

P2.01-86: Genetic Profiling of Circulating Cell-Free DNA from Cerebrospinal Fluid and Plasma in ALK-Positive Lung Cancer with Brain Metastases
Liang Shi
Beijing Chest Hospital Capital Medical University, China

P2.01-87: Profiling the Symptom Burden of Patients with Metastatic NSCLC Receiving Either Chemotherapy or Targeted Therapy: Real-World Data
Qiling Shi
The University of Texas MD Anderson Cancer Center, USA

P2.01-88: C-Reactive Protein (CRP) as a Predictive Marker for Survival in Patients with Advanced NSCLC Treated with First Line Pembrolizumab Monotherapy
Yuji Shibata
Yokohama Medical Center, Japan

P2.01-89: Synergistic Cytotoxicity Through MAPK/ERK Pathway and ALK Inhibition in Crizotinib Resistant EML4-ALK-Positive Lung Cancer
Nensi Shrestha
University of Otago, New Zealand

P2.01-90: PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small Cell Lung Cancer Patients with or without EGFR Mutation
Teerada Siripoon
Ramathibodi Hospital, Thailand

P2.01-91: Treatment Patterns in Patients with Stage IIIB-IV NSCLC in Clinical Practice: Retrospective Analysis of a UK Trust Database
Michael Snee
The Leeds Teaching Hospitals NHS Trust, UK

P2.01-92: “All-In-One” Window: A New Way of Looking at Chest CT Studies in Thoracic Oncology
Aninemie Snoeckx
Antwerp University Hospital and University of Antwerp, Belgium

P2.01-93: The Analysis of the Soluble Programmed Death-1 of Lung Cancer Patients with Different Characteristics
Xia Song
ShanXi Cancer Hospital, China

P2.01-94: Diagnostic Patterns of Non-Small Cell Lung Cancer at Princess Margaret Cancer Centre
Mike Sung
Princess Margaret Cancer Centre, Canada

P2.01-95: Assessment the Fitness for Chemotherapy of NSCLC Patients using 6MWT
Zsuzsanna Szalai
Petz Aladár County Teaching Hospital Győr, Hungary

P2.01-96: Dysgeusia Associated with Nutritional and Quality of Life Parameters in Non-Small Cell Lung Cancer Patients Naïve to Chemotherapy
Jenny Turcott
National Cancer Institute of Mexico, Mexico

P2.01-97: Prognostic Factors in Resected Lung Mucinous Adenocarcinoma: Clinical and Pathological Features
Daisuke Ueda
Hiroshima University, Japan

P2.01-98: Single-Isocenter Volumetric-Modulated Arc Radiosurgery for Non-Small-Cell Lung Cancer Patients with Multiple Brain Metastases
Megumi Uto
Kyoto University Graduate School of Medicine, Japan

P2.01-99: Can NGS NSCLC Testing Be Implemented Without in House Expertise? Clinical Utility of the First FDA-Approved Lung Cancer NGS End-To-End Solution
Anagh Vora
Thermo Fisher Scientific, USA

P2.01-100: Different Genetic Mutations Enriched in Circulating Tumor DNA Predict Different Metastatic Sites in Lung Adenocarcinoma Patients
Liyun Miao
Nan Jing Drum Tower Hospital, China

P2.01-101: Dynamic Monitoring of Gene Alterations with ctDNA by NGS for EGFR Mutated Lung Adenocarcinoma Treated with Gefitinib in BENEFIT Study (CTONG 1405)
Jie Wang
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.01-102: Comprehensive Next-Generation Sequencing Guided Targeted Therapies Improve Clinical Outcomes of Lung Cancer Patients
Zhaoxia Wang
Cancer Medical Center, the Second Affiliated Hospital of Nanjing Medical University, China

P2.01-103: Neutrophil-to-Lymphocyte Ratio as a Predictor of Immunotherapy Treatment Outcomes in Advanced Non-Small Lung Cancer
Xiao Wang
Johns Hopkins University School of Medicine, USA

P2.01-104: Plasma T-Cell-Derived Circulating DNA in Advanced NSCLC is Not Correlated with TIL but has a Potential of Prognostic Value
Chandia Vinayawuttikun
Faculty of Medicine Chulalongkorn University, Thailand

P2.01-105: Tumor Treating Fields Plus Standard of Care for Non-Small Cell Lung Cancer Following Platinum Failure: Phase 3 LUNAR Study
Uri Weinberg
Novocure GmbH, Switzerland
P2.01-106: A Comparative Analysis of Genomic Alterations by Tumor Tissue and Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer
Go-un Woo
Seoul National University Bundang Hospital, Korea

P2.01-107: Analysis of Mutation Detection by ctDNA on the Basis of Metastatic Sites in Lung Adenocarcinoma Patients
Renhua Guo
Jiangsu Province Hospital, China

P2.01-108: Temporal Heterogeneity of Resistant Mutations in Sequential ALK TKI Treated Lung Cancer Revealed by NGS-Based Liquid Biopsy
Yu Yang
The Second Affiliated Hospital of Harbin Medical University, China

P2.01-109: Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC
Guangjian Yang
National Cancer Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.01-110: Unique Genomic Profile Revealed by Malignant Pleural Effusion
Zhihua Guo
First Affiliated Hospital of Guangzhou Medical College, China

P2.01-111: Clinical Features and Prognosis of Eighty-Five Patients with Primary Pulmonary Lymphoepithelioma-Like Carcinoma
Qin Yin
The First Affiliated Hospital of Guangzhou Medical University, China, China

P2.01-112: Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients with Lung Cancer Treated with Nivolumab
Takashi Yokoi
Hyogo College of Medicine, Japan

P2.01-113: Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)
Luo-Sheng Yong
National Taiwan University, Taiwan

P2.01-114: The Correlation Among PD-L1 Expression, TMB and Lung Immune Prognostic Index in Chinese Patients with Advanced Lung Adenocarcinoma
Pei Yuan
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.01-115: Evaluation of EGFR T790M of Cell Free Circulating DNA in Plasma by Droplet Digital PCR for Progressive Non-Small Cell Lung Cancer
Zhihong Zhang
The First Affiliated Hospital of Nanjing Medical University, China

P2.01-116: The Potential of Assessing Blood Tumor Mutation Burden (bTMB) Using a Large Panel
Kai Zhang
Union Hospital, Tongji Medical College, Huazhong University and Science Technology, China

P2.01-117: Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Xuefeng Xia
Geneplus-Beijing Institute, China

P2.01-118: LINE-1 Retrotransposition Promotes the Occurrence and Progression of Lung Squamous Cell Carcinoma
Jinpu Yu
Tianjin Medical University Cancer Institute & Hospital, China

P2.01-119: Phase III Randomized Trial of Palonosetron and Dexamethasone with Aprepitant to Prevent Full Dose Single-Day Cisplatin-Based CINV in Lung Cancer
Yongchang Zhang
Hunan Cancer Hospital, China

P2.01-120: First Study to Evaluate the Efficacy of SB Oral Solution to Prevent Neutropenia and FN Induced by Platinum-Based Chemotherapy in Lung Cancer
Yongchang Zhang
Hunan Cancer Hospital, China

P2.01-121: Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma
Chengzhi Zhou
The First Affiliated Hospital Of Guangzhou Medical University, China

Qinghua Zhou
West China Hospital, Sichuan University, China

P2.01-123: Translational Medicine of Lung Cancer Metastasis: From Bench to Bedside
Qinghua Zhou
West China Hospital, Sichuan University, China

P2.01-124: SIB-IMRT in Symptomatic Brain Metastases for NSCLC: A Randomized Controlled Study of WBRT Comparing 25Gy and 30Gy
Jian Zhu
Taizhou Hospital, China

P2.01-125: EGFR Mutations by NGS in Advanced Squamous Cell Lung Cancer
Govind Babu
Kidwai Memorial Institute Of Oncology, India

P2.01-126: MicroRNA-330-3p Modulates Tumor Vascular Normalization After Hypofractionated Radiotherapy by Targeting p-STAT3/ HIF-1 Alpha Pathway
Xiaorong Dong
Huazhong University of Science and Technology, China

P2.01-127: Efficacy of Endostar Combined with Whole Brain Radiotherapy in Patients with NSCLC Brain Metastases
Xiaorong Dong
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

P2.01-128: Low Positivity Rate in T790M Detection with ctDNA in NSCLC and Post EGFR-TKI Progression – Timing or Sensitivity?
Carlos Gil Ferreira
Neotorax Oncologia D’or, Brazil

P2.01-129: Potential Impact of KRAS Molecular Profiling of Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Nagla Karim
University of Cincinnati, USA

P2.01-130: Detection of Actionable Mutation Status in Advanced Non-Small Cell Lung Cancer by Next-Generation Sequencing of Circulating Tumor DNA
Xia Song
Shanxi Cancer Hospital, Shanxi Medical University Cancer Hospital, China

P2.01-131: Apatinib as an Alternative for Advanced Non-Small Cell Lung Cancer
Jieixia Zhang
The First Affiliated Hospital of Guangzhou Medical University, China

P2.01-132: Comparison Molecular Profiles in NSCLC by Using Different NGS Platforms and Different Variant Frequency Cutoff
Thanyanan Reungwetwattana
Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand
P2.03 BIOLOGY

P2.03-01 – P2.03-12 Characterization

P2.03-01: Prevalence of EGFR Alterations in Chilean Lung Cancer Patients: A Retrospective Study
Hector Galindo
Pontificia Universidad Catolica de Chile, Chile

P2.03-02: Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP)
Ramón Palermo
ICO Bellvitge, Spain

P2.03-03: Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective
Kirstin Perdrizet
University of Toronto, Canada

P2.03-04: Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience
Kirstin Perdrizet
University of Toronto, Canada

P2.03-05: Biologic Profiling of Brain Metastasis from Non-Small Cell Lung Cancer
Tomohito Saito
Kansai Medical University, Japan

P2.03-06: Serum Syndechan-1 Levels in Patients with Nonsmall Cell Lung Cancer
Ibrahim Tek
Medicana International Ankara Hastanesi, Turkey

P2.03-07: Radiomic Signatures Linked to Genetic Alterations as Detected by Next-Generation Sequencing: A Radiogenomics Analysis of Early-Stage NSCLC
Sibo Tian
Emory University, USA

P2.03-08: Molecular Spectrum of Patients with MSH2 Mutations in Chinese Non-Small Cell Lung Cancer
Chunwei Xu
Fujian Cancer Hospital, China

P2.03-09: The Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study
Chunwei Xu
Fujian Cancer Hospital, China

P2.03-10: Gene Mutational Profiling Of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS
Chunwei Xu
Fujian Cancer Hospital, China

P2.03-11: PDGFRα Defines a Unique Molecular Subtypes of Chinese Non-Small Cell Lung Cancer Patients
Chunwei Xu
Fujian Cancer Hospital, China

P2.03-12: EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer
Shun Lu
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

P2.03-13 – P2.03-24 In vitro

P2.03-13: SWATH MS Analysis of Serine Hydrolase Activity in Human Lung Adenocarcinoma for Biomarker Discovery
Sven Hillinger
University Hospital Zürich, Switzerland

P2.03-14: PKCζ-PAK1 Pathway Modulates Sensitivity to Therapy in EGFR, KRAS Mutant and Squamous Cell Non-Small Cell Lung Cancer (NSCLC)
Masaoki Ito
Hiroshima University Hospital, Japan

P2.03-15: Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC
Niki Karachaliou
Instituto Oncológico Dr Rosell (IOR), Hospital Universitario Sagrat Cor, Spain

P2.03-16: TGF-β-Induced EMT and Stemness Characteristics are Associated with Epigenetic Regulation in Lung Cancer
Seung Joon Kim
The Catholic University of Korea, Korea

P2.03-17: EGFR T790M Mutation may not be Generated through Selection by EGFR-TKI from Randomly Occurring Mutations in Vitro Using ENU
Yoshihisa Kobayashi
Dana-Farber Cancer Institute, USA

P2.03-18: X-Inactivation Specific Transcript (XIST)-Mediated miRNA Sequestration in NSCLC
Erin Marshall
BC Cancer Research Centre, Canada

P2.03-19: RET-Mediated Activation of Erzrin is Associated with Cell Motility and Survival in a Subset of Lung Adenocarcinomas
Serisha Moodley
Queen’s University, Canada

P2.03-20: Factor XIIA-Expressing Inflammatory Monocytes Promote Lung Squamous Cancer through Fibrin Cross-Linking
Chad Pecot
UNC Lineberger Comprehensive Cancer Center, USA

P2.03-21: Mechanistic Investigation of DRD1 in Lung Cancer
Leila Toulabi
National Cancer Institute, USA

P2.03-22: OCT4&SOX2 Specific CTLs Plus PD-1 Inhibitor Had Synergistic Effect on Killing CSC And Treating Drug-Resistant Lung Cancer Mice
Fang Hu
Shanghai Chest Hospital, Shanghai Jiaotong University, China

P2.03-23: MicroRNA-30e Inhibits Cell Proliferation and Invasion in Non-Small Cell Lung Cancer via Directly Targeting SOX9
Lei Zhao
The First Affiliated Hospital of Dalian Medical University, China

P2.03-24: CD90 Enhances Metastasis by Epithelial-Mesenchymal Transdifferentiation in Lung Adenocarcinoma
Xiangdong Zhou
Southwest Hospital of Third Military Medical University, China

P2.03-25 – P2.03-37 Prognosis

P2.03-25: Loss of Expression Rather Than Cytoplasmic Mislocalization of RUNX3 Predicts Worse Outcome in Non-Small Cell Lung Cancer
Xiaohui Chen
Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, China

P2.03-26: A Prospective Cohort Study of TMB and Determinants of ctDNA Detection by Comprehensive Genomic Profiling in Stage I Lung Adenocarcinomas
Kehzhong Chen
Peking University People’s Hospital, China

P2.03-27: Polymorphisms in Folate Metabolism Related Genes Affect the Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer
Sun Ha Choi
Lung Cancer Center, Kyungpook National University Chilgok Hospital, Korea

P2.03-28: Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer
Carlo Genova
Ospedale Policlinico San Martino, Italy
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P2.04 IMMUNOONCOLOGY</strong></td>
<td></td>
</tr>
<tr>
<td><strong>P2.04-01 – P2.04-19 Biomarkers</strong></td>
<td></td>
</tr>
</tbody>
</table>
| **P2.04-01: Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells.** Luis Antonio Cabrera-Miranda  
Instituto Nacional de Cancerologia, Mexico | P2.04-10: Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients  
Francesco Passiglia  
University Hospital of Palermo, Italy |
| **P2.04-02: Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab.** Carlo Genova  
Ospedale Policlinico San Martino, Italy | **P2.04-11: An IL-8/IFN-gamma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients with NSCLC.** Francesco Passiglia  
Department of Surgical, Oncological and Stomatological Disciplines, Section of Medical Oncology, University of Palermo, Italy |
| **P2.04-03: NF-κB and HIF-1α Play Important Roles in Regulating PD-L1 Expression by EGFR or KRAS Mutants in Non-Small Cell Lung Cancer Cells.** Jie Wang  
Cancer Hospital Chinese Academy of Medical Sciences, China | **P2.04-12: A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.** Sara Piloto  
University of Verona, Azienda Ospedaliera Universitaria Integrata (AOUI), Italy |
| **P2.04-04: Expression of Intratumoral Programmed Cell Death-Ligand 1 (PD-L1) and Intratumoral CD4+T Cell, CD8+ T Cell and FOXP3+ T Cell in Lung Cancer.** Yasuto Jin  
Hiratsuka Kyousai Hospital, Japan | **P2.04-13: The Immune Checkpoint, HVEM Contribute to Immune Escape in Non-Small Cell Lung Cancer Lacking PDL1 Expression.** Shengxiang Ren  
Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, China |
| **P2.04-05: Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.** Pawel Krawczyk  
Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland | **P2.04-14: Tumor Mutational Burden Assessed by a Targeted NGS Assay Predicts Benefit from Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients.** Sacha Rothschild  
University Hospital Basel, Switzerland |
| **P2.04-06: Increased Plasma Cell % and Decreased B-Cells in Tumor Immune Infiltrates Are Associated with Worse Prognosis in Lung Adenocarcinomas.** Hee Eun Lee  
Mayo Clinic, USA | **P2.04-15: Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naive Lesions.** Kenichi Suda  
Kindai University Faculty of Medicine, Japan |
| **P2.04-07: Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand-1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues.** Xu Wang  
The First Hospital of Jinlin University, China | **P2.04-16: Correlation Between Programmed Death Ligand 1(PD-L1) Expression and Solid Component on HRCT in Stage I Lung Cancer Patients.** Ryosuke Tsugitomi  
St. Luke's International Hospital, Japan |
| **P2.04-08: Platinum-Based Chemotherapy is Associated with Altered PD-L1 Expression in Lung Cancer.** Judit Moldvay  
National Koranyi Institute of Pulmonology, Hungary | **P2.04-17: Pre-Therapy Radiomic Features Can Distinguish Hyperprogression from Other Response Patterns to PD1/PD-L1 Inhibitors in NSCLC.** Pranjal Vaidya  
Case Western Reserve University, USA |

---

**P2.03-29: Prognostic Significance of Phosphorylated Fyn in Patients with Lung Adenocarcinoma.** Shigeto Nishikawa  
Graduate School of Medicine, Kyoto University, Japan

**P2.03-30: Proteins Involved in Necroptosis and DNA Damage Repair and Survival of Stage I Non-Small-Cell Lung Cancer Patients.** Jeong-Seon Ryu  
Inha University Hospital, Korea

**P2.03-31: LncRNA RGMB-AS1 Affects Lung Adenocarcinoma Prognosis by Regulating Microtube Associated Genes: A Genome-Wide Analysis in Silicon.** Xiaoshun Shi  
Nanjang Hospital, China

**P2.03-32: Genome-Wide Analysis of m6A-Modified RNA Binding Proteins Associated with Lung Cancer Survival.** Xiaoshun Shi  
Nanjang Hospital, China

**P2.03-33: Anti-Aging Gene, Klotho is a Predictive Factor of Pemetrexed for Lung Cancer Treatment.** Kyoshiro Takegahara  
Nippon Medical School Hospital, Japan

**P2.03-34: The Relationship Between Treatment Response and Serum EGFR Level in Nonsmall Cell Lung Cancer.** Ibrahim Tek  
Medicana International Ankara Hastanesi, Turkey

**P2.03-35: Non-Small-Cell Lung Cancer with SMO Gene Variants of Uncertain Significance Share Distinct Molecular Features.** Chunwei Xu  
Fujian Cancer Hospital, China

**P2.03-36: DNA Methylation: A More Sensitive Marker for Treatment Monitoring?** Yu Chen  
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

**P2.03-37: The Efficiency of Octamer-4 Specific Cytotoxic T Cells Induce By CD40-B Cells in Killing Lung Cancer Stem-Like Cells.** Fang Hu  
Shanghai Chest Hospital, Shanghai Jiaotong University, China

---

**P2.04-01 – P2.04-19 Biomarkers**

**P2.04-01: Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells.** Luis Antonio Cabrera-Miranda  
Instituto Nacional de Cancerologia, Mexico

**P2.04-02: Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab.** Carlo Genova  
Ospedale Policlinico San Martino, Italy

**P2.04-03: NF-κB and HIF-1α Play Important Roles in Regulating PD-L1 Expression by EGFR or KRAS Mutants in Non-Small Cell Lung Cancer Cells.** Jie Wang  
Cancer Hospital Chinese Academy of Medical Sciences, China

**P2.04-04: Expression of Intratumoral Programmed Cell Death-Ligand 1 (PD-L1) and Intratumoral CD4+T Cell, CD8+ T Cell and FOXP3+ T Cell in Lung Cancer.** Yasuto Jin  
Hiratsuka Kyousai Hospital, Japan

**P2.04-05: Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.** Pawel Krawczyk  
Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland

**P2.04-06: Increased Plasma Cell % and Decreased B-Cells in Tumor Immune Infiltrates Are Associated with Worse Prognosis in Lung Adenocarcinomas.** Hee Eun Lee  
Mayo Clinic, USA

**P2.04-07: Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand-1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues.** Xu Wang  
The First Hospital of Jinlin University, China

**P2.04-08: Platinum-Based Chemotherapy is Associated with Altered PD-L1 Expression in Lung Cancer.** Judit Moldvay  
National Koranyi Institute of Pulmonology, Hungary

**P2.04-09: Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.** Marcelo Negrao  
UT MD Anderson Cancer Center, USA

---

**P2.04-10: Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients.** Francesco Passiglia  
University Hospital of Palermo, Italy

**P2.04-11: An IL-8/IFN-gamma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients with NSCLC.** Francesco Passiglia  
Department of Surgical, Oncological and Stomatological Disciplines, Section of Medical Oncology, University of Palermo, Italy

**P2.04-12: A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.** Sara Piloto  
University of Verona, Azienda Ospedaliera Universitaria Integrata (AOUI), Italy

**P2.04-13: The Immune Checkpoint, HVEM Contribute to Immune Escape in Non-Small Cell Lung Cancer Lacking PDL1 Expression.** Shengxiang Ren  
Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, China

**P2.04-14: Tumor Mutational Burden Assessed by a Targeted NGS Assay Predicts Benefit from Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients.** Sacha Rothschild  
University Hospital Basel, Switzerland

**P2.04-15: Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naive Lesions.** Kenichi Suda  
Kindai University Faculty of Medicine, Japan

**P2.04-16: Correlation Between Programmed Death Ligand 1(PD-L1) Expression and Solid Component on HRCT in Stage I Lung Cancer Patients.** Ryosuke Tsugitomi  
St. Luke's International Hospital, Japan

**P2.04-17: Pre-Therapy Radiomic Features Can Distinguish Hyperprogression from Other Response Patterns to PD1/PD-L1 Inhibitors in NSCLC.** Pranjal Vaidya  
Case Western Reserve University, USA
P2.04-18: The Association Between IDO Activity and Clinical Prognosis in Patients with Non-Small Cell Lung Cancer After Radiotherapy
Yaping Xu
Shanghai Pulmonary Hospital, China

P2.04-19: Correlation of Clinicopathological Characteristics with Tumor Mutation Burden in Chinese Patients with NSCLC
Shun Lu
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

P2.04-20: Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLC
Mehmet Altan
MD Anderson Cancer Center, USA

P2.04-21: Real World Experience of Immune Checkpoint Inhibitors in NSCLC: Our First 10 Months Experience at Leeds Cancer Centre, UK
Kathryn Ellenger
St James’s University Hospital, UK

Natalia Khranovska
National Cancer Institute of Ukraine, Ukraine

P2.04-23: Immune-Related Adverse Events: The Growing Pains of Immunooncology
Meghan Mooradian
Massachusetts General Hospital, USA

P2.04-24: Nivolumab in the “Real World”: Are the Results of Clinical Trials Reproducible?
Inmaculada Ramos García
Hospital Universitario Virgen de la Victoria, Spain

P2.04-25: Randomized Clinical Trial Comparing Immunotherapy Plus SABR (I-SABR) Versus SABR Alone for Early Stage NSCLC
Joe Chang
MD Anderson Cancer Center, USA

P2.04-26: Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC
Grace Dy
Roswell Park Comprehensive Cancer Center, USA

P2.04-27: Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC
James Lorens
University of Bergen, Norway

P2.04-28: Use of Immune Checkpoint Inhibitors (ICIs) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (PS)
Jonathan Thompson
Medical College of Wisconsin, USA

P2.04-29: Preliminary Results With Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC)
Xu-Chao Zhang
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China

P2.04-30: PD-1/PD-L1 Inhibition Might be an Option for the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma
Yi-Long Wu
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China

P2.06-01: Short-Term Outcome of Entire Pleural Intensity-Modulated Radiotherapy in a Neoadjuvant Setting for Malignant Mesothelioma
Ji Hyun Hong
Seoul St. Mary’s Hospital, Korea

P2.06-02: Feasibility of Intensity Modulated Radiotherapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma Patients
Oscar Arieta
Instituto Nacional de Cancerologia, Mexico

P2.06-03: Can We Predict Pathological Nodal Positivity in Malignant Pleural Mesothelioma from Preoperative Clinical Variables?
Silviu Buderi
St Bartholomew’s Hospital, UK

P2.06-04: Throughput of a Specialist Mesothelioma Multidisciplinary Team Meeting at a Radical Treatment Centre in the United Kingdom.
Edward Caruana
Glensfield Hospital, UK

P2.06-05: TTFields Applied to the Torso of Fibrosarcoma: Safety Meta-Analysis of 176 Patients from four Phase I-II Trials
Giovanni Ceresoli
Cliniche Humanitas Gavazzeni, Department of Oncology, Italy

P2.06-06: Role of GITRL-GITR System in Promoting Proliferation of Malignant Mesothelioma
Mei-Lin Chan
Princess Margaret Cancer Centre and Toronto General Hospital, University Health Network, Canada

P2.06-07: Genomic Deletion of BAP1 and CDKN2A are Better MM Diagnostic Biomarkers.
Yuen Yee Cheng
The University of Sydney, Australia

P2.06-08: ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma
Puey Ling Chia
Olivia Newton-John Cancer Research Institute, Australia

P2.06-09: MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in pts with Malignant Mesothelioma
Dean Fennell
University of Leicester & Leicester University Hospitals, UK

P2.06-10: Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress
Nobukazu Fujimoto
Okayama Rosai Hospital, Japan

P2.06-11: A Phase I/II Study of Intrapleural Ad-SGE-REIC Administration in Patients with Refractory Malignant Pleural Mesothelioma
Yasushi Goto
National Cancer Center Hospital, Japan

P2.06-12: Improving Quality of Care for Pleural Mesothelioma: 2018 National Mesothelioma Audit Results for England and Wales
Susan Harden
Royal College of Physicians of London, UK

P2.06-13: Poor Nutritional Status Is a Poor Prognostic Factor in Malignant Pleural Mesothelioma
Isabelle Opitz
University Hospital of Zurich, Switzerland

P2.06-14: Does Size Matter? A Population-Based Analysis of Malignant Pleural Mesothelioma
Jiaxi He
Guangzhou Medical University First Affiliated Hospital, China

P2.06-15: Malignant Pleural Mesothelioma in Young Adult People in Uganda
Nehemiya Igulu Bandese
Uganda Cancer Institute, Uganda
P2.06-16: An Important Driver of Mesothelioma Drug Resistance and a Potential Novel Therapeutic Target
Karin Schelch
Institute of Cancer Research, Austria

P2.06-17: Real-World Accuracy of Malignant Pleural Mesothelioma (MPM) Preoperative Magnetic Resonance Imaging (MRI) for Staging the Diaphragm.
Sharyn Katz
University of Pennsylvania Perelman School of Medicine, USA

P2.06-18: Comparison of Exubtation Time of Pleurectomy/Decortication with Lobectomy Under General Anesthesia Using Desflurane
Keisuke Kawata
National Hospital Organization Yamaguchi-Ube Medical Center, Japan

P2.06-19: Targeting Polyamines as Potential Adjutant Therapy in Malignant Pleural Mesothelioma Xenograft Models
Sze Kwan Lam
The University of Hong Kong, Hong Kong

P2.06-20: Bacteria as Novel Anti-Mesothelioma Agents
Sally Lansley
Institute for Respiratory Health, Australia

P2.06-21: Low Intratumoral Platinum Concentration is Associated with Unfavorable Clinical Outcome in Malignant Pleural Mesothelioma
Viktoria Laszlo
Medical University Vienna, Austria

P2.06-22: Proposal of a New Local Recurrence Score for Patients with Malignant Pleural Mesothelioma
Isabelle Opitz
University Hospital of Zurich, Switzerland

P2.06-23: Association of Two BRM Promoter Polymorphisms and Tobacco Exposure with Malignant Pleural Mesothelioma (MPM) Risk and Survival
Min Joon Lee
University of Toronto Faculty of Medicine; Princess Margaret Cancer Centre, Canada

P2.06-24: The Impact of Demographic and Socioeconomic Factors on Survival of Patients with Mesothelioma in the USA
Rami Manochakian
Mayo Clinic, USA

P2.06-25: Combined Immune Checkpoint Blockade in Malignant Pleural Mesothelioma: In Vivo Validation of in Vitro Results
Jan Van Meerbeeck
Department of Pulmonology, Antwerp University Hospital, Belgium

P2.06-26: Ribonucleotide Reductase Subunit M1 but not M2 is Associated to Better PFS in Patients with Advanced Stage Mesothelioma
Saé Muñiz-Hernández
National Cancer Institute, Mexico

P2.06-27: Extrapleural Pneumonectomy, Radiation Therapy, and Chemotherapy for Epitheloid Malignant Pleural Mesothelioma
Kazuoni Okabe
Yamaguchi Ube Medical Center, Japan

P2.06-28: Assessment of Chest Wall Motion Using Structured Light Plethysmography (SLP) in Mesothelioma and Benign Pleural Disease
Nicola Oswald
University of Birmingham, UK

P2.06-29: Expression of Estrogen Receptor Beta (ERb) and its Prognostic Value in the Pleural Mesothelioma.
Jerónimo Rodríguez-Cid
Instituto Nacional de Enfermedades Respiratorias, Mexico

P2.06-30: Association of Histopathological Patterns of Mesotheioma and Response to Treatment with Chemotherapy
Jerónimo Rodríguez-Cid
Instituto Nacional de Enfermedades Respiratorias, Mexico

P2.06-31: Inhibition of Heat Shock Protein 70 Function Suppresses Proliferation in Mesothelioma Cells
Kosuke Sakai
Saitama Medical Center, Japan

P2.06-32: YB-1 - A Key Factor in Mesothelioma Aggressive Growth and Behaviour
Karim Schelch
Asbestos Diseases Research Institute, Australia

P2.06-33: Heterogeneity in Care Pathways for Patients with Malignant Pleural Mesothelioma Presenting at a Quaternary Thoracic Oncology Center in Quebec
Aya Siblini
Division of Thoracic Surgery, McGill University Health Center, Canada

P2.06-34: Inhibition of the HGF/c-Met Pathway for Malignant Mesothelioma with an Intra-Thoracic Injection of the NK4 Expressing Adenoviral Vectors
Yu Zhi Zhang
Royal Brompton and Harefield NHS Foundation Trust, UK

P2.06-35: Pleurectomy Decortication Versus Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma: SPARCS Data
Maaïke Van Gerwen
Icahn School of Medicine at Mount Sinai, USA

P2.06-36: EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM
Jan Van Meerbeeck
University Hospital Antwerp, Belgium

P2.06-37: Four Immunohistochemical Assays to Measure the PD-L1 Expression in Malignant Pleural Mesothelioma
Takuya Watanabe
Nagoya City University Graduate School of Medical Sciences, Japan

P2.06-38: Mesothelioma Stem Cells May Be the Critical Factor of Treatment Failure
Licun Wu
Princess Margaret Cancer Centre and Toronto General Hospital, University Health Network, Canada

P2.06-39: Next Generation Sequencing Reveals Genetic Landscape of Malignant Mesothelioma
Xuefeng Xia
Geneplus-Beijing, China

P2.06-40: VISTA is Highly Expressed in Malignant Pleural Mesothelioma (MPM) and Independent of PD-L1 Expression
Marjorie Zauderer
Memorial Sloan Kettering Cancer Center, USA

P2.06-41: Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC
Yu Zhi Zhang
Royal Brompton and Harefield NHS Foundation Trust, UK

P2.06-42: AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma.
Federica Zito Marino
University of Campania “Luigi Vanvitelli”, Naples, Italy, Italy

P2.06-01 - P2.09-08 IO

P2.09-01: Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma
Hui Yu
University of Colorado Anschtz Medical Campus, USA
P2.09-02: Comprehensive Assessment of PD-L1 Immunohistochemistry on Paired Tissue and Cytology Specimens in Non-Small Cell Lung Cancer
Andréanne Gagné
Institut Universitaire de Cardiologie et de Pneumologie de Québec (Quebec City Heart and Lung Institute), Canada

P2.09-03: Rapid-Immunocytochemistry for Evaluation of Surgical Margin in Sublobar Pulmonary Resection
Nobuyasu Kurihara
Akita University Graduate School of Medicine, Japan

P2.09-04: PD-L1 Expression in Primary Lung Adenocarcinoma and its Relation with EGFR / KRAS Mutation and Clinicopathological Features
Lin Li
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P2.09-05: Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001
Aaron Lisberg
University of California, USA

P2.09-06: Expression of PD-L1 on Routine Non-Small Cell Lung Carcinoma Sections: Comparative Assessment of SP263 (Ventana) and 22C3 (DAKO pharmDx)
Anne Marie Quinn
Wythenshawe Hospital, Manchester NHS Foundation Trust, UK

P2.09-07: Does Metastatic Site Matter for PD-L1 Testing in Stage IV NSCLC?
Hangjun Wang
McGill University Health Center & McGill University, Canada

P2.09-08: Clinical Outcomes of Histology Versus Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer
Ying Wang
McMaster University, Juravinski Hospital and Cancer Centre, Canada

P2.09-09 – P2.09-16 Molecular

P2.09-09: Precision and Repeatability of VENTANA DLL3 (SP347) Assay Immunohistochemistry Assay in Fine Needle Aspirations of Small Cell Lung Cancer
Brittany Admire
Ventana Medical Systems, Inc, USA

P2.09-10: qRT-PCR as an Efficient and Reliable Diagnostic Screening Approach for the Detection of EML4-ALK Fusion Gene in NSCLC Samples: A Pilot Study
Anuradha Choughule
Tata Memorial Centre, India

P2.09-11: TMB Estimated with Targeted NGS in Early Stage Squamous Cell Carcinoma: Correlation with PD-L1 Expression and Lymphocyte Density
Susana Hernandez
Hospital Universitario HM Sanchinarro, Spain

P2.09-12: EGFR Mutation Status in Squamous Cell Carcinoma or Non-Small Cell Carcinoma Favor Squamous Cell Carcinoma Diagnosed from Small Lung Biopsies
Hsiang-Ling Ho
Molecular Pathology, Taiwan

P2.09-13: Correlation of ROS1 (SP384) Immunohistochemistry with ROS1 Rearrangement Determined by Fluorescence in Situ Hybridization
Catherine Le
Ventana Medical Systems, USA

P2.09-14: The Detection of EGFR Gene Mutation from Washing Solution of Bronchoscopic Examination
Rie Nakahara
Tochigi Cancer Center, Japan

P2.09-15: A Next Generation Sequencing (NGS) RNA-Scan Multiplex Panel (QIAseq) to Identify Gene-Rearranged Non-Small Cell Lung Cancer
Rebecca Tay
The Christie NHS Foundation Trust, UK

P2.09-16: Heterogeneity Analyses of MSLCs—Especially in the EGFR Mutation-Positive Ones
Yinghui Xu
The First Hospital of Jilin University, China

P2.09-17 – P2.09-32 Pathology

P2.09-17: A Call to Action: Rapid Collection of Post-Mortem Lung Cancer Tissue in the Community to Enable Lung Cancer Research
Theresa Boyle
H. Lee Moffitt Cancer Center and Research Institute, USA

P2.09-18: A Clinicopathological Analysis of Pulmonary Sclerosing Pneumocytoma in Korea: A Multicenter Study
Han Kyeom Kim
Korea University Guro hospital, Korea

P2.09-19: Utilising Heterogeneity: Using a Digital Database of Lung Cancers and Immune Profile to Complement Subjective Assessment
Alexander Haragan
University of Liverpool, UK

P2.09-20: Minor Components of Solid Pattern is a Significant Poor Prognostic Factor in Pathological Stage I Lung Adenocarcinoma
Miao Huang
Peking University Cancer Hospital & Institute, China

P2.09-21: Women with Synchronous or Metachronous Lung and Ovarian Cancers: A Multi-Institutional Report
Silvia Novello
San Luigi University Hospital, Italy

P2.09-22: Relevance of Results of Intraoperative Pleural Lavage Cytology and Histological Subtype in Lung Adenocarcinoma
Masashi Mikubo
Kitasato University School of Medicine, Japan

P2.09-23: A Combination of Podoplanin and E-Cadherin Expression in Lung SqCC may be a Poor Prognostic Indicator: A Propensity Score-Matched Analysis.
Ryo Miyata
Graduate School of Medicine, Kyoto University, Japan

P2.09-24: MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
Rebecca Mosher
Mersana Therapeutics, USA

P2.09-25: Abundant Tumor Promoting Stromal Cells in Lung Adenocarcinoma with Hypoxic Regions
Hiroshi Nakamura
Juntendo University, Japan

P2.09-26: Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma
Takashi Ohno
Tottori University, Faculty of Medicine, Japan

P2.09-27: Prognostic Significance of Vascular Invasion in Pathological Stage IA Lung Adenocarcinoma According to the 8th Edition of the TNM Classification
Joji Samejima
Kanagawa Cancer Center, Japan
P2.10-06: The Risk of Lung Cancer Among Women Who Start Smoking As Teenagers
Malcolm Tagbarha
University of Abuja, Nigeria

P2.10-07: Health Professional’s Perception Towards Smoking: A Cross-Sectional Study from Bangalore, India.
Satheesh Thungappa
HCG Bangalore Institute of Oncology
Speciality Centre, India

P2.10-08: Smoking Prevention Project in School Population: My Health Is in My Own Hands
Tomi Kovacevic
Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia

P2.10-09: The Beliefs, Orientation, Knowledge, Understanding, Attitudes And Treatment Access To Lung Cancer Amongst Rural Men In Nigeria
Malcolm Tagbarha
University of Abuja, Nigeria

P2.10-10: Lung Cancer Survival in Younger Patients (<40 Years): Analysis of Surveillance, Epidemiology and End Results Program Data
Marisa Bittoni
The Ohio State University, USA

P2.10-11: Impact of Smoking on Multiple Primary Cancers Survival – A Retrospective Analysis
Anna Doboszyńska
University of Warmia and Mazury, Collegium Medicum, Poland

P2.10-12: Prevalence, Pattern and Factors Associated with Dual Tobacco Use in a Rural Community in South Eastern Nigeria
Uzochukwu Ofonakara
Federal Teaching Hospital, Nigeria

P2.10-13: When Lung Cancer Was Rare: An Historical Study of Prevalence from 1760
Luc Ollivier
CHRU Brest, France

P2.10-14: The Evaluation of Relationship Between Radon Gas and Lung Cancers in Trabzon
Fazıl Aydın
Karadeniz Technical University, Turkey

P2.10-15: RADON: #1 Cause of Lung Cancer in Non-Smokers
Kelley Bush
Government of Canada, Canada

P2.10-16: Finding the Relations Between Lung Cancer and Associated Risk Factors in Pakistani Population
Arooj Fatima
Shaukat Khanum Cancer Hospital and Research Centre, Pakistan

P2.10-17: Environmental Tobacco Smoke Exposure and EGFR Mutations in Non-Smokers with Lung Cancer: A Dose-Response Analysis of Published Data
Wenhua Liang
The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, China State Key Laboratory of Respiratory Disease, China

P2.11-01: Blood Transcriptomics Enables Detection of Pre-Invasive & Minimally-Invasive Lung Adenocarcinoma
Baohui Han
Shanghai Chest Hospital, China

P2.11-02: Direct Comparison of New Solid Nodules Detected in Women and Men During Incidence Screening Rounds of the NELSON Trial
Joan Walter
University of Groningen, University Medical Center Groningen, Netherlands

P2.11-03: Cardiovascular Risk Prediction in a Community-Based Lung Cancer Screening Programme
Haval Balata
Manchester University NHS Foundation Trust, UK

P2.11-04: Treatment Capacity Required for Implementing Lung Cancer Screening in the United States
Erik Blom
Erasmus MC, Netherlands

P2.11-05: Recruitment Strategies for the Lung Cancer Screening Pilot for People at High Risk
Gail Darling
Cancer Care Ontario, Canada

P2.11-06: A New Histoplasmosis Antibody Enzyme Immunoassay for the Diagnosis of Lung Benign Nodules
Stephen Deppen
Vanderbilt University Medical Center, USA

P2.11-07: Lung Cancer in a Tertiary Care Setting: So Near, Yet So Far
Kranti Garg
Government Medical College and Hospital, India
P2.11-08: Tumor Autoantibody Panel Can Improve the Accuracy of Early Diagnosis in Lung Cancer Presenting with GGNs /Solid Nodules
Yayi He
Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P2.11-09: Uncommon EGFR Mutation Analysis from Urine of Lung Cancer Patients
Prista Hikmawati
Sebelas Maret University, Indonesia

P2.11-10: Potential Utility of a Positive EarlyCDT®-Lung Blood Biomarker Test in Indeterminate Pulmonary Nodules
James Jett
Oncimmune LLC, USA

P2.11-11: Identification of the Genetic Determinants of Susceptibility to Lung Cancer in a Moroccan Cohort
Houda Kaanane
Faculty of Medicine and Pharmacy of Casablanca, Morocco

P2.11-12: Metabolomic Analysis in Lung Cancer for Screening and Early Detection
Naohiro Kajiwara
Tokyo Medical University, Japan

P2.11-13: Precise Early Detection of Lung Cancer and Blood Cell Circuit
Oleg Kashets
Roshal Hospital, Russia

P2.11-14: Malignancy Associated Change and The LuCED® Test for Detection of Early Stage Lung Cancer
Michael Meyer
VisionGate, USA

P2.11-15: Identifying Patients for Whom Lung Cancer Screening is Preference-Sensitive: A Microsimulation Study
Rafael Meza
University of Michigan, USA

P2.11-16: Comparison of Two Lung Cancer Screening Programs in One Medical Center - Does Experience of the Screening Team and Indications Affect the Results?
Marcin Ostrowski
Medical University of Gdansk, Poland

P2.11-17: MicroRNAs in Exhaled Breath Condensate and Bronchial Brushings as Biomarkers for Early Diagnosis of Lung Cancer
Bijay Pattnaik
All India Institute of Medical Sciences, India

P2.11-18: A Comprehensive Lung Cancer Screening Program: 5 Years in Review
April Plank
Stony Brook Medicine, USA

P2.11-19: MicroRNAs as Liquid Biopsy Biomarkers for Early Detection in Lung Cancer.
Patricia Reis
Sao Paulo State University - UNESP, Brazil

P2.11-20: Lung EpiCheck TM - Results of the Training and Test Sets of a Methylation-Based Blood Test for Early Detection of Lung Cancer
Joanna Chorostowska-Wynimko
National Institute of Tuberculosis and Lung Diseases, Poland

P2.11-21: Factors Predicting Attrition in Community-Based Healthcare Network Lung Cancer Screening Programs
Candice Wilshire
Swedish Cancer Institute, USA

P2.11-22: Use of Electronic Medical Records for Tobacco Use and Lung Cancer Screening Documentation in a Large Urban Academic Medicine Practice
Giselle Suarez-Abreu
Rutgers University New Jersey Medical School, USA

P2.11-23: Risk Perception Among a Lung Cancer Screening Population
John Goffin
Juravinski Cancer Centre, Canada

P2.11-24: Impact of Screening Interval Length on New Nodules Detected in Incidence Rounds of CT Lung Cancer Screening: the NELSON Trial
Joan Walter
University of Groningen, University Medical Center Groningen, Netherlands

P2.11-25: Lung Cancer Screening Implementation in Community Practice: Kaiser Permanente Washington Experience 2015-2018
Karen Wernli
Kaiser Permanente Washington Health Research Institute, USA

P2.11-26: First of its Kind Multi-Pronged Training for PCPs in an Epicenter of Lung Cancer – What Was Achieved in Two Years?
Celeste Worth
University of Louisville, USA

P2.11-27: A Rapid Access Lung Cancer Clinic Reduces Variation in Lung Cancer Diagnostic and Treatment Services.
Robert Zielinski
Western Sydney University, Australia

P2.11-28: A Focus Group and Interview Study to Explore the Information-Needs of Lung Cancer Screening Participants
Mamta Ruparel
University College London, UK

P2.11-29: Impact of an Information-Film to Promote Informed Decision-Making in Individuals Taking Part in a Lung Cancer Screening Demonstration Pilot
Mamta Ruparel
University College London, UK

P2.11-29a: Modified Lung-RADS Improves Performance of Screening LDCT in a Population with High Prevalence of Non-Smoking-Related Lung Cancer
En-Kuei Tang
Kaohsiung Veterans General Hospital, Taiwan

P2.12-01 – P2.12 – 09 Clinical Trial/Therapeutics

P2.12-01: Efficacy of Belotecan as Second-Line Treatment for Recurrent Small Cell Lung Cancer: A Phase IIb Randomized Multicenter Study
Jin-Hyoung Kang
Seoul St. Mary’s Hospital, Korea

P2.12-02: Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC)
Muhammad Furqan
University of Iowa Hospitals and Clinics, USA

P2.12-03: Phase I/II Trial Of177Lu-DOTA0-Tyr3-Octreotate (Lutathera) And Nivolumab for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Chul Kim
Georgetown University, USA

P2.12-04: Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy
Natalya Nazarenko
Ipsen Bioscience, USA

P2.12-05: SUKSES (Small Cell Lung Cancer Umbrella Korea Studies): A Phase II Biomarker-Driven Umbrella Study in Relapsed or Refractory SCLC
Keunchil Park
Keumchil Park
Samsung Medical Center, Korea

P2.12-06: The Efficacy of Apatinib Plus Topotecan as Laterline Therapy for Advanced Small Cell Lung Cancer
Haiying Qin
307 Hospital of PLA, China

P2.12-07: Utility of Stereotactic Body Radiotherapy in Pulmonary Carcinoid Tumors
Robert Ramirez
Ochsner Medical Center - Kenner, USA
P2.12-08: Network Meta-Analysis of Angiogenesis Inhibitors on Survival of Patients with Small Cell Lung Cancer
Xiaoshun Shi
Nanfang Hospital, China

P2.12-09: Efficacy and Safety of Carboplatin and Paclitaxel for Patients Preexisting Interstitial Lung Disease with Small Cell Lung Cancer
Ayumi Uchiyama
Jichi Medical University Hospital, Japan

P2.12-10 - P2.12-12 Prognostic Model
P2.12-10: Novel Prognostic Model for Limited-Stage Small-Cell Lung Cancer
Hanbo Chen
London Health Sciences Centre, Canada
P2.12-11: A Prognostic Model Integrating Immunohistochemistry Markers for Extensive-Disease Small-Cell Lung Cancer
Rui Fu
Guangdong Lung Cancer Institute, China
P2.12-12: Plasma Vitamin D Level is an Independent Prognosis Factor for Extensive-Disease Small-Cell Lung Cancer
Xu Wang
The First Hospital of Jilin University, China

P2.12-13 – P2.12-19 Radiation
P2.12-13: Effectiveness of Hypofractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Propensity Score Analysis
Hanbo Chen
London Health Sciences Centre, Canada
P2.12-14: Stereotactic Radiosurgery for Brain Metastases in Small Cell Lung Cancer.
Elizabeth Dudnik
Rabin Medical Center, Israel
P2.12-15: Prognostic and Predictive Covariates in Limited-Stage Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial
Corinne Faire-Finn
University of Manchester, UK
P2.12-16: Significant Tumor Regression and Toxicity with Nivolumab Plus Ipilimumab in Small Cell Lung Cancer Patients Following Radiation
Brendan Gilmore
Rush University Medical Center, USA

P2.12-17: Prophylactic Cranial Irradiation Can Not Provide Survival Benefits for Resected Small Cell Lung Cancer Without Lymph Node Involvement
Baohui Han
Shanghai Chest Hospital, China

P2.12-18: Interstitial Lung Abnormalities are a Risk Factor for Radiation Pneumonitis in Patients with Limited-Stage Small-Cell Lung Cancer
Fangjuan Li
Shanghai Pulmonary Hospital Tongji University School of Medicine, China

P2.12-19: Prophylactic Cranial Irradiation in Extensive Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Wenyu Li
First Hospital of China Medical University, China

P2.13 TARGETED THERAPY
P2.13-01 – P2.13-07 ALK
P2.13-01: Brigatinib Use in England – Where Next?
Fabio Gomes
The Christie NHS Foundation Trust, UK
P2.13-02: ALK-Translocation and Brain Metastases: A Retrospective Study. Correlation Between Clinical Outcome, Disease Burden and Management.
Oscar Grundberg
Karolinska University Hospital, Sweden
P2.13-03: Real-Life Experience with Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients
Maximilian Hochmair
Department of Respiratory and Critical Care Medicine, and Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology, Otto Wagner Hospital, Austria
P2.13-04: Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib: A Multicenter Cohort Retrospective Study.
Di Ma
Cancer Institute and Hospital Chinese Academy of Medical Sciences Peking Union Medical College, China

P2.13-05: Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients with Advanced ALK-Positive NSCLC.
Di Ma
Cancer Institute and Hospital Chinese Academy of Medical Sciences Peking Union Medical College, China

P2.13-06: TP53 Status in Relation to Response to Anti-ALK Agents in Patients with EML4-ALK-Translocated NSCLC
Paola Ulivi
Istituto Scientifico Romagno lo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy
Kaihua Lu
The First Affiliated Hospital of Nanjing Medical University, China

P2.13-08 – P2.13-32 EGFR
P2.13-08: Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC.
Pasi Jänne
Dana Farber Cancer Institute, USA
P2.13-09: Efficacy and Safety of Osimertinib After Prior EGFR TKI: Analysis of Patients Underrepresented in Randomized Clinical Trials
Luiz H. Araujo
Instituto Nacional de Câncer (INCA), Brazil
P2.13-10: Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC
Lauren Byers
UT MD Anderson Cancer Center, USA
P2.13-11: EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP*)
Andrés Cardona
Foundation for Clinical and Applied Cancer Research - FICMAC, Colombia
P2.13-12: The deNovo T790M Mutation Recovered by ddPCR is Associated with a Poor Response to 1st and 2nd Generation EGFR-TKI in Lung Adenocarcinoma.
Yoon Soo Chang
Yonsei University College of Medicine, Korea
Parneet Cheema
Sunnybrook Odette Cancer Centre, University of Toronto, Canada
P2.13-14: The Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy
Joanna Chorostowska-Wynimko
National Institute of Tuberculosis and Lung Diseases, Poland

P2.13-15: Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TPS3 Mutations and Primary Resistance Mechanisms
Yun Fan
Zhejiang Cancer Hospital, China

P2.13-16: Preference of Adjuvant Treatments for EGFR-Mutant Resected NSCLC Patients: Results of a Nationwide Survey in China
Wenhua Liang
The First Affiliated Hospital of Guangzhou Medical University, China

P2.13-17: Non-Small Cell Lung Cancer in the Very Young: More EGFR/ALK Mutation Rate Than the Elder
ChienHui He
Taipei Veterans General Hospital, Taiwan

P2.13-18: A Multicenter Prospective Biomarker Study to Explore Mechanisms of Aftatinib Resistance Based on Digital PCR and Next-Generation Sequencing
Eiji Iwama
Department of Comprehensive Clinical Oncology Faculty of Medical Sciences, Kyushu University, Japan

P2.13-19: Prognostic Value Inferred from the Quantitative Measurement of EGFR Mutation Using PNA-Clamping Method in Advanced EGFR Mutant NSCLC Patients
Mi-hyun Kim
School of Medicine, Pusan National University, Korea

P2.13-20: The Comparative Effectiveness of Gefitinib Versus Erlotinib on the Intracranial Progression-Free Survival in Patients with Brain Metastasis
Yao-Wen Kuo
National Taiwan University Hospital, Taiwan

P2.13-21: MET Addiction Can be Circumvented Through EGFR Inhibition Via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLC
Xue Lin Kwang
National Cancer Center Singapore, Singapore

P2.13-22: Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
Jae Cheol Lee
Asan Medical Center, University of Ulsan College of Medicine, Korea

P2.13-23: Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC
Haiyan Li
Taizhou Hospital, China

P2.13-24: Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients
Jordi Remon
Gustave Roussy, France

P2.13-25: Analysis of EGFR Mutations Using Circulating Tumour DNA (ctDNA) in Non-Small Cell Lung Cancer Patients in North East Scotland
Paula Scott
Aberdeen Royal Infirmary Genetics, UK

P2.13-26: Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated with First-Line TKI
Santhya Sharma
Monter Cancer Center, Northwell Health, USA

P2.13-27: Development, Internal Validation, and Calibration of a Risk Score to Predict Survival in Patients with EGFR Mutant NSCLC
Ross Soo
National University Cancer Institute, Singapore, Singapore

P2.13-28: Comparison of ddPCR and NGS in Liquid Biopsy to Pathology Results in EGFR-Mutated NSCLC
Christi Steendam
Erasmus MC, Netherlands

P2.13-29: IL-22 Confers Resistance To EGFR-TKIs In Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification
Xiyi Lu
First Affiliated Hospital of Nanjing Medical University, China

P2.13-30: High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer with EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study
Shucui Zhang
Beijing Chest Hospital, Capital Medical University, China

P2.13-31: p.(Leu747Pro) Mutation Leads to Misdiagnosis in EGFR Mutation Assessment – Analysis in a Cohort of 1841 Polish NSCLC Patients
Joanna Chorostowska-Wynimko
National Institute of Tuberculosis and Lung Diseases, Poland

P2.13-32: TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2
Jouhara Chouitarr
Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, USA

P2.13-33 – P2.13-41 General

P2.13-33: A Case Report of Exceptional Clinical Response to MEK Inhibition in a Patient with NRAS Mutation Positive NSCLC
Donna Graham
The Christie NHS Foundation Trust, UK

P2.13-34: Long Intergenic Non-Coding RNA 00665 Induces Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer
Xiyi Lu
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, China

P2.13-35: Inhibition of H3K27 Demethylation is Toxic in Poorly Differentiated Small Cell Lung Cancer
Timothy Lochmann
Virginia Commonwealth University, USA

P2.13-36: Analysis of CDK4/6 Pathway Activity in Lung Adenocarcinoma Patients with Oncogenic Driver Mutations in China
Shun Lu
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

P2.13-37: Chloroquine overcomes acquired resistance to icotinib in vitro and in vivo through STAT3/STMN1 pathway
Xin Lyu
The Second Affiliated Hospital of Xi’an Jiaotong University, China

P2.13-38: Impact of Tyrosine Kinase Inhibitor (TKI) Dose on Outcomes of Patients with Lung Cancer
Emily Miao
St. John’s University, USA

P2.13-39: A Phase Ib Trial of the HSP90 Inhibitor AUY922 in Combination with Pemetrexed in Metastatic Non-Squamous, Non-Small Cell Lung Cancer Patients
Zorawar Noor
University of California, Los Angeles, USA
POSTERS 2 | TUESDAY, SEPTEMBER 25, 2018

P2.13-40: ABP 215 and Bevacizumab in NSCLC Patients: Time Course and Magnitude of Response in the Phase 3 Comparative Trial (MAPLE)
Valdimir Hanes
Amgen, Inc., USA

P2.13-41: A Novel Mitochondria-Based Targeting to Restore Therapeutic Response in Cisplatin- and Gefitinib-Resistant Human Lung Cells
Qinghua Zhou
West China Hospital, Sichuan University, China

P2.13-42 - P2.13-46 Rare Targets

P2.13-42: Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer
Joop De Langen
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Netherlands

P2.13-43: Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
Pasi Jänne
Dana-Farber Cancer Institute, USA

P2.13-44: Targeting NFE2L2 Mutations in Advanced Squamous Cell Lung Cancers with the TORC1/2 Inhibitor TAK-228
Paul Paik
Memorial Sloan Kettering Cancer Center, USA

P2.13-45: SHERLOC: A Phase 2 Study of Seribantumab in Combination with Docetaxel in Patients with Heregulin Positive, Advanced NSCLC
Lecia Sequist
Massachusetts General Hospital, USA

P2.13-46: Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients
Shao W. Yang
Nanjing Medical University, China

P2.15-01 - P2.15-33 Costs, Disparities

P2.15-01: CANscript™ as a Patient-Derived Predictive Platform for individualizing Treatment in Lung Cancer
K Govind Babu
Kidwai Memorial Institute of Oncology, India

P2.15-02: Gender-Associated Differences in Patients with Lung Cancer Treated at an Argentinean University Hospital in the Last 10 Years
Carolina Gabay
Instituto de Oncología Angel H.Roffo, University of Buenos Aires, Argentina

P2.15-03: Availability and Reimbursement of Diagnostic Testing and Novel Anti-Cancer Drugs for NSCLC in CEE: Results of a CECOG Survey
Luka Brčić
Medical University of Graz, Austria

P2.15-04: Costs of Cares on the Month Before Death of Patients with Lung Cancer: A French National Database Survey
Olivier Bylicki
University Paris-Est, Paris Est Créteil (UPEC), University CEPiA (Clinical Epidemiology and Ageing), EA 7376- IMRB, France

P2.15-05: Prescribing Patterns of Physicians and Financial Implications for Lung Cancer Treatment at the End of Life
Josephine Feliciano
Johns Hopkins Medicine, USA

P2.15-06: Examination of Optimal Timing of Post-Surgical Surveillance for Early Stage Lung Cancer Patients and Association with Outcomes
Leah Backhus
Stanford University, USA

P2.15-07: Lung Cancer in the Young
Marco Galvez Nino
Instituto Nacional de Enfermedades Neoplasicas, Peru

P2.15-08: Impact and Feasibility of a Support Group for Women with Lung Cancer
Paul Wheatley-Price
Department of Medicine, University of Ottawa/The Ottawa Hospital Research Institute/Lung Cancer Canada, Canada

P2.15-09: The Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients with Advanced NSCLC in 2017
Daniel Moldaver
Cornerstone Research Group, Canada

P2.15-10: Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non–Small Cell Lung Cancer.
Badr Id Said
Princess Margaret Cancer Centre, Canada

P2.15-11: Clinical Outcome of Pulmonary Resection for Non–Small Cell Lung Cancer in Extremely Elderly Patients (85-Year-Old or Over)
Hiroaki Inoue
Onomichi Municipal Hospital, Japan

P2.15-12: Exparel vs. Bupivicaine for Postoperative Analgesia After VATS Lung Resection: Results of a Randomized Control Trial
Sanddeep Khandhar
Inova Fairfax Hospital, USA

P2.15-13: Implementation of a Democratized Approach to Multi-Omic Molecular Profiling Via the LungMATCH Program.
Jennifer King
Lung Cancer Alliance, USA

P2.15-14: Survivorship of Advanced Lung Cancer Patients with Psychiatric Disorders and Malnutrition Risk
Tomi Kovacevic
Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia

P2.15-15: Differentiating Characteristics of Patients Seeking a Second Opinion: A Survey on Non-Small Cell Lung Cancer Patients
Sara Hayes
Health Union LLC, USA

P2.15-16: Clinical Economic Impact of Improved Genotyping in Patients with Advanced Non–Small Cell Lung Adenocarcinoma (NSCLC)
David Gandara
UC Davis Comprehensive Cancer Center, USA

P2.15-17: Patient Care in Advanced Lung Cancer: Unmet Needs
Jean-François Morere
Hôpital Paul Brousse, France

P2.15-18: Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia
Aylen Vanessa Ospina Serrano
ICCAL Hospital Universitario Fundacion Santa Fe de Bogota, Colombia

P2.15-19: Inequality of Access to Novel Lung Cancer Therapies in Europe
Hazel O’Sullivan
University Hospital Limerick, Ireland

P2.15-20 - P2.15-37 Impact and Feasibility of a Support Group for Women with Lung Cancer

P2.15-21: Gender-Associated Differences in Patients with Lung Cancer Treated at an Argentinean University Hospital in the Last 10 Years
Carolina Gabay
Instituto de Oncología Angel H.Roffo, University of Buenos Aires, Argentina

P2.15-22: Availability and Reimbursement of Diagnostic Testing and Novel Anti-Cancer Drugs for NSCLC in CEE: Results of a CECOG Survey
Luka Brčić
Medical University of Graz, Austria

P2.15-23: Costs of Cares on the Month Before Death of Patients with Lung Cancer: A French National Database Survey
Olivier Bylicki
University Paris-Est, Paris Est Créteil (UPEC), University CEPiA (Clinical Epidemiology and Ageing), EA 7376- IMRB, France

P2.15-24: Prescribing Patterns of Physicians and Financial Implications for Lung Cancer Treatment at the End of Life
Josephine Feliciano
Johns Hopkins Medicine, USA

P2.15-25: Examination of Optimal Timing of Post-Surgical Surveillance for Early Stage Lung Cancer Patients and Association with Outcomes
Leah Backhus
Stanford University, USA

P2.15-26: Lung Cancer in the Young
Marco Galvez Nino
Instituto Nacional de Enfermedades Neoplasicas, Peru

P2.15-27: Impact and Feasibility of a Support Group for Women with Lung Cancer
Paul Wheatley-Price
Department of Medicine, University of Ottawa/The Ottawa Hospital Research Institute/Lung Cancer Canada, Canada

P2.15-28: The Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients with Advanced NSCLC in 2017
Daniel Moldaver
Cornerstone Research Group, Canada

Badr Id Said
Princess Margaret Cancer Centre, Canada

P2.15-30: Patient Care in Advanced Lung Cancer: Unmet Needs
Jean-François Morere
Hôpital Paul Brousse, France

P2.15-31: Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia
Aylen Vanessa Ospina Serrano
ICCAL Hospital Universitario Fundacion Santa Fe de Bogota, Colombia

P2.15-32: Inequality of Access to Novel Lung Cancer Therapies in Europe
Hazel O’Sullivan
University Hospital Limerick, Ireland

P2.15-33 Costs, Disparities

P2.15-34: Costs of Cares on the Month Before Death of Patients with Lung Cancer: A French National Database Survey
Olivier Bylicki
University Paris-Est, Paris Est Créteil (UPEC), University CEPiA (Clinical Epidemiology and Ageing), EA 7376- IMRB, France

P2.15-35: Prescribing Patterns of Physicians and Financial Implications for Lung Cancer Treatment at the End of Life
Josephine Feliciano
Johns Hopkins Medicine, USA

P2.15-36: Examination of Optimal Timing of Post-Surgical Surveillance for Early Stage Lung Cancer Patients and Association with Outcomes
Leah Backhus
Stanford University, USA

P2.15-37: Lung Cancer in the Young
Marco Galvez Nino
Instituto Nacional de Enfermedades Neoplasicas, Peru
P2.15-20: Educating The Multispecialty Team on Molecular Testing Related to Immunotherapy Jeffrey Gregg UC Davis Comprehensive Cancer Center, USA

P2.15-21: Post Resection Lung Cancer Surveillance: Comparisons of Practice Between STS, ESTS and JACS Members Cecilia Pompili University of Leeds, UK

P2.15-22: Optimal Glycemic Control Improves Prognosis for Lung Cancer Patients with Diabetes Mellitus Baohui Han Shanghai Chest Hospital, China

P2.15-23: Are there Ethnic Disparities in the Clinical Outcomes of Non-Small Cell Lung Cancer Hispanics Treated with Immunotherapy? Luis Raez Memorial Cancer Institute/Florida International University, USA

P2.15-24: Comparison of Pemetrexed Administered q 3 Weeks vs q 4 Weeks as Maintenance Therapy in NSCLC: Analysis of Real World Data from a Single Institution Sruthi Reddy Roswell Park Comprehensive Cancer Center, USA

P2.15-25: NIVEX TRIAL (GECP 1605): Nivolumab in the Real World: Spanish Expanded Access Program Experience in Pretreated Advanced NSCLC Patients Delvys Rodríguez-Abreu Hospital Insular de Gran Canaria, Spain

P2.15-26: Rates and Economic Burden of Adverse Events in Patients With Metastatic NSCLC Treated with EGFR-TKIs Janakiraman Subramanian Saint Luke’s Cancer Institute, USA

P2.15-27: Lung Volume Change After Lobectomy Estimated by Three-Dimensional Image Analysis System Hirofumi Suzuki Osaka General Hospital of West Japan Railway Company, Japan

P2.15-28: Effect of Insurance Types on Tumor Recurrence and Overall Survival in Resectable Non-Small Lung Cancer Patients in Northern Thailand Nirush Lertprasertsuke Chiang Mai University, Thailand

P2.15-29: Eligibility for Anti-Angiogenic Treatments in Patients with Squamous Non-Small Cell Lung Cancer (SQ-NSCLC): EPIQUAMAB Study (GFPC 2015-01) Alain Vergnenegre CHU Dupuytren, France

P2.15-30: Marital Status and Survival in Patients with Lung Cancer Buhai Wang Northern Jiangsu People’s Hospital, China

P2.15-31: The Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014 Ying Wang University of British Columbia, Canada

P2.15-32: Novice Training : The Time Course for Developing Competence in Single Port Video-Assisted Thoracoscopic Lobectomy Ching Feng Wu Chang Gung Memorial Hospital, Taiwan

P2.15-33: Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens After Panel Testing by NGS? Chunxia Su Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P2.15-34: Validation of a Gene Expression-Based Nomogram of de Novo T790M on Outcome for Resected NSCLC from EGFR Mutant Cohort of Japan Molecular Epidemiology (JME) Study Yoshiya Matsumoto Graduate School of Medicine, Osaka City University, Japan

P2.15-35: The Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer on Chest CT Scan Using Deep Learning Algorithm Kyongmin Beck Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea

P2.15-36: CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC Enriqueita Felip Vall d’Hebron Institute of Oncology, Spain

P2.15-37: Prognostic Value of Lymphovascular Invasion and Its Effect on Patterns of Recurrence in T1-3NO Non-Small Cell Lung Cancer Yeon Sil Kim Seoul St. Mary’s Hospital, Korea

P2.16-02: Predicting Pathological Noninvasiveness in T1 Non-Small Cell Lung Cancer on Chest CT Scan Using Deep Learning Algorithm

P2.16-03: Impact of de Novo T790M on Outcome for Resected NSCLC from EGFR Mutant Cohort of Japan Molecular Epidemiology (JME) Study

P2.16-07: Impact of Tumor Location and Histological Sub-Type of Non-Small Cell Lung Cancer on Patient Survival Alan McWilliam University of Manchester, UK

P2.16-08: Prognostic Role of Combined Pulmonary Fibrosis and Emphysema (CPFE) in Patients with Clinical Stage I Lung Cancer. Yasuhiro Tsutani Hiroshima University, Japan

P2.16-10: Prognostic Impact of Postoperative C-Reactive Protein for Non-Small Cell Lung Cancer Following Lobectomy Shuichi Shinohara Chubu Rosai Hospital, Japan

P2.16-11: Prognostic Role of Combined Pulmonary Fibrosis and Emphysema (CPFE) in Patients with Clinical Stage I Lung Cancer. Yasuhiro Tsutani Hiroshima University, Japan

P2.16-12: Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy Gavitt Woodard University of California, San Francisco, USA

P2.16-13: A Proposal of Classification for Subsolid Nodule: Prognostic Impact of T Descriptor Erjia Zhu Shanghai Pulmonary Hospital, China
P2.16-14 - P2.16-24 Radiation Oncology

P2.16-14: Results of Stereotactic Radiation Therapy (SABR) in Early Stage Lung Cancer: Turkish Radiation Oncology Group (TROG) Study
    Banu Atalar
    Acibadem University, Turkey

P2.16-15: Toxicities and Survival after Stereotactic Ablative Radiotherapy (SABR) for Centrally Located Lung Tumors
    Banu Atalar
    Acibadem University, Turkey

P2.16-16: SABRTOOTH: A Fasibility Study of SABR Versus Surgery in Patients with Peripheral Stage I NSCLC Considered to be at Higher Risk for Surgery.
    Kevin Franks
    Leeds Cancer Centre, St James’s University Hospital, UK

P2.16-17: Hypo-Fractionated Accelerated Radiotherapy in Central Early Non-Small Cell Lung Cancer: Leeds Cancer Centre Experience.
    Kevin Franks
    St James’s University Hospital, UK

P2.16-18: Study of Interstitial Lung Disease and Acute Exacerbation in Patients Receiving Radiation Therapy for Lung Cancer in Japan.
    Yasuhiro Hagiwara
    Hospital of the National Institute of Radiological Sciences, Japan

P2.16-19: Feasibility and Outcomes of Radiofrequency Ablation as Salvage Modality After Hypofractionated Radiation/SBRT for Early NSCLC
    Ritika Harjani Hinduja
    The Ottawa Hospital- Cancer Centre, Canada

P2.16-20: Prognostic Utility of PET in Non-Small Cell Lung Cancer After Empiric Stereotactic Body Radiotherapy (SBRT)
    Shaakir Hasan
    Allegheny Health Network Cancer Institute, USA

P2.16-21: Post-Treatment Survival Difference Between Lobectomy and Stereotactic Ablative Radiotherapy in Stage I Non-Small Cell Lung Cancer in England
    Neal Navani
    University College London, UK

P2.16-22: Comparing Two Common Radiotherapy Regimens in Non-Small Cell Lung Cancer - A Retrospective Study
    Stephen Harrow
    Beatson West of Scotland Cancer Centre, UK

P2.16-23: Focal Therapy for Small Lung Cancer with Ethanol Release Heat-Generating Polymer
    Junichi Shimada
    Kyoto Prefectural University of Medicine, Japan

P2.16-24: Racial Differences in Treatment and Survival of Stage I NSCLC: A Comparison of Veterans Affairs (VA) and SEER-Medicare Populations
    Christina Williams
    Durham VA Health Care System, USA

P2.16-25 – P2.16-51 Surgery

P2.16-25: Lower Hiliar Lymph Node Upstaging in Early NSCLC Vats Surgery is Related to Tumor Location and Does Not Affect Survival
    Marc Boada
    Hospital Clinic de Barcelona, Spain

P2.16-26: Lung Cancer Resection in Patients with Criteria for Lung Cancer Screening Provides Satisfactory Short Term Results
    David Boulate
    Hopital Marie Lanelongue, France

    Toyofumi Chen-Yoshikawa
    Graduate School of Medicine, Kyoto University, Japan

P2.16-28: Comparison of Outcomes of VATS Segmentectomy Versus Lobectomy for Non-Small Cell Lung Cancer Using a Propensity Score Matching Analysis
    Yoo-hwa Hwang
    SMG-SNU Boramae Medical Center, Korea

P2.16-29: Clinical Outcomes of Surgically Resected Extraabdominal Chest Wall Desmoid Tumors
    Seok Kim
    Chonnam National University Hwasun Hospital, Korea

P2.16-30: Surgical Strategy for Clinical Stage IA Non-Small Cell Lung Cancer Patients with Risk Factors of Pathological Invasion and/or Metastasis
    Terumoto Koike
    Niigata University Graduate School of Medical and Dental Sciences, Japan

P2.16-31: Examination of the Intersegmental Isolation Method in the Segmental Resection Considering Respiratory Function Preservation
    Katsuo Kojima
    Karatsu Red-Cross Hospital, Japan

P2.16-32: Survival Implications and Factors Associated with the Anatomic Level of Incomplete Non-Small-Cell Lung Cancer (NSCLC) Resection
    Yu-Sheng Lee
    University of Memphis School of Public Health, USA

P2.16-33: Adenosquamous Carcinoma of the Lung: Comparison of Surgical Outcomes with Squamous Cell and Adenocarcinoma
    Huseyin Melek
    Uludag University, Turkey

P2.16-34: Visceral Pleural Invasion is Closely Associated with Nodal Spread in cStage IA Lung Adenocarcinoma
    Tetsuya Mizuno
    Aichi Cancer Center Hospital, Japan

P2.16-35: Analysis of Pre and Intraoperative Factors Related to the Operation Time of Lobectomy in VATS: Is the Shape of Thoracic Cavity a Predictive Factor?
    Takuya Nagashima
    Kanagawa Cancer Center, Japan

P2.16-36: Adjuvant Chemotherapy is Effective for Completely Resected Stage IB Non-Small Cell Lung Cancer
    Masao Nakata
    Kawasaki Medical School, Japan

P2.16-37: The Introduction of Robotic Lobectomy for Non-Small Cell Lung Cancer in South East Asia: A 5-Year Single Centre Study
    Kingsfield Ong
    Tan Tock Seng Hospital, Singapore

P2.16-38: Characteristics of Preoperative N Staging in Patients with Optimal Pathologic N Staging of Non Small Cell Lung Cancer(NSCLC)
    Meredith Ray
    University of Memphis School of Public Health, USA

P2.16-39: The Application of 3D Medical Image Analyzer and a Fluorescence Guided Surgery for Pulmonary Sublobar Resection
    Yasuo Sekine
    Tokyo Women’s Medical University Yachiyo Medical Center, Japan

P2.16-40: Impact of Preoperative Pectoralis Muscle Quantity and Density on Outcome After Complete Resection of Non-Small Cell Lung Cancer
    Changbo Sun
    The University of Tokyo Hospital, Japan
**P2.16-41: Intraoperative Computed Tomography After Tumor Marking with Metal Clips for Non-Palpable Lung Tumors**
Yoshinasa Tokunaga
Kochi Health Sciences Center, Japan, Japan

**P2.16-42: Standard Mediastinoscopy Versus Video-Assisted Mediastinoscopic Lymphadectomy in Clinical N1 Non-Small Cell Lung Cancer**
Akif Turna
Istanbul University, Cerrahpasa Medical Faculty, Turkey

**P2.16-43: Diabetes is a Negative Prognostic Factor in Non-Small Cell Lung Cancer Patients Undergoing Resectional Surgery**
Akif Turna
Istanbul University, Cerrahpasa Medical Faculty, Turkey

**P2.16-44: Long-Term Outcome of Pulmonary Segmentectomy for c-IA Non-Small Cell Lung Cancer**
Hironobu Wada
Chiba University Graduate School of Medicine, Japan

**P2.16-45: Should Patients with Stage IB Non-Small Cell Lung Cancer Receive Adjuvant Chemotherapy?**
Jia Wang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

**P2.16-46: Clinical Outcomes and Treatment Strategies of Sarcomatoid Carcinoma of the Lung**
Yan Wang
The 4th Hospital of Hebei Medical University, China

**P2.16-47: “Improved aBVA Method” and “Anterior VAB Method” Result in Analogous Survival Benefits During Right Upper Lobectomy**
Jin Xia
Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, China

**P2.16-48: Outcomes of Stage I Lung Cancer Patients Treated with Segmentectomy via Three-Dimensional Uniportal VATS Versus Two-Dimensional Approach**
Chengliang Yang
Shenyang Chest Hospital, China

**P2.16-49: Which Nomogram is More Reliable to Predict Recurrence of Pathological Stage IA Lung Adenocarcinoma Treated by Surgery?**
Lu Yang
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

**P2.16-50: Do Patients Have Preconceived Ideas on Various Surgical Approaches? Patient Perspective: Open vs. Minimally Invasive Surgery (PROMIS) Survey.**
Ching Yeung
The Ottawa Hospital, Canada

Tanel Laisaar
Tartu University, Estonia

---

**P2.17 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC**

**P2.17-01: Trimodality Therapy (TT) in the Treatment of Stage IIIA Non-Small Cell Lung Cancer (NSCLC)**
Tahir Mehmood
Northwest General Hospital and Research Centre, Pakistan

**P2.17-02: Cardiopulmonary Exercise Tests in Lung Cancer Patients Treated Radical Radiotherapy and Chemotherapy – Feasibility Study**
Nazia Mohammed
Beatson West of Scotland Cancer Centre, UK

**P2.17-03: A Propensity-Matched Analysis of Neoadjuvant Chemoradiotherapy and Adjuvant Chemoradiotherapy for IIA(N2) Non-Small Cell Lung Cancer**
Yaping Xu
Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P2.17-04: Imiquimod Attenuates Radiation-Induced Pulmonary Fibrosis**
Guler Yavas
Sekuç University, Turkey

**P2.17-05: Consolidation Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiotherapy**
Fatma Basal
Ankara Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Turkey

**P2.17-06: Functional Lung Imaging in Radiotherapy for Lung Cancer: A Systematic Review and Meta-Analysis**
Nicholas Bucknell
Peter MacCallum Cancer Center, Australia

**P2.17-07: Concurrent Chemoradiotherapy (ConCRT) using Cisplatin-Vinorelbine in Locally Advanced (LA) Non-Small Cell Lung Cancer (NSCLC)**
Haris Charalambous
Bank of Cyprus Oncology Centre, Cyprus

**P2.17-08: Heart Motion in Lung Radiotherapy: How Representative Are Delineations Based on 3DCT, Average and Maximum Projection Scans?**
David Cobben
University of Manchester-The Christie NHS foundation Trust, UK

**P2.17-09: Exploring the Impact of Age on the Efficacy of Adjuvant Chemotherapy After Radical Resection in Non-Small Cell Lung Cancer**
Catherine Davidson
Northern Ireland Cancer Centre, UK

**P2.17-10: Daily Low-Dose Cisplatin and High Dose Radiotherapy for Elderly Patients with Stage III NSCLC is Well Tolerated.**
E.M.T. Dieleman
AMC, Netherlands

**P2.17-11: Impact of Quantitatively Assessed Emphysema on Chest Tube Drainage After Lobectomy for Non-Small Cell Lung Cancer**
Tomasz Gil
Jagiellonian University, John Paul II Hospital, Poland

**P2.17-12: Eliminating Radiation Resistance of Non-Small Cell Lung Cancer By DHA Trough Abrogating Immunity Escaping via Inhibiting PD-L1 Expression**
Xiaomei Gong
Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

**P2.17-13: Genome-Wide Copy Number Alterations Profiling Predict Efficacy of Resected Stage II-IIIA Lung Adenocarcinoma**
Xiaohong Han
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, China
P2.17-14: How Should Positive Margin for Bronchial Stumps (R1) Be Evaluated in Patients Undergoing Bronchoplasty for Lung Cancer?
Kazunori Hata
Juntendo University School of Medicine, Japan

P2.17-15: Mediastinoscopic Assessment of N2 Disease and Optimisation of Surgical Treatment of N2 Disease in NSCLC
George Karimundackal
Tata Memorial Hospital, India

P2.17-16: Radical en Bloc Resection for Lung Cancer Invading the Spine
Masato Kato
Hiramatsu Hospital, Japan

P2.17-17: Multimodal Treatment in Pathologically Confirmed Single-Station Resectable IIIA-N2 Non-Small Cell Lung Cancer: A Single Center Experience
Margarita Majem
Hospital de la Santa Creu i Sant Pau, Spain

P2.17-18: A Prognostic Score for Patients Receiving Multimodal Treatment for Locally-Advanced Non-Small Cell Lung Cancer
Maurice Dantes
University Hospital, LMU Munich, Germany

P2.17-19: Concurrent Chemoradiotherapy with Carboplatin-Paclitaxel Versus Cisplatin-Etoposide for Stage III NSCLC Patients – Review of Literature
Tahir Mehmood
Northwest General Hospital and Research Centre, Pakistan

P2.17-20: Systematic Literature Review of Chemoradiotherapy Versus Radiotherapy Alone in Elderly Patients with Stage III Non-Small Cell Lung Cancer
Tahir Mehmood
Northwest General Hospital and Research Centre, Pakistan

P2.17-21: Efficacy of Concurrent Carboplatin-Paclitaxel Chemoradiotherapy with 66 Gy for Elderly Patients with Stage III Non-Small Cell Lung Cancer
Sachiko Miura
Nara Medical University, Japan

P2.17-22: Cardiac Biomarkers in CART Study (CARDiac Toxicity in Lung Cancer Patients After Chemo-Radiotherapy).
Nazia Mohammed
Beaton West of Scotland Cancer Centre, UK

P2.17-23: Optimal Therapy of Stage III NSCLC: The Role of Surgery in the Era of Immunotherapy
Sara Moore
BC Cancer, Canada

P2.17-24: Does the Change in Body Mass Index During Induction Chemo/Chemoradiotherapy Affect the Outcome of Surgery in Locally Advanced NSCLC?
Huseyin Melek
Uludag University, Turkey

P2.17-25: Post-Treatment Neutrophil to Lymphocyte Ratio in Locally Advanced NSCLC Patients Treated with Concurrent Chemoradiotherapy
Eun Young Park
Department of Radiation Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Korea

P2.17-26: Quantifying the Interfractional Motion of the Esophagus During Radiation Therapy for Locally Advanced Non Small Cell Lung Cancer
Hui Liu
Sun Yat-sen University Cancer Center, China

P2.17-27: IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy
Naiyer Rizvi
Columbia University Medical Center and NewYork-Presbyterian Hospital, USA

David Chun Cheong Tsui
University of Alberta, Canada

P2.17-29: Is Collagen Vascular Disease-Associated Interstitial Lung Disease a High Risk for Lung Cancer Surgery?
Yukio Watanabe
Juntendo University School of Medicine, Japan

P2.17-30: Serum Lipoprotein(A) Correlates with the Effect of Endostar Combined with Concurrent Chemoradiotherapy in Patients with Locally Advanced LSCC
Haihua Yang
Taizhou Hospital, China

P2.17-33: Role of Adjuvant Therapy in Pulmonary Adenosquamous Carcinoma
Jiaxi He
Guangzhou Medical University First Affiliated Hospital, China
# Posters at a Glance

**Wednesday September 26, 2018 | Poster Session 3**

<table>
<thead>
<tr>
<th>Section</th>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.01</td>
<td>Advanced NSCLC</td>
</tr>
<tr>
<td>P3.03</td>
<td>Biology</td>
</tr>
<tr>
<td>P3.04</td>
<td>Immunooncology</td>
</tr>
<tr>
<td>P3.07</td>
<td>Nursing and Allied Professionals</td>
</tr>
<tr>
<td>P3.08</td>
<td>Oligometastatic NSCLC</td>
</tr>
<tr>
<td>P3.09</td>
<td>Pathology</td>
</tr>
<tr>
<td>P3.11</td>
<td>Screening and Early Detection</td>
</tr>
<tr>
<td>P3.12</td>
<td>Small Cell Lung Cancer/NET</td>
</tr>
<tr>
<td>P3.13</td>
<td>Targeted Therapy</td>
</tr>
<tr>
<td>P3.15</td>
<td>Treatment in the Real World - Support, Survivorship, Systems Research</td>
</tr>
<tr>
<td>P3.16</td>
<td>Treatment of Early Stage/Localized Disease</td>
</tr>
<tr>
<td>P3.17</td>
<td>Treatment of Locoregional Disease - NSCLC</td>
</tr>
<tr>
<td>P.3 CR</td>
<td>Case Reports</td>
</tr>
</tbody>
</table>
P3.01-06: Concomitant Plasma-Genotyped T790M Positivity and Small Cell Carcinoma Transformation in EGFR-Mutated NSCLC Sourin Bhuniya All India Institute of Medical Sciences, India

P3.01-07: Outcome and Prognostic Factors in ALK+ve Metastatic Adenocarcinoma of Lung: Single Center Experience From Eastern India Bivas Biswas Tata Medical Center, India

P3.01-08: Gender Differences in Lung Cancer Survival Marko Jakopovic University Hospital Center Zagreb, Croatia

P3.01-09: Impact of Urban or Rural Residence on Overall Survival for Patients with Metastatic Non-Squamous NSCLC Jacqueline Brown University of Virginia, USA

P3.01-10: Dyspnea as a Prognostic Factor in Hispanic Patients with Non-Small Cell Lung Cancer Cohort Saul Campos-Gomez Centro Oncologico Estatal ISSEMYM, Mexico

P3.01-11: Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Andrés Cardona Foundation for Clinical and Applied Cancer Research - FICMAC, Colombia

P3.01-12: EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil. Gilberto Castro Jr Instituto de Cáncer do Estado de São Paulo (ICESP), Brazil

P3.01-13: Prognosis of Non-driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC) Anna Chalmers University of Utah, USA

P3.01-14: mTORC1 Regulates the Radiosensitivity of NSCLC Cells with Wildtype PI3KCA and KRAS Genes by Affecting EMT Yuan Chen Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

P3.01-15: Efficacy of Paclitaxel Plus TS1 Against Non-Small Cell Lung Cancer Previously Treated Yuh-Min Chen Taipei Veterans General Hospital, Taiwan

P3.01-16: Low Dose Apatinib Combined with EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure Mingda Chen Tangshan People’s Hospital, China

P3.01-17: Long Survivors with Advanced Lung Cancer - Efficacy and Tolerability of Nivolumab Ewa Chmielowska Oncology Center, Poland

P3.01-18: Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients with Lung Cancer Jang Ho Cho Samsung Medical Center, Korea

P3.01-19: Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients Cliff Molife Eli Lilly and Company, USA

P3.01-20: Advanced NSCLC Treatment and Outcomes After Nivolumab Girish Mallesara Calvary Mater Newcastle, Australia

P3.01-01: Prospective Comparison of Four Plasma Testing Platforms for T790M and Effectiveness of Osimertinib in Chinese NSCLC Patients Yi-Long Wu Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P3.01-02: Patients with a Smaller Primary Tumor and Fewer Metastases Could be Cured Even in Advanced Non-Small Cell Lung Cancer Takuya Aoki Tokai University School of Medicine, Japan

P3.01-03: The Cost Benefit from Second Line Immunotherapy in Metastatic NSCLC: ASCO Value Framework Prospective Ahmed Badawy Alexandria University, Egypt

P3.01-04: Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience. Kiran Virik Queen’s University, Canada

P3.01-05: Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy Marta Batus Rush University Medical Center, USA

P3.01-06: Concomitant Plasma-Genotyped T790M Positivity and Small Cell Carcinoma Transformation in EGFR-Mutated NSCLC Sourin Bhuniya All India Institute of Medical Sciences, India

P3.01-07: Outcome and Prognostic Factors in ALK+ve Metastatic Adenocarcinoma of Lung: Single Center Experience From Eastern India Bivas Biswas Tata Medical Center, India

P3.01-08: Gender Differences in Lung Cancer Survival Marko Jakopovic University Hospital Center Zagreb, Croatia

P3.01-09: Impact of Urban or Rural Residence on Overall Survival for Patients with Metastatic Non-Squamous NSCLC Jacqueline Brown University of Virginia, USA

P3.01-10: Dyspnea as a Prognostic Factor in Hispanic Patients with Non-Small Cell Lung Cancer Cohort Saul Campos-Gomez Centro Oncologico Estatal ISSEMYM, Mexico

P3.01-11: Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Andrés Cardona Foundation for Clinical and Applied Cancer Research - FICMAC, Colombia

P3.01-12: EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil. Gilberto Castro Jr Instituto de Cáncer do Estado de São Paulo (ICESP), Brazil

P3.01-13: Prognosis of Non-driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC) Anna Chalmers University of Utah, USA

P3.01-14: mTORC1 Regulates the Radiosensitivity of NSCLC Cells with Wildtype PI3KCA and KRAS Genes by Affecting EMT Yuan Chen Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

P3.01-15: Efficacy of Paclitaxel Plus TS1 Against Non-Small Cell Lung Cancer Previously Treated Yuh-Min Chen Taipei Veterans General Hospital, Taiwan

P3.01-16: Low Dose Apatinib Combined with EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure Mingda Chen Tangshan People’s Hospital, China

P3.01-17: Long Survivors with Advanced Lung Cancer - Efficacy and Tolerability of Nivolumab Ewa Chmielowska Oncology Center, Poland

P3.01-18: Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients with Lung Cancer Jang Ho Cho Samsung Medical Center, Korea

P3.01-19: Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients Cliff Molife Eli Lilly and Company, USA

P3.01-20: Advanced NSCLC Treatment and Outcomes After Nivolumab Girish Mallesara Calvary Mater Newcastle, Australia

P3.01-01: Prospective Comparison of Four Plasma Testing Platforms for T790M and Effectiveness of Osimertinib in Chinese NSCLC Patients Yi-Long Wu Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P3.01-02: Patients with a Smaller Primary Tumor and Fewer Metastases Could be Cured Even in Advanced Non-Small Cell Lung Cancer Takuya Aoki Tokai University School of Medicine, Japan

P3.01-03: The Cost Benefit from Second Line Immunotherapy in Metastatic NSCLC: ASCO Value Framework Prospective Ahmed Badawy Alexandria University, Egypt

P3.01-04: Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience. Kiran Virik Queen’s University, Canada

P3.01-05: Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy Marta Batus Rush University Medical Center, USA
P3.01-24: The Importance to Switch from EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma
Daisuke Eriguchi
Tokyo Medical University, Japan

P3.01-25: Feasibility of Moderate Hypofractionated Thoracic Irradiation for Non-Small Cell Lung Cancer Patients with Very Limited Lung Function
Maurice Dantes
University Hospital, LMU Munich, Germany

Corinne Faivre-Finn
University of Manchester-The Christie NHS foundation trust, UK

P3.01-27: Characterization and Sensitization of Non-Small Cell Lung Cancer Cell Line Variants Selected for Resistance to Osimertinib
Peter Ferguson
London Regional Cancer Program, Canada

P3.01-28: The Clinical Impact of Comprehensive cfDNA Genomic Testing in Lung Cancer
Laila Roisman
Soroka University Medical Center, Israel

P3.01-29: St. Iv Lung Adenocarcinoma Treated by First-Line EGFR-Tyrosine Kinase Inhibitors-Survival, EGFR Mutation, Histologic Subtype
Tomasz Gil
Jagiellonian University, John Paul II Hospital, Poland

P3.01-30: Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan
Yasushi Goto
National Cancer Center Hospital, Japan

P3.01-31: Prognostic Factors in Patients with Resected Pathological N2 Non-Small Cell Lung Cancer
Tatsuya Goto
Niigata University, Japan

P3.01-32: An Open-Label, Non-Randomized, Biomarker Study of Concordance in Non-Invasive and Tissue Tests for T790M Detection in NSCLC
Jeffrey Gregg
UC Davis Comprehensive Cancer Center, USA

P3.01-33: EGFR Mutation in Patients with NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis
Mahmut Gumus
Istanbul Medeniyet University, Turkey

P3.01-34: Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
Tetsunari Hase
Nagoya University Graduate School of Medicine, Japan

P3.01-35: Outcomes in Advanced Non-Small Cell Lung Cancer After Discontinuation of PD-1 Checkpoint Inhibitor Due to Toxicity. A Retrospective Study
Jonathon Hill
Crown Princess Mary Cancer Centre, Australia

P3.01-36: Prognostic Factors in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Marta Honorio
Hospital Prof. Fernando Fonseca, Portugal

P3.01-37: Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients with Wild-Type EGFR: TORG 1320
Shinobu Hosokawa
Japanese Red Cross Okayama Hospital, Japan

P3.01-38: Therapeutic Effects of FMNP-MSC for Hyperthermia on Lung Cancer A549 in Nude Mice
Runlei Hu
Hangzhou First People’s Hospital, China

P3.01-39: Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib Progress
Chunwei Xu
Fujian Cancer Hospital, China

P3.01-40: Treatment of Super Elderly Patients for Non-Small Cell Lung Cancer in Japan
Tatsuya Ibe
National Hospital Organization West Saitama Central Hospital, Japan

P3.01-41: Anatomical and Clinical Basis of #11 LN by Systematic Bilateral Mediastinal Nodal Dissection for Left Lung Cancer through Median Sternotomy
Shingo Ikeda
Mitsui Memorial Hospital, Japan

P3.01-42: Phase II Trial Allowed Surgery After Induction Chemotherapy of CBDCA+PTX, Bevacizumab in Patients with Stages IIIA-IV Nonsquamous NSCLC
Kazuhiro Imai
Akita University Graduate School of Medicine, Japan

P3.01-43: Predictive Value of Computed Tomography Characteristics for Nivolumab Response in Pretreated Non-Small Cell Lung Cancer
Hisao Imai
Gunma Prefectural Cancer Center, Japan

P3.01-44: CYFRA 21-1 As a Predictor to Response to Chemotherapy and Overall Survival in Patients with Advanced NSCLC
Kashif Iqbal
Nuclear Medicine, Oncology and Radiotherapy Institute, Pakistan

P3.01-45: Multifactorial Gene Alterations in EGFR Bypass Pathway are Induced by Afatinib in T790M-Mutant NSCLC Resistant to Osmertinib
Hidenobu Ishii
Kurume University School of Medicine, Japan

Syed Jafri
UT Health McGovern School of Medicine, USA

P3.01-47: Clinical Characteristics and Outcome for Patients with Advanced Lung Adenocarcinoma Treated with First-Line Pemetrexed Plus Platinum
Xue Ji
Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P3.01-48: The Efficiency of Low-Dose Apatinib in Treatment of Advanced Lung Squamous Cell Carcinoma
Yu-Ming Jia
The Second People’s Hospital of Yibin, China

P3.01-49: Efficiency of Low-Dosage Apatinib Monotherapy in Treatment of Advanced Lung Squamous Cell Carcinoma
Hua Jiang
The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, China
P3.01-50: Identification of EGFR Mutational Profile in Lung Cancer Moroccan Cohort
Houda Kaanane
Faculty of Medicine and Pharmacy of Casablanca, Morocco

P3.01-51: Outcomes with Systemic Chemotherapy in Advanced NSCLC Patients with Performance Status 2 and Above and without Driver Mutation
Harish Kancharla
All India institute of Medical Sciences, India

P3.01-52: The Role of Serum Carcinoembryonic Antigen to Predict the Response of Treatment in Non-Small Cell Lung Cancer Patients
Muhammed Ali Kaplan
Dicle University Diyarbakir, Turkey

P3.01-53: Comparison of the Treatment Efficacy of Osimertinib in Young and Elderly Patients with T790M-Positive NSCLC
Yasuhiro Kato
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P3.01-54: A Historical Comparison of Patients with Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan
Takahisa Kawamura
Shizuoka Cancer Center, Japan

P3.01-55: SF2: A PCYT-2 Inhibitor Prototype is Capable of Inducing Cytotoxicity in NSCLC
Bárbara Kawamura
FMUSP, Brazil

P3.01-56: Hyperprogression and Pseudoprogression in Patients with Non-Small Cell Lung Cancer on Checkpoint Blocking Immunotherapy
Seoree Kim
Catholic Medical University, Korea

P3.01-57: Real-World (RW) Predictors of Immunooncology (IO) vs Chemotherapy (C) Use in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Bruce Feinberg
Cardinal Health, USA

P3.01-58: Relative Abundance Of EGFR Mutations in Plasma Predicts Tumor Response to EGFR-TKI in Advanced Lung Adenocarcinoma
Yuping Li
Department of Respiratory, The First Affiliated Hospital of Wenzhou Medical University, China

P3.01-59: Comparison of Lobectomy, Segmentectomy and Wedge Resection for Early Stage NSCLC: A Direct and Network Meta-Analysis
Wang Liang
Peking University Cancer Hospital and Institute, China

P3.01-60: A Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient with Acquired MET Amplification
Ying Liang
Sun Yat-sen University Cancer Center, China

P3.01-61: EGFR and KRAS Mutational Status and Significance in Greek Patients with Advanced Non Small Cell Lung Cancer
George Fountzilas
Hellenic Cooperative Oncology Group (HeCOG), Greece

P3.01-62: A New Method for Non-Invasive Prediction of Radiotherapy: SDH5 Depletion Enhances Radiosensitivity by Regulating P53
Jun Liu
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

P3.01-63: Baseline Biomarkers for Predictors of Efficacy to Nivolumab in Advanced Non-Squamous Non-Small Cell Lung Cancer
Kristen Marrone
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA

P3.01-64: Preliminary Data of Diverse Therapies in Patients with Advanced Non-Small-Cell Lung Cancer Harbouring RET-Rearrangement
Chang Lu
Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P3.01-65: First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients with EGFR-Mutant Metastatic NSCLC Receiving TKIs
Jingbo Wang
National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences, Peking Union Medical College, China

P3.01-66: Clinicopathological Characteristics and Mutation Status of Pulmonary Invasive Mucinous Adenocarcinoma
Fangliang Lu
Peking University Cancer Hospital, China

P3.01-67: Integrated Network Analysis to Understand the Potential Mechanisms of Hydroxychloroquine in Non-Small Cell Lung Cancer Treatment
Jingyun Chen
The Second Affiliated Hospital of Xi’an Jiaotong University, China

P3.01-68: Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients with Advanced NSCLC Harboring EGFR Mutations
Dongqing Lv
Taizhou Hospital, China

P3.01-69: Stereotactic Ablative Radiotherapy Improves Progression-Free Survival & Local Control in Oligometastatic Lung Cancer Patients
Federico Maldonado
Instituto Nacional de Cancerologia, Mexico

P3.01-70: Meta-Analysis of Metformin in Combination with Platinum Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer
Karin Maren
Juntendo University School of Medicine, Japan

P3.01-71: Results of Extended Resection in T4 Non-Small Cell Lung Cancer
Kazumi Matsunaga
Juntendo University School of Medicine, Japan

Shunsaku Miyachi
Okayama University Hospital, Japan

P3.01-73: Talc Versus Minocycline and OK-432 Pleurodesis for Malignant Pleural Effusion.
EISUKE Mochizuki
Fujieda Municipal General Hospital, Japan

P3.01-74: Clinical and Radiological Predictors of Efficacy to Nivolumab in NSCLC: A Multi-Institutional, Retrospective Cohort Study.
Rebecca Moor
Princess Alexandra Hospital, Australia
P3.01-75: RELAY+, an Exploratory Study of Gefitinib with Ramucirumab in Untreated Patients with EGFR Mutation-Positive Metastatic NSCLC
Makoto Nishio
The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan

P3.01-76: Clinical Background and Response to Chemotherapy in NSCLC Patients with MET Exon14 Skipping Mutation or High MET Gene Copy Number
Kaname Nosaki
National Kyushu Cancer Center, Japan

P3.01-77: Clinical Characteristics of Korean Lung Cancer Patients with Programmed Death-Ligand 1 Expression
In-Jae Oh
Chonnam National University Medical School, Hwasun Hospital, Korea

P3.01-78: The Cytology Samples and Plasma Specimens were Feasible for the EGFR Molecular Testing.
Tatsuo Ohira
Tokyo Medical University, Japan

P3.01-79: Intracerebral Efficacy of Immune Check-Point Inhibitors in NSCLC Patients with Brain Metastases
Fumiyoshi Ohyanagi
Jichi Medical University, Saitama Medical Center, Japan

P3.01-80: Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients with NSCLC Harboring EGFR Mutations.
Naoko Okura
Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan

P3.01-81: Long-Term Outcome of Surgically Resected Unsuspected N2 Lung Adenocarcinoma
Byung Jo Park
Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

P3.01-82: Survival Impact of Surgery in the Treatment of Stage IIIB-IVA Non-Small Cell Lung Cancer
Ji Young Park
Hallym University Sacred Heart Hospital, Korea

P3.01-83: Use of Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vescicular Stomatitis Virus in Preclinical Models of NSCLC
Manish Patel
University of Minnesota, USA

P3.01-84: The Association of CDKN2A Gene Mutation with Clinicopathological Features and Prognosis in Advanced Lung Cancer Patients
Xiujuan Qu
The First Hospital of China Medical University, China

P3.01-85: Real-World Gefitinib 1st Line Treatment of Patients with Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience
Davorin Radosavljevic
Institute for Oncology and Radiology of Serbia, Serbia

P3.01-86: Treatment Outcomes with Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients with Advanced NSCLC
Shabnam Rehman
Roswell Park Cancer Institute, USA

P3.01-87: Efficacy and Safety of Pembrolizumab in Non-Small Cell Lung Cancer in Our Institution: A Retrospective Study
Nobuhiko Saijo
National Hospital Organization Kinki-chuo Chest Medical Center, Japan

P3.01-88: Clinical and Molecular Analysis of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid
Maria Sereno Moyano
Infanta Sofia University Hospital, Spain

P3.01-89: Upfront Surgery Versus Neoadjuvant Treatment Followed by Surgery in Pathologic N2 Non-Small Cell Lung Cancer
Byoung Yong Shim
Division of Medical Oncology, Department of Internal Medicine, St. Vincent Hospital, Korea

P3.01-90: A Phase II Study Evaluating Continuation of EGFR-TKIs Beyond Progressive Disease Followed by the Addition of CDDP+PEM+Bev
Satoshi Shoji
Niigata University Graduate School of Medical and Dental Sciences, Japan

P3.01-91: Computing the Impact of Immunotherapy on the Non-Small Cell Lung Cancer (NSCLC) Therapeutic Landscape
George Simon
The University of Texas MD Anderson Cancer Center, USA

P3.01-92: Blood Test Parameters as Prognostic Factors in EGFR-Mutated Non-Small Cell Lung Cancer Treated With TKIs
Jelena Spasic
Institute for Oncology and Radiology of Serbia, Serbia

P3.01-93: Osimertinib-Related Hematological and Pulmonary Toxicities in Advanced NSCLC Patients: Combined Analysis of Phase III Trials
Sirman Swarup
Texas Tech University Health Sciences Center, USA

P3.01-94: Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer
Konstantinos Syrigos
National and Kapodistrian University of Athens, Greece

P3.01-95: EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer
Konstantinos Syrigos
National and Kapodistrian University of Athens, Greece

P3.01-96: Clinical Characteristics of Non-Small Cell Lung Cancer Harboring Mutations in Exon 20 Of EGFR or HER2
Masayuki Takeda
Kindai University Faculty of Medicine, Japan

P3.01-97: Which is Better Prognostic Factor, PS, Inflammatory Marker, or PD-L1 Expression in Treating NSCLC with Nivolumab: A Retrospective Analysis
Akihiro Tamiya
Kinki-chuo Chest Medical Center, Japan

P3.01-98: Osimertinib-Related Hematological and Pulmonary Toxicities in Advanced Non-Small Cell Lung Cancer Treated With TKIs
Davorin Radosavljevic
Institute for Oncology and Radiology of Serbia, Serbia

P3.01-99: Effect of Pembrolizumab on Patients Harboring Uncommon Epidermal Growth Factor Receptor Mutations
Yoshikiko Taniguchi
National Hospital Organization Kinki-Chuo Chest Medical Center, Japan

P3.01-100: Risk of Gastrointestinal and Hepatic Toxicities in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Osimertinib
Kyaw Thein
Texas Tech University Health Sciences Center, USA

P3.01-101: A Retrospective Study of Lung Cancer that has Progressed to Brain Metastasis Alone
Kenjiro Tsuruoka
Osaka Medical College Hospital, Japan
P3.01-102: Potential Predictors of Unexpected Readmission After Lung Resection
Shinsuke Uchida
National Cancer Center Hospital, Japan

P3.01-103: Efficacy of Crizotinib in Chinese Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Multicenter Retrospective Study
Shouzheng Wang
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P3.01-104: EGFR-RADS1 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report
Chunwei Xu
Fujian Cancer Hospital, China

P3.01-105: Retrospective Analysis of Efficacy and Safety in Chinese Elderly Patients Treated with Nab-Paclitaxel
Shuhang Wang
Beijing Cancer Hospital, China

P3.01-106: Real-World Data to Evaluate the Clinical Benefit of NGS for Directing Lung Adenocarcinoma Treatment
Zhaoxia Wang
The Second Affiliated Hospital of Nanjing Medical University, China

P3.01-107: Correlation Study of Bone Metastasis and Cholesterol Level in Patients with Lung Adenocarcinoma
Yan Wang
The 4th Hospital of Hebei Medical University, China

P3.01-108: Oncologist Treatment Considerations and Selection in EGFR M+ NSCLC
Thomas Wehler
Evangelisches Krankenhaus Hamm, Germany

P3.01-109: Real-World Patient-Reported Outcome Assessment of Patients with Metastatic Non-Small Cell Lung Cancer
Loretta Williams
The University of Texas MD Anderson Cancer Center, USA

P3.01-110: Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review
Cliff Molife
Eli Lilly and Company, USA

P3.01-111: Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations
Yutaka Yamada
Ibaraki Prefectural Central Hospital & Cancer Center, Japan

P3.01-112: The Prognosis of Lung Cancer Patients with Unexpected Malignant Pleural Effusion and Without Pleural Dissemination Detected at Thoracotomy
Takashi Yamamichi
Tokyo Medical University Hospital, Japan

P3.01-113: A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (CTONG1506)
Qing Zhou
Guangdong General Hospital, Guangzhou, China

P3.01-114: Dissociation of Heart and Great Vessels for Long Tracheal Tumors and Lung Cancer Invaded Trachea: The Chinese Experience.
Qinghua Zhou
West China Hospital, Sichuan University, China

P3.01-115: Liposomal Paclitaxel Versus Gemcitabine: Which is Better?
Xiangdong Zhou
Southwest Hospital of Third Military Medical University, China

P3.01-116: Randomized Clinical Trial on Three Different Platinum Based Chemotherapy in Advanced NSCLC in Bangladeshi Population
Ferdous Begum
National Institute of Cancer Research and Hospital, Bangladesh

P3.03 BIOLOGY

P3.03-01 – P3.03-10 Characterization

P3.03-01: BRAF V600 and Non-V600 Mutations in Chinese Lung Cancer
Yang Gao
Department of Thoracic Surgery, Xiangya Hospital of Central South University, China

P3.03-02: Single-Cell RNA-Seq in Human Lung Cancer
Jinhong Kim
Dalhousie University, Canada

P3.03-03: Differential Microbiota Features in Lung Tumor and Adjacent Normal Tissues in Lung Cancer Patients
Qixing Mao
Jiangsu Cancer Hospital, China

P3.03-04: Is the Ciliary Function of the Lesion Bronchus Maintained in Patients with Lung Cancer?
Toshiyuki Sawa
Gifu Municipal Hospital, Japan

P3.03-05: Comparative Transcriptomic Analysis of Lung-iPSC, NSCLC, and SCLC: Potential Implications for iPSC Modeling of Lung Cancer
Vivek Shukla
National Cancer Institute, USA

P3.03-06: Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes
Tomas Tokar
University Health Network, Canada

P3.03-07: Co-Occurring Genomic Alterations in EGFR Altered Chinese Lung Adenocarcinoma Patients
Minghui Wang
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, China

P3.03-08: Analysis of ESR1 Mutation Spectrum from Non-Small-Cell Lung Cancer in Chinese Patients
Chunwei Xu
Fujian Cancer Hospital, China

P3.03-09: Molecular Spectrum of KIT Mutations Detection in Chinese Non-Small Cell Lung Cancer Patients
Chunwei Xu
Fujian Cancer Hospital, China

P3.03-10: Transcriptomic Differences Between Early and Late Stage Lung Adenocarcinoma
Dongsheng Yue
Tianjin Medical University Cancer Institute and Hospital, China

P3.03-11 – P3.03-19 In vitro

P3.03-11: Lung Cancer Stem Cells on Immune Modulation in Tumorous Microenvironment
Huei-Wen Chen
National Taiwan University, Taiwan

P3.03-12: Cyclic Mechanical Strain and Myoferlin Modulates Lung Adenocarcinoma Cell Proliferation and Erlotinib Resistance
Youjin Cho
The Ohio State University, USA
P3.03-30: Clinical Significance of Urothelial Carcinoma Associated 1 in Lung Cancer
Hongsu Wu
Department of Radiation Oncology, Shanghai Pulmonary Hospital, Shanghai, People’s Republic of China, China

P3.03-29: The Prognostic Effect of Tumor Mutation Burden and Smoking History in Resected EGFR Mutant Non-Small Cell Lung Cancer
Hadas Sorotsky
Princess Margaret Cancer Centre, Canada

P3.03-28: LKB1 Mutation Status is Associated with Poor Radiation Outcome in Patients with Non-Small Cell Lung Cancer
Priyadurai Sitthideatphaiboon
Chulalongkorn University/King Chulalongkorn Memorial Hospital, Thailand

P3.03-27: Somatic BRCA1/2 Mutations in Non-Small Cell Lung Cancer
Radiumhospitalet, Norway

P3.03-26: Tumor Immune Microenvironment in NSCLC is Predictive of Prognosis After Surgery
Asa Öjlert
Institute for Cancer Research -OUS-, Norway

P3.03-25: Squamous Cell Carcinoma-Associated Bronchial Dysplasias Demonstrate Altered T-helper Lymphocyte Differentiation
Daniel Merrick
University of Colorado, Anschutz Medical Campus, USA

P3.03-24: Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging
Greg Haro
University of California, USA

P3.03-23: A Propensity Score Matching Cohort Study on Prognosis of the Diversity of MUC1 Expression in Patients with Lung Adenocarcinoma
Chundong Gu
The First Affiliated Hospital of Dalian Medical University, China

P3.03-22: IL-1β as a New Early Predictive Biomarker for Non-Small Cell Lung Cancers Outcome
Carlotta Giorgi
University of Ferrara, Italy

P3.03-21: CXCR4 Overexpression is Associated with Poor Survival Outcome After Recurrence in Early Stage Non-Small Cell Lung Cancer Patients
Andrea Fung
University of Calgary, Canada

P3.03-20: IL-1α and CD8+ TILs Expressions in Patients with Surgically Resected Non-Small Cell Lung Cancer
Piyada Sitthideatphaiboon
Chulalongkorn University/King Chulalongkorn Memorial Hospital, Thailand

P3.03-19: The Lysyl Oxidase like-1 Promotes NSCLC Tumorigenecity Through Increased Matrix Reorganization and Stiffness
Cédric Zeltz
Princess Margaret Cancer Centre/UHN, Canada

P3.03-18: Collagen Type XI Promotes Lung Adenocarcinoma Dissemination Via Integrin α2 andDDR1
Cédric Zeltz
Princess Margaret Cancer Centre/UHN, Canada

P3.03-17: Roles of α7nAchR Signaling in Lung Cancer
Yu-Feng Wei
E-Da Hospital/I-Shou University, Taiwan

P3.03-16: 3D Morphometric Detection of Mismatch Repair Deficiency in Human Lung Adenocarcinoma Cell Lines using the Cell-CT® Platform
Daniel Sussman
VisionGate, USA

P3.03-15: Lung Cancer Regulation of Glucose Metabolic Stress Response
Laila Roisman
Soroka University Medical Center, Israel

P3.03-14: Downregulation of FOXM1 Inhibits Tumor Proliferation, Colony Formation and Spheroid Formation of Non-Small Cell Lung Cancer
Yoichi Otaki
University of Texas Southwestern Medical Center, USA

P3.03-13: Downregulation of miRNA-506 Mediates EGFR-TKI Resistance Through Inducing Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines
Inamul Haque
University of Kansas Medical Center, USA

P3.03-12: E-Da Hospital/I-Shou University, Taiwan
Yu-Feng Wei
E-Da Hospital/I-Shou University, Taiwan

P3.03-11: The Lysyl Oxidase like-1 Promotes NSCLC Tumorigenecity Through Increased Matrix Reorganization and Stiffness
Cédric Zeltz
Princess Margaret Cancer Centre/UHN, Canada

P3.03-10: The Prognostic Effect of Tumor Mutation Burden and Smoking History in Resected EGFR Mutant Non-Small Cell Lung Cancer
Hadas Sorotsky
Princess Margaret Cancer Centre, Canada

P3.03-09: Correlation Between PD-L1 Expression and Expression of CDK4 and SPOP in Non-Small Cell Lung Cancer
Masaaki Inoue
Shimonoseki City Hospital, Japan

P3.03-08: Identifying Resistance to Immune Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in Pts with NSCLC
Ticiana Leal
University of Wisconsin Carbone Cancer Center, USA

P3.03-07: Biomarkers

P3.03-06: Prognostic Significance of Serum CXCL12 Level in Patients with Surgical Resected Lung Adenocarcinoma
Jung-Jyh Hung
Taipei Veterans General Hospital and National Yang-Ming University, Taiwan

P3.03-05: Programmed Death-Ligand 1 of Cytology Specimens as a Promising Method for Maker Evaluation in Patients of Non-Small Cell Lung Cancer
Zhengwei Dong
Shanghai Pulmonary Hospital, China

P3.03-04: Prognostic Value of MHC-I, PD-L1 and CD8+ TILs Expressions in Patients with Surgically Resected Non-Small Cell Lung Cancer
Xu Wang
Cancer Center, The First Hospital of Jilin University, China

P3.03-03: Association of Functional Polymorphism in CTLA-4 Gene with Survival in Non-Small Cell Lung Cancer: A Brazilian Study
Marcelo Balancin
University of São Paulo, Brazil

P3.03-02: Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC
Mark Awad
Dana-Farber Cancer Institute, USA

P3.03-01: Combined Plasma cfDNA Mutations and a Serum Proteomic Signature may Identify Non-Responders to Anti PD-1 Treatment in NSCLC
Arno Amann
Medical University Innsbruck, Austria

P3.04-16: Clinical Significance of Somatic BRCA1/2 Mutations in Non-Small Cell Lung Cancer
Radiumhospitalet, Norway

P3.04-15: Downregulation of FOXM1 Inhibits Tumor Proliferation, Colony Formation and Spheroid Formation of Non-Small Cell Lung Cancer
Yoichi Otaki
University of Texas Southwestern Medical Center, USA

P3.04-14: Downregulation of miRNA-506 Mediates EGFR-TKI Resistance Through Inducing Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines
Inamul Haque
University of Kansas Medical Center, USA

P3.03-13: Downregulation of miRNA-506 Mediates EGFR-TKI Resistance Through Inducing Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines
Inamul Haque
University of Kansas Medical Center, USA

P3.03-12: E-Da Hospital/I-Shou University, Taiwan
Yu-Feng Wei
E-Da Hospital/I-Shou University, Taiwan

P3.03-11: The Lysyl Oxidase like-1 Promotes NSCLC Tumorigenecity Through Increased Matrix Reorganization and Stiffness
Cédric Zeltz
Princess Margaret Cancer Centre/UHN, Canada

P3.03-10: The Prognostic Effect of Tumor Mutation Burden and Smoking History in Resected EGFR Mutant Non-Small Cell Lung Cancer
Hadas Sorotsky
Princess Margaret Cancer Centre, Canada

P3.03-09: Correlation Between PD-L1 Expression and Expression of CDK4 and SPOP in Non-Small Cell Lung Cancer
Masaaki Inoue
Shimonoseki City Hospital, Japan

P3.03-08: Identifying Resistance to Immune Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in Pts with NSCLC
Ticiana Leal
University of Wisconsin Carbone Cancer Center, USA

P3.03-07: Biomarkers

P3.03-06: Prognostic Significance of Serum CXCL12 Level in Patients with Surgical Resected Lung Adenocarcinoma
Jung-Jyh Hung
Taipei Veterans General Hospital and National Yang-Ming University, Taiwan

P3.03-05: Programmed Death-Ligand 1 of Cytology Specimens as a Promising Method for Maker Evaluation in Patients of Non-Small Cell Lung Cancer
Zhengwei Dong
Shanghai Pulmonary Hospital, China

P3.03-04: Prognostic Value of MHC-I, PD-L1 and CD8+ TILs Expressions in Patients with Surgically Resected Non-Small Cell Lung Cancer
Xu Wang
Cancer Center, The First Hospital of Jilin University, China

P3.03-03: Association of Functional Polymorphism in CTLA-4 Gene with Survival in Non-Small Cell Lung Cancer: A Brazilian Study
Marcelo Balancin
University of São Paulo, Brazil

P3.03-02: Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC
Mark Awad
Dana-Farber Cancer Institute, USA

P3.03-01: Combined Plasma cfDNA Mutations and a Serum Proteomic Signature may Identify Non-Responders to Anti PD-1 Treatment in NSCLC
Arno Amann
Medical University Innsbruck, Austria

P3.04-16: Clinical Significance of Somatic BRCA1/2 Mutations in Non-Small Cell Lung Cancer
Radiumhospitalet, Norway

P3.04-15: Downregulation of FOXM1 Inhibits Tumor Proliferation, Colony Formation and Spheroid Formation of Non-Small Cell Lung Cancer
Yoichi Otaki
University of Texas Southwestern Medical Center, USA

P3.04-14: Downregulation of miRNA-506 Mediates EGFR-TKI Resistance Through Inducing Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines
Inamul Haque
University of Kansas Medical Center, USA
P3.04-09: Analysis of Repertoire Features of T Cell Receptor in Treat-Naive EGFR Wild-Type Lung Cancer Patients by High-Throughput Sequencing
Yangyang Liu
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

P3.04-10: Monocytes and Neutrophils as Predictive Markers of Response to Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer
Kaushal Parikh
Westchester Medical Center/New York Medical College, USA

P3.04-11: The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
Nir Peled
Soroka University Medical Center, Israel

P3.04-12: Prognostic and Predictive Role of Peripheral Blood Biomarkers in NSCLC Patients Treated with Checkpoint, a Single-Center Experience.
Domenico Galetta
Clinical Cancer Center “Giovanni Paolo II”, Bari, Italy

P3.04-13: PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)
Noemi Reguart
Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

P3.04-14: TMB and Immune Checkpoint Inhibitor Gene Expression are Unrelated in NSCLC Patients
Christopher Szeto
NantOmics, LLC, USA

P3.04-15: IDO and Tim3 Gene Expression is Correlated in NSCLC Patients with Low PD1L Gene Expression
Christopher Szeto
NantOmics, USA

P3.04-16: A Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC
Cristina Teixidó
Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

P3.04-17 - P3.04-21 Outcomes
P3.04-17: Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
Umang Ondhia
Hoffmann-La Roche Limited, Canada

P3.04-18: The Efficacy and Safety of Solid Tumors Combination Therapy with Immune Checkpoint Inhibitor: A Systematic Review and Meta-Analysis
YiMing Weng
Renmin Hospital of Wuhan University, China

P3.04-19: Do Advanced Lung Cancer Patients Derive Similar Survival Benefits from Immunotherapy? A Systematic Review and Meta-Analysis
Jacques Raphael
University of Toronto, Canada

P3.04-20: Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC
Mike Sung
Princess Margaret Cancer Centre, Canada

P3.04-21: Antibiotics Attenuate the Clinical Benefit of Anti-PD-(L)1 Immunotherapies in Chinese Patients with Advanced Non-Small Cell Lung Cancer
Sha Zhao
Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, China

P3.04-22 - P3.04-29 Trials
P3.04-22: Response of Brain Metastases in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy and Brain Directed Radiotherapy
Alessandra Curioni Fontecedro
University Hospital Zurich, Switzerland

P3.04-23: Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC
Naiyer Rizvi
Columbia University Medical Center, USA

P3.04-24: EMPOWER-Lung 2: Cemiplimab and Ipilimumab 4 Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 US0%, a Phase 3 Study
Naiyer Rizvi
Columbia University Medical Center, USA

P3.04-25: EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC with PD-L1 <50%
Naiyer Rizvi
Columbia University Medical Center, USA

P3.04-26: EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%
Naiyer Rizvi
Columbia University Medical Center, USA

P3.04-27: An Allogeneic Tumor Cell Lysate Vaccine Induces Immune Responses to Lung Cancer Associated Antigens: Preliminary Results of a Phase II Study
David Schrump
NCI/CCR/NIH, USA

P3.04-28: Can Ipilimumab Restore Immune Response in Advanced NSCLC After Progression on Anti PDI/PDL1 Agents?
Michal Sternschuss
Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Israel

P3.04-29: Efficacy of Re-Treatment with Immune Checkpoint Inhibitors in Patients with Pretreated Advanced Non-Small Cell Lung Carcinoma
Takayuki Takahama
Kindai University Faculty of Medicine, Japan

P3.07 NURSING AND ALLIED PROFESSIONALS

P3.07-01 – P3.07-06 Nursing
P3.07-01: Telephone Preassessment Clinic Incorporating Holistic Needs
Vanessa Beattie
Aintree Hospital, UK

P3.07-02: Expectations, Standards and Performance Framework to Support the Lung Cancer Support Nurse in Lung Foundation Australia
Vanessa Brunelli
Queensland University of Technology, Australia

P3.07-03: The Clinical Benefit of Anti-PD-(L)1 Targeted Therapeutics in Solid Tumors Combination Therapy with Immune Checkpoint Inhibitor: A Systematic Review and Meta-Analysis
Jacques Raphael
University of Toronto, Canada

P3.07-04: A Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC
Cristina Teixidó
Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

P3.07-05: Analysis of Repertoire Features of T Cell Receptor in Treat-Naive EGFR Wild-Type Lung Cancer Patients by High-Throughput Sequencing
Yangyang Liu
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

P3.07-06: Prognostic and Predictive Role of Peripheral Blood Biomarkers in NSCLC Patients Treated with Checkpoint, a Single-Center Experience.
Domenico Galetta
Clinical Cancer Center “Giovanni Paolo II”, Bari, Italy

P3.07-07: Telephone Preassessment Clinic Incorporating Holistic Needs
Vanessa Beattie
Aintree Hospital, UK

P3.07-08: Expectations, Standards and Performance Framework to Support the Lung Cancer Support Nurse in Lung Foundation Australia
Vanessa Brunelli
Queensland University of Technology, Australia
P3.07-03: Lung Cancer Clinical Nurse Specialist & Palliative Care Nurse Specialist - A Dual Role
Karen Clayton
East Cheshire NHS Trust, UK

P3.07-04: Massage Chair Encounters Favorably Impact Outpatient Oncology RN’s Perceived Level of Stress, BP, HR
Mary Ellen Hand
Rush University Medical Center, USA

P3.07-05: Can Improving Working Partnerships with Primary Care Prevent Avoidable Emergency Admissions for Patients with Lung Cancer?
June Morley
Kings Mill Hospital, UK

P3.07-06: Receiving a Diagnosis Of MESothelioma (RADIO Meso): Recommendations for Practice to Improve the Patient Experience
Bethany Taylor
The University of Sheffield, UK

P3.07-07: Multidisciplinary Supportive Care Assessment in Lung Cancer – A Case Study Example
Faye Dickinson
Guy’s and St Thomas’ NHS Foundation Trust, UK

P3.07-08: Pain Management in Lung Cancer
Abdallah El Meziane
Cheikh Khalifa Ibn Zayd Hospital, Morocco

P3.07-09: Characterization of the Nutritional Status in Lung Cancer Patients: A Retrospective Study
Henrique Queiroga
Hospital São João, Portugal

P3.07-10: What Do People Living with Lung Cancer Want and Need from the Recovery Package
Josie Roberts
The Rotherham NHS Foundation Trust, UK

P3.07-11: Survivorship After Lung Cancer Surgery – SOLACE – A Macmillan Funded Project
Charlotte Merriman
Oxford University Hospitals, UK

P3.07-12: Improving Cardiac Tamponade Outcomes Through Less Invasive Interventions and Earlier Recognition
Kristie Murphy
Memorial Sloan Kettering Cancer Center, USA

P3.07-13: Non-Oncology Provider Immunotherapy Needs Assessment
Enza Nguyen
St. Joseph Hospital, USA

P3.07-14: Collaborations of Pharmacists with Lung Cancer Treatment by Prepared Patients Controlled Analgesia (PCA) for Perioperative Pain Control
Kumiko Tani
Kagawa University Hospital, Japan

P3.08 OLIGOMETASTATIC NSCLC

P3.08-01: Treatment Outcomes in Oligometastatic Disease of Non Small Cell Lung Cancer: A Single Center Experience
Pinar Akın Kabalak
Ankara Atatürk Chest Disease and Thoracic Surgery Training and Research Hospital, Turkey

P3.08-02: Oligometastatic Non Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy (SBRT), a Single Institution Experience
Davide Franceschini
Humanitas Clinical and Research Center, Italy

P3.08-03: Stereotactic Radiotherapy of Lung Cancer with Synchronous Bilateral Noduli or Oligometastatic Disease
Tine Schytte
Odense University Hospital, Denmark

P3.08-04: OMEGA, A Randomized Trial of Local Ablative Therapy Vs. Conventional Treatment in Oligometastatic NSCLC – Trial in Progress
Maurizio Infante
University and Hospital Trust - Ospedale Borgo Trento, Italy

P3.08-05: Stereotactic Body Radiation Therapy (SBRT) Outcomes in Elderly Patients with Lung Oligometastases
Luis Larrea
Hospital NISA Virgen del Consuelo, Spain

P3.08-06: Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors
Oscar Juan-Vidal
Hospital Universitari i Politècnic La Fe, Spain

P3.08-07: An Institution Review of Outcomes of Lung Stereotactic Body Radiotherapy in Various Oligometastatic Disease States
Brendan Chia
National Cancer Centre, Singapore, Singapore

P3.08-08: Outcomes of Pulmonary Metastasectomy in Breast Cancer: Prognosis Based on the Metastatic Lung Tumor Study Group of Japan
Makoto Endoh
Yamagata Prefectural Central Hospital, Japan

P3.08-09: Surgical Resection of Pulmonary Oligo-Recurrence of Non-Small Cell Lung Cancer
Yoshitaka Kitamura
Hyogo Cancer Center, Japan

P3.08-10: A Retrospective Study of Oligo-Recurrence in Patients with Resected Non-Small Cell Lung Cancer
Taku Nakagawa
Omagari Kosei Medical Center, Japan

P3.08-11: Differences in Evaluations of Early Thorax CT’s Post Lung Stereotactic Body Radiotherapy (SBRT)
Fazilet Oner Dincbas
Istanbul University Cerrahpasa Medical Faculty, Turkey

P3.08-12: Long-Term Outcome After Adrenalectomy for Isolated Adrenal Metastasis in Otherwise Operable Patients With NSCLC - Two Institutions Study
Danail Petrov
Saint Sophia University Hospital for Active Treatment of Pulmonary Diseases, Bulgaria

P3.08-13: Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series
Rodney Wegner
Allegheny Health Network Cancer Institute, USA

P3.08-14: Long-Term Survival Following Surgical Resection of Isolated Brain Metastasis in Non-Small Cell Lung Cancer
Wen-jiu Wu
Mackay Memorial Hospital, Taiwan

P3.08-15: Lung Squamous Cell Carcinoma with Solitary Ocular Metastasis, Successful Treatment: An Interesting and Rare Case Report
Ye Guo
The First Hospital of Jinlin University, China
P3.08-16: Prognostic Value of PDL-1 Expression and Correlation Between Primary Tissue and Brain Metastases in Oligometastatic NSCLC
Vimal Krishnan
CHUM, Canada

P3.08-17: Paediatric Motion Management Solutions for Particle Therapy Based Thoracic Stereotactic Ablative Body Radiotherapy (SABR)
Fiona Hegi-Johnson
Peter MacCallum Cancer Centre, Australia

P3.08-18: Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT
Edyta Urbanska
University of Copenhagen, Rigshospitalet, Finsens Center, Denmark

P3.08-18a - MR Perfusion and Spectroscopy to Distinguish Radiation Necrosis from Tumor Progression for Brain Metastases Treated with SRS
Christel de Poorter
Iridium Cancer Network / University of Antwerp, Belgium

Cristian Ortiz-Villalón
Karolinska University Hospital, Sweden

P3.09-06: The Link Between Tumor Promoting Fibrous Microenvironment and Immunosuppressive Microenvironment in Stage I Lung Adenocarcinoma
Takashi Sakai
National Cancer Center Hospital East, Japan

P3.09-07: Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer
Negar Rassaei
Penn State Hershey Medical Center, USA

P3.09-08 - P3.09-20 Molecular
P3.09-08: Tumor Heterogeneity and Molecular Profile of NSCLC in Thai Population
Thanyanan Reungwetwattana
Ramathibodi Hospital, Thailand

P3.09-09: “Prevalence of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Carcinoma Lungs at a Cancer Center in Nepal”
Banita Gurung
Nepal Cancer Hospital And Resaearch Center, Nepal

P3.09-10: Circulating Cell-Free DNA (cfDNA) Molecular Profile of Thai NSCLC Patients Using Difference Variant Frequency of NGS
Nareeart Iemwimangsa
Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand

P3.09-11: Genomic Organization at Large Scales (GOALS) within Nuclei and Cell Sociology for Predicting Lung Cancer Outcomes
Calum Macaulay
British Columbia Cancer Agency Research Centre, Canada

P3.09-12: Molecular and Immunohistochemical Correlates of RB1 Inactivation in Small Cell Lung Carcinoma
Navin Mahadevan
Brigham and Women’s Hospital, USA

P3.09-13: Molecular Profiling Suggests the Different Mechanisms Among Local Invasiveness in Resected Human Lung Adenocarcinoma
Toshi Menju
Graduate School of Medicine, Kyoto University, Japan

P3.09-14: Pathobiology of Notch2 in Lung Cancer
Yamato Motooka
Toronto General Hospital, Univeristy of Toronto, Canada

P3.09-15: Genetic Profiling of Idiopathic Pulmonary Fibrosis Associated Non-Small Cell Lung Cancer by Targeted Next-Generation Sequencing
Kohei Otsubo
Cancer Center, Kyushu University Hospital, Japan

P3.09-16: Transcriptome Profiling for Subtyping NSCLC: Off the Beaten Path(Ologist)
Lars Petersen
University of Calgary, Canada

P3.09-17: Molecular Profile in Lung Adenocarcinoma. A Muticenter Study in Cordoba, Argentina.
Norma Pilnik
Cordoba University, Argentina

P3.09-18: Identification of MET exon 14 Skipping Mutations by FusionPlexTM Solid Tumor Panel
Laura Tafe
Dartmouth-Hitchcock Medical Center, USA

P3.09-19: Matched Thai Lung Cancer Patients Tissue and cfDNA Molecular Profile by NGS
Narumol Trachu
Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand

P3.09-20: A Simple and Versatile Next-Generation Sequencing Technology for Co-Detection of RNA Structural Variants and DNA Mutations in Lung Cancer
Huiping Zhu
Asuragen Inc., USA

P3.09-21 - P3.09-27 Pathology
P3.09-21: Mixed Mucoepidermoid Carcinoma and Adenocarcinoma of the Lung: A Case Report and a Literature Review
Yu-Deok Choi
Chonnam National University Medical School, Korea
P.3.09-22: Correlation Between Maximum Tumour Diameter Measurement on CT-Scan and Histopathological Specimen: An Indian Experience
Manoj Gowda
All India Institute of Medical Sciences, New Delhi, India

P.3.09-23: Accuracy and Reproducibility of Touch Imprint Cytology in Resected Lung Cancer
Masatoshi Kakihana
Tokyo Medical University, Japan

P.3.09-24: The Concordance of Histological Diagnosis from Transbronchial Biopsy and Resected Specimen of Lung Cancers
Yoshiteru Kidokoro
Tottori University Hospital, Japan

P.3.09-25: Survival Analysis in Young Adults with Lung Carcinoma
Jessica Nicolau
Centro de Investigação Translacional em Oncologia (CTO), Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Brazil

P.3.09-26: Concordance of Surgical Resections and Fine Needle Biopsy-Derived Cell Block Sections for PD-L1 22C3 Immunohistochemistry
Joerg Schwock
University Health Network, Canada

P.3.09-27: Histopathologic Parameters Define Features of Treatment Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer
Annikka Weissferdt
The University of Texas MD Anderson Cancer Center, USA

P.3.11-01: Methylation Markers That Correlate with Occult Lymph Node Metastases of NSCLC and a Preliminary Prediction Model
Wenhua Liang
The First Affiliated Hospital of Guangzhou Medical University; China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, China

P.3.11-02: Lung Cancer Screening in a High Incidence Population: Results of Low-Dose CT Screenings in a Northern Kentucky Community Healthcare System
Royce Calhoun
St. Elizabeth Healthcare, USA

P.3.11-03: Implementing Lung Cancer Screening in Canada: Evidence on Adherence and Budget Impact from the Pan-Canadian Early Detection Study
Sonya Cressman
The British Columbia Cancer Agency, Canada

P.3.11-04: Trends and Barriers in Lung Cancer Screening Implementation Across the United States.
Jennifer King
Lung Cancer Alliance, USA

P.3.11-05: Use of Electronic Medical Record (EMR)-Embedded Clinical Decision Support Tools Improves Lung Cancer Screening Rates
John Doty
Atrium Health, USA

P.3.11-06: Improving Lung Cancer Screening Completion Rates in a Primary Care Practice in Large Urban Academic Medical Center
Linda Dowling
Rush University Medical Center, USA

P.3.11-07: The Quality of Screening: Comparing the Rush Lung Cancer Screening Program to the NLST and the VA Lung Cancer Screening Demonstration Project
Linda Dowling
Rush University Medical Center, USA

P.3.11-08: Lung Cancer Screening at an Academic Medical Center: Early Patterns of Practice
Linda Dowling
Rush University Medical Center, USA

P.3.11-09: Shared Decision Making: A Decision Aid for the Primary Practitioner
Fred Grannis
City of Hope National Medical Center, USA

P.3.11-10: Lung Cancer Screening Shared Decision Making: Decision-Aid for the Patient
Fred Grannis
City of Hope National Medical Center, USA

P.3.11-11: Improving Timeliness of Lung Cancer Diagnostic Services with the Implementation of Coordinated Care via a “Navigation Day”
Michael Gulak
University of Ottawa, Canada

P.3.11-12: Comparison of Cancer Screening Adherence According to Smoking Status: Korean National Health and Nutrition Examination Survey 2010-2012
Yong Saing Kim
Gachon University Gil Medical Center, Korea

Martin Ledson
Liverpool Heart & Chest, UK

P.3.11-14: Low Rates of Lung Cancer Screening Among Doctors in Mexico
Omar Macedo-Pérez
Instituto Nacional de Cancerología, Mexico

P.3.11-15: Lung Cancer Symptom Perception and Intervention Preferences in the UK’s Most Deprived Communities: A Qualitative Study
Kate Brain
Cardiff University, UK

P.3.11-16: Comparative Analysis of Health-Care Resources and Economic Costs of Lung Cancer Patients Treated Medically or Surgically in Catalunya
Laureano Molins
Hospital Clinic of Barcelona, Spain

P.3.11-17: Gender Comparison in Lung Cancer Screening
Simran Randhawa
Einstein Medical Center, USA

P.3.11-18: Implementing One Stop Lung Clinic to Improve Diagnostic Timeliness in Lung Cancer Patients in the North of England
Vytis Dudzevicius
James Cook University Hospital, UK

P.3.11-19: Improving Lung Cancer Screening Rates in an Underserved Outpatient Clinic
Carlos Rodriguez
Mount Sinai Beth Israel Hospital, USA

P.3.11-20: Patterns and Predictors of Adherence to Recommended Follow-Up After Low-Dose Computed Tomography Screening for Lung Cancer
Lori Sakoda
Kaiser Permanente Northern California, USA

P.3.11-21: The Development of a Robust Radiology Quality Assurance (QA) Program in a Provincial High-Risk Lung Cancer Screening Pilot (HRL CSP)
Heidi Schmidt
Cancer Care Ontario, Canada

P.3.11-22: The Path to National Lung Cancer Screening Program in Israel
Shani Shilo
Israel Lung Cancer Foundation, Israel

P.3.11-23: Adherence to Annual Low-Dose CT Lung Cancer Screening at a Large Academic Institution
Lucy Spalluto
Vanderbilt University Medical Center, USA
P3.12 SMALL CELL LUNG CANCER/NET

P3.12-01 – P3.12–09 New Target/Biology

P3.12-01: Targeting Mitochondrial Metabolism as a Selective Therapeutic Approach in Small Cell Lung Cancer (SCLC)  
Shantanu Banerji  
CancerCare Manitoba, Canada

P3.12-02: Dynamics of DLL3 and ASCL1 Expression in SCLC Over Disease Course  
Anna Farago  
Massachusetts General Hospital Cancer Center, USA

P3.12-03: Targeting DLL3 with AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC  
Michael Giffin  
Amgen Inc., USA

P3.12-04: Linc00173 Modulates Chemoresistance of Small Cell Lung Cancer by Binding hnRNPA2B1 and hnRNPI to Regulate CHK2 Level  
Linliang Guo  
Zhujiang Hospital, Southern Medical University, China

P3.12-05: The Pattern of PD-L1 Expression in Thoracic Neuroendocrine Tumors  
Nagla Karim  
University of Cincinnati, USA

P3.12-06: SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study  
Taofeek Owonikoko  
Emory University, USA

P3.12-07: MicroRNA Deregulation in a Typical Carcinoid Tumor: Potential Role of Immune Response and Invasion in Tumorigenesis  
Ana Seneda  
São Paulo State University (UNESP), Faculty of Medicine, Botucatu, Brazil

P3.12-08: The Role of Contactin 1 on Acquired Resistance to Pegylated Arginase in Small Cell Lung Cancer  
Sheng Yan  
The University of Hong Kong, Hong Kong

P3.12-09: Smad4 Mutation Confers Acquired Neuroendocrine Phenotype in Transformation of Lung Adenocarcinoma to Small Cell Lung Cancer  
Jie Zhang  
Shanghai Pulmonary Hospital, China

P3.12-10 – P3.12–14 Other

P3.12-10: Immunogenomic Characteristics of SCLC and LCNEC Redefined Molecular Subgroups  
Xue-Tao Li  
School of Medicine, South China University of Technology, China

P3.12-11: Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients  
Laura Mezquita  
Gustave Roussy, France

P3.12-12: Genomic Profiling of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC) Reveals Distinct Mutational Landscape  
Lin Wu  
Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, China

Hui Yu  
University of Colorado Anschutz Medical Campus, USA

P3.12-14: Genomic Profiling of Chinese Small Cell Lung Cancer and the Implications for Therapy  
Hong Zhong  
People’s Hospital of Beihai, The 9th Affiliated Hospital of Guangxi Medical University, China

P3.12-15 – P3.12-17 Radiology/Staging

P3.12-15: 68 Ga DOTA PET/CT in Staging of Broncho-Pulmonary Carcinoid Tumors. Is there a Real Benefit?  
George Karimundackal  
Tata Memorial Hospital, India

P3.12-16: Prognostic Impact of M Descriptors of the 8th Edition of TNM Classification for Extensive Disease-Small Cell Lung Cancer  
Masayuki Shirasawa  
Kitasato University School of Medicine, Japan

P3.12-17: A Retrospective Study Examining the Role of PET-CT in the 8th TNM Staging System of SCLC  
Salomon Tendler  
Karolinska Institutet, Sweden

P3.13 TARGETED THERAPY

P3.13-01 – P3.13–07 ALK

P3.13-01: Detecting ALK Rearrangements in NSCLC Patients: IHC, FISH or NGS Fusion?  
Alfredo Addeo  
HUG, Switzerland

P3.13-02: Lymphocytic Pleural Effusion Due to Crizotinib Usage: First Case in Literature  
Pinar Akın Kabalak  
Ankara Atatürk Chest Disease and Thoracic Surgery Training and Research Hospital, Turkey

A. John Iafrate  
Massachusetts General Hospital, USA
P3.13-04: Lorlatinib in Anaplastic Lymphoma Kinase and Proto-Oncogene Tyrosine-Protein Kinase ROS-Positive Non-Small Cell Lung Cancer
Marthe Paats
Erasmus MC, Netherlands

P3.13-05: Use of Crizotinib in a Patient with a Ros Mutation Causing Elevated CPK and Resulting in Dose Limiting: Case Report
Ana Cecilia Vasconcelos
IMIP, Brazil

P3.13-06: Analysis of ALK Rearrangement Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion
Chunwei Xu
 Fujian Cancer Hospital, China

P3.13-07: The Effect of Crizotinib in Patients of Non Small Cell Lung Cancer with Brain Metastases: A Retrospective Analysis
Jiexia Zhang
State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, China

P3.13-08 – P3.13-24 EGFR

P3.13-08: Assessment of EGFR Gene Mutations In cf-DNA in Monitoring of Response to EGFR TKIs in Patients with Lung Adenocarcinoma
Kamila Wojas-Krawczyk
Medical University, Poland

P3.13-09: ALTER-0303 Study: Tumor Mutation Index (TMI) For Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line
Baohui Han
Shanghai Chest Hospital, China

P3.13-10: Factors Associated with Long-Term Survival of Stage IV NSCLC Patients on First-Line EGFR-Targeting Therapy
Amanda Gibson
University of Calgary, Canada

P3.13-11: Advanced Nsc1 with Gefitinib or Erlotinib for Five or Longer - Retrospective Slovakian Study
Peter Berzinec
Specialised Hospital of St Zorardus Zobor, Slovakia

P3.13-12: A Lung Adenocarcinoma with Concomitant EGFR and de novo MET Amplification Response Well to Combination of TKI and Bevacizumab
Qian Chu
Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, China

P3.13-13: Afinatinib in Lung Adenocarcinoma Harboring de novo EGFR Exon 20 Insertions
Marcos Costa
Osvaldo Cruz Hospital, Brazil

P3.13-14: Identification of Novel Mutations by High-Throughput Sequencing in T790M Wildtype/cMET Unamplified NSCLC with Acquired Resistance to EGFR TKIs
Chenguang Li
Tianjin Medical University Cancer Institute and Hospital, China

P3.13-15: First-Line Afinatinib Dose Initiation and Adjustment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Chong-Kin Liam
University of Malaya, Malaysia

P3.13-16: Concomitant EML4-ALK Rearrangement and EGFR Mutation in Non-Small Cell Lung Cancer Patients: Data from Eastern Indian Hospital
Prasanta Mohapatra
All India Institute of Medical Sciences, India

P3.13-17: A Retrospective Study: Central Nervous System Response to Osimertinib in Patients with Advanced NSCLC
Yuxin Mu
National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, China

P3.13-18: Mechanisms of Acquired Resistance to Afinatinib Clarified with Liquid Biopsy
Tomomi Nakamura
Saga University, Japan

P3.13-19: Surgery for cIIIB Lung Adenocarcinoma After Response to Erlotinib, Survival and Management of Postoperative Oligoprogressions
Danail Petrov
Saint Sophia University Hospital for Active Treatment of Pulmonary Diseases, Bulgaria

P3.13-20: Frequency of EGFR Mutations in Patients with Adenocarcinoma Lung Cancer. Comparative Study Between Public and Private Mexican Health Services
Jeronimo Rodriguez-Cid
Instituto Nacional de Enfermedades Respiratorias, Mexico

P3.13-21: Apatinib Plus Icotinib as First-Line Therapy For EGFR Co-Mutations NSCLC in Chinese Patients: An Exploratory Study
Yanhong Shang
Affiliated Hospital of Hebei University, China

P3.13-22: Real World Study of Afinatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer
Hisashi Tanaka
Hirosaki University, Japan

P3.13-23: EGFR-TKIs Combined Hydroxyacamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion
Xiyi Lu
The First Affiliated Hospital of Nanjing Medical University, China

P3.13-24: Efficacy of EGFR-TKIs Compared with Chemotherapy as First-Line Therapy in Patients with EGFR Rare Mutation Advanced Lung Adenocarcinoma
Huijuan Wang
Henan Cancer Hospital, China
P3.13-29: Patient-Derived Xenograft Models (PDX) of Lung Squamous Cell Carcinoma (SCC) for Preclinical Studies
Tae Ho Kim
Samsung Medical Center, Korea

P3.13-30: Driver Mutation in Heavy Smoker Patient with Squamous Cell Carcinoma Metastatic Lung Cancer: Case Report
Bárbara Maria Luz
IMIP, Brazil

P3.13-31: Creating a Precision Medicine Pipeline for Lung Cancers
Paola Marignani
Dalhousie University Tupper Medical Building 9F1, Canada

P3.13-32: Drug Sensitivity of Lung Adenocarcinoma Towards Inducers of Epigenetic Modifications
Isabelle Moneke
Medical Center - University of Freiburg, Germany

P3.13-33 - P3.13-35 Rare Targets

P3.13-33: Lung Adenocarcinoma Harboring RET Fusion and Dramatic Response to Combination of Vandetanib (VAN) and Everolimus (EVE): A Case Report from Brazil
Carolina Haddad
BP - A Beneficencia Portuguesa de Sao Paulo, Brazil

P3.13-34: RET Gene, a New Choice for NSCLC
Yinghui Xu
The First Bethune Hospital of Jilin University, China

P3.13-35: Antitumor Effect of Neratinib Targeting HER2-Altered Lung Cancer
Yusuke Ogoshi
Okayama University Graduate School of Medicine, Japan

P3.15-02: Carboplatin Dose Calculated Using Different Formula for eGFR and Their Comparison with Actual Dose Administered in Lung Cancer Patients
Digambar Behera
Postgraduate Institute of Medical Education and Research (PGIMER), India

P3.15-03: Capturing the Patient Experience for the Treatment of EGFR Exon 20 Mutations in Non-Small Cell Lung Cancer
Aaron Galaznik
Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, USA

P3.15-04: An Interdisciplinary Educational Program Dedicated to Non-Small Cell Lung Cancer Patients to Improve their Quality of Life
Laurence Bigay-Gamé
LARREY Hospital, France

P3.15-05: Patient Reported Outcomes (PROs) as Performance Measures After Surgery for Lung Cancer
Majken Brenserud
University of Southern Denmark, Denmark

P3.15-06: Capillary Leak Syndrome in a Primary Lung Adenocarcinoma Patient with Thrombocytopenia from Interleukin-11 Treatment
Huafei Chen
Zhejiang Rongjun Hospital, China

P3.15-07: A Literature Review and Assessment of Lung Cancer Quality Indicators
Kim-Lin Chiew
Sydney West Cancer Network, Australia

P3.15-08: Patient-Reported Outcomes (PROs) in Patients with Lung Resection: Open Versus Minimal Invasive Surgery
Quiling Shi
University of Texas MD Anderson Cancer Center, USA

P3.15-09: Are Lung Cancer Patients Receiving Education Materials? The Healthcare Provider Perspective on Distribution Gaps and Possible Solutions
Andrea Ferris
LUNGevity Foundation, USA

P3.15-10: Survival Impact of Peripheral Blood Ratios in Lung Cancer According Clinical Stage
Claudio Flores
Oncosalud - AUNA, Peru

P3.15-11: Association Between Peripheral Blood Ratios and Clinical Stage Disease in Lung Cancer
Claudio Flores
Oncosalud - AUNA, Peru

P3.15-12: Survival Impact of Patient Enrollment in Antineoplastic Drug Trials for Stage IV Non-Small Cell Lung Cancer (NSCLC)
Bernardo Goulart
Fred Hutchinson Cancer Research Center, USA

P3.15-13: Surgical Management of Huge Pulmonary Arteriovenous Malformations: Our Experience
Fadil Gradica
University Hospital Shefqet Ndroqi, Albania

P3.15-14: Using Creative Co-Production to Develop a Treatment Decision Support Tool for People with Malignant Pleural Effusion
Angela Tod
University of Sheffield, UK

P3.15-15: ALI Could Be a One of Prognostic Survival Factor for Non-Small Cell Lung Cancer Patients
Yoichiro Hamamoto
National Hospital Organization West Saitama Central Hospital, Japan

P3.15-16: Management of Patients with ALK-Translocated NSCLC: A Simulation-Based Assessment of Medical Oncologists’ Practice Decisions
Emily Van Laar
Medscape Education, USA

P3.15-17: Lung Cancer Symptom Burden and Quality of Life: Findings from the Cancer Experience Registry
Julie Olson
Cancer Support Community, USA

P3.15-18: Comparison of Pain Control Effects and Side Effects Early After VATs Lobectomy Between IV-PCA, Epidural-PCA and On-Q
Joonho Jung
Ajou University School of Medicine, Korea

P3.15-19: Risk Factors for Osteoporosis in Lung Cancer Patients
Kyung Ho Kang
Korea University College of Medicine, Korea

P3.15-20: Palliative Sedation in Lung Cancer Patients Whom Needs Immediate or Elective Intractable Symptom Control
Fatih Kose
Baskent University, Turkey
P3.15-21: Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Chong-Kin Lam
University of Malaya, Malaysia

Akihiro Nagoya
Osaka University Graduate School of Medicine, Japan

P3.15-23: Data Mining the Internet and Crowdsourcing in Guiding Patient Decision-Making
Shaneel Pathak
Caregiver to NSCLC patient, Canada

Thanynan Reungwetwattana
Ramathibodi Hospital, Thailand

P3.15-25: Assessment of Depression Among Advanced Stage Lung Cancer Patients in Developing Country
Guru Sah
B. P. Koirala Memorial Cancer Hospital, Nepal

P3.15-26: Safety of Nivolumab in Thoracic Malignancies: Results from a Single Institution in Bangladesh
Md Shuayb
Square Hospitals Ltd., Bangladesh

P3.15-27: Initial Response to First Line Treatment is the Best Predictor of the Patient Survival in Advanced NSCLC
Nazim Turhal
Anadolu Medical Center, Turkey

P3.15-28: Prognostic Nutritional Index for Predicting Postoperative Complications After Surgery Thoracic Tumor Involving the Neighboring Structures
Isamu Watanabe
Juntendo University School of Medicine, Japan

P3.15-29: Defining the Symptom Burden of Non-Small Cell Lung Cancer
Meagan Whisenant
The University of Texas MD Anderson Cancer Center, USA

P3.15-30: Treatment Patterns and Survival of Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) in the Era of Novel Therapies
Dimas Yusuf
Cross Cancer Institute, Canada

Yongchang Zhang
Hunan Cancer Hospital, China

P3.16-01 – P3.16-11 Other

P3.16-01: A Multi-Omic Study Reveals BTG2 as a Reliable Prognostic Marker for Early-Stage Non-Small Cell Lung Cancer
David Christiani
Harvard School of Public Health, USA

P3.16-02: Phase III Study of Canakinumab (ACZ885) as Adjuvant Therapy in Patients with Surgically Resected NSCLC
Edward Garon
David Geffen School of Medicine at UCLA/TRIO-US Network, USA

P3.16-03: Uncommon EGFR Mutations as a Worse Prognostic Factor for Surgically Resected Lung Adenocarcinoma
Kazuhiro Ikeda
Sakaide Citizen Hospital, Japan

P3.16-04: Comparison of 2D and 3D Consolidation to Tumor Ratios to Predict Less Invasive Lung Adenocarcinoma
Toshihiro Ikeda
Sakaide Citizen Hospital, Japan

P3.16-05: A Nanotechnology-Enabled Strategy for Image-Guided Transbronchial and Transpleural Photothermal Therapy of Peripheral Lung Cancer
Tomonari Kinoshita
Yokohama Medical Center, Japan

P3.16-06: Does Comprehensive Mutation Analysis Add Prognostic Value in Resected Early Stage Lung Adenocarcinoma?
Peter Kneuerz
The Ohio State Wexner Medical Center, USA

P3.16-07: The Impact of Clinical and Molecular Profile of Resected EGFR-Mutant Non-Small Cell Lung Cancer on the Risk of Developing Brain Metastases
Moskovitz
Rambam Health Care Campus, Israel

P3.16-08: Baseline Quality of Life is Influenced by the Duration of Abstinence from Smoking in Candidates to Lung Cancer Surgery
Cecilia Pompili
University of Leeds, UK

P3.16-09: High Preoperative D-Dimer Level Predicts Early Recurrence After Surgery for Non-Small Cell Lung Cancer
Yuki Shinya
Chiba University Graduate School of Medicine, Japan

P3.16-10: Radiomic Features on CT are Prognostic of Recurrence as well as Predictive of Added Benefit of Adjuvant Chemotherapy in ES-NSCLC
Pranjal Vaidya
Case Western Reserve University, USA

P3.16-11: Pattern of Recurrence of Completely Resected Lung Adenocarcinoma Varies According to EGFR Mutation Status
Katsuya Watanabe
Yokohama Medical Center, Japan

P3.16-12 – P3.16-19 Radiation Oncology

P3.16-12: Standard Conventional Lobectomy vs Stereotactic Body Radiotherapy in Patients with Early Stage Non-Small Cell Lung Cancer (NSCLC) – A Review
Prakash Balakrishnan
Wellington Regional Hospital, New Zealand

P3.16-13: Long-Term Outcomes of Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer in Patients Less Than 70 Years of Age
Zhe Chen
University of Yamanashi Hospital, Japan

P3.16-14: SBRT in Early Stages of Lung Cancer
Luis Fernández Fornos
Hospital General Universitario de Elche, Spain

P3.16-15: Kinetic Energy Distribution for Gated Technique at Lung Ablative Body Radiotherapy (SABR)
Kaile Li
John R Marsh Cancer Center, USA

P3.16-16: Long Term Outcomes of Body Gamma-Ray Ablative Radiotherapy for Patients with Stage I/II Non-Small Cell Lung Cancer
Hongqi Li
Airforce General Hospital, China
P3.16-17: Cardiac Sparing in Stereotactic Body Radiotherapy of Early Stage NSCLC Patients
Jose Belderbos
The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Netherlands

P3.16-18: Modern Radiotherapy Increases Patient Access to Curative Intent Radiotherapy in Non-Small Cell Lung Cancer
Karen Tumelty
Northern Ireland Cancer Centre, UK

P3.16-19: Clinical Outcomes of Stereotactic Body Radiation Therapy for T2N0M0 Non-Small Cell Lung Cancer
Yaping Xu
Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P3.16-20 – P3.16-48 Surgery

P3.16-20: Feasibility of Limited Resection for Peripheral Small-Sized Non-Small Cell Lung Cancer According to FDG Accumulation and Imaging Findings
Masato Aragaki
Hokkaido University Graduate School of Medicine, Japan

P3.16-21: Robotic Thoracic Surgery in Lung Cancer Resection – A Comprehensive Review
Prakash Balakrishnan
Wellington Regional Hospital, New Zealand

P3.16-22: Wedge Resection for Small Pulmonary Lesions with Preoperative Bronchoscopic Barium Marking
Tatsuo Furuya
Otsu City Hospital, Japan

Fadil Gradica
University Hospital Shefqet Ndroqi, Albania

P3.16-24: Prognostic Value of Positive Lymph Node Ratio in Non-Small Cell Lung Cancer
Jiaxi He
Guangzhou Medical University First Affiliated Hospital, China

P3.16-25: Impact of Diabetes Mellitus on Survival Outcome in Patients with Pathological Stage IA Non-Small Cell Lung Cancer
Shunki Hirayama
Juntendo University School of Medicine, Japan

P3.16-26: Anatomic Segmentectomy in Stage I Non-Small-Cell Lung Cancer Reveals Equivalent Long-Term Outcomes Compared to Lobectomy
Alireza Hoda
Medical University of Vienna, Austria

P3.16-27: Clinical Outcome of Preoperative Intervention Bronchoscopy Followed by Surgery
Yasufumi Kato
Kanto Central Hospital, Japan

P3.16-28: Surgery of Stage I Non-Small Cell Lung Cancer in Patients Aged 70 Years or Older
Osamu Kawamata
Onomichi Municipal Hospital, Japan

P3.16-29: Prediction of Lymph Node Metastases in Clinical T1aN0M0 Non-Small Cell Lung Cancer
Tung-Ming Tsai
National Taiwan University Hospital and National Taiwan University College of Medicine, Taiwan

P3.16-30: The Impact of the Surgical Approach on Lymph Node Upstaging in Curative Intent Lung Cancer Surgery
Khaled Mardanzai
University Clinic Essen, Germany

P3.16-31: Younger Patients Operated for Lung Cancer Have Better Overall Survival
Tomasz Marjanski
Medical University of Gdańsk, Poland

P3.16-32: A Study of Postoperative Recurrence in Pathological Stage I Non-Small Cell Lung Cancer Patients
Kotaro Mizuno
Department of Thoracic Surgery, Nagoya City East Medical Center, Japan

P3.16-33: Characteristics and Risk Factors of Recurrence After Segmentectomy in Patients With Clinical Stage I Non-Small Cell Lung Cancer
Akihiro Nakamura
Niigata University, Japan

P3.16-34: The Impact of Preoperative Exercise Therapy on the Surgical Outcomes of Patients with Lung Cancer and COPD: A Systematic Review and Meta-Analysis
Wu Nan
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

P3.16-35: Stair Climbing Exercise May Ameliorate Pulmonary Function Impairment in Patients at One Month After Lung Cancer Resection
Wu Nan
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

P3.16-36: Adjuvant Chemotherapy May Improve the Outcome of Patients with Non-Small-Cell Lung Cancer with Metastasis of Intrapulmonary Lymph Nodes
Wu Nan
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

P3.16-37: Comparison of Long-Term Outcomes Between VATS and Open Lobectomies for Stage I NSCLC: Propensity Score-Matching Analysis
Risa Oda
Nagoya City University Graduate School of Medical Sciences, Japan

P3.16-38: Systematic Review and Meta-Analysis of Methods to Predict Postoperative Lung Function Following Lung Cancer Resection
Nicola Oswald
University of Birmingham, UK

P3.16-39: Which Surgery for Ground Glass Opacity Lung Nodules?
Sara Ricciardi
University of Pisa, Italy

P3.16-40: Delayed Cut-End Recurrence After Wedge Resection for Pulmonary Ground-Glass Opacity Adenocarcinoma
Keigo Sekihara
National Center for Global Health and Medicine, Japan

P3.16-41: Postoperative Pembrolizumab for the Patients with Pathologic Stage I Adenocarcinoma with Solid or Micropapillary Pattern
Sumin Shin
Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea

P3.16-42: Early Stage Non-Small Cell Lung Cancer Survival in a Chilean Private Teaching Hospital
Francisco Suárez
Clínica Santa María, Chile
P3.16-43: Is Sublobar Resection for Stage I Invasive Adenocarcinoma (M2-cm) Feasible?  
Yuriko Terada  
The University of Tokyo Hospital, Japan

P3.16-44: Robotic-Assisted Thoracic Surgery for Early-Stage Non-Small-Cell Lung Cancer: Initial Experience in Brazil  
Ricardo Terra  
Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Instituto do Câncer do Estado de São Paulo; Hospital Sirio Libanes; Hospital Israelita Albert Einstein, Brazil

P3.16-45: The Rates and Survival of Surgically-Resolved Second Primary Lung Cancers in Patients Undergoing Resection of an Initial Primary Lung Cancer  
John Varlotto  
University of Massachusetts, USA

P3.16-46: The Comparison Between Non-Intubated and Intubated Thoracoscopic Resection for Pulmonary Nodule: A Meta-Analysis  
Yaokai Wen  
The First Affiliated Hospital of Guangzhou Medical University, China

P3.16-47: Analysis of The Novel Chest Tube (Coaxial Drain) for Lung Cancer Surgery  
Masahiko Harada  
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P3.16-48: Is Preoperative SUV(Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer?  
Perran Yumuk  
Marmara University Medical School, Marmara University Pendik Training & Research Hospital, Turkey

P3.17 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC

P3.17-01: PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients from Brazil  
Marclesson Alves  
Pronutrir Oncology Hospital, Brazil

P3.17-02: Increasing Radiation Dose to Central Structures is Associated with Worse Survival Following Thoracic Proton Reirradiation  
Jessika Contreras  
Washington University School of Medicine, USA

P3.17-03: Survival and Side Effects in Non-Small Cell Lung Cancer Patients Treated with Combination of Chemotherapy and Conformal Radiotherapy  
Simonida Crvenkova  
University Clinic of Radiotherapy and Oncology, Macedonia

P3.17-04: Dealing with the N2 Disesase in Non-Small Cell Lung Cancer- on the Edge  
Soo-Youn Ham  
Kangbuk Samsung Medical Center, Korea

P3.17-05: Multimodality Treatment for Superior Sulcus Non-Small-Cell Lung Carcinomas  
Masaahiko Harada  
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P3.17-06: Impact of Integrating PET-CT in Radiotherapy Planning of Non Small Cell Carcinoma Lung: Dosimetric and Radiobiological Comparison  
Rakesh Kapoor  
Postgraduate Institute of Medical Education and Research (PGIMER), India

P3.17-07: The Beneficial Effect of the High Dose Irradiation During Concurrent Chemoradiation in Locoregional Advanced Non-Small Cell Lung Cancer  
Chul Seung Kay  
The Catholic University of Korea Incheon St. Mary Hospital, Korea

P3.17-08: Assessing Primary Lung Cancer Lesion Using Ratio Metrics of T1 and T2-Weighted Images in Magnetic Resonance Imaging  
Hui Liu  
Sun Yat-sen University Cancer Center, China

P3.17-09: Retrospective Analysis of the Efficacy and Safety of Multimodal Treatment for Locally-Advanced NSCLC in Elderly Patients  
Francesca Mazzoni  
University Hospital Careggi, Italy

P3.17-10: Outcome of Surgical Resection for Superior Sulcus Tumor: Experience at a Single Institution  
Seiji Omura  
Keio University, School of Medicine, Japan

P3.17-11: Duo Synchronous Primary Lung Tumours Mimicking a Solitary Spiculated Cavitatory Mass on Computed Tomographic Imaging  
Kingsfield Ong  
Tan Tock Seng Hospital, Singapore

P3.17-12: Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress  
Helen Ross  
Mayo Clinic Arizona, USA

P3.17-13: SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients with Stage IIIA(N2) NSCLC — A Multicenter Single-Arm Phase II Trial  
Sacha Rothschild  
University Hospital Basel, Switzerland

P3.17-14: A Case of a Patient Harboring an EGFR -T790M Mutation Positive in Squamous Cell Lung Cancer  
Carlos Carracedo Gonzales  
Aliada Clinic, Peru

P3.17-15: Therapeutic Outcome of Surgery for Superior Sulcus Tumor  
Akira Sakurada  
Institute of Development, Aging and Cancer, Japan

P3.17-16: Adenocarcinoma or Epidermoid? The Importance of the Histological Subdivision  
Silvia Sequero  
Hospital Campus de la Salud, Spain

P3.17-17: Stage III: Analysis to Assist in the Decision of Surgery Against Quimio-Radiotherapy  
Silvia Sequero  
Hospital Campus de la Salud, Spain

P3.17-18: Towards Individualizing Patient Selection in Proton Therapy for Lung Cancer Using the Model-Based Approach  
Suliana Teoh  
CRUK/MRC Oxford Institute for Radiation Oncology Gray Laboratories, UK

P3.17-19: First Relapse and Survival Five Years After Radical Radiotherapy for Lung Cancer  
Gerard Walls  
Cancer Centre Belfast City Hospital, UK

P3.17-20: Impact of Significant Primary Tumor Size Reduction on Radiation Dose to Normal Structures in Patients Receiving Definitive Chemoradiotherapy  
Meng Welliver  
The Ohio State University CCC, USA

P3.17-21: Surgical Treatment for Centrally Located or Hilar Invasive Locally Advanced Lung Cancer  
Motohiro Yamashita  
Shikoku Cancer Center, Japan
P3.CR-01: To Better Understand the Anatomical Proximity of Cardiac Plexus to Prevent Lethal Arrhythmias Associated with Lung Cancer Surgery
Kurumi Fukui
Mitsui Memorial Hospital, Japan

P3.CR-02: SBRT of Lung Primary After Complete Resolution of Metastatic Disease in Case of EGFR Mutated Adenocarcinoma Lung: A Case Report
Saroj Majumdar
All India Institute of Medical Sciences, India

P3.CR-03: Pulmonary Spindle Cell Neoplasm - Neoadjuvant Treatment and Response
Kyaw Thein
Texas Tech University Health Sciences Center, USA

P3.CR-04: Lung Cancer with Concurrent ROS1 Rearrangement and KRAS Mutation: A Case Report
Youcai Zhu
Zhejiang Rongjun Hospital, China

P3.CR-05: The Role of Patient Engagement in Improved Outcomes in Lung Cancer Care
Anne Marie Cerato
Lung Cancer Canada, Canada

P3.CR-06: Effect of Palliative Care and Cancer Rehabilitation on Lung Cancer Survivorship - Patient’s Perspective
Satoko Kono
ARUN, Japan

P3.CR-07: Comprehensive Genomic Profiles for a Mediastinal Tumor Suspected of Synovial Sarcoma: A Case Report
Kota Araki
Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan

P3.CR-08: Clonally Related Primary ALK Rearrangement Adenocarcinoma and Associated Metastatic Lesions: A Case Report
Chunwei Xu
Fujian Cancer Hospital, China

P3.CR-09: MET-UBE2H fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma with “MET fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma
Chunwei Xu
Fujian Cancer Hospital, China

P3.CR-10: HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer and Response to Crizotinib
Chunwei Xu
Fujian Cancer Hospital, China

P3.CR-11: ROS1 Fusion and MET Amplification Dual Drive Coexistence in Lung Adenocarcinoma and Response to Crizotinib: A Case Report
Chunwei Xu
Fujian Cancer Hospital, China

P3.CR-12: A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
Youcai Zhu
Zhejiang Rongjun Hospital, China

P3.CR-13: Dual Drive Coexistence of EML4-ALK Fusion and TPM3-ROS1 Fusion Lung Adenocarcinoma: A Case Report
Youcai Zhu
Zhejiang Rongjun Hospital, China

P3.CR-14: A Case of EGFR Tyrosine Kinase Inhibitor (TKI), Osimertinib Induced Pneumonitis in a Patient with Recurrent Fevers of Unknown Origin
Young Chae
Northwestern Memorial Hospital, USA

P3.CR-15: Squamous Cell Carcinoma Diagnosed While on Immunotherapy for Lung Adenocarcinoma: A Unique Clinical Case
Marta Soares
Instituto Português de Oncologia do Porto, Portugal

P3.CR-16: A Case of Toxic Hepatic Event Occurring in Combination Treatment with Nivolumab and Anti-Tuberculosis in Advanced Lung Cancer
Tae Hoon Kim
Bundang CHA Medical Center, CHA University, Korea

P3.CR-17: An Interesting Case of Long-Term Immunotherapy Response in Metastatic NSCLC
Swati Kulkarni
Windsor Regional Cancer Program, Canada

P3.CR-18: Central Nervous System Activity of Checkpoint Inhibitor in Non-Small-Cell Lung Cancer
Marta Pereira-Lima
Hospital De Clinicas De Porto Alegre, Brazil

Leticia Maria Neves de Carvalho
Americas Oncologia, Brazil

Takeshi Uenami
National Hospital Organization Toneyama National Hospital, Japan

P3.CR-21: Utility of Thoracoscopy in Diagnosis of Lung Tumour in Pleural Effusion
Naveen Pandhi
Government Medical College, India

P3.CR-22: Pulmonary Tuberculosis – A Chameleon; Mimicking Lung Cancer on Imaging
Srijna Rana
Government Medical College, India

J. Turner
University of Tennessee Graduate School of Medicine, USA

P3.CR-24: Surgical Resection of 30 Years’ Recurring Pneumonia: 1 Case of Giant Bronchopulmonary Sequestration
Jun Zhang
China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

P3.CR-25: Finding the Ways to Determine the Prognosis of Pulmonary Carcinoids with Certain Genes/Markers in Pakistan
Arooj Fatima
Shaukat Khanum Cancer Hospital and Research Centre, Pakistan
P3.CR-26: Mediastinal Lipoma in Adult: A Case Report
Amira Anwar
Pondok Indah Hospital, Jakarta, Indonesia, Indonesia

P3.CR-27: Surgical Treatment of a Rare Case of Mediastinal Masson's Tumor Mimicking a Thymoma
Angela De Palma
University of Bari “Aldo Moro”, Italy

P3.CR-28: Simultaneous Presentation of Mediastinal Malignant Peripheral Nerve Sheath Tumor with Intrapulmonary Metastasis, an Extremely Rare Case
Akif Turna
Istanbul University Cerrahpasa Medical Faculty, Turkey

Akif Turna
Istanbul University Cerrahpasa Medical Faculty, Turkey

P3.CR-30: Pleural Diseases on Single Lung After Pneumonectomy for Cancer
Veronica Manolache
Oncology Institute Bucharest, Romania

P3.CR-31: A Case of Thymoma with Autoimmune Hepatitis Following Preoperative Chemotherapy
Tomoki Nishimura
Kyoto Prefectural University of Medicine, Japan

Kyung Joo Park
Ajou University School of Medicine, Korea

P3.CR-33: Trichoptysis, Hemoptysis and Chest Pain: A Very Rare Presentation of Anterior Mediastinal Teratoma in a Young Patient
Asma Saidane
University of Medicine Tunisia, Tunisia

P3.CR-34: A Giant Ganglioneuroma of the Thoracic Spine
Asma Saidane
University of Medicine Tunisia, Tunisia

P3.CR-35: A Rare Giant Thoracic Desmoid Tumor / A Case Report
Asma Saidane
University of Medicine Tunisia, Tunisia

Akif Turna
Istanbul University Cerrahpasa Medical School, Turkey

P3.CR-37: Extensive Resection for Invasive Atypical Carcinoid of Thymus: 1 Case Report
Jun Zhang
China Medical University Lung Cancer Center, The First Hospital of China Medical University, China
All sessions listed on the following pages are not part of the IASLC CME accredited scientific program.

SECTION 8

Sponsor and Exhibit Information

TAKE ACTION
Against Lung Cancer!
INDUSTRY SUPPORTED
SYMPOSIA AND WORKSHOPS

SUNDAY, SEPTEMBER 23, 2018

08:00 - 11:30  WS04: ROCHE SCIENTIFIC SYMPOSIUM: CLINICAL DECISION SUPPORT FOR MANAGEMENT OF LUNG CANCER PATIENTS AND FUTURE DIRECTIONS IN THE ERA OF PRECISION MEDICINE (SIGN UP REQUIRED)

ROOM: 206 F

08:00  WS04.01: Welcome & Introduction
08:15  WS04.02: Protein-based Biomarkers as Tools to Support Clinical Decision Making for Lung Cancer Patients with Results from the Laboratory
Rafael Molina, University of Barcelona, Spain

08:45  WS04.03: Using Immunohistochemistry in Differential Diagnosis and Predictive Assessment of Lung Cancer
Mark Kockx, Histogenex, Belgium

09:15  WS04.04: Clinical Utility of Liquid Biopsy to EGFR Mutation Detection in NSCLC
Adrian Sacher, Princess Margaret Cancer Centre & University of Toronto, Canada

09:45  Break
10:00  WS04.06: Circulating Tumor DNA: Solid Tumor MRD Detection and Potential Clinical Utility
Aadel Chaudhuri, Washington University, USA

10:30  WS04.07: University of Missouri’s Experience with the NAVIFY Tumor Board Solution in HemOnc Tumor Board
Richard Hammer, University of Missouri, USA

11:00  WS04.08: Panel Discussion

09:45 - 11:15  ISS01: SYMPOSIUM SUPPORTED BY TAKEDA: NEW INSIGHTS AND CLINICAL IMPLICATIONS FOR THE TREATMENT OF ALK+ NSCLC

ROOM: 105

CHAIRS: NATASHA LEIGHL, CANADA, ROBERT C. DOEBELE, USA, KAREN RECKAMP, USA & LUIS PAZ-ARES, SPAIN

BREAKFAST PROVIDED

Agenda:
09:45  Welcome and Introductions
Natasha Leighl, Canada

09:52  Insights Into Mechanisms of Resistance and Characterizing Oncogenic Drivers in ALK+ NSCLC
Robert C. Doebele, USA

10:14  Current Landscape of ALK Inhibitors and Key Data
Karen Reckamp, USA

10:36  How to Integrate New Agents and Disease Monitoring Practices Into Optimal Patient Care
Luis Paz-Ares, Spain

10:58  Panel Discussion
11:13  Conclusion

11:30 - 13:00  ISS02: SYMPOSIUM SUPPORTED BY INCYTE: NOVEL IMMUNOTHERAPY STRATEGIES IN LUNG CANCER

ROOM: 107

CHAIRS: FRANCES SHEPHERD, CANADA, MARINA GARASSINO, ITALY & LEORA HORN, USA

LUNCH PROVIDED

Agenda:
11:30  Welcome and Introductions
Frances Shepherd, Canada

11:35  Treating NSCLC: Where Are We Today With Immunotherapies?
Frances Shepherd, Canada

12:00  How Can We Select Patients for Novel Therapeutic Approaches?
Marina Garassino, Italy

12:50  Panel Discussion
13:00 - 14:30 | ISS03: SYMPOSIUM SUPPORTED BY LILLY ONCOLOGY: STEERING IMPROVED OUTCOMES IN NON-DRIVER MUTATION LUNG CANCER: PROGRESS AND CHALLENGES

ROOM: 106
CHAIR: MARK SOCINSKI, USA

SNACKS AND REFRESHMENTS PROVIDED

Agenda:
13:00 Welcome and Introduction
Mark Socinski, USA
13:05 Histological and Molecular Profiling
Keith Kerr, UK
13:20 Optimal Sequencing of Therapy for Non-Driver Lung Cancer: Chemotherapy + Immunotherapy
Penelope Bradbury, Canada
13:40 Optimal Sequencing of Therapy for Non-Driver Lung Cancer: Chemotherapy + Anit-Angiogenics
James Yang, Taiwan
14:00 Identifying and Treating Patients with Refractory or Aggressive Lung Cancer
Corey Langer, USA
14:20 Faculty Discussion and Audience Questions

14:30 - 16:00 | ISS04: SYMPOSIUM SUPPORTED BY BRISTOL-MYERS SQUIBB: REFINING THE FOCUS IN LUNG CANCER: NEW DATA AND EMERGING BIOMARKERS

ROOM: 105
CHAIR: ROSALYN JUERGENS, CANADA

SNACKS AND REFRESHMENTS PROVIDED

Agenda:
16:00 Welcome and Introduction
Pasi Janne, USA
16:05 Exploring Our Therapeutic Options in the First-Line: What’s New?
Pasi Janne, USA
16:20 Assessing the Impact of the Latest Data on Practice
Entire Panel
16:35 Controversies in First-Line Management of EGFR-Mutant NSCLC
Entire Panel
17:00 Current and Evolving Treatments: Cases in Point
Entire Panel
17:25 Concluding Remarks and Ask the Faculty
Pasi Janne, USA

Please note: Industry Supported Symposia and Workshops are not part of the IASLC CME accredited scientific program.

From Clinical Trials to Real-World Experience: Practical Management of NSCLC, SCLC, and Mesothelioma Treatment - Case Studies
Presentation
Full Panel
07:00 - 08:00 ISS07: SYMPOSIUM SUPPORTED BY CLINICAL CARE OPTIONS, LLC: STRATEGIES TO MAXIMIZE THE CLINICAL BENEFIT OF EGFR TKIS IN ADVANCED NSCLC

ROOM: 107
CHAIR: SHIRISH GADGEEL, USA
FACULTY: HEATHER WAKELEE, USA & HELENA A. YU, USA

Agenda:
07:00 Welcome and Overview
07:05 Selecting First-Line Therapy in the Setting of EGFR-Mutated NSCLC
07:20 Selecting Second-Line Therapy and Beyond in the Setting of EGFT-Mutated NSCLC
07:35 Future Directions in Treatment Strategies for EGFR-Mutated NSCLC
07:50 Conclusions and Audience Question and Answer Session

Breakfast Provided

07:00 - 08:00 ISS06: SYMPOSIUM SUPPORTED BY MEDSCAPE: NTRK FUSIONS IN NSCLC - PRACTICE CHANGING IN 2018 AND BEYOND?

ROOM: 106
CHAIR: RAMASWAMY GOVINDAN, USA

Agenda:
06:30 Breakfast & Registration
07:00 Welcome and Introductions
Ramaswamy Govindan, USA
A Case Example of Lung Cancer and NTRK Fusions: Making the Diagnosis
Luis E. Raez, USA
A Case Example of Lung Cancer and NTRK Fusions: Management
Alexander Drilon, USA
Sizing Up Resistance: Getting in Front of the Problem
Trever G. Bivona, USA
Personalizing Therapy in Patients with NTRK Fusions: Will It Go the Way of EGFR?
Ramaswamy Govindan, USA
07:55 Questions and Answer
### 07:00 - 08:00  
**ISS08: SYMPOSIUM SUPPORTED BY FOUNDATION MEDICINE: IMPLEMENTING LIQUID BIOPSIES INTO CLINICAL PRACTICE: CHALLENGES, ACHIEVEMENTS AND PROGRESS**

**ROOM:** PLENARY HALL  
**BREAKFAST PROVIDED**  
**FACULTY:** IGNATIUS OU, USA, RUBEN CABANILLAS, SPAIN & NIR PELED, ISRAEL

### 12:00 - 13:30  
**ISS09: SYMPOSIUM SUPPORTED BY MERCK: PEMBROLIZUMAB: THE EVOLVING STANDARD OF CARE IN ADVANCED AND EARLY-STAGE LUNG CANCER**

**ROOM:** PLENARY HALL  
**CHAIR:** QUINCY CHU, CANADA  
**LUNCH PROVIDED**

#### Agenda:

- **12:00** Welcome and Introduction  
  Quincy Chu, Canada

- **12:00** First- and Second-Line Use of Immune Checkpoint Inhibitor Monotherapy for Metastatic NSCLC  
  Martin Reck, Germany

- **12:15** Combination Options in First-Line Metastatic NSCLC  
  Silvia Novello, Italy

- **12:30** Future Utilization of Immunotherapy  
  Quincy Chu, Canada

- **12:45** Patient Selection – Cases on the Use of Monotherapy, Chemotherapy/IO Combinations, and IO/IO Combinations  
  Joachim Aerts, Netherlands

- **13:00** Panel Discussion

- **13:25** Closing Remarks  
  Quincy Chu, Canada

### 18:00 - 19:30  
**ISS10: SYMPOSIUM SUPPORTED BY BOEHRINGER INGELHEIM: OVERCOMING CHALLENGES IN THORACIC MALIGNANCIES: EXPERT INSIGHTS**

**ROOM:** 106  
**CHAIR:** DAVID R. GANDARA, USA  
**SNACKS AND REFRESHMENTS PROVIDED**

#### Agenda:

- **18:00** Meeting Welcome and Introductions  
  David R. Gandara, USA

- **18:05** Clinical Considerations in EGFR Mutation-Positive NSCLC: Does Treatment Sequence Matter?  
  Barbara Melosky, Canada

- **18:20** Clinical Consideration in EGFR Mutation-Positive NSCLC: The Challenge of Preventing and Managing Brain Metastases  
  Noemi Reguart, Spain

- **18:35** Panel Discussion: Treatment Considerations in Adenocarcinoma  
  All Faculty

- **18:50** Maximising the Clinical Potential of TKIs for Patients with Squamous NSCLC  
  David R. Gandara, USA

- **19:10** Panel Discussion: Treatment Considerations in SqCC of the Lung  
  All Faculty

- **19:25** Meeting Close  
  David R. Gandara, USA
TUESDAY, SEPTEMBER 25, 2018

07:00 - 08:00  ISS11: SYMPOSIUM SUPPORTED BY PFIZER: FUTURE OPTIONS FOR ALK+ METASTATIC NSCLC

ROOM: 105
CHAIR: GEOFFREY LIU, CANADA

BREAKFAST PROVIDED

Agenda:
07:00 Welcome and Introduction
Geoffrey Liu, Canada
07:05 Recent Advances in Treating ALK+ NSCLC: An Evolving Landscape
Ben Solomon, Australia
07:25 Navigating the Spectrum of Resistance Mutations in ALK+ NSCLC: How to Identify and Treat Them
Alice Shaw, USA
07:45 Panel Q&A
All Faculty

07:00 - 08:00  ISS12: SYMPOSIUM SUPPORTED BY ROCHE: SELECTING THE RIGHT CANCER IMMUNOTHERAPY REGIMEN FOR THE RIGHT PATIENT IN FIRST-LINE LUNG CANCER

ROOM: 106

BREAKFAST PROVIDED

Agenda:
Spotlight on Cancer Immunotherapy: Scientific Advances and Evolving Clinical Practice in First-Line Lung Cancer
Suresh Ramalingam, USA
Optimising Treatment for First-Line NSCLC
Vassiliki Papadimitrakopoulou, USA
Ross Soo, Singapore
Putting It All Into Perspective: What Does This Mean for Our Patients?
All Faculty

12:00 - 13:30  ISS14: SYMPOSIUM SUPPORTED BY NOVARTIS: EXPERT PERSPECTIVES ON THE MANAGEMENT OF NSCLC IN CLINICAL PRACTICE: ARE NOVEL APPROACHES REALISTIC?

ROOM: PLENARY HALL

LIGHT LUNCH PROVIDED

Agenda:
12:00 Welcome and Introductions
Daniel Tan, Singapore
12:05 The Current Therapeutic Landscape for Molecularly-Driven NSCLC
Scott Laurie, Canada
12:20 Expert Insights: Selecting Patients for Targeted Therapy
Scott Laurie, Canada
12:30 Resistance and the Ongoing Challenge to Delay Disease Progression
Daniel Tan, Singapore
12:45 Expert Insights: Tackling Resistance to Targeted Therapy
Daniel Tan, Singapore

Please note: Industry Supported Symposia and Workshops are not part of the IASLC CME accredited scientific program.
12:55  Immunotherapy in NSCLC: Clinical Considerations and Future Frontiers
Laura Chow, USA

13:10  Expert Insights: Practicalities of Immunotherapy in the Clinic
Laura Chow, USA

13:20  Panel Q&A, Summary and Close

18:00 - 19:30 ISS15: SYMPOSIUM SUPPORTED BY ASTRAZENECA: STAGE III NSCLC: COMBINING IMMUNOTHERAPIES WITH STANDARD TREATMENTS… WHO, WHEN, WHY?
ROOM: 106
CHAIR: HOSSEIN BORGHAEI, USA

SNACKS AND REFRESHMENTS PROVIDED

Agenda:
17:30  Registration and Dinner
18:00  Introduction: Immunotherapy and CRT
       Hossein Borghaei, USA
18:15  The Surgical Oncologist’s Perspective
       David Waller, UK
18:30  The Radiation Oncologist’s Perspective
       Corinne Faivre-Finn, UK
18:45  The Medical Oncologist’s Perspective
       Scott Antonia, USA
19:00  Panel Discussion
19:15  Question and Answer Session

WEDNESDAY, SEPTEMBER 26, 2018

12:00 - 13:30 ISS16: SYMPOSIUM SUPPORTED BY ABBVIE: BIOMARKER DRIVEN SCLC TREATMENT: FACT OR FICTION?
ROOM: PLENARY HALL
LUNCH PROVIDED

Agenda:
12:00  Introductions
       Peter Ellis, Canada
12:05  Expanding Options in Treatment of SCLC: Unmet Needs and New Targets
       Peter Ellis, Canada
12:25  Incorporating Biomarker Testing in SCLC Patient Evaluation: Current Challenges and Lessons Learned from NSCLC
       Philippe Joubert, Canada
12:50  Changing Treatment Paradigm in SCLC: Emerging Data on Use of Biomarkers in SCLC Treatment
       David P. Carbone, USA
13:20  Panel Discussion and Closing Remarks
Jean-Charles Soria – Developing and Preparing for Earlier Treatments in Lung Cancer

Earlier is better as we can treat in a curative intent setting. The immune system is stronger and we have a significant opportunity to provide enduring effect.

Curative treatments are emerging, but we need to build new approaches for early stage disease with the right biomarkers, the right evidence and engagement of the right members of the MDT.

Carl Barrett – Early Detection and Monitoring of Lung Cancer

Screening has started, but we need innovation (e.g. plasma-based methods and biomarkers) to make it easier and to extend to a broader at risk population.

Preventing metastatic relapse needs to become the focus for development, identifying residual disease and risk of relapse, e.g. through use of ctDNA.

Speaker: Anagh Vora, M.D. FCAP
Sr. Medical Director, Head, Medical Affairs
Immuno-Oncology and Molecular Diagnostics
Thermo Fisher Scientific

Session objectives:

• Learn what are the key factors which should be always considered when asking for a biomarker test
• Discuss the pros and cons of utilizing external laboratory services versus in house capabilities
• Reflect on the role of the broad genomic profiling in precision oncology today and in future
• Provide a forum for multiple stakeholders—clinicians, laboratories, and patients discussion

Ramaswamy Govindan
Professor of Medicine/Director of Medical Oncology Washington University School of Medicine, St. Louis, Missouri

Clive Morris, MD
Chief Executive Officer, Inivata

Speakers: Ramaswamy Govindan
Professor of Medicine/Director of Medical Oncology Washington University School of Medicine, St. Louis, Missouri

Clive Morris, MD
Chief Executive Officer, Inivata
EXHIBIT INFORMATION

LOCATION

MTCC North Building, Level 300, Exhibit Halls B+C

Sunday, Sept. 23 20:30 – 22:00 (Welcome Reception)
Monday, Sept. 24 09:30 – 18:30
Tuesday, Sept. 25 09:30 – 18:30
Wednesday, Sept. 26 09:30 – 14:00

Complimentary coffee, tea & refreshments will be served in the Exhibit Hall in the morning and afternoon. Food Kiosks will be available to purchase snacks and meals during the lunch break.

Exhibit Showcase Sessions
See left page for full session details:

Tuesday, September 25, 2018

09:55 - 10:25 EXH01: AstraZeneca Exhibit Showcase Session:
The Visions and Science for Earlier Treatment

12:15 – 13:15 EXH02: Thermo Fisher Exhibit Showcase Session:
The Way We Test Matters for Patient Outcomes

17:00 – 17:30 EXH03: Inivata Exhibit Showcase Session:
Liquid Biopsy: Providing Accurate Insights for Advanced NSCLC Patients - A Closer Look at the Validation and Utility of the InVisionFirst™-Lung Test

Poster Sessions
All poster presentations have been assigned a consecutive publication number for locating the abstract/poster in this brochure, the Abstract Book and the Poster Boards in the Exhibit Hall.

<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1: Poster Session 1</td>
<td>Monday, September 24</td>
</tr>
<tr>
<td>P2: Poster Session 2</td>
<td>Tuesday, September 25</td>
</tr>
<tr>
<td>P3: Poster Session 3</td>
<td>Wednesday, September 26</td>
</tr>
</tbody>
</table>

Poster Pick Up Counter
Poster Presenters who had their poster printed by the Conference, can pick up their poster at the Poster Pick Up Counter at the Exhibit Information Booth in the Exhibit Hall during the following times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, September 24</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Tuesday, September 25</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Wednesday, September 26</td>
<td>08:00 – 12:00</td>
</tr>
</tbody>
</table>

Posters Online
All abstracts accepted for poster presentation will be presented as traditional printed posters to be displayed on poster boards in the Exhibit Hall. In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the Virtual Meeting (http://library.iaslc.org), which is free of charge to all delegates.
## EXHIBITOR LISTING

### By Company

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND#</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Inc</td>
<td>2405</td>
</tr>
<tr>
<td>American Society of Clinical Oncology</td>
<td>2907</td>
</tr>
<tr>
<td>AmoyDX</td>
<td>206</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>1802</td>
</tr>
<tr>
<td>Bayer Healthcare Pharmaceuticals, Inc.</td>
<td>412</td>
</tr>
<tr>
<td>Biocept, Inc.</td>
<td>508</td>
</tr>
<tr>
<td>Biodiesix, Inc.</td>
<td>207</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>801</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>1302</td>
</tr>
<tr>
<td>Broncus Medical Inc.</td>
<td>2008</td>
</tr>
<tr>
<td>Celgene Corporation</td>
<td>401</td>
</tr>
<tr>
<td>Dava Oncology, LP</td>
<td>113</td>
</tr>
<tr>
<td>Ezlife Bio Inc.</td>
<td>406</td>
</tr>
<tr>
<td>F. Hoffmann-La Roche</td>
<td>1312</td>
</tr>
<tr>
<td>F. Hoffmann-La Roche (Business Suite)</td>
<td>2012</td>
</tr>
<tr>
<td>Geneseeq Technology Inc.</td>
<td>509</td>
</tr>
<tr>
<td>Global Lung Cancer Coalition</td>
<td>613</td>
</tr>
<tr>
<td>Guardant Health, Inc.</td>
<td>409</td>
</tr>
<tr>
<td>Health Canada - Radon Education and Awareness</td>
<td>408</td>
</tr>
<tr>
<td>IASLC</td>
<td>100</td>
</tr>
<tr>
<td>Inivata</td>
<td>2009</td>
</tr>
<tr>
<td>International Thoracic Oncology Nurses Forum (ITONF)</td>
<td>2901</td>
</tr>
<tr>
<td>KALC 2018</td>
<td>2903</td>
</tr>
<tr>
<td>Lilly Oncology</td>
<td>1306</td>
</tr>
<tr>
<td>Login Canada</td>
<td>513</td>
</tr>
<tr>
<td>Loxo Oncology</td>
<td>107</td>
</tr>
<tr>
<td>Lung Cancer Canada</td>
<td>2900</td>
</tr>
<tr>
<td>Mayo Medical Laboratories</td>
<td>112</td>
</tr>
<tr>
<td>Merck &amp; Co</td>
<td>2400</td>
</tr>
<tr>
<td>MyGene Diagnostics</td>
<td>413</td>
</tr>
<tr>
<td>Neo-Genomics</td>
<td>106</td>
</tr>
<tr>
<td>Novartis</td>
<td>706</td>
</tr>
<tr>
<td>Novocure</td>
<td>2906</td>
</tr>
<tr>
<td>Oncimmune USA LLC</td>
<td>2904</td>
</tr>
<tr>
<td>Optellum</td>
<td>2905</td>
</tr>
<tr>
<td>PER Global, LLC</td>
<td>506</td>
</tr>
<tr>
<td>Pfizer Oncology</td>
<td>812</td>
</tr>
<tr>
<td>Polish Lung Cancer Group</td>
<td>2902</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>2208</td>
</tr>
<tr>
<td>Spectrum Pharmaceuticals</td>
<td>405</td>
</tr>
<tr>
<td>Takeda Oncology</td>
<td>1808</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>2908</td>
</tr>
<tr>
<td>TP Therapeutics, Inc.</td>
<td>114</td>
</tr>
<tr>
<td>Trans-Hit Bio</td>
<td>2108</td>
</tr>
<tr>
<td>Univadis</td>
<td>213</td>
</tr>
</tbody>
</table>

### By Booth Number

<table>
<thead>
<tr>
<th>STAND#</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>IASLC</td>
</tr>
<tr>
<td>106</td>
<td>Neo-Genomics</td>
</tr>
<tr>
<td>107</td>
<td>Loxo Oncology</td>
</tr>
<tr>
<td>112</td>
<td>Mayo Medical Laboratories</td>
</tr>
<tr>
<td>113</td>
<td>Dava Oncology, LP</td>
</tr>
<tr>
<td>114</td>
<td>TP Therapeutics, Inc.</td>
</tr>
<tr>
<td>206</td>
<td>AmoyDX</td>
</tr>
<tr>
<td>207</td>
<td>Biodiesix, Inc.</td>
</tr>
<tr>
<td>213</td>
<td>Univadis</td>
</tr>
<tr>
<td>401</td>
<td>Celgene Corporation</td>
</tr>
<tr>
<td>405</td>
<td>Spectrum Pharmaceuticals</td>
</tr>
<tr>
<td>406</td>
<td>Ezlife Bio Inc.</td>
</tr>
<tr>
<td>408</td>
<td>Health Canada - Radon Education and Awareness</td>
</tr>
<tr>
<td>409</td>
<td>Guardant Health, Inc.</td>
</tr>
<tr>
<td>412</td>
<td>Bayer Healthcare Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>413</td>
<td>MyGene Diagnostics</td>
</tr>
<tr>
<td>506</td>
<td>PER Global, LLC</td>
</tr>
<tr>
<td>508</td>
<td>Biocept, Inc.</td>
</tr>
<tr>
<td>509</td>
<td>Geneseeq Technology Inc.</td>
</tr>
<tr>
<td>513</td>
<td>Login Canada</td>
</tr>
<tr>
<td>613</td>
<td>Global Lung Cancer Coalition</td>
</tr>
<tr>
<td>706</td>
<td>Novartis</td>
</tr>
<tr>
<td>801</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>812</td>
<td>Pfizer Oncology</td>
</tr>
<tr>
<td>1302</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>1306</td>
<td>Lilly Oncology</td>
</tr>
<tr>
<td>1312</td>
<td>F. Hoffmann-La Roche</td>
</tr>
<tr>
<td>1802</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>1808</td>
<td>Takeda Oncology</td>
</tr>
<tr>
<td>2008</td>
<td>Broncus Medical Inc.</td>
</tr>
<tr>
<td>2009</td>
<td>Inivata</td>
</tr>
<tr>
<td>2012</td>
<td>F. Hoffmann-La Roche (Business Suite)</td>
</tr>
<tr>
<td>2108</td>
<td>Trans-Hit Bio</td>
</tr>
<tr>
<td>2208</td>
<td>Scanlan International, Inc.</td>
</tr>
<tr>
<td>2400</td>
<td>Merck &amp; Co</td>
</tr>
<tr>
<td>2405</td>
<td>AbbVie Inc</td>
</tr>
<tr>
<td>2900</td>
<td>Lung Cancer Canada</td>
</tr>
<tr>
<td>2901</td>
<td>International Thoracic Oncology Nurses Forum (ITONF)</td>
</tr>
<tr>
<td>2902</td>
<td>Polish Lung Cancer Group</td>
</tr>
<tr>
<td>2903</td>
<td>KALC 2018</td>
</tr>
<tr>
<td>2904</td>
<td>Oncimmune USA LLC</td>
</tr>
<tr>
<td>2905</td>
<td>Optellum</td>
</tr>
<tr>
<td>2906</td>
<td>Novocure</td>
</tr>
<tr>
<td>2907</td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td>2908</td>
<td>Thermo Fisher Scientific</td>
</tr>
</tbody>
</table>
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to improve treatments across four therapeutic areas: immunology, oncology, virology and neuroscience.

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise includes both marketed products and clinical development compounds which reflect the company’s approach to research: prioritizing targets and pathways with the potential to impact the way that cancer is treated.

The American Society of Clinical Oncology (ASCO) is the world’s leading professional society of multidisciplinary medical professionals who treat people with cancer. Join ASCO at the meeting and receive a free gift and access to valuable benefits. Already a member? Stop by to pick up your free collectable ASCO pin!

AmoyDx is a molecular diagnostic product manufacturer and service provider for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS and Super-ARMS, AmoyDx has a full portfolio of molecular diagnostic kits including but not limited to EGFR, ROS1 and approved by CFDA and CE-IVD.

Biocept aims to improve the lives of patients through innovative cancer diagnostic products and services. By identifying specific molecular alterations in both circulating tumor cells (CTCs) and ctDNA, Biocept helps oncologists open targeted and immunotherapy options for patients with cancer. Biocept also offers services to other laboratory testing providers.

Biodesix is a molecular diagnostics company at the forefront of innovation in oncology. We discover, develop and deliver blood-based diagnostics to answer unmet clinical questions across the continuum of lung disease and improve the standard of care for patients.

At Boehringer Ingelheim we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients – it drives everything we do.

Broncus Medical, the leader in virtual bronchoscopic navigation, has developed Archimedes™ total lung access platform, including BTPNA - Bronchoscopic Trans-Parenchymal Nodule Access. Now Broncus has combined Bronchoscopic Thermal Vapor Ablation (BTVA) to treat emphysematous segments. Broncus Medical is proud to introduce next generation pulmonary technology from access, diagnose to treatment.

Celgene Corporation is a global biopharmaceutical company that is helping healthcare providers turn incurable cancers into chronic, manageable diseases, as well as manage serious inflammatory conditions through innovative therapies.

AVA Oncology, LP provides multiple services across the drug development process with the goal of ultimately generating more effective cancer therapies for patients and physicians. DAVA accelerates clinical research timelines through MD-to-MD focused trial education, hosts non-CME scientific exchange programs and develops strategic and educational oncology tools.

EZLife Bio Inc. is reshaping detection with EFIRM: Only 20 xL of patient sample is needed to achieve nearly perfect detection of ctDNA targets in 30 minutes without DNA extraction and amplification. Our platform has been published in “American Journal of Respiratory and Critical Care Medicine” and “Clinical Cancer Research”.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.

Geneseeq Technology Inc. specializes in personalized cancer care, and aims to provide treatment solutions based on the comprehensive analyses of patients' genomic profiles using next-generation sequencing (NGS). Our products cover genetic testing for liquid biopsy, solid tumors and blood cancer, as well as NGS and bioinformatic analysis services for research.

The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.
Since its introduction in 2014, the Guardant360® assay has been ordered over 70,000 times to help inform which therapy may be effective for advanced stage cancer patients with solid tumors. It is supported by more than 70 peer-reviewed journal publications, which address its analytical validity, clinical validity, and clinical utility.

Radon is a colourless and odourless radioactive gas produced naturally from uranium degradation in soil and rock. It is the second leading cause of lung cancer with over 3000 Canadians death every year from radon-induced lung cancer. Health Canada is asking everyone to take action on radon.

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 7,000 lung cancer specialists in over 100 countries.

Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care. Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment.

The International Thoracic Oncology Nursing Forum (ITONF) is an international organisation for those who are directly caring for people with lung cancer or mesothelioma in a nursing role. This network provides an opportunity for debate, education and knowledge transfer throughout the continuum of treatment.

Korean Association for Lung Cancer - 2018 KALC International Conference “Beyond the Limit” - November 22 - 24, 2018 Lotte Hotel World, Jamsil, Seoul, Korea kalcic.or.kr

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.

Login Canada, is the Canadian Book Industry’s largest source of Scientific, Technical and Medical books. This proudly Canadian company has been serving the health sciences community for over 25 years. They bring quality publishers and exceptional customer service together.
At Loxo Oncology, our research focuses on developing highly selective medicines for patients with genomically defined cancers. Our programs are designed to leverage recent advances in genomic testing to identify the patients most likely to benefit from medicines that selectively inhibit a single cancer-driving molecular target.

Lung Cancer Canada is the only national charity focused exclusively on lung cancer. Our mission is to increase awareness about lung cancer, support patients living with lung cancer and the individuals who care for them and provide educational resources to lung cancer patients, their family members and health care professionals.

As the global reference laboratory for Mayo Clinic, Mayo Medical Laboratories will help you advance patient care, strengthen your practice, and broaden access to specialized testing. Through partnerships with Mayo Clinic clinicians and health care providers around the world, we are able to offer the most sophisticated test catalog in the world.

For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases around the world.

MyGene Diagnostics provides comprehensive diagnostics services to improve quality of life, lower cost for patients and hospitals. Established in 2015 at Guangzhou International Biotech Island, MyGene Diagnostics is quickly rising as the top-ranked clinical laboratory providing early and companion cancer diagnostics services with cutting-edge technologies including digital PCR and NGS.

NeoGenomics specializes in cancer genetics testing and information services with the most comprehensive oncology-focused testing menus globally to diagnose and treat cancer. NeoGenomics operates CLIA certified laboratories serving the needs of pathologists, oncologists, academic centers, hospital systems, Pharma, and managed care organizations. Visit neogenomics.com to learn more about our global locations.

At Novartis, our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.
Oncimmune’s EarlyCDT®-Lung is a blood test measuring a panel of seven autoantibodies specific for lung cancer-associated antigens and is being utilized by physicians to assess the risk of a pulmonary nodule being malignant. The test’s high specificity and positive predictive value (PPV) complements the high sensitivity of computed tomography (CT).

Optellum is developing precision medicine software solutions that accelerate early diagnosis & treatment of lung cancer. We showcase NIHR IDEAL, the first prospective multi-centre trial of a lung cancer prediction digital biomarker based on imaging & Artificial Intelligence, led by Oxford University Hospitals with co-authors of BTS & NICE guidelines.

PER Global, LLC is a medical education company with a focus on oncology and hematology. Since 2015, we have sponsored multiple EACCME-accredited congresses and webcasts throughout Europe, featuring internationally-renowned faculty, that enable healthcare professionals to remain current and responsive to advances in medical care for patients with cancer.

Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on people living with cancer. Our growing pipeline of biologics, small molecules, and immunotherapies is focused on identifying and translating the best scientific breakthroughs into clinical application. Learn more about Pfizer Oncology here: pfizer.com/science/oncology-cancer

Spectrum Pharmaceuticals, Inc. is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the company. More information available at spprx.com.

Polish Lung Cancer Group (PolGRP) - multidisciplinary association from 2002. Its primary role is didactic and educational equally spreading lung cancer knowledge in Poland. In November organizes annual conference with IASLC accreditation - „Best of WCLC”. Develops Virtual Lung Cancer Units. Its Lung Cancer Registry contains above 35,000 records.

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Proudly crafting Scanlan® LEGACY Needle Holders and Forceps; featuring our new revolutionary Scan- II™ handle design. Full line Scanlan® VATS instruments including D’Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps and Khan Decortication Grasper.

We endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Our combined legacy in oncology includes a broad range of paradigm-changing therapies for hematologic cancers and solid tumors.
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support clinical oncology research with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.

TP Therapeutics (tptherapeutics.com) is a clinical-stage company developing oncology therapies with a focus on addressing drug resistance. Its lead investigational therapy, Repotrectinib (TPX-0005), is a potent kinase inhibitor for ALK, ROS1, and NTRK. Repotrectinib is being evaluated in a Phase 1/2 study with advanced solid tumors harboring ALK/ROS1/NTRK1-3 (TRIDENT-1, NCT03093116).

Trans-Hit Bio is the worldwide biospecimen access CRO with the most extensive collection capability for biospecimens and clinical samples through an unrivaled worldwide partnered network of biorepositories and clinical sites, facilitating direct interactions between our customers and hospital-based biobanks allowing the scientific-and medical expertise of academics to be drawn upon and leveraged. trans-hit.com

Univadis is a free, time-saving medical news & education community designed exclusively for healthcare professionals. Unique executive summaries tame the onslaught of medical literature and keep clinicians up to date in just a few minutes per day. Concise, interactive educational presentations from our experts help clinicians stay on top of practice-changing research and trends.

LUNG CANCER NEWS

The IASLC Lung Cancer News, the IASLC’s bi-monthly newspaper, features the latest information on lung cancer research, patient care, tobacco control, expert commentary from lung cancer thought leaders around the world and more.

Look for the IASLC Lung Cancer News in your delegate bag or pick up a copy at the IASLC Booth in the Exhibit Hall.

LungCancerNews.org
IASLC and the 19th World Conference on Lung Cancer gratefully acknowledge the generous support of its official sponsors.
LOXO ONCOLOGY IS ORCHESTRATING A NEW INVESTIGATIONAL APPROACH TO RESEARCHING RET-ALTERED CANCERS

RET alterations can act as primary oncogenic drivers, setting the scene for constitutively active RET signaling that directs cancer growth1-3

RET=rearranged during transfection.

NCT03157128: A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion–Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation

Primary Outcome Measures:
Phase 1: Maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D)
Phase 2: Overall response rate (ORR) as assessed by IRC

Secondary Outcome Measures:
• Safety
• Pharmacokinetics
• Duration of response (DOR)
• Time to response
• Clinical benefit rate
• Progression-free survival
• Overall survival
• CNS metrics (ORR, DOR)

For full eligibility requirements, visit ClinicalTrials.gov

For more information about enrolling a patient or conducting a trial at your institution, visit LoxoRETtrials.com or call 1-855-RET-4-292

STUDY DESIGN

Advanced solid tumors

Target exposure

Advanced solid tumors with RET alteration/increased RET activity
Prior therapy with multikinase inhibitors that inhibit RET allowed

MTD/RP2D

• Advanced RET fusion–positive solid tumors (e.g. non-small cell lung cancer, thyroid, pancreatic, colorectal, and others)*
• Advanced RET-mutant medullary thyroid cancer*
• Other advanced RET-altered solid tumors

* Bona fide RET fusion, ATA moderate- and high-risk RET mutation.

CNS=central nervous system, IRC=independent review committee.

Exploring New Treatments in SMALL CELL Lung Cancer

are committed to transforming outcomes for patients with lung cancers, whose treatment options are currently limited. Our bold ambition is to eliminate lung cancer as a cause of death.

Visit us at Booth #1802 to learn more.
Get Social
at the IASLC 19th World Conference on Lung Cancer

JOIN THE CONVERSATION!

Remember to use the official hashtag:
#WCLC2018

MEDICINES THAT MAKE A MEANINGFUL DIFFERENCE

For more than 140 years, Lilly has been working to develop practice-changing medicines that make a meaningful difference for people living with cancer. Our quest is to accelerate the pace and progress of cancer care, including medicines designed to help people with rare and under-covered diseases.

To learn more about Lilly Oncology’s commitment to cancer and patient-driven innovation, contact a Lilly representative at the Lilly booth or visit LillyOncology.com.
Led by the International Association for the Study of Lung Cancer (IASLC), the Lung Cancer Awareness Month Coalition (LCAMC) is a unique effort composed of more than 30 global non-profis focused on thoracic cancers. Each November, the coalition unites for Lung Cancer Awareness Month (LCAM) to combat the stigma that surrounds lung cancer, showcase the diverse lives touched by this disease and increase awareness for recent scientific advances now making a positive difference in the lives of patients around the world.

Help us fight stigma and spread hope! Whether you are a patient, caregiver, physician or advocate, you can take action and contribute to LCAM by:

• Sharing your lung cancer story at www.LCAM.org;
• Stopping by the IASLC Booth (Booth #100) within the exhibit hall to learn more; and
• Follow us on social media:
  Twitter: @LCAM_org
  Facebook: www.facebook.com/LCAM.org/

www.LCAM.org
**EarlyCDT®–Lung**
A simple blood test to assess malignancy risk in indeterminate pulmonary nodules

**IMPROVE YOUR RISK ASSESSMENT OF MALIGNANCY IN PULMONARY NODULES**

- **EarlyCDT-Lung** measures the immune response to lung cancer from a blood test
- High Specificity complements CT scan
- Test performance is independent of all other current risk assessment methods

**EarlyCDT®-Lung Reclassifies With High PPV Malignancy Risk in Nodules > 10% Initial Risk**

**Initial Risk** = Swensen/ Mayo Model Calculated Risk

- Test result reclassifies risk to High per ACCP guidelines
- **High result (PPV)**
- **Moderate or High result (PPV)**
- Initial Risk unchanged on No Significant Level of Autoantibodies Detected result
- EarlyCDT®-Lung not validated below 10% risk

*Risk categories in accordance with ACCP guidelines. [https://doi.org/10.1378/chest.12-2351](https://doi.org/10.1378/chest.12-2351)*

A nodule risk calculator combining the Swensen/ Mayo model with EarlyCDT-Lung is available at [http://oncimmune.com/nodule-calculator](http://oncimmune.com/nodule-calculator)

**SCAN THE QR CODE TO FIND OUT MORE**

**COME SEE US IN BOOTH #2904**
Novocure™ researchers are investigating a breakthrough technology for treating patients with solid tumors, such as mesothelioma and lung cancer. And that’s just the beginning. ...

Learn more about our clinical research at Novocure.com and visit booth #2906

©2018 Novocure. All rights reserved. Novocure is a trademark of Novocure. NOV-160

NOTES
SECTION 9

CASTRO CHRISTIAN D...............................................................P2.13-11
CASTRELLON AURELIO ............................................................MA19.06
CASTILLO SERGI .................................................................P3.09-16
CASTRO VILLEGAS DIEGO .......................................................P3.01-94
CASTRO J RIBILERTO .................................................................P2.13-21
CASTRO J M MONTEZ .............................................................P3.01-12
CASTRO JUAN ...............................................................................P2.06-31
CATARINO ANTONIO .................................................................P1.01-06
CATARINO DANIELLE C .............................................................P3.04-12
CATINO ANNAMARIA .................................................................P2.01-11
CATEFUI LILIA ...........................................................................P1.01-10
CAUSI JUSTINA ......................................................................MA04.11
CAVALLESCO GIORGI .................................................................P3.03-22
CAVALLESCO GIAMPIERO .........................................................P3.03-22
CAVALLIER J ...............................................................................P2.01-16
CAVALLINI MARIA .................................................................P1.04-11
CAVALLONI MIA .................................................................P1.04-11
CAVACCI ANNA ......P1.16-28, P1.17-04
CAY SENLER FILIZ ........................................................................P2.03-34
CAZARIA ARRILATA PILAR .........................................................P3.16-02
CEBOLO SOFIA .................................................................P1.01-09
CEBON JONATHAN ....................................................................P2.06-17
CENTONZEO GIANNI .................................................................P1.04-11
CEPHEI M ...............................................................P3.01-104, P3.03-08, P3.03-09, P3.CR-08,
CERETE C GABRIELE .................................................................P1.01-09
CERESOLI GIOVANNI .................................................................P1.06-05
CERETO MARIE ........................................................................P2.05-05
CHABLE MICHAEL ...................................................................MA15.07
CHAI C ..........................................................................................P2.15-09
CHAI HAN ....................................................................................P2.13-10
CHAI J ........................................................................................P1.01-10
CHAO YINKAI .............................................................................P2.15-32
CHAN Tsz TONG .................................................................P1.01-11
CHANG HAN-RO .................................................................PL02.01
CHANG YANG ...........................................................................P3.08-07
CHANG ZHENG .................................................................P3.15-30
CHANG ZHEN .................................................................P1.04-05
CHANG ZHEN-CHI .................................................................P3.01-94
CHAPA ADRIEL ...............................................................MA01.01, MA01.02, P2.01-16
CHAPMAN FABIO .................................................................P3.03-08
CHAPUT NATALIE .................................................................P3.01-02
CHARABILLOS HARISS ..............................................................P1.10-12, P2.17-07
CHARA LUIS E .................................................................MA01.01, P1.01-69
CHARLES ANDREAS .................................................................P1.01-18
CHAO YINJIAN .................................................................P1.01-107, P1.01-108
CHEN WICHLANG .................................................................P3.16-19
CHENG YU .................................................................MA15.01, P1.03-02, P1.03-03, P1.03-04, P1.03-06, P1.03-07,
CHEN XIAOQIAN .................................................................P3.01-12
CHEN XIAoya .................................................................MA26.05, P1.01-111, P3.04-21
CHEN XIAOYA .................................................................MA19.06, P2.01-110, P2.01-107,
CHEN XUWEI .................................................................P1.16-35
CHEN YAN .................................................................P1.01-17, P1.01-62
CHEN YI .................................................................MA01.10, P1.01-11, P1.01-108
CHEN YI.................................................................JCSE01.15, P1.09-03, P1.09-01
CHENG YU .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG ZHEN .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG JING .................................................................P1.04-05
CHENG JING .................................................................P3.03-08, P3.09-09,
CHENG JING .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
CHENG YANG .................................................................P3.01-04, P3.03-08, P3.09-09,
Nam Taek-Keun ............................................................. P1.02-10
Namba Kei ...................................................................... P2.16-36
Nanjing Hiroshi ................................................................. P1.09-28, P2.09-03
Nakan Kejun ................................................................. P1.07-101, P1.07-108
Nakano Yu ........................................................................ P1.01-23, P1.01-24, P1.01-41
Nao Higuchi ...................................................................... P1.03-17
Nakamura Katsuhiro ....................................................... P1.12-02, P1.12-16
Nakamura Yumi ................................................................ P2.01-41, P2.01-42, P2.01-43
Nakao Yoko ...................................................................... P1.01-87, P1.01-97, P1.01-99
Napoli Francesca .............................................................. P1.13-20
Narayanan Kivi ................................................................. P2.04-08
Narayanan Vijnai .............................................................. P2.01-42
Nardone Valerio ............................................................... P2.01-21
Narula Nisent ................................................................. P1.12-01, P2.09-04
Naruse Ichiro ..................................................................... P1.01-92
Na Seung ........................................................................... P2.16-15
Nazar Abdul ................................................................. P2.16-40
Nasekemi Emilia ............................................................... P3.08-12
Nash Tony ......................................................................... P1.01-88
Natalie R. B. ..................................................................... P1.11-30
Nathan Faith ..................................................................... OA05.06
Naumkin Neil ................................................................. MA18.11, MS09.01, P2.11-29, P2.11-26
Nauroz Alejandro ............................................................... MA08.05, P3.12-11
Navarro Fatima ................................................................. P2.15-29
Nave Niccolò ..................................................................... P3.11-25
Nayon Rossie ..................................................................... E07.03
Navrathenak Raman .......................................................... P2.14-30
Nazarke Jennifer ............................................................... P2.14-31
Neal Hillary ...................................................................... P1.06-02
Neal Joel W. ..................................................................... MA15.12, P1.01-71, P1.01-72, P1.01-76
Neal Richard ................................................................. P3.13-15
Nechustan Hovav ................................................................ P2.01-12
Ngh Raky ........................................................................... P1.13-20
Nicoletti Marcello V .......................................................... MA06.02, OA02.06, P2.04-09
Neffman Victoria .............................................................. P1.04-30
Nelson Alan ...................................................................... P2.17-14, P3.03-16, P3.03-02
Nematollahi Massey .......................................................... MTE12.02, MTE03.02
Nemesure Barbara ............................................................ P2.11-18
Nemoto Kenji ................................................................... P1.01-92
Neminger Elsa ................................................................... P2.01-04
Neri Shinya ...................................................................... P3.09-06
Neron Yem ......................................................................... P2.13-09
Neri Bruno ......................................................................... P2.03-01
Nesic Seljol Salim ............................................................. P2.01-83
Nesti Agnese ..................................................................... P3.16-19
Nevius Nathalie ............................................................... MA10.03
Newmans-Thomas David .................................................. OA12.08, P2.13-15
Newton Gareth ................................................................ P3.11-15
Ng Gui .............................................................................. MA12.05, P1.03-17
Ng Isaac S. ........................................................................ P2.12-27
Ng Ji .................................................................................. P2.09-29
Ng Kenneth ....................................................................... P1.01-76
Ng Kevin W. ..................................................................... MA24.06, OA08.03
Nguyen Mai ................................................................. MA13-12, MA23.04
Ngocmua T miał ............................................................... P3.01-24
Nguyen Manh ................................................................. P2.15-23
Nguyen Tritle ..................................................................... P2.15-23
Nguyen Tu ........................................................................ P1.13-25
Nguyen Van Anh .............................................................. MA01.09, P1.01-74, P2.06-40
Nicholas Alan ................................................................. MA04.09, MA04.10
Nicholas Alan ................................................................. MA10.05, MA09.03, P1.09-25, P2.06-41
Nicholson Sioban .............................................................. M15.09
Nichols Samantha ............................................................. P1.12-15
Nicolaus Jessica S ............................................................... P3.09-25
Nicolaus Simon ............................................................... P2.01-14
Nicoletti Stefania Vittoria Luisa ........................................ P1.01-14
Nicolson Marianne .......................................................... MA02.05, MA03.12, P1.15-25, P1.15-26
Nicolas Claudio ............................................................... P1.11-03, P1.13-14, P2.04-05, P3.13-08
Nicolso MT ....................................................................... P1.01-18
Niles Merton ................................................................. P3.08-03
Nirman T ................................................................. P3.08-19, P3.08-10
Niemeier Anna-Larissa N ................................................ MA09.08
Nien Chiang ................................................................. MA24.01, P2.16-47, P2.17-32
Nie Kong ................................................................. MA21.01, P1.13-10
Nie Wei ................................................................................. AO07.06
Nie Si-Shi ........................................................................... P2.09-33
Nikaj Akiko ..................................................................... P3.01-13
Niim Yoko ......................................................................... P3.01-02
Nijjar Tarah ........................................................................ MA20.09
Nikolajos Christos ........................................................... P2.09-35
Nikolayev Alexander ......................................................... P1.04-07
Nikolic Neda ..................................................................... P1.01-31
Nikolic Vladimir ............................................................. P2.01-85
Nikolnakos Petros .......................................................... P1.01-62
Nilsson Monique .............................................................. P2.04-09
Ninomiya Hironori .......................................................... P1.16-43
Nishita Hiroshi .................................................................. P3.16-10
Nishikawa Kazuo ................................................................ P1.02-21, P1.02-22
Nishikawa Shigeto ............................................................. P2.03-29, P2.09-23, P3.09-13
Nishimura Hiroaki ............................................................ P2.06-31
Nishimura Naoko ............................................................ P3.04-26
Nishimura Tatsushi .......................................................... P1.09-32
Nishimura Yoshihiro ........................................................ P1.01-48
Nishimura Toshiyuki ........................................................ P1.13-41, P1.13-42
Nishimura Yukio ............................................................. P2.01-40
Nishino Masaya ............................................................... MA12.09, P1.01-75, P1.01-73
Nishiyama Yasuhiko .......................................................... P2.11-21
Nishiyasu Yatsuko ............................................................ P2.04-27
Nishizawa Hikaru ............................................................ P1.01-75
Nishizawa Yoshihiro ........................................................ P1.01-20
Nishizawa Yoshio ........................................................... P2.04-23, P2.04-24, P2.04-25
Nishio Hiroshi ................................................................. MA10.05, P1.01-35, P1.01-36
Nishiyama Rika .................................................................. P2.13-22
Nispanen Ilkka ................................................................. MA09.08, MA09.10, P1.01-31
Nisshiro ...
TRK FUSION PROTEINS ARE A PRIMARY ONCOGENIC DRIVER ACROSS MULTIPLE TUMORS IN ADULTS AND CHILDREN\textsuperscript{1,2}

Look below the surface to find out what’s driving the tumor.

Learn more about TRK fusion cancer at trkcancer.com

\begin{itemize}
  \item TRK, tropomyosin receptor kinase.
\end{itemize}
OPDIVO® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving OPDIVO.1

Please consult the OPDIVO Product Monograph at https://www.bms.com/assets/bms/ca/documents/productmonograph/OPDIVO_EN_PM.pdf for indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use.

The Product Monograph is also available by calling us at: 1-866-463-6267.

ALK - anaplastic lymphoma kinase; EGFR - epidermal growth factor receptor

Please see the product information specific to your country prior to prescribing OPDIVO.